
<html lang="en"     class="pb-page"  data-request-id="f4bfcc93-12ce-44d4-8f2c-8dc34210ef56"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-7;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.9b02080;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer’s Disease" /></meta><meta name="dc.Creator" content="Sònia  Abás" /></meta><meta name="dc.Creator" content="Sergio  Rodríguez-Arévalo" /></meta><meta name="dc.Creator" content="Andrea  Bagán" /></meta><meta name="dc.Creator" content="Christian  Griñán-Ferré" /></meta><meta name="dc.Creator" content="Foteini  Vasilopoulou" /></meta><meta name="dc.Creator" content="Iria  Brocos-Mosquera" /></meta><meta name="dc.Creator" content="Carolina  Muguruza" /></meta><meta name="dc.Creator" content="Belén  Pérez" /></meta><meta name="dc.Creator" content="Elies  Molins" /></meta><meta name="dc.Creator" content="F. Javier  Luque" /></meta><meta name="dc.Creator" content="Pilar  Pérez-Lozano" /></meta><meta name="dc.Creator" content="Steven  de Jonghe" /></meta><meta name="dc.Creator" content="Dirk  Daelemans" /></meta><meta name="dc.Creator" content="Lieve  Naesens" /></meta><meta name="dc.Creator" content="José  Brea" /></meta><meta name="dc.Creator" content="M. Isabel  Loza" /></meta><meta name="dc.Creator" content="Elena  Hernández-Hernández" /></meta><meta name="dc.Creator" content="Jesús A.  García-Sevilla" /></meta><meta name="dc.Creator" content="M. Julia  García-Fuster" /></meta><meta name="dc.Creator" content="Milica  Radan" /></meta><meta name="dc.Creator" content="Teodora  Djikic" /></meta><meta name="dc.Creator" content="Katarina  Nikolic" /></meta><meta name="dc.Creator" content="Mercè  Pallàs" /></meta><meta name="dc.Creator" content="Luis F.  Callado" /></meta><meta name="dc.Creator" content="Carmen  Escolano" /></meta><meta name="dc.Description" content="Imidazoline I2 receptors (I2-IR), widely distributed in the CNS and altered in patients that suffer from neurodegenerative disorders, are orphans from a structural point of view, and new I2-IR liga..." /></meta><meta name="Description" content="Imidazoline I2 receptors (I2-IR), widely distributed in the CNS and altered in patients that suffer from neurodegenerative disorders, are orphans from a structural point of view, and new I2-IR liga..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 9, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02080" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02080" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02080" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02080" /></link>
        
    
    

<title>Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer’s Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02080" /></meta><meta property="og:title" content="Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer’s Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0015.jpeg" /></meta><meta property="og:description" content="Imidazoline I2 receptors (I2-IR), widely distributed in the CNS and altered in patients that suffer from neurodegenerative disorders, are orphans from a structural point of view, and new I2-IR ligands are urgently required for improving their pharmacological characterization. We report the synthesis and three-dimensional quantitative structure–activity relationship (3D-QSAR) studies of a new family of bicyclic α-iminophosphonates endowed with relevant affinities for human brain I2-IR. Acute treatment in mice with a selected compound significantly decreased  Fas-associated protein with death domain (FADD)  in the hippocampus, a key signaling mediator of neuroprotective actions. Additionally, in vivo studies in the familial Alzheimer’s disease 5xFAD murine model revealed beneficial effects in behavior and cognition. These results are supported by changes in molecular pathways related to cognitive decline and Alzheimer’s disease. Therefore, bicyclic α-iminophosphonates are tools that may open new therapeutic avenues for I2-IR, particularly for unmet neurodegenerative conditions." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02080"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02080">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02080&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02080&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02080&amp;href=/doi/10.1021/acs.jmedchem.9b02080" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3610-3633</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02011" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b02004" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.0c01324"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Bicyclic α-Iminophosphonates as High Affinity Imidazoline I<sub>2</sub> Receptor Ligands for Alzheimer’s Disease</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Sònia Abás</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sònia Abás</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=S%C3%B2nia++Ab%C3%A1s">Sònia Abás</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sergio Rodríguez-Arévalo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sergio Rodríguez-Arévalo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sergio++Rodr%C3%ADguez-Ar%C3%A9valo">Sergio Rodríguez-Arévalo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrea Bagán</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea Bagán</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Bag%C3%A1n">Andrea Bagán</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christian Griñán-Ferré</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christian Griñán-Ferré</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Gri%C3%B1%C3%A1n-Ferr%C3%A9">Christian Griñán-Ferré</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Foteini Vasilopoulou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Foteini Vasilopoulou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Foteini++Vasilopoulou">Foteini Vasilopoulou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Iria Brocos-Mosquera</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Iria Brocos-Mosquera</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, University of the Basque Country, UPV/EHU, E-48940 Leioa, Bizkaia, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Iria++Brocos-Mosquera">Iria Brocos-Mosquera</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carolina Muguruza</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carolina Muguruza</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, University of the Basque Country, UPV/EHU, E-48940 Leioa, Bizkaia, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carolina++Muguruza">Carolina Muguruza</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0477-5757" title="Orcid link">http://orcid.org/0000-0002-0477-5757</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Belén Pérez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Belén Pérez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Therapeutic and Toxicology, Autonomous University of Barcelona, E-08193 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bel%C3%A9n++P%C3%A9rez">Belén Pérez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elies Molins</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elies Molins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institut de Ciència de Materials de Barcelona (CSIC), Campus UAB, E-08193 Cerdanyola, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elies++Molins">Elies Molins</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1012-0551" title="Orcid link">http://orcid.org/0000-0003-1012-0551</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">F. Javier Luque</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">F. Javier Luque</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Nutrition, Food Sciences and Gastronomy, School of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), and Institute of Theoretical and Computational Chemistry (IQTCUB), University of Barcelona, E-08921 Santa Coloma de Gramanet, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=F.+Javier++Luque">F. Javier Luque</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8049-3567" title="Orcid link">http://orcid.org/0000-0002-8049-3567</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pilar Pérez-Lozano</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pilar Pérez-Lozano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Unit of Pharmaceutical Technology, Pharmacy and Pharmaceutical Technology, and Physical Chemistry Department, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pilar++P%C3%A9rez-Lozano">Pilar Pérez-Lozano</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6899-066X" title="Orcid link">http://orcid.org/0000-0001-6899-066X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven de Jonghe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven de Jonghe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven++de+Jonghe">Steven de Jonghe</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3872-6558" title="Orcid link">http://orcid.org/0000-0002-3872-6558</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dirk Daelemans</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dirk Daelemans</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dirk++Daelemans">Dirk Daelemans</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lieve Naesens</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lieve Naesens</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lieve++Naesens">Lieve Naesens</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">José Brea</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">José Brea</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Innopharma screening platform, BioFarma research group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jos%C3%A9++Brea">José Brea</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">M. Isabel Loza</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">M. Isabel Loza</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Innopharma screening platform, BioFarma research group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=M.+Isabel++Loza">M. Isabel Loza</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elena Hernández-Hernández</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elena Hernández-Hernández</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IUNICS University of the Balearic Islands (UIB), and Health Research Institute of the Balearic Islands (IdISBa), Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Hern%C3%A1ndez-Hern%C3%A1ndez">Elena Hernández-Hernández</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jesús A. García-Sevilla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jesús A. García-Sevilla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IUNICS University of the Balearic Islands (UIB), and Health Research Institute of the Balearic Islands (IdISBa), Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jes%C3%BAs+A.++Garc%C3%ADa-Sevilla">Jesús A. García-Sevilla</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">M. Julia García-Fuster</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">M. Julia García-Fuster</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IUNICS University of the Balearic Islands (UIB), and Health Research Institute of the Balearic Islands (IdISBa), Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=M.+Julia++Garc%C3%ADa-Fuster">M. Julia García-Fuster</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Milica Radan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Milica Radan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Milica++Radan">Milica Radan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Teodora Djikic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Teodora Djikic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Teodora++Djikic">Teodora Djikic</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katarina Nikolic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katarina Nikolic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katarina++Nikolic">Katarina Nikolic</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mercè Pallàs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mercè Pallàs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmacology Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Merc%C3%A8++Pall%C3%A0s">Mercè Pallàs</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3095-4254" title="Orcid link">http://orcid.org/0000-0003-3095-4254</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luis F. Callado</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luis F. Callado</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, University of the Basque Country, UPV/EHU, E-48940 Leioa, Bizkaia, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luis+F.++Callado">Luis F. Callado</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Carmen Escolano</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carmen Escolano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +34 934024542. E-mail: <a href="/cdn-cgi/l/email-protection#aecdcbddcdc1c2cfc0c1eedbcc80cbcadb"><span class="__cf_email__" data-cfemail="2a494f594945464b44456a5f48044f4e5f">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carmen++Escolano">Carmen Escolano</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9117-8239" title="Orcid link">http://orcid.org/0000-0002-9117-8239</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02080&amp;href=/doi/10.1021%2Facs.jmedchem.9b02080" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3610–3633</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 9, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 December 2019</li><li><span class="item_label"><b>Published</b> online</span>9 March 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 April 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02080" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02080</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3610%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DS%25C3%25B2nia%2BAb%25C3%25A1s%252C%2BSergio%2BRodr%25C3%25ADguez-Ar%25C3%25A9valo%252C%2BAndrea%2BBag%25C3%25A1n%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D7%26contentID%3Dacs.jmedchem.9b02080%26title%3DBicyclic%2B%25CE%25B1-Iminophosphonates%2Bas%2BHigh%2BAffinity%2BImidazoline%2BI2%2BReceptor%2BLigands%2Bfor%2BAlzheimer%25E2%2580%2599s%2BDisease%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3633%26publicationDate%3DApril%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02080"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1167</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02080" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer’s Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sònia&quot;,&quot;last_name&quot;:&quot;Abás&quot;},{&quot;first_name&quot;:&quot;Sergio&quot;,&quot;last_name&quot;:&quot;Rodríguez-Arévalo&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Bagán&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Griñán-Ferré&quot;},{&quot;first_name&quot;:&quot;Foteini&quot;,&quot;last_name&quot;:&quot;Vasilopoulou&quot;},{&quot;first_name&quot;:&quot;Iria&quot;,&quot;last_name&quot;:&quot;Brocos-Mosquera&quot;},{&quot;first_name&quot;:&quot;Carolina&quot;,&quot;last_name&quot;:&quot;Muguruza&quot;},{&quot;first_name&quot;:&quot;Belén&quot;,&quot;last_name&quot;:&quot;Pérez&quot;},{&quot;first_name&quot;:&quot;Elies&quot;,&quot;last_name&quot;:&quot;Molins&quot;},{&quot;first_name&quot;:&quot;F.&quot;,&quot;last_name&quot;:&quot;Javier Luque&quot;},{&quot;first_name&quot;:&quot;Pilar&quot;,&quot;last_name&quot;:&quot;Pérez-Lozano&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;de Jonghe&quot;},{&quot;first_name&quot;:&quot;Dirk&quot;,&quot;last_name&quot;:&quot;Daelemans&quot;},{&quot;first_name&quot;:&quot;Lieve&quot;,&quot;last_name&quot;:&quot;Naesens&quot;},{&quot;first_name&quot;:&quot;José&quot;,&quot;last_name&quot;:&quot;Brea&quot;},{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;Isabel Loza&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Hernández-Hernández&quot;},{&quot;first_name&quot;:&quot;Jesús&quot;,&quot;last_name&quot;:&quot;A. García-Sevilla&quot;},{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;Julia García-Fuster&quot;},{&quot;first_name&quot;:&quot;Milica&quot;,&quot;last_name&quot;:&quot;Radan&quot;},{&quot;first_name&quot;:&quot;Teodora&quot;,&quot;last_name&quot;:&quot;Djikic&quot;},{&quot;first_name&quot;:&quot;Katarina&quot;,&quot;last_name&quot;:&quot;Nikolic&quot;},{&quot;first_name&quot;:&quot;Mercè&quot;,&quot;last_name&quot;:&quot;Pallàs&quot;},{&quot;first_name&quot;:&quot;Luis&quot;,&quot;last_name&quot;:&quot;F. Callado&quot;},{&quot;first_name&quot;:&quot;Carmen&quot;,&quot;last_name&quot;:&quot;Escolano&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;3610-3633&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02080&quot;},&quot;abstract&quot;:&quot;Imidazoline I2 receptors (I2-IR), widely distributed in the CNS and altered in patients that suffer from neurodegenerative disorders, are orphans from a structural point of view, and new I2-IR ligands are urgently required for improving their pharmacological characterization. We report the synthesis and three-dimensional quantitative structure–activity relationship (3D-QSAR) studies of a new family of bicyclic α-iminophosphonates endowed with relevant affinities for human brain I2-IR. Acute treatment in mice with a selected compound significantly decreased Fas-associated protein with death domain (FADD) in the hippocampus, a key signaling mediator of neuroprotective actions. Additionally, in vivo studies in the familial Alzheimer’s disease 5xFAD murine model revealed beneficial effects in behavior and cognition. These results are supported by changes in molecular pathways related to cognitive decline and Alzheimer’s disease. Therefore, bicyclic α-iminophosphonates are tools that may open new therapeutic avenu&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02080&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02080" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02080&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02080" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02080&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02080" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02080&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02080&amp;href=/doi/10.1021/acs.jmedchem.9b02080" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02080" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02080" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02080%26sid%3Dliteratum%253Aachs%26pmid%3D32150414%26genre%3Darticle%26aulast%3DAb%25C3%25A1s%26date%3D2020%26atitle%3DBicyclic%2B%25CE%25B1-Iminophosphonates%2Bas%2BHigh%2BAffinity%2BImidazoline%2BI2%2BReceptor%2BLigands%2Bfor%2BAlzheimer%25E2%2580%2599s%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D7%26spage%3D3610%26epage%3D3633%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/jmcmar.2020.63.issue-7/20200409/jmcmar.2020.63.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Imidazoline I<sub>2</sub> receptors (I<sub>2</sub>-IR), widely distributed in the CNS and altered in patients that suffer from neurodegenerative disorders, are orphans from a structural point of view, and new I<sub>2</sub>-IR ligands are urgently required for improving their pharmacological characterization. We report the synthesis and three-dimensional quantitative structure–activity relationship (3D-QSAR) studies of a new family of bicyclic α-iminophosphonates endowed with relevant affinities for human brain I<sub>2</sub>-IR. Acute treatment in mice with a selected compound significantly decreased  Fas-associated protein with death domain (FADD)  in the hippocampus, a key signaling mediator of neuroprotective actions. Additionally, <i>in vivo</i> studies in the familial Alzheimer’s disease 5xFAD murine model revealed beneficial effects in behavior and cognition. These results are supported by changes in molecular pathways related to cognitive decline and Alzheimer’s disease. Therefore, bicyclic α-iminophosphonates are tools that may open new therapeutic avenues for I<sub>2</sub>-IR, particularly for unmet neurodegenerative conditions.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The imidazoline receptors (IRs) (nonadrenergic receptors for imidazolines)<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> have attracted the attention of the scientific community during decades building a body of knowledge that place them as relevant biological targets.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> IRs are classified in I<sub>1</sub>-, I<sub>2</sub>-, and I<sub>3</sub>-types depending on the specific radiolabeled ligands that recognize their binding sites. These receptors are situated in different locations and are involved in different physiological functions.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> I<sub>1</sub>-, I<sub>2</sub>-, and I<sub>3</sub>-IRs have been unequally studied. Pharmacologically, I<sub>1</sub>-IRs are well characterized and understood, leading to the clinically approved antihypertensive drugs moxonodine<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and rilmenidine.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The most unknown are I<sub>3</sub>-IRs, identified in pancreatic β-cells and involved in insulin secretion.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Regarding I<sub>2</sub>-IRs, although structurally undescribed, a considerable understanding has been achieved on these heterogeneous receptors by using well-characterized I<sub>2</sub>-IR ligands.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> I<sub>2</sub>-IRs are widely distributed in the brain and, at the molecular level, are located in the outer membrane of mitochondria. Selective I<sub>2</sub>-IR ligands have proven that I<sub>2</sub>-IRs are involved in analgesia,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> inflammation,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and a plethora of human brain disorders.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Dysregulation of the levels of I<sub>2</sub>-IRs is a hallmark in illnesses such as glial tumors,<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Huntington’s disease,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Parkinson’s disease,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and depression,<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> among others. In particular, I<sub>2</sub>-IRs are reported to be increased in the brains of patients that suffered from Alzheimer’s disease (AD).<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> Recently, two I<sub>2</sub>-IR ligands, CR4056 (<b>1</b>) and [<sup>13</sup>C]BU99008 (<b>2</b>), have been progressed to clinical trials. CR4056 (<b>1</b>),<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> described as the first-in-class I<sub>2</sub>-IR ligand embodying analgesic properties, is in clinical phase II studies for osteoarthritis and postoperative dental pain, and [<sup>13</sup>C]BU99008 (<b>2</b>)<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> is in early clinical phase I for PET diagnosis for patients that suffer from AD.</div><div class="NLM_p">The implication of I<sub>2</sub>-IRs in many physiological and pathological processes emphasizes their pharmacological relevance, and the deserve in-depth studies. Since the structural data for I<sub>2</sub>-IRs remains unknown, the discovery of better and more selective I<sub>2</sub>-IR ligands is crucial to build a comprehensive understanding of the pharmacological implications of I<sub>2</sub>-IR.</div><div class="NLM_p">Although there are a few exceptions, LSL60101 (<b>3</b>) and most notably the clinical candidate CR4056 (<b>1</b>), the vast majority of known I<sub>2</sub>-IR ligands (idazoxan, <b>4</b>; tracizoline, <b>5</b>, and 2-BFI, <b>6</b>) are 2-substituted 2-imidazolines without further decoration in the 1-, 4-, and 5-positions (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative I<sub>2</sub>-IR ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to explore new imidazoline-based I<sub>2</sub>-IR ligands moving out of the comfort zone offered by the rather structurally homogeneous I<sub>2</sub>-IR ligands reported so far (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), we have recently disclosed a family of (2-imidazolin-4-yl)phosphonates.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> The putative therapeutic relevance of a member of this new family of I<sub>2</sub>-IR ligands, MCR5 (<b>7</b>), was validated in a murine model of neurodegeneration, the senescence accelerated mouse-prone 8 (SAMP8).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> An improvement in the cognitive decline and related biomarkers was found when MCR5 (<b>7</b>) was orally administered to the animals. This study was the first <i>in vivo</i> evidence that reinforced I<sub>2</sub>-IRs as a promising target for the treatment of cognitive impairment associated with multiple neurodegenerative diseases.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">Separately, we had reported that the diastereoselective [3 + 2] cycloaddition of diethyl isocyanomethylphosphonate with 10 diversely substituted maleimides in acetonitrile under AgOAc catalysis furnished a series of bicycles of general structure <b>Ia</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>a).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The presence within this series of compounds of an α-iminophosphonate unit, also featured in the above-mentioned (2-imidazolin-4-yl)phosphonates, prompted us to evaluate whether these bicyclo derivatives would also behave as I<sub>2</sub>-IR ligands. We indeed found that two of these 10 already reported compounds, <b>8a</b> and <b>8c</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>b), displayed an affinity for the I<sub>2</sub>-IRs similar to that of idazoxan, <b>4</b> (see below). These promising results encouraged us to resume our research with this family of bicyclic α-iminophosphonates with the twofold aim of further exploring the scope of the aforementioned [3 + 2] cycloaddition reaction and of establishing their structure–activity relationships (SARs) as I<sub>2</sub>-IR ligands.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. (a) General Structure of Bicyclic α-Iminophosphonates <b>Ia</b> (Previously Reported) and <b>Ib</b> (Reported Herein),<sup>a</sup> (b) Chemical Structures of <b>8a</b> and <b>8c</b>, and (c) Chemical Structure of MCR5 (<b>7</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: <i>N</i>-substituted maleimide derivative (1.5 mmol), PhosMic (1 mmol), AgOAc (0.06 mmol), acetonitrile, room temperature, overnight.</p></p></figure><div class="NLM_p last">Herein, we explore the synthetic scope of the [3 + 2] cycloaddition reaction of α-substituted PhosMic derivatives and diversely substituted maleimides. Particular attention was given to derivatives including a phenyl substituent in the α-position of the phosphonate leading to general structures <b>9</b> depicted as <b>Ib</b> in the <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>a, in order to resemble the structure of MCR5, <b>7</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>c). We also assessed the pharmacological profile and selectivity of a wide range of bicyclic α-iminophosphonates through competition binding studies against the selective I<sub>2</sub>-IR radioligand [<sup>3</sup>H]2-[(2-benzofuranyl)-2-imidazoline] ([<sup>3</sup>H]2-BFI).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Selectivity versus two related targets, the I<sub>1</sub>-IR and the α<sub>2</sub>-adrenergic receptor (α<sub>2</sub>-AR), was evaluated through competition studies using the selective radioligands [<sup>3</sup>H]clonidine and [<sup>3</sup>H]RX821002 (2-methoxyidazoxan), respectively. Complementarily, we performed 3D-QSAR studies. Compound <b>9d</b> (named also B06), endowed with outstanding I<sub>2</sub>-IR affinity and excellent selectivity index regarding I<sub>1</sub>-IR and α<sub>2</sub>-AR, was selected for further studies. We first compared the affinity for the human I<sub>2</sub>-IR of <b>9d</b> with those of the standards shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. Additionally, the affinity for I<sub>2</sub>-IR from different species was considered for idazoxan (<b>4</b>) and <b>9d</b>. Next, we performed preliminary drug metabolism and pharmacokinetics (DMPK) studies for <b>9d</b>, including chemical stability, parallel artificial membrane permeability assay (PAMPA)–blood–brain barrier (BBB) permeability assay, solubility, cytotoxicity, microsomal stability, cytochromes inhibition, and safety. Finally, we characterized its <i>in vivo</i> neuroprotective effects in the 5xFAD murine model of AD.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46835" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46835" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6"> Synthesis and Structural Characterization</h4><div class="NLM_p">Considering the previously described compounds <b>8a</b> and <b>8c</b> as promising starting points for designing potent I<sub>2</sub>-IR ligands, we resolved to prepare bicyclic compounds functionally close to MCR5 (<b>7</b>) by including an α-phenyliminophosphonate moiety in their structure. To this end, we decided to increase the scope of the original [3 + 2] cycloaddition by using diversely α-substituted PhosMic derivatives (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. α-Substituted PhosMic derivatives used in this work.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The preparation of the α-substituted PhosMic derivatives was performed adapting previously described procedures (for references and experimental procedures, see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Supporting Information</a>). Briefly, the four phenylisocyanomethylphosphonates <b>10a</b>, <b>10b</b>, <b>10c</b>, and <b>11</b> were prepared by conversion of the required (α-aminophenyl)phosphonate derivative to the corresponding formamide followed by dehydration with phosphorus oxychloride. While diethyl (α-aminophenyl)phosphonate is a commercially available compound, the other three precursors were synthesized according to published procedures. A different approach was followed for the α-benzylisocyano derivatives <b>10d</b> and <b>10e</b>. Alkylation of commercially available PhosMic with either benzylbromide or 4-fluorobenzylbromide, using potassium <i>tert</i>-butoxide furnished diethyl benzylisocyanomethylphosphonate <b>10d</b> and diethyl 4-fluorobenzylisocyanomethylphosphonate <b>10e</b>, respectively.</div><div class="NLM_p">The maleimides used in the cycloaddition reaction were commercially available or were prepared following previously described procedures.</div><div class="NLM_p">Gratifyingly, although the targeted compounds feature increased steric hindrance in the α-phosphonate position, our previously optimized set of conditions for the [3 + 2] cycloaddition reaction of maleimides with PhosMic also worked for the current set of α-substituted PhosMic derivatives.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In this way, 36 new bicycloderivatives (<a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>) having a quaternary stereocenter, were synthesized in medium to high yields (<a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). The products were purified by column chromatography, and when they were solids, analytical samples were obtained by recrystallization. For the sake of clarity in the <a class="ref internalNav" href="#sec2_2" aria-label="section">section</a> I<sub>2</sub>-IR Binding Activity and Structure–Activity Relationships, the new α-substituted bicycles, depicted in <a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>, were ordered and numbered attending to the SAR discussion.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Procedure for the Synthesis of Bicyclic α-Iminophosphonates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Compounds prepared in previous work (R = H)<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and compounds prepared in this work (R = Ph, 4FPh, 4-MeOPh, PhCH<sub>2</sub>, 4FPhCH<sub>2</sub>). Reagents and conditions: (a) <i>N</i>-substituted maleimide derivative (1.5 mmol), α-substituted PhosMic (<b>10a</b>, <b>10b</b>, <b>10c</b>, <b>10d</b>, <b>10e</b>, 1 mmol), AgOAc (0.06 mmol), acetonitrile, room temperature, overnight.</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0013.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Second Round of Compounds Synthesized, Featuring Modified <i>N</i>-Maleimide Substituents Inspired by Compounds <b>9a</b> and <b>9b</b>, R′ = Alkyl, and <b>9c</b> and <b>9d</b>, R′ = Aryl<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>-alkyl- or <i>N</i>-aryl-substituted maleimide derivative (1.5 mmol), α-PhenylPhosMic (<b>10a</b>, 1 mmol), AgOAc (0.06 mmol), acetonitrile, room temperature, overnight.</p></p></figure><div class="NLM_p">Analogously to our previous work,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> all the [3 + 2] cycloaddition reactions occurred in a diastereoselective manner, and only one of the two possible diastereoisomers was formed. The relative configuration of the three stereocenters in the new compounds was unambiguously confirmed by X-ray crystallographic analysis for five examples, and the stereochemistry of the other compounds was assigned by comparison of their <sup>1</sup>H and <sup>13</sup>C NMR spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Tables S12 and S13</a>).</div><div class="NLM_p">As previously noted, the [3 + 2] cycloaddition reaction between α-substituted PhosMic derivatives and diversely substituted maleimides was completely diastereoselective, only one of the two possible diastereoisomers was observed. Iminophosphonates <b>9b</b>, <b>9c</b>, <b>9d</b>, <b>9v</b>, and <b>9ab</b> were recrystallized as monocrystals from ethyl acetate. Their relative configuration was unambiguously confirmed by X-ray crystallographic analysis, indicating a <i>trans</i> relationship between the hydrogen atoms on the bridged positions and the substituent at the α phosphonate carbon atom (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structures of <b>9b</b>, <b>9c</b>, <b>9d</b>, <b>9v</b>, and <b>9ab</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Finally, the origin of the diastereoselective [3 + 2] cycloaddition was investigated by quantum mechanical (QM) calculations that were performed for the addition of <i>N</i>-methylmaleimide to α-phenylPhosMic (in this latter case, the ethyl groups were replaced by methyl in order to reduce the cost of QM computations). In addition, a silver cation bound to acetonitrile was introduced to account for the catalytic effect on the chemical reaction. Reactants, transition states, and products for the <i>cis</i> and <i>trans</i> [3 + 2] cycloadditions were determined from geometry optimizations at the B3LYP/6-31+G(d) (LANL2DZ for silver) level, and the nature of the stationary points was verified from the analysis of the vibrational frequencies. The geometries of the transition states point out that the cycloaddition occurs via an asynchronous concerted process as the length of the bond that is formed by carbon atom 3a is shorter than the bond formed by carbon atom 6a by 0.51 and 0.23 Å in the <i>cis</i> and <i>trans</i> addition, respectively (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Moreover, a significant deviation from linearity is observed in the isocyano group, as the C–N–C angle is close to 144° in the two transition states. The results also point out that the transition state leading to the <i>trans</i> addition was more stable by 2.3 kcal mol<sup>–1</sup> relative to the <i>cis</i> cycloaddition (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Table S1</a>), presumably due to the destabilizing electrostatic interactions between the oxygen atoms of the phosphonate and maleimide moieties. The preferred stability of the <i>trans</i> transition state was further checked by geometry optimizations performed for the <i>cis</i> and <i>trans</i> cycloadditions with the MN15L density functional, leading to a free energy difference of 1.2 kcal mol<sup>–1</sup> favoring the <i>trans</i> cycloaddition. The contribution due to the solvation effects in acetonitrile was determined by means of continuum solvation calculations (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). The results (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Table S1</a>) reveal that solvation leads to a slight destabilization of the transition state relative to the reactants. Nevertheless, this effect cancels out for the <i>cis</i> and <i>trans</i> addition, which can be understood from the similar structural features of the two transition states. Overall, these results justify the preferential formation of the diastereoselective compound originating from the <i>trans</i> cycloaddition (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representation of the transition states for the <i>cis</i> and <i>trans</i> [3 + 2] cycloaddition between <i>N</i>-methylmaleimide and α-phenylPhosMic (ethyl groups substituted by methyl) located from B3LYP calculations (C···C distances in Å; C–N–C angle in deg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> I<sub>2</sub>-IR Binding Activity and Structure–Activity Relationships</h3><div class="NLM_p">The pharmacological activity of the compounds depicted in <a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a> was evaluated through competition binding studies against the selective I<sub>2</sub>-IR radioligand [<sup>3</sup>H]2-BFI and the selective α<sub>2</sub>-AR radioligand [<sup>3</sup>H]RX821002. The studies were performed in membranes from post-mortem human frontal cortex, a brain area that shows an important density of I<sub>2</sub>-IR and α<sub>2</sub>-AR.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Idazoxan (<b>4</b>), a compound with well-established affinity for I<sub>2</sub>-IR (p<i>K</i><sub>i</sub> = 7.27 ± 0.07) and α<sub>2</sub>-AR (p<i>K</i><sub>i</sub> = 7.51 ± 0.07), was used as reference. The inhibition constant (<i>K</i><sub>i</sub>) for each compound was obtained and is expressed as the corresponding p<i>K</i><sub>i</sub> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The selectivity for these two receptors was expressed by the I<sub>2</sub>-IR/α<sub>2</sub>-AR index, calculated as the antilogarithm of the ratio between p<i>K</i><sub>i</sub> value for I<sub>2</sub>-IR and p<i>K</i><sub>i</sub> value for α<sub>2</sub>-AR (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Competition experiments against [<sup>3</sup>H]2-BFI were monophasic for most of the compounds (for a few exceptions, see below).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. I<sub>2</sub>-IR and α<sub>2</sub>-AR Binding Affinities (p<i>K</i><sub>i</sub>) of Five Previously Reported Compounds <b>8</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and New Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0014.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Selectivity I<sub>2</sub>-IR/α<sub>2</sub>-AR expressed as the antilog (p<i>K</i><sub>i</sub> I<sub>2</sub>-IR – p<i>K</i><sub>i</sub> α<sub>2</sub>-AR).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">The best fit of the data for <b>9d</b>, <b>9f</b>, <b>9m</b>, and <b>9r</b> was to a two-site binding model of binding with high p<i>K</i><sub>i</sub> (p<i>K</i><sub>iH</sub>) and low p<i>K</i><sub>i</sub> (p<i>K</i><sub>iL</sub>) affinities for both binding sites, respectively.</p></div></div><div></div></div><div class="NLM_p">Among the set of 10 bicycles of general structure <b>Ia</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>a) already reported,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> five representative compounds, <b>8a</b>, <b>8b</b>, <b>8c</b>, <b>8d</b>, and <b>8e</b>, were selected for evaluation as potential I<sub>2</sub>-IR ligands considering the substitution in the <i>N</i>-maleimide by an alkyl (<b>8a</b>), cycloalkyl (<b>8b</b>), unsubstituted phenyl (<b>8c</b>), electron withdrawing-disubstituted phenyl (<b>8d</b>), and electron donating-substituted phenyl (<b>8e</b>) groups.</div><div class="NLM_p">Pleasantly, <b>8a</b> and <b>8c</b> displayed p<i>K</i><sub>i</sub> I<sub>2</sub> affinity of 6.79 and 7.73, respectively, in the range of that of idazoxan (<b>4</b>) (7.41). However, no promising results were found for <b>8b</b>, <b>8d</b>, and <b>8e</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). As a first structural approximation, we turned our attention to compounds bearing a quaternary center in the α-position by including a phenyl group. In this manner, the new compounds would resemble the α-phenyliminophosphonate moiety of MCR5, <b>7</b> (in pink color in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>a,c). In order to maintain the homology with the first series of evaluated compounds (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, R = H), analogous maleimide derivatives were considered to give access to compounds <b>9a</b>, <b>9b</b>, <b>9c</b>, <b>9d</b>, and <b>9e</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, R = phenyl). Indeed, this change was highly positive for the whole series, increasing the p<i>K</i><sub>i</sub> I<sub>2</sub> affinity for all the phenyl-substituted derivatives compared to their unsubstituted congeners, with the added benefit, in three cases (<b>9a</b>, <b>9d</b>, and <b>9e</b>), of an enhanced I<sub>2</sub>-IR/α<sub>2</sub>-AR selectivity ratio up to 195. A remarkable benefit in the I<sub>2</sub>-IR affinity, p<i>K</i><sub>i</sub> I<sub>2</sub> 9.74 (<i>K</i><sub>i</sub> = 0.18 nM), was observed in <i>N</i>-cyclohexyl derived <b>9b</b>, 4-fold improvement compared with analogous <b>8b</b>, with an I<sub>2</sub>-IR/α<sub>2</sub>-AR selectivity of 5. The rise in the affinity was also conserved in compounds bearing an <i>N</i>-arylimide substitution. In particular, the presence of an <i>N</i>-phenyl group <b>9c</b> led to an outstanding activity binding p<i>K</i><sub>i</sub> I<sub>2</sub> 10.28 (<i>K</i><sub>i</sub> = 52.48 pM) but not I<sub>2</sub>-IR/α<sub>2</sub>-AR selectivity. Gratifyingly, introduction of halogen atoms (3-chloro-4-fluoro) in the <i>N</i>-phenyl ring of <b>9c</b> giving congener <b>9d</b> kept a nice affinity, with a p<i>K</i><sub>i</sub> I<sub>2</sub> 8.56. Of note, <b>9d</b> fitted significantly better to a two-site binding model, with a high p<i>K</i><sub>i</sub> I<sub>2</sub> 8.61 (<i>K</i><sub>i</sub><sub>H</sub> = 2.45 nM) and a low p<i>K</i><sub>i</sub> I<sub>2</sub> 4.29 (<i>K</i><sub>i</sub><sub>L</sub> = 51.2 μM), with the high-affinity site representing a calculated 37% of the specific binding of [<sup>3</sup>H]2-BFI at 2 nM concentration.</div><div class="NLM_p">The enhancement, in terms of both affinity and selectivity, observed when moving from the α-unsubstituted to the α-substituted phosphonates prompted us to briefly consider additional variations. The introduction in the α-phosphonate position of <i>p</i>-fluorophenyl (<b>12c</b>) or <i>p</i>-methoxyphenyl (<b>13c</b>), benzyl (<b>14c</b>), and <i>p</i>-fluorobenzyl (<b>15c</b>) groups was highly deleterious for the affinity (p<i>K</i><sub>i</sub> I<sub>2</sub> = 6.59 for <b>14c</b> and p<i>K</i><sub>i</sub> I<sub>2</sub> < 3 up to 5.35 for <b>12c</b>, <b>13c</b>, and <b>15c</b>, respectively). However, for the <i>p</i>-substituted phenyl derivatives, the further introduction of halogen atoms (3-chloro-4-fluoro) in the <i>N</i>-phenyl ring (compounds <b>12d</b> and <b>13d</b>) nicely restored the affinity (p<i>K</i><sub>i</sub> I<sub>2</sub> 7.55 for <b>12d</b> and p<i>K</i><sub>i</sub> I<sub>2</sub> 7.87 for <b>13d</b>). Additionally, due to the lack of binding of <b>12d</b> and <b>13d</b> to α<sub>2</sub>-AR, their I<sub>2</sub>-IR/α<sub>2</sub>-AR selectivity was outstanding, 14791 and 74131, respectively.</div><div class="NLM_p">Taking into account the aforementioned results for a second round of compounds, the general structure depicted in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> was conserved, featuring the unsubstituted phenyl group in the α-position of the phosphonate and modifying the substituents in the maleimide. New compounds were classified in two groups taking into consideration whether an alkyl or an aryl substituent was introduced in the <i>N</i>-maleimide.</div><div class="NLM_p">Inspired by <b>9a</b> and <b>9b</b>, compounds bearing alkyl substituents with different lengths, <b>9f</b> and <b>9g</b>, ramified alkyl, <b>9h</b>, and polycycloalkane, <b>9i</b>, were prepared. From <b>9a</b>, the elongation of the <i>N</i>-alkyl chain, from methyl to ethyl, led to <b>9f</b>, with an increase in the affinity to p<i>K</i><sub>i</sub> I<sub>2</sub> = 8.37 (<i>K</i><sub>i</sub> = 4.3 nM) and in the I<sub>2</sub>-IR/α<sub>2</sub>-AR selectivity to 331, while the <i>n</i>-propyl derivative, <b>9g</b>, demonstrated much lower affinity, p<i>K</i><sub>i</sub> I<sub>2</sub> = 4.02. For <b>9f</b>, the best fit was a two-site model of binding with a high p<i>K</i><sub>i</sub> I<sub>2</sub> = 8.95 and a low p<i>K</i><sub>i</sub> I<sub>2</sub> = 5.86; high affinity site occupancy is 62%. Further increase of the size of the <i>N</i>-alkyl substituent to a <i>tert</i>-butyl, <b>9h</b>, or an adamantylmethyl, <b>9i</b>, did not improve the affinity. Taking together the affinity values for <b>9a</b>, <b>9b</b>, <b>9f</b>, <b>9g</b>, <b>9h</b> and <b>9i</b>, it seems that small and large substituents are compatible with good affinity values but that conformational freedom, as in <b>9g</b>, is deleterious.</div><div class="NLM_p">Compounds <b>9j</b>, <b>9k</b>, <b>9l</b>, and <b>9m</b>, with <i>N</i>-benzyl, <i>N</i>-phenethyl, <i>N</i>-4-fluorophenethyl, and <i>N</i>-phenylpropyl substituents, respectively, were accessed to increase the examples in the SAR study. However, their affinities revealed a remarkable decrease in the biological properties, leading to p<i>K</i><sub>i</sub> I<sub>2</sub> = 5.26, 6.35, <3, and 3.84 values, respectively.</div><div class="NLM_p last">Taking into account that <b>9c</b> displayed an outstanding affinity for I<sub>2</sub>-IR but lacked selectivity over α<sub>2</sub>-AR, further R′ = aryl derivatives were explored. As we knew that <b>9d</b> (p<i>K</i><sub>i</sub> I<sub>2</sub> = 8.56, I<sub>2</sub>-IR/α<sub>2</sub>-AR = 195) was endowed with excellent affinity and remarkable selectivity, we mainly focused on electron withdrawing groups (<b>9n</b>, <b>9o</b>, <b>9p</b>, <b>9q</b>, <b>9r</b>, <b>9s</b>, <b>9t</b>, <b>9u</b>, <b>9v</b>, <b>9w</b>, <b>9x</b>, and <b>9y</b>), although a few electron donating substituents were briefly examined (<b>9z</b>, <b>9aa</b>, and <b>9ab</b>). Overall, neither these new phenyl derivatives nor the <i>N</i>-naphthyl derivative <b>9ac</b> outperformed the excellent affinity of <b>9c</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), although <b>9z</b> (p<i>K</i><sub>i</sub> I<sub>2</sub> = 7.90) had an improved I<sub>2</sub>-IR/α<sub>2</sub>-AR ratio of 602. Finally, <b>9ad</b> with an <i>N</i>-(2-chloro-3-pyridyl) substituent gave a p<i>K</i><sub>i</sub> I<sub>2</sub> = 7.96, in the range of standard idazoxan (<b>4</b>), but it offered as an outstanding advantage a null affinity for α<sub>2</sub>-AR, leading to an I<sub>2</sub>-IR/α<sub>2</sub>-AR selectivity of 91201.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Selectivity for I<sub>2</sub>-IR versus I<sub>1</sub>-IR</h3><div class="NLM_p">After evaluating the affinity of the indicated compounds for α<sub>2</sub>-AR, we assessed the affinity of some representative compounds for I<sub>1</sub>-IR. To this end, I<sub>1</sub>-IR binding site assays were conducted in membranes obtained from the rat kidney using moxonidine, a known I<sub>1</sub>-IR selective compound, as reference. The results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, and only <b>8e</b> deserves a mention with a p<i>K</i><sub>i</sub> I<sub>1</sub> 8.09. Gratifyingly, the values for the rest of the assessed compounds led to the conclusion that there was not a significant interaction with I<sub>1</sub>-IR, highlighting the I<sub>2</sub>-IR selective behavior of this family of ligands.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. I<sub>1</sub>-IR Potencies (pIC<sub>50</sub>) of Representative Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">pIC<sub>50</sub>, [<sup>3</sup>H]-clonidine</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">moxonidine</td><td class="colsep0 rowsep0" align="char" char=".">8.45 ± 0.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.13 ± 0.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="char" char=".">5.14 ± 0.54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="char" char=".">5.47 ± 0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8d</b></td><td class="colsep0 rowsep0" align="char" char="."><3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8e</b></td><td class="colsep0 rowsep0" align="char" char=".">8.09 ± 0.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="char" char=".">6.19 ± 0.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="char" char=".">7.54 ± 0.79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9c</b></td><td class="colsep0 rowsep0" align="char" char=".">6.74 ± 0.74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9d</b></td><td class="colsep0 rowsep0" align="char" char=".">3.04 ± 0.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9e</b></td><td class="colsep0 rowsep0" align="char" char=".">3.22 ± 0.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14c</b></td><td class="colsep0 rowsep0" align="char" char=".">5.12 ± 0.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9j</b></td><td class="colsep0 rowsep0" align="char" char=".">5.87 ± 0.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9k</b></td><td class="colsep0 rowsep0" align="char" char=".">7.98 ± 0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9x</b></td><td class="colsep0 rowsep0" align="char" char=".">5.26 ± 0.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9z</b></td><td class="colsep0 rowsep0" align="char" char=".">7.19 ± 0.33</td></tr></tbody></table></div></div><div class="NLM_p last">Overall, considering its excellent I<sub>2</sub>-IR affinity (<i>K</i><sub>i</sub> = 2.8 nM) and the remarkable selectivity versus α<sub>2</sub>-AR (<i>K</i><sub>i</sub> = 53 μM) and I<sub>1</sub>-IR (<i>K</i><sub>i</sub> = 912 μM), we identified <b>9d</b> as the most promising compound for performing further studies.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Comparison of I<sub>2</sub>-IR Human Receptor Binding Affinities (p<i>K</i><sub>i</sub>) of <b>9d</b> and Other Ligands and across Species</h3><div class="NLM_p">A problem typically encountered when working with I<sub>2</sub>-IR ligands is that the binding experiments reported in the bibliography have been performed in a variety of non-human species and using tissues from different anatomical parts (e.g., kidney, whole brain, cortex). Another factor of potential discrepancies is that different radioligands have been used. Overall, this makes difficult the comparison among studies. For this reason and in order to better place <b>9d</b> as a new I<sub>2</sub>-IR ligand, unprecedented experiments of displacement of [<sup>3</sup>H]2-BFI<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> in samples from post-mortem human brains were performed with clinical candidates [<sup>13</sup>C]BU99008 (<b>2</b>)<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and CR4056 (<b>1</b>)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and the widely used I<sub>2</sub>-IR ligands tracizoline (<b>5</b>), LSL60101 (<b>3</b>), and 2-BFI (<b>6</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. I<sub>2</sub>-IR and α<sub>2</sub>-AR Binding Affinities (p<i>K</i><sub>i</sub>) of BU99008 <b>2</b>, CR4056 <b>1</b>, Tracizoline <b>5</b>, LSL60101 <b>3</b>, and <b>9d</b> in Post-mortem Human Brain Cortical Membranes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">[<sup>3</sup>H]-2-BFI I<sub>2</sub> p<i>K</i><sub>i</sub>, two sites</th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">high-affinity</th><th class="colsep0 rowsep0" align="center" char=".">low-affinity</th><th class="colsep0 rowsep0" align="center" char="±">high-affinity site (%)</th><th class="colsep0 rowsep0" align="center" char=".">[<sup>3</sup>H]-RX821002 α<sub>2</sub> p<i>K</i><sub>i</sub></th><th class="colsep0 rowsep0" align="center" char=".">selectivity I<sub>2</sub>-IR/α<sub>2</sub>-AR for [<sup>3</sup>H]-2-BFI (high-affinity site)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BU99008, <b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">6.89 ± 0.21</td><td class="colsep0 rowsep0" align="char" char=".">3.82 ± 0.30</td><td class="colsep0 rowsep0" align="char" char="±">51 ± 6</td><td class="colsep0 rowsep0" align="char" char=".">4.37 ± 0.17</td><td class="colsep0 rowsep0" align="char" char=".">331</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CR4056, <b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">7.72 ± 0.31</td><td class="colsep0 rowsep0" align="char" char=".">5.45 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">29 ± 6</td><td class="colsep0 rowsep0" align="char" char=".">2.65 ± 1.24</td><td class="colsep0 rowsep0" align="char" char=".">117490</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tracizoline, <b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">8.48 ± 0.51</td><td class="colsep0 rowsep0" align="char" char=".">6.48 ± 0.32</td><td class="colsep0 rowsep0" align="char" char="±">38 ± 13</td><td class="colsep0 rowsep0" align="char" char=".">4.33 ± 0.22</td><td class="colsep0 rowsep0" align="char" char=".">14125</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2-BFI, <b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">9.87 ± 0.33</td><td class="colsep0 rowsep0" align="char" char=".">7.94 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 5</td><td class="colsep0 rowsep0" align="char" char=".">6.64 ± 0.38</td><td class="colsep0 rowsep0" align="char" char=".">1698</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LSL60101, <b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">9.03 ± 0.21</td><td class="colsep0 rowsep0" align="char" char=".">5.25 ± 0.24</td><td class="colsep0 rowsep0" align="char" char="±">49 ± 4</td><td class="colsep0 rowsep0" align="char" char=".">5.17 ± 1.32</td><td class="colsep0 rowsep0" align="char" char=".">7244</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9d</b></td><td class="colsep0 rowsep0" align="char" char=".">8.61 ± 0.28</td><td class="colsep0 rowsep0" align="char" char=".">4.29 ± 0.20</td><td class="colsep0 rowsep0" align="char" char="±">37 ± 4</td><td class="colsep0 rowsep0" align="char" char=".">6.27 ± 0.56</td><td class="colsep0 rowsep0" align="char" char=".">219</td></tr></tbody></table></div></div><div class="NLM_p">As previously observed with <b>9d</b>, the affinity data found for BU99008 (<b>2</b>) and CR4056 (<b>1</b>) fit best to a two-site model of binding. In particular, BU99008 (<b>2</b>) showed a p<i>K</i><sub>iH</sub> I<sub>2</sub> = 6.89 (<i>K</i><sub>iH</sub> = 128 nM) and p<i>K</i><sub>i</sub><sub>L</sub> I<sub>2</sub> = 3.82 (<i>K</i><sub>i</sub><sub>L</sub> = 151 μM), and a good I<sub>2</sub>-IR/α<sub>2</sub>-AR selectivity ratio of 331. CR4056 (<b>1</b>) showed a p<i>K</i><sub>i</sub><sub>H</sub> I<sub>2</sub> = 7.72 (<i>K</i><sub>i</sub><sub>H</sub> = 19.0 nM) and p<i>K</i><sub>i</sub><sub>L</sub> I<sub>2</sub> = 5.45 (<i>K</i><sub>i</sub><sub>L</sub> = 3.5 μM) with an excellent I<sub>2</sub>-IR/α<sub>2</sub>-AR selectivity of 117490. The percentage of occupancy for the high affinity site was different for BU99008 (<b>2</b>) (51%) compared with CR4056 (<b>1</b>) (29%). Other well-established I<sub>2</sub>-IR ligands, tracizoline (<b>5</b>), LSL60101 (<b>3</b>), and 2-BFI (<b>6</b>) also resulted in clearly biphasic curves. Tracizoline (<b>5</b>) displayed a p<i>K</i><sub>i</sub><sub>H</sub> I<sub>2</sub> = 8.48 (<i>K</i><sub>i</sub><sub>H</sub> = 3.3 nM) and p<i>K</i><sub>i</sub><sub>L</sub> I<sub>2</sub> = 6.48 with an excellent I<sub>2</sub>-IR/α<sub>2</sub>-AR selectivity of 14125. 2-BFI (<b>6</b>) had a p<i>K</i><sub>i</sub><sub>H</sub> I<sub>2</sub> = 9.87 (<i>K</i><sub>i</sub><sub>H</sub> = 0.13 nM) and p<i>K</i><sub>i</sub><sub>L</sub> I<sub>2</sub> = 7.94, with a good I<sub>2</sub>-IR/α<sub>2</sub>-AR selectivity of 1698, and LSL60101 (<b>3</b>) a p<i>K</i><sub>i</sub><sub>H</sub> I<sub>2</sub> = 9.03 (<i>K</i><sub>i</sub><sub>H</sub> = 0.9 nM) and p<i>K</i><sub>i</sub><sub>L</sub> I<sub>2</sub> = 5.25 (<i>K</i><sub>i</sub><sub>L</sub> = 5.6 μM), with a good I<sub>2</sub>-IR/α<sub>2</sub>-AR selectivity of 7244. The high-affinity site represented 38%, 21%, and 49% occupancy for tracizoline (<b>5</b>), 2-BFI (<b>6</b>), and LSL60101 (<b>3</b>), respectively (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Previous studies have reported [<sup>3</sup>H]2-BFI identifying two binding sites in rabbit,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> rat,<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> and human brain.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> It remains unclear whether these two sites observed represent distinct receptors or interconvertible conformational states of the I<sub>2</sub>-IR. For tracizoline (<b>5</b>), a single binding site of p<i>K</i><sub>i</sub> I<sub>2</sub> = 8.72, similar to the affinity described for human tissues, was described in the rabbit kidney membranes.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In the rat cerebral cortex, LSL60101 (<b>3</b>) shows lower affinity than in human tissues, with a <i>K</i><sub>i</sub><sub>H</sub> = 350 nM and <i>K</i><sub>i</sub><sub>L</sub> = 116 μM.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">Therefore, compounds BU99008 (<b>2</b>), tracizoline (<b>5</b>), and 2-BFI (<b>6</b>), which have a nonsubstituted 2-(imidazolin-2-yl) group, CR4056 (<b>1</b>) and LSL60101 (<b>3</b>), which feature an imidazole ring, and the structurally dissimilar <b>9d</b> have similar affinity profiles to I<sub>2</sub>-IR in human brain.</div><div class="NLM_p">Of note, the ability of BU99008 (<b>2</b>) to displace [<sup>3</sup>H]2-BFI from I<sub>2</sub>-IR in rat brain was fit to a two-site model of binding, with a <i>K</i><sub>i</sub><sub>H</sub> = 1.4 ± 0.6 nM and <i>K</i><sub>i</sub><sub>L</sub> = 238.6 ± 63.3 nM and with a percentage fraction of high occupancy of 58% ± 7%. That is, an enhanced affinity by 100 times in rat brain compared with human brain, the % of occupancy being similar in the high site. Regarding selectivity, a good I<sub>2</sub>-IR/α<sub>2</sub>-AR ratio of 909 was reported in rat, 4.5 times higher than that found in human. Of note, the opposite trend was found for CR4056 (<b>1</b>): the inhibition recorded in rat whole-brain for [<sup>3</sup>H]2-BFI binding was IC<sub>50</sub> of 596 ± 76 nM, with an improved affinity of 19 nM shown in human brain.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Therefore, significant differences between species occur within the two I<sub>2</sub>-IR ligands in clinical trials, BU99008 (<b>2</b>) and CR4056 (<b>1</b>).</div><div class="NLM_p">In an attempt to incorporate additional data regarding the differences in I<sub>2</sub>-IR binding affinities between species, idazoxan (<b>4</b>) and <b>9d</b> were investigated (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In our hands, idazoxan (<b>4</b>) gave similar results in human frontal cortex, p<i>K</i><sub>i</sub> 7.74, as compared to rat brain cortex, p<i>K</i><sub>i</sub> 7.17, and had considerably less affinity in mouse brain cortical membranes, p<i>K</i><sub>i</sub> 5.68. Importantly, differences for <b>9d</b> were found not only among species but also in its binding characteristics. As previously mentioned, the binding to I<sub>2</sub>-IR in human frontal cortex displayed a biphasic curve, whereas a monophasic one was observed in rat and mouse brain cortex with affinity values of p<i>K</i><sub>i</sub> 6.92 and 6.41, respectively.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. I<sub>2</sub>-IR Binding Affinities (p<i>K</i><sub>i</sub>) of Idazoxan <b>4</b> and <b>9d</b> in the Brain Cortex of Different Species</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center" char=".">mice</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">idazoxan, <b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">7.74 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">7.17 ± 0.11</td><td class="colsep0 rowsep0" align="char" char=".">5.68 ± 0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9d</b></td><td class="colsep0 rowsep0" align="char" char=".">8.61 ± 0.28</td><td class="colsep0 rowsep0" align="char" char=".">4.29 ± 0.20</td><td class="colsep0 rowsep0" align="char" char=".">6.92 ± 0.35</td><td class="colsep0 rowsep0" align="char" char=".">6.41 ± 0.39</td></tr></tbody></table></div></div><div class="NLM_p last">Finally, in order to verify if the high affinity site observed for <b>9d</b> in competition experiments against [<sup>3</sup>H]2-BFI corresponded to the I<sub>2</sub>-IR, we performed additional experiments in the presence of MCR5 (<b>7</b>), a high-affinity I<sub>2</sub>-IR selective compound previously reported by our group.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Interestingly, in the presence of MCR5 (<b>7</b>) (10<sup>–5</sup> M), the <b>9d</b> competition curve against [<sup>3</sup>H]2-BFI became monophasic (p<i>K</i><sub>i</sub> = 6.96 ± 0.46), and the high-affinity site recognized by <b>9d</b> was completely blocked. These results confirm that the high affinity site bound by <b>9d</b> is the I<sub>2</sub>-IR.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 3D-QSAR Study</h3><div class="NLM_p">3D-QSAR studies were performed to rationalize the differences in activity and gain insights for improved bicyclic α-iminophosphonate-based I<sub>2</sub>-IR ligands. 3D-QSAR models were created using Pentacle program,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> which calculates GRIND descriptors (GRIND and GRIND2) from molecular interaction fields, and were evaluated by internal and external validation parameters (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Tables S2 and S3</a>). The data set included structurally diverse bicyclic α-iminophosphonates (<a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>) with a wide range of binding activity on I<sub>2</sub>-IR (p<i>K</i><sub>i</sub> I<sub>2</sub> = 3.11–10.28) and α<sub>2</sub>-AR (p<i>K</i><sub>i</sub> α<sub>2</sub> = 3.38–10.27) ensuring the good quality and applicability of the 3D-QSAR models. Additionally, we added four I<sub>2</sub>-IR standard ligands (tracizoline, <b>5</b>; idazoxan, <b>4</b>; BU99008, <b>2</b>; LSL60101, <b>3</b>) in both data sets to compare and validate our results. Created 3D-QSAR models were used to analyze statistically significant variables that describe distance between chemical groups in the examined compounds. These variables are presented as interactions between two same (e.g., DRY–DRY) or different (e.g., DRY–TIP) MIF probes in PLS coefficient plots (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Figures S1 and S2</a>).</div><div class="NLM_p">Describing the most significant GRIND variables with positive and negative influence on I<sub>2</sub>-IR and α<sub>2</sub>-AR binding activity gave us the deeper insight into crucial interactions for enhancing activity and selectivity on I<sub>2</sub>-IR against α<sub>2</sub>-AR. Based on comprehensive 3D-QSAR analysis presented in <a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Supporting Information</a>, we can conclude that the presence of two steric hot spots (var183, TIP–TIP), such as halogen atoms (3-chloro-4-fluoro) in the <i>N</i>-phenyl ring at the distance range 6.00–6.40 Å, may be crucial for enhancing I<sub>2</sub>-IR binding activity and selectivity. The highest values are calculated for compounds <b>13d</b> and <b>12d</b>, which possess high selectivity toward I<sub>2</sub>-IR (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Likewise, var19 (DRY–DRY, 7.60–8.00 Å) implies that introduction of hydrophobic regions such as phenyl ring in the <i>N</i>-maleimide group may be crucial for establishing favorable van der Waals interactions with aromatic amino acids of the active pocket of I<sub>2</sub>-IR (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B). Comparing to compounds that possess <i>N</i>-alkyl substituents instead of <i>N</i>-phenyl, such as <b>8a</b> or <b>9a</b>, we can conclude that introduction of this aromatic ring positively correlates with I<sub>2</sub>-IR binding activity. Contrarily, the α<sub>2</sub>-AR model pointed out a negative DRY–DRY variable (var25, 10.00–10.40 Å), which suggests that introduction of a phenyl substituent in the α-phosphonate position negatively correlates with α<sub>2</sub>-AR activity. This is in agreement with experimental findings, which show that α-substituted ligands possess higher affinity and selectivity toward I<sub>2</sub>-IR (<b>8a</b>, <b>8c</b>, <b>8d</b>, and <b>8e</b>). Additionally, analysis of negative variables var200 (TIP–TIP, 12.80–13.20 Å), var314 (DRY–N1, 13.60–14.00 Å), and var377 (DRY–TIP, 16.40–16.80 Å) emphasizes that introduction of bulkier substituents in the <i>N</i>-maleimide group unfavorably affects the fit in the binding site of I<sub>2</sub>-IR and may decrease the potency of I<sub>2</sub> ligands (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B). The highest values of these variables are pronounced in compounds <b>9z</b>, <b>9m</b>, <b>9k</b>, <b>9j</b>, <b>9ab</b>, and <b>9ac</b>.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representation of positive (in red) interactions of <b>9c</b> (A) and <b>13d</b> (B) in I<sub>2</sub>-IR 3D-QSAR model. The steric hot spots (TIP) are presented in green and hydrophobic regions (DRY) in yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representation of negative (in blue) interactions of <b>9m</b> (A) and <b>9ac</b> (B) in I<sub>2</sub>-IR 3D-QSAR model. The steric hot spots (TIP) are presented in green, hydrophobic regions (DRY) in yellow, and H-bond acceptor regions (N1) in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> <i>In Silico</i> Analysis of Physicochemical and Pharmacokinetic Parameters</h3><div class="NLM_p"><i>In silico</i> analysis of key parameters is one of the most important steps in drug discovery processes.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Thus, ADMET Predictor software 9.5,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and SwissADME web tool<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> were used to foresee ADMET and physicochemical properties on the most potent bicyclic α-iminophosphonate I<sub>2</sub>-IR ligands (p<i>K</i><sub>i</sub> > 7) and four standards. The obtained results are presented in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Supporting Information</a> (Tables S4 and S5) including solubility and lipophilicity, BBB-penetration, elimination rate, and interactions with targets. Note that introduction of aromatic rings increases log <i>P</i> values and affinity for albumin, while it decreases the water solubility (<b>9d</b>, <b>9z</b>, <b>12d</b>, and <b>13d</b>). Based on results obtained from different computational methods, we can conclude that all examined compounds possess good water solubility and lipophilicity. Furthermore, calculated values of topological polar surface area (TPSA) descriptor revealed acceptable polarity of all molecules. The Lipinski’s Rule of 5 was used to describe drug-likeness properties of compounds based on physicochemical analysis (<i>M</i> log <i>P</i> ≤ 4.15; MW ≤ 500; N or O ≤ 10; OH or NH ≤ 5). Because of the slightly higher molecular weight, <b>9z</b> and <b>13d</b> violated only one rule. Analysis of pharmacokinetic parameters shows that all compounds possess high BBB permeation. Compared to standards, bicyclic α-iminophosphonates have lower percentage of unbound drug in plasma. Also, they are estimated to have lower metabolic CYP risk compared to idazoxan. Only three compounds, <b>9z</b>, <b>12d</b>, and <b>13d</b> were identified as P-gp inhibitors. Performed calculations also show that bicyclic α-iminophosphonates possess lower toxicity risk, while compound <b>13d</b> had no predicted toxicity.<named-content content-type="anchor" rid="fig5" type="simple"></named-content><named-content content-type="anchor" rid="fig6" type="simple"></named-content></div><div class="NLM_p last">The theoretical effort paved the way to continue with crucial <i>in vitro</i> experiments (drug-like) due to the lack of warnings that had stopped the progress of this family of α-iminophosphonates as I<sub>2</sub>-IR ligands.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> BBB Permeation Assay</h3><div class="NLM_p last">Considering the localization of I<sub>2</sub>-IR in the CNS, a good ability to cross the BBB is an essential requirement for developing effective I<sub>2</sub>-IR ligands with potential therapeutic applications in the neuroprotective field. For this reason, the <i>in vitro</i> permeability (<i>P</i><sub>e</sub>) of all the novel compounds was determined by using the PAMPA–BBB permeability assay (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Table S6</a>). In particular, our representative compound <b>9d</b> had a <i>P</i><sub>e</sub> value of (9.7 ± 0.7) × 10<sup>–6</sup> cm s<sup>–1</sup>, well above the threshold established for high BBB permeation (<i>P</i><sub>e</sub> > 5.198 × 10<sup>–6</sup> cm s<sup>–1</sup>). Thus, compounds were considered suitable to envisage further <i>in vitro</i> and <i>in vivo</i> studies oriented to in-depth pharmacological profiling of the new family of I<sub>2</sub>-IR ligands.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Cytotoxicity</h3><div class="NLM_p last">All the synthesized compounds were devoid of cytotoxicity in human embryonic lung fibroblast cell cultures (highest concentration tested, 100 μM). Further evaluation of eight selected compounds, including the outstanding I<sub>2</sub>-IR ligands <b>9d</b>, <b>9b</b>, and <b>9c</b> and representative compounds <b>8d</b>, <b>9e</b>, <b>8b</b>, <b>9x</b>, and <b>9j</b> was performed in different mammalian cell lines, such as HeLa (human cervix carcinoma), Vero (African green monkey kidney), MDCK (Mandin-Darby canine kidney), and MT4 (human T-lymphocyte). Serial compound dilutions were added to semiconfluent cell cultures, and after 3–5 days incubation at 37 °C, cytotoxicity was estimated by microscopic inspection of cell morphology and by colorimetric cell viability assays. None of the compounds produced any cytotoxicity at 100 μM, the highest concentration tested. Additionally, the cytotoxicity of <b>9d</b> was tested in MRC-5 (human embryonic lung fibroblast) cells (CC<sub>50</sub> > 100 μM).</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> ADME–DMPK Profiling of <b>9d</b></h3><div class="NLM_p">In order to further progress <b>9d</b> to <i>in vivo</i> assays with the confidence that the <i>in silico</i> studies offered (see above), we evaluated its physicochemical properties, such as solubility and chemical stability, microsomal stability, cytochromes inhibition, hERG inhibition, and plasma protein binding.</div><div class="NLM_p">The solubility of <b>9d</b> was determined in several media. An excellent solubility of 92 μM was found in 1% DMSO and 99% PBS buffer. Additional solvents, methanol, acetonitrile, and water, were also evaluated with good solubility.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> To evaluate the stability of <b>9d</b>, forced degradation studies were performed under various stress conditions for a period of 9 weeks, with HPLC and <sup>1</sup>H NMR monitoring every week.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Particularly, <b>9d</b> was subjected to the effect of daylight with temperatures between 0 and 23 °C and a relative humidity of 25–85%, to the effect of high temperature (thermal stability at 75 °C), and to the continuous light of a 100 W (230 V) bulb. Analysis by HPLC showed that the compound was completely stable under all the aforementioned conditions. Overall, these studies confirmed that <b>9d</b> is sufficiently stable to undertake further experiments.</div><div class="NLM_p last">Selected compound <b>9d</b> was further studied <i>in vitro</i> for ascertaining their microsomal stability, CYP inhibition, and protein plasma binding. The microsomal stability was assessed in three species (human, mouse, and rat), considering that the affinity and selectivity studies were performed in human samples, the cognition studies were envisaged in mice, and the hypothermia evaluation was planned in mice and rats (see below). Compound <b>9d</b> showed good microsomal stability (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Table S7</a>) and inhibited neither cytochromes [CYP1A2, CYP2C9, CYP2C19, CYP3A4 (BFC and DBF), and CYP2D6] nor hERG. Plasma protein binding was measured in mice and human species (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Table S8</a>) with a slight difference that should be taken into consideration if <b>9d</b> progress through additional preclinical studies.</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Receptor Characterization Panel</h3><div class="NLM_p last">In a Lead Profiling Screen (Eurofins)<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> of 44 potential off targets, <b>9d</b> showed a clean ancillary pharmacology (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Table S9</a>). Only one target, the cholecystokinin type A receptor (CCK<sub>A</sub>), was inhibited more than 50% at the tested concentration of 10 μM. CCK receptors belong to the G-protein-coupled receptor superfamily and are involved in a range of biological actions mediated by two distinct receptor types, CCK<sub>A</sub> (present in gastrointestinal tract and discrete regions of the brain) and CCK<sub>B</sub> (present in the CNS).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Compound <b>9d</b> exhibited an IC<sub>50</sub> of 5.94 μM upon CCK<sub>A</sub> and an IC<sub>50</sub> > 10 μM for CCK<sub>B</sub>. Taking into account the relative high IC<sub>50</sub> of <b>9d</b> for CCK<sub>A</sub> and the lack of significant interaction with the other off targets evaluated, we conclude that <b>9d</b> shows a very selective profile.</div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Hypothermic Effects of <b>9d</b></h3><div class="NLM_p">It is known that I<sub>2</sub>-IR ligands such as idazoxan (<b>4</b>) or 2-(4,5-dihydroimidazol-2-yl)quinoline (BU224) induce hypothermia in rats.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> We have also found hypothermic effects with compound MCR5 (<b>7</b>) in mice.<a onclick="showRef(event, 'ref25 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref27">(25,27)</a></div><div class="NLM_p">In the same line, acute <b>9d</b> (20 mg/kg) exposure induced hypothermia in adult CD1 mice as observed by reductions of core body temperature (ranging from −1.8 to −3.0 °C) measured 1 h postinjection (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A,C, day 1). To test for differences between species, a pilot study was performed in adult rats, which showed that acute <b>9d</b> (20 and 35 mg/kg) treatment induced moderate drops in temperature (−0.4 to −1.0 °C) as measured 1 and 2 h postinjection (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). Repeated administration of <b>9d</b> (20 mg/kg, 5 days) in mice revealed the induction of tolerance to the acute hypothermic effect of this drug from day 2 of treatment (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C), effects previously observed for other I<sub>2</sub>-IR compounds.<a onclick="showRef(event, 'ref25 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref27">(25,27)</a></div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Hypothermic effects of <b>9d</b> (B06) in rodents. (A) Acute effect of <b>9d</b> (20 mg/kg, ip) in mice. Columns are means ± SEM of the difference (Δ, 1 h minus basal value) in body temperature (°C) for each treatment group. ***<i>p</i> < 0.001 vs control group (Student’s <i>t</i>-test). (B) Acute effect of <b>9d</b> (20 or 35 mg/kg, ip) in rats. Columns are means ± SEM of the difference (Δ, 1, 2, or 3 h minus basal value) in body temperature (°C) for each treatment group. #<i>p</i> < 0.05 for dose of 20 mg/kg and **<i>p</i> < 0.01 and ***<i>p</i> < 0.001 for dose of 35 mg/kg vs control group (repeated measures ANOVA followed by Sidak’s comparison test). (C) Repeated (5 days) effect of <b>9d</b> (20 mg/kg, ip) in mice. Circles are means ± SEM of the daily difference (Δ, 1 h minus basal value) in body temperature (°C) for each treatment group. *<i>p</i> < 0.05 vs control group (repeated measures ANOVA followed by Sidak’s comparison test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Of note, hypothermia is well established as having a neuroprotective effect in cerebral ischemia and even mild temperature drops cause significant neuroprotection.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Also, hypothermia has been clinically used to improve the neurological outcome under various pathological conditions, including stroke and traumatic brain injury.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> Thus, the hypothermic effects showed by <b>9d</b> might be a relevant feature that could mediate neuroprotection.</div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Effects of Acute and Repeated Treatments with <b>9d</b> on Hippocampal FADD Protein Content in Mice</h3><div class="NLM_p">FADD multifunctional protein is an adaptor of cell death receptors that can also mediate antiapoptotic or neuroprotective actions in rodents.<a onclick="showRef(event, 'ref25 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref25 ref53 ref54">(25,53,54)</a> Acute treatment with <b>9d</b> significantly decreased (−30%) the content of FADD protein in the hippocampus when compared to vehicle-treated mice (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, left panel). Following repeated (5 days) administration, no effects were observed on FADD modulation (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, right panel). The significant decrease in hippocampal pro-apopototic FADD following acute <b>9d</b> treatment suggests that this compound might be mediating some of its neuroplastic or neuroprotective actions through the regulation of this key brain marker, similarly with other I<sub>2</sub>-IR compounds.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of acute (20 mg/kg, ip) and repeated (20 mg/kg, ip, 5 days) treatments with <b>9d</b> (B06) on the contents of FADD protein in the hippocampus of mice. Columns are means ± SEM of FADD in <b>9d</b>- and vehicle-treated groups. *<i>p</i> < 0.05 vs control group (Student’s <i>t</i>-test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 5xFAD <i>in Vivo</i> Behavioral Studies on Selected Compound <b>9d</b></h3><div class="NLM_p">Recently, we reported the first <i>in vivo</i> study that validates I<sub>2</sub>-IR as a target for cognitive impairment using a mouse model of age-related cognitive decline and late-onset AD, the SAMP8, a murine model that displays a phenotype of accelerated aging.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> To further support the effect of I<sub>2</sub>-IR ligands as a putative treatment for neurodegenerative diseases, herein we evaluate <b>9d</b> in the 5xFAD, a well-established murine model of early on-set AD.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><div class="NLM_p">Because one of the signs of AD is memory loss (cognitive decline), the effect of orally administered <b>9d</b> (5 (mg/kg)/day for 28 days) on cognitive performance was evaluated in the novel object recognition test (NORT). The NORT is a widely used behavioral task to assess visual recognition memory.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> This brain activity relies on the hippocampus and involves the cortex to remember and recognize new and old objects. The NORT is based on an animal’s innate preference for novelty. The task consists of three parts: a habituation phase; a training phase, where mice are presented with two identical objects; and a trial phase, in which following an interval time (2 or 24 h) memory was assessed by presenting the mice with a trained object and a novel one. Mice with cognitive ability preserved preferentially explore the novel object in the different time exposition studied. After a 2 h acquisition trial, one of the familiar objects was replaced with a novel object, and the time spent investigating each of the objects was recorded, and the discrimination index (DI) was calculated as the percentage of novel object interaction time relative to total interaction time during the retention trial. As expected, untreated 5xFAD did not exhibit differences between exploration times for the familiar and novel objects (DI close to 0), indicating deterioration or loss of memory for the familiar object. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A, the oral administration of <b>9d</b> to 5xFAD enhanced recognition memory at short-term, reaching DI values of WT mice (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A). Of note, 24 h after the retention trial, <b>9d</b> treated 5xFAD mice, explored the novel object for a longer time, obtaining a higher DI, indicative of preserved memory for the familiar object presented during the acquisition trial (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). These results suggest that compound <b>9d</b> enhanced recognition memory during the NORT in 5xFAD mice.</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. DI of NORT in 6-month-old (WT C, <i>n</i> = 12), 5xFAD (C, <i>n</i> = 14) control mice and 5xFAD mice after treatment with <b>9d</b> (B06) at 5 mg/kg for 4 weeks (<i>n</i> = 25). Summary from (A) Short-Term Memory and (B) Long-Term Memory. Values represented are mean ± standard error of the mean (SEM). One-way ANOVA followed by (Tukey post hoc test); <i>P</i>-value: *<i>p</i> < 0.05 vs WT-Control, <sup>$</sup><i>p</i> < 0.05; <sup>$$</sup><i>p</i> < 0.01 vs 5xFAD-Control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Effects of Selected Compound <b>9d</b> in 5xFAD Hippocampus: Neuroinflammation and Oxidative Stress Parameters</h3><div class="NLM_p">Inflammation is an omnipresent sign in neurodegeneration and can act as a propagation method for the deleterious effects for the characteristic event in AD.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Oxidative stress (OS) is another key risk factor that can promote ignition of degenerative processes.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The reduction in the memory impairment of the <b>9d</b> treated animals prompted us to determine indicators of brain neuroinflammation and OS by comparison of WT and 5xFAD mice (vehicle and <b>9d</b> treated). 5xFAD mice had higher gene expression of <i>Cxcl10</i> (C-X-C motif chemokine 10) and <i>Tnf-α</i> (tumor necrosis factor α) compared to WT mice (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A) that decreased after treatment of 5xFAD mice with <b>9d</b> (5 (mg/kg)/day). Of note, it has been reported that TNF-α contributes to amyloidogenesis via β-secretase regulation, apart from being involved in AD-related brain neuroinflammation.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In fact, when amyloid precursor protein (APP) processing was studied in treated 5xFAD mice, an increase in sAPPα, correlating with a significant decrease in sAPPβ protein levels, was determined compared with untreated mice (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B).</div><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Gene expression of inflammatory markers, <i>Cxcl10</i> and <i>Tnf-α</i>, and OS markers, <i>iNOS</i> and <i>Hmox1</i> (<i>n</i> = 4 for each group). (B) H<sub>2</sub>O<sub>2</sub> concentration (<i>n</i> = 10 for each group) and (C) representative Western blot and bar chart sAPPα and sAPPβ (<i>n</i> = 4–6 for each group) in the hippocampus of 6-month-old female WT, 5xFAD Control mice, and 5xFAD mice after treatment with <b>9d</b> (B06) at 5 mg/kg for 4 weeks. Bars represent mean ± standard error of the mean (SEM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In reference to OS, 5xFAD mice showed no changes in gene expression for <i>iNOS</i> (inducible nitric oxide synthase, a pro-oxidant key driver)<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> and <i>Hmox1</i> (an enzyme implicated in antioxidant defense) (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Those results correlated with published results in 5xFAD mice, and in agreement, <b>9d</b> treatment did not modify either <i>iNOS</i> or <i>Hmox1</i> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). Nonetheless, total levels of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), although not significant, were higher in 5xFAD than in the WT and were reduced after <b>9d</b> treatment (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C). The increase of OS, without increases in <i>iNOS</i> expression, was also described in 5xFAD mice; concretely the increase in 4-HNE (4-hydroxy-2-nonenal), a protein derivative obtained when reactive species of oxygen, ROS (such as H<sub>2</sub>O<sub>2</sub>), increase, is significant in 6-month-old 5xFAD mice compared to WT mice.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> All the evaluated parameters are consistent with a mild reduction in the oxidative environment in treated 5xFAD mice.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55166" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55166" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">To sum up, we have explored the scope of diastereoselective [3 + 2] cycloaddition reaction of α-substituted-PhosMic derivatives with diversely substituted maleimides leading to a family of bicyclic α-iminophosphonates. A combination of X-ray crystallographic analyses and NMR studies allowed a full stereochemical characterization, and theoretical calculations provided a basis to justify the excellent diastereoselectivity observed. The pharmacological profiling of the new compounds led to the identification of high affinity and selective I<sub>2</sub>-IR ligands devoid of α<sub>2</sub>-AR and I<sub>1</sub>-IR affinities. 3D-QSAR study revealed key structural parameters for the design of future promising structures, and theoretical DMPK and physicochemical parameters were calculated in order to rule out warnings to continue the medicinal chemistry program. DMPK and cytotoxicity assays and a safety panel were carried out for the selected compound <b>9d</b>. Taking in account the improvement in the cognitive impairment in a 5xFAD model treated with <b>9d</b>, modulation of I<sub>2</sub>-IR can be proposed as a new therapeutic strategy for AD treatment.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76735" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76735" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> General Information</h4><div class="NLM_p last">Reagents, solvents, and starting products were acquired from commercial sources. The term “concentration” refers to vacuum evaporation using a Büchi rotavapor. When indicated, the reaction products were purified by flash chromatography on silica gel (35–70 μm) with the indicated solvent system. The melting points were measured in a MFB 59510M Gallenkamp instruments. IR spectra were performed in a spectrophotometer, Nicolet Avantar 320 FTR-IR or Spectrum Two FT-IR, and only noteworthy IR absorptions (cm<sup>–1</sup>) are listed. NMR spectra were recorded in CDCl<sub>3</sub> at 400 MHz (<sup>1</sup>H) and 100.6 MHz (<sup>13</sup>C), and 162 MHz (<sup>31</sup>P). Chemical shifts are reported in δ values downfield from TMS or relative to residual chloroform (7.26 ppm, 77.0 ppm) as an internal standard. Data are reported in the following manner: chemical shift, multiplicity, coupling constant (<i>J</i>) in hertz (Hz), integrated intensity, and assignment (when possible). Multiplicities are reported using the following abbreviations: s, singlet; d, doublet; dd, doublet of doublets; ddd, double doublet of doublets; dq, double quadrupet; t, triplet; qu, quintet; m, multiplet; br s, broad signal; app, apparent. Assignments and stereochemical determinations are given only when they are derived from definitive two-dimensional NMR experiments (g-HSQC–COSY). The accurate mass analyses were carried out using a LC/MSD-TOF spectrophotometer. The elemental analyses were carried out in a Flash 1112 series Thermofinnigan elemental microanalyzer (A5) to determine C, H, and N. HPLC-MS (Agilent 1260 Infinity II) analysis was conducted on a Poroshell 120 EC-C15 (4.6 mm × 50 mm, 2.7 μm) at 40 °C with mobile phase A (H<sub>2</sub>O + 0.05% formic acid) and B (ACN + 0.05% formic acid) using a gradient elution and flow rate 0.6 mL/min. The DAD detector was set at 254 nm, the injection volume was 5 μL, and oven temperature was 40 °C. All tested compounds possess a purity of at least 95%.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> General Procedure for the [3 + 2] Cycloaddition Reaction</h4><div class="NLM_p">To a solution of silver acetate (0.06–0.1 mmol) and maleimide (1.0–1.5 mmol) in acetonitrile was added diethyl α-methylisocyanomethylphosphonate, diethyl α-phenylisocyanomethylphosphonate, diphenyl α-phenylisocyanomethylphosphonate, diethyl α-(4-fluorophenyl)isocyanomethylphosphonate, diethyl α-(4-methoxyphenyl)isocyanomethylphosphonate, or diethyl α-benzylisocyanomethylphosphonate (1.0 mmol). The reaction mixture was stirred at room temperature overnight and concentrated, and the resulting residue was purified by column chromatography to afford pure products.</div><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-Methyl-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9a</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (13 mg, 0.08 mmol), <i>N</i>-methylmaleimide (133 mg, 1.2 mmol), acetonitrile (6 mL), and diethyl α-phenylisocyanomethylphosphonate (202 mg, 0.8 mmol) gave <b>9a</b> (184 mg, 64%) as a yellowish oil, after column chromatography (EtOAc/hexane 95:5). IR (NaCl) 3472, 2981, 1709, 1432, 1281, 1248, 1051, 967 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.15 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.27 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 2.70 (s, 3H, NCH<sub>3</sub>), 3.83 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.01–4.18 (m, 4H, H-6a and C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.34 (ddd, <i>J</i> = 8.5, 4.0, 1.0 Hz, 1H, H-3a), 7.29–7.37 (m, 3H, ArH), 7.68–7.70 (m, 2H, ArH), 7.95 (dd, <i>J</i> = 5.5, 1.0 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.1 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.2 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 25.0 (NCH<sub>3</sub>), 47.7 (d, <i>J</i> = 2.0 Hz, C-6a), 60.5 (C-3a), 63.4 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.6 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 85.6 (d, <i>J</i> = 154.0 Hz, C-1), 127.6 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.4 (d, <i>J</i> = 2.5 Hz, CHAr), 128.5 (d, <i>J</i> = 6.0 Hz, 2CHAr), 133.2 (d, <i>J</i> = 4.5 Hz, C-<i>ipso</i>), 162.5 (d, <i>J</i> = 11.5 Hz, C-3), 172.1 (d, <i>J</i> = 5.5 Hz, CO), 172.5 (d, <i>J</i> = 14.0 Hz, CO). MS-EI <i>m</i>/<i>z</i> 364 M<sup>+</sup> (36), 255 (31), 227 (73), 199 (23), 170 (41), 143 (21), 142 (100), 115 (58). HRMS C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 365.1262; found, 365.1261. Purity 97.0% (<i>t</i><sub>R</sub> = 3.89 min).</div></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-Cyclohexyl-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9b</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (15 mg, 0.09 mmol), <i>N</i>-cyclohexylmaleimide (403 mg, 2.3 mmol), acetonitrile (12 mL), and diethyl α-phenylisocyanomethylphosphonate (380 mg, 1.5 mmol) gave <b>9b</b> (494 mg, 76%) as a white solid, after column chromatography (EtOAc). Mp 128–132 °C (EtOAc). IR (NaCl) 3467, 2934, 2858, 1705, 1370, 1249, 1191, 1025, 971, 755 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.06–1.13 (m, 3H, CH<sub>2</sub>cycl), 1.16 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.21 (m, 1H, CH<sub>2</sub>cycl), 1.25 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.51–1.54 (m, 2H, CH<sub>2</sub>cycl), 1.57–1.69 (m, 3H, CH<sub>2</sub>cycl), 1.85 (m, 1H, CH<sub>2</sub>cycl), 3.60 (m, 1H, CHcycl), 3.90 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.03 (dd, <i>J</i> = 18.5, 8.5 Hz, 1H, H-6a), 4.06–4.18 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.25 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a), 7.29–7.35 (m, 3H, ArH), 7.61–7.63 (m, 2H, ArH), 8.00 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.1 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.2 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 24.7 (CH<sub>2</sub>cycl), 25.6 (2CH<sub>2</sub>cycl), 27.8 (CH<sub>2</sub>cycl), 28.6 (CH<sub>2</sub>cycl), 47.5 (d, <i>J</i> = 2.5 Hz, C-6a), 51.9 (CHcycl), 59.9 (C-3a), 63.3 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.6 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 85.7 (d, <i>J</i> = 156.0 Hz, C-1), 127.7 (d, <i>J</i> = 1.6 Hz, 2CHAr), 128.2 (CHAr), 128.3 (CHAr), 128.4 (CHAr), 133.6 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i>), 162.8 (d, <i>J</i> = 12.0 Hz, C-3), 172.1 (d, <i>J</i> = 5.5 Hz, CO), 172.5 (d, <i>J</i> = 12.0 Hz, CO). MS-EI <i>m</i>/<i>z</i> 432 M<sup>+</sup> (60), 323 (30), 295 (95), 223 (12), 170 (78), 142 (100), 115 (35), 81 (15). HRMS C<sub>22</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 433.1892; found, 433.1887. Anal. Calcd for C<sub>22</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>P: C, 61.10%; H, 6.76%; N, 6.48%. Found: C, 61.42%; H, 6.81%; N, 6.47%.</div></div><div id="sec4_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-4,6-Dioxo-1,5-diphenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9c</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (4 mg, 0.02 mmol), <i>N</i>-phenylmaleimide (104 mg, 0.6 mmol), acetonitrile (3 mL), and diethyl α-phenylisocyanomethylphosphonate (101 mg, 0.4 mmol) gave <b>9c</b> (108 mg, 64%) as a white solid, after column chromatography (EtOAc). Mp 158–160 °C (EtOAc). IR (NaCl) 3479, 2969, 1713, 1496, 1390, 1239, 1021, 969 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.10 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.19 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.85 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 3.99–4.14 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.17 (dd, <i>J</i> = 18.5, 9.0 Hz, 1H, H-6a), 4.40 (ddd, <i>J</i> = 8.5, 3.0, 1.6 Hz, 1H, H-3a), 6.62–6.65 (m, 2H, ArH), 7.15–7.30 (m, 6H, ArH), 7.61–7.63 (m, 2H, ArH), 7.97 (dd, <i>J</i> = 4.5, 1.6 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.2 (d, <i>J</i> = 4.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.3 (d, <i>J</i> = 4.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.2 (d, <i>J</i> = 2.0 Hz, C-6a), 60.2 (C-3a), 63.4 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.6 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.2 (d, <i>J</i> = 157.0 Hz, C-1), 126.0 (2CHAr), 127.9 (CHAr), 128.0 (CHAr), 128.4 (d, <i>J</i> = 6.0 Hz, CHAr), 128.5 (CHAr), 128.6 (CHAr), 128.7 (CHAr), 129.0 (2CHAr), 131.1 (C-<i>ipso</i>), 133.5 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i>), 162.5 (d, <i>J</i> = 12.0 Hz, C-3), 170.9 (d, <i>J</i> = 5.5 Hz, CO), 171.6 (d, <i>J</i> = 11.5 Hz, CO). MS-EI <i>m</i>/<i>z</i> 426 M<sup>+</sup> (43), 317 (20), 289 (47), 244 (11), 170 (43), 142 (100), 115 (43), 81 (11). HRMS C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 427.1418; found, 427.1417. Anal. Calcd for C<sub>22</sub>H<sub>23</sub>N<sub>2</sub>O<sub>5</sub>P: C, 61.97%; H, 5.44%; N, 6.57%. Found: C, 62.18%; H, 5.36%; N, 6.43%.</div></div><div id="sec4_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(3-Chloro-4-fluorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9d</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (8 mg, 0.05 mmol), <i>N</i>-(3-chloro-4-fluorophenyl)maleimide (250 mg, 1.1 mmol), acetonitrile (6 mL), and diethyl α-phenylisocyanomethylphosphonate (187 mg, 0.7 mmol) gave <b>9d</b> (189 mg, 54%) as a white needles, after column chromatography (EtOAc). Mp 185–186 °C (EtOAc). IR (NaCl) 3437, 2956, 1718, 1499, 1256, 1050, 980 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.20 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.95 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.09–4.20 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.25 (dd, <i>J</i> = 18.0, 8.0 Hz, 1H, H-6a), 4.47 (m, 1H, H-3a), 6.63 (ddd, <i>J</i> = 9.0, 4.0, 3.0 Hz, 1H, ArH), 6.72 (dd, <i>J</i> = 6.5, 2.5 Hz, 1H, ArH), 7.05 (t, <i>J</i> = 8.5 Hz, 1H, ArH), 7.35–7.39 (m, 3H, ArH), 7.67 (m, <i>J</i> = 5.0 Hz, 2H, ArH), 8.05 (d, <i>J</i> = 4.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.3 (t, <i>J</i> = 5.5 Hz, 2CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.5 (C-6a), 60.1 (C-3a), 63.7 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.8 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.2 (d, <i>J</i> = 156.0 Hz, C-1), 116.8 (d, <i>J</i> = 22.5 Hz, CHAr), 121.5 (d, <i>J</i> = 19.5 Hz, C-<i>ipso</i>), 126.1 (d, <i>J</i> = 8.0 Hz, CHAr), 127.4 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i>), 128.1 (2CHAr), 128.3 (d, <i>J</i> = 5.5 Hz, 2CHAr), 128.6 (CHAr), 128.8 (CHAr), 133.5 (d, <i>J</i> = 3.0 Hz, C-<i>ipso</i>), 157.7 (d, <i>J</i> = 251.0 Hz, C-<i>ipso</i>), 162.0 (d, <i>J</i> = 12.5 Hz, C-3), 170.6 (d, <i>J</i> = 5.5 Hz, CO), 171.3 (d, <i>J</i> = 11.0 Hz, CO). <sup>31</sup>P NMR (162 MHz) δ 19.71. MS-EI <i>m</i>/<i>z</i> 478 M<sup>+</sup> (2), 341 (12), 281 (41), 207 (100), 191 (11), 147 (14), 73 (31). HRMS C<sub>22</sub>H<sub>22</sub>ClFN<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 479.0935; found, 479.0933. Anal. Calcd for C<sub>22</sub>H<sub>21</sub>ClFN<sub>2</sub>O<sub>5</sub>P: C, 55.18%; H, 4.42%; N, 5.85%. Found: C, 55.28%; H, 4.49%; N, 5.56%.</div></div><div id="sec4_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5<i>-</i>(4<i>-</i>Methoxyphenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9e</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (4 mg, 0.02 mmol), <i>N</i>-(4-methoxyphenyl)maleimide (122 mg, 0.6 mmol), acetonitrile (3 mL), and diethyl α-phenylisocyanomethylphosphonate (102 mg, 0.4 mmol) gave <b>9e</b> (119 mg, 65%) as a white solid, after column chromatography (EtOAc). Mp 167 °C (EtOAc). IR (NaCl) 3477, 2981, 2930, 1715, 1513, 1384, 1251, 1024, 970, 755 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.18 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.73 (s, 3H, OCH<sub>3</sub>), 3.92 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.09–4.19 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.25 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a), 4.45 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a), 6.60–6.64 (m, 2H, ArH), 6.77–6.81 (m, 2H, ArH), 7.30–7.39 (m, 3H, ArH), 7.68–7.70 (m, 2H, ArH), 8.04 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.2 (d, <i>J</i> = 3.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.3 (d, <i>J</i> = 3.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.1 (d, <i>J</i> = 2.0 Hz, C-6a), 55.4 (OCH<sub>3</sub>), 60.1 (C-3a), 63.5 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.6 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.2 (d, <i>J</i> = 157.5 Hz, C-1), 114.3 (2CHAr), 123.6 (C-<i>ipso</i>), 127.2 (2CHAr), 127.9 (2CHAr), 128.3 (CHAr), 128.4 (CHAr), 128.5 (CHAr), 133.5 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i>), 159.5 (C-<i>ipso</i>), 162.4 (d, <i>J</i> = 12.0 Hz, C-3), 171.1 (d, <i>J</i> = 5.0 Hz, CO), 171.8 (d, <i>J</i> = 11.5 Hz, CO). HRMS C<sub>23</sub>H<sub>26</sub>N<sub>2</sub>O<sub>6</sub>P [M + H]<sup>+</sup> 457.1519; found, 457.1523. Anal. Calcd for C<sub>23</sub>H<sub>25</sub>N<sub>2</sub>O<sub>6</sub>P: C, 60.52%; H, 5.52%; N, 6.14%. Found: C, 60.71%; H, 5.75%; N, 5.98%.</div></div><div id="sec4_1_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-1-(4-Fluorophenyl)-4,6-dioxo-5-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>12c</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (10 mg, 0.06 mmol), <i>N</i>-phenylmaleimide (156 mg, 0.9 mmol), acetonitrile (4 mL), and diethyl α-(4-fluorophenyl)isocyanomethylphosphonate (164 mg, 0.6 mmol) gave <b>12c</b> (159 mg, 60%) as a white solid, after column chromatography (EtOAc/hexane 4:1). Mp 191–193 °C (EtOAc). IR (ATR) 3491, 2991, 2909, 1775, 1718, 1598, 1506, 1377, 1242, 1189, 1016, 982, 742, 598 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.20 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.29 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.93 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.08–4.19 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.25 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a), 4.49 (dq, <i>J</i> = 8.5, 1.5 Hz, 1H, H-3a), 6.79–6.81 (m, 2H, ArH), 7.03–7.08 (m, 2H, ArH), 7.29–7.35 (m, 3H, ArH), 7.70–7.73 (m, 2H, ArH), 8.04 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.5 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.1 (d, <i>J</i> = 3.0 Hz, C-6a), 60.5 (C-3a), 63.8 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.9 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 85.9 (d, <i>J</i> = 156.0 Hz, C-1), 114.9 (d, <i>J</i> = 2.0 Hz, CHAr), 115.1 (d, <i>J</i> = 2.0 Hz, CHAr), 126.2 (2CHAr), 129.0 (CHAr), 129.3 (2CHAr), 129.4 (dd, <i>J</i> = 4.0, 3.5 Hz, C-ipso), 130.6 (d, <i>J</i> = 6.0 Hz, CHAr), 130.7 (d, <i>J</i> = 6.0 Hz, CHAr), 131.1 (C<i>-ipso</i>), 162.8 (d, <i>J</i> = 12.0 H, C-3), 162.9 (dd, <i>J</i> = 246.0, 2.5 Hz, C<i>-ipso</i>), 171.0 (d, <i>J</i> = 6.0 Hz, CO), 171.8 (d, <i>J</i> = 12.0 Hz, CO). HRMS C<sub>22</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 445.1323; found, 445.1324. Anal. Calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>5</sub>P: C, 59.46%; H, 4.99%; N, 6.30%. Found: C, 59.90%; H, 5.13%; N, 6.20%.</div></div><div id="sec4_1_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(3-Chloro-4-fluorophenyl)-1-(4-fluorophenyl)-4,6-dioxo-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>12d</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (7 mg, 0.04 mmol), <i>N</i>-(3-chloro-4-fluorophenyl)maleimide (135 mg, 0.6 mmol), acetonitrile (3 mL), and diethyl α-(4-fluorophenyl)isocyanomethylphosphonate (108 mg, 0.4 mmol) gave <b>12d</b> (124 mg, 62%) as a white solid, after column chromatography (EtOAc). Mp 179–181 °C (EtOAc). IR (ATR) 3483, 2962, 2903, 1719, 1504, 1236, 1051, 1012, 978, 739, 593 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.20 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.94 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.08–4.19 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.25 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a), 4.49 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a), 6.71 (m, 1H, ArH), 6.87 (dd, <i>J</i> = 6.5, 2.5 Hz, 1H, ArH), 7.04–7.09 (m, 3H, ArH), 7.68–7.71 (m, 2H, ArH), 8.02 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.5 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.2 (d, <i>J</i> = 3.0 Hz, C-6a), 60.3 (C-3a), 63.9 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.9 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.0 (d, <i>J</i> = 156.0 Hz, C-1), 115.1 (dd, <i>J</i> = 21.0, 2.0 Hz, 2CHAr), 117.1 (d, <i>J</i> = 22.0 Hz, CHAr), 121.8 (d, <i>J</i> = 19.0 Hz, C<i>-ipso</i>), 126.1 (CHAr), 127.4 (d, <i>J</i> = 3.0 Hz, C<i>-ipso</i>), 128.7 (CHAr), 129.2 (dd, <i>J</i> = 4.0, 3.0 Hz, C<i>-ipso</i>), 130.6 (dd, <i>J</i> = 7.0, 2.0 Hz, 2CHAr), 157.9 (d, <i>J</i> = 251.0 Hz, C<i>-ipso)</i>, 162.4 (d, <i>J</i> = 12.0 Hz, C-3), 163.0 (d, <i>J</i> = 249.5, 3.0 Hz, C-<i>ipso</i>), 170.5 (d, <i>J</i> = 5.0 Hz, CO), 171.5 (d, <i>J</i> = 13.0 Hz, CO). HRMS C<sub>22</sub>H<sub>21</sub>ClF<sub>2</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 497.0839; found, 497.0840. Anal. Calcd for C<sub>22</sub>H<sub>20</sub>ClF<sub>2</sub>N<sub>2</sub>O<sub>5</sub>P: C, 53.19%; H, 4.06%; N, 5.64%. Found: C, 53.45%; H, 4.24%; N, 5.46%.</div></div><div id="sec4_1_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-1-(4-Methoxyphenyl)-4,6-dioxo-5-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>13c</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (8 mg, 0.05 mmol), <i>N</i>-phenylmaleimide (138 mg, 0.8 mmol), acetonitrile (4 mL), and diethyl α-(4-methoxyphenyl)isocyanomethylphosphonate (142 mg, 0.5 mmol) gave <b>13c</b> (155 mg, 69%) as a white solid, after column chromatography (EtOAc/hexane 4:1). Mp 184–186 °C (EtOAc). IR (ATR) 3481, 2986, 2914, 1785, 1713, 1607, 1511, 1386, 1247, 1189, 1021, 737, 694, 598 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.20 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.79 (s, 3H, OCH<sub>3</sub>), 3.92 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.08–4.18 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.23 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a), 4.46 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a), 6.76–6.78 (m, 2H, ArH), 6.88 (d, <i>J</i> = 9.0 Hz, 2H, ArH), 7.27–7.32 (m, 3H, ArH), 7.60–7.63 (m, 2H, ArH), 8.02 (dd, <i>J</i> = 5.5, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.4 (d, <i>J</i> = 5.0 Hz, 2CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.3 (d, <i>J</i> = 3.0 Hz, C-6a), 55.3 (OCH<sub>3</sub>), 60.3 (C-3a), 63.5 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.8 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.0 (d, <i>J</i> = 157.0 Hz, C-1), 113.4 (d, <i>J</i> = 2.0 Hz, 2CHAr), 125.5 (d, <i>J</i> = 4.0 Hz, C<i>-ipso</i>), 126.3 (2CHAr), 128.8 (CHAr), 129.2 (2CHAr), 129.9 (d, <i>J</i> = 6.0 Hz, 2CHAr), 131.2 (C<i>-ipso</i>), 159.7 (d, <i>J</i> = 2.0 Hz, C<i>-ipso)</i>, 162.3 (d, <i>J</i> = 12.0 Hz, C-3), 171.2 (d, <i>J</i> = 6.0 Hz, CO), 171.9 (d, <i>J</i> = 12.0 Hz, CO). HRMS C<sub>23</sub>H<sub>26</sub>N<sub>2</sub>O<sub>6</sub>P [M + H]<sup>+</sup> 457.1523; found, 457.1520. Anal. Calcd For C<sub>23</sub>H<sub>25</sub>N<sub>2</sub>O<sub>6</sub>P: C, 60.52%; H, 5.52%; N, 6.14%. Found: C, 60.85%; H, 5.51%; N, 5.94%.</div></div><div id="sec4_1_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(3-Chloro-4-fluorophenyl)-1-(4-methoxyphenyl)-4,6-dioxo-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>13d</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (8 mg, 0.05 mmol), <i>N</i>-(3-chloro-4-fluorophenyl)maleimide (181 mg, 0.8 mmol), acetonitrile (4 mL) and diethyl α-(4-methoxyphenyl)isocyanomethylphosphonate (142 mg, 0.5 mmol) gave <b>13d</b> (170 mg, 67%) as a white solid, after column chromatography (EtOAc). Mp 227–228 °C (EtOAc). IR (ATR) 3481, 2986, 2905, 1771, 1718, 1612, 1497, 1386, 1237, 1184, 1026, 968, 752, 656 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.21 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.81 (s, 3H, OCH<sub>3</sub>), 3.94 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.09–4.18 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.22 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a), 4.46 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a), 6.69–6.73 (m, 2H, ArH), 6.89 (d, <i>J</i> = 9.0 Hz, 2H, ArH), 7.07 (m, 1H, ArH), 7.59 (d, <i>J</i> = 7.5 Hz, 2H, ArH), 8.02 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.4 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.5 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.6 (d, <i>J</i> = 3.0 Hz, C-6a), 55.3 (OCH<sub>3</sub>), 60.1 (C-3a), 63.7 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.8 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.0 (d, <i>J</i> = 158.0 Hz, C-1), 113.5 (d, <i>J</i> = 1.0 Hz, 2CHAr), 117.0 (d, <i>J</i> = 22.0 Hz, CHAr), 121.7 (d, <i>J</i> = 19.0 Hz, C<i>-ipso</i>), 125.3 (d, <i>J</i> = 4.0 Hz, C<i>-ipso</i>), 126.2 (d, <i>J</i> = 8.0 Hz, CHAr), 127.5 (d, <i>J</i> = 4.0 Hz, C<i>-ipso</i>), 128.7 (CHAr), 129.8 (d, <i>J</i> = 6.0 Hz, 2CHAr), 157.9 (d, <i>J</i> = 250.0 Hz, C<i>-ipso</i>), 159.9 (d, <i>J</i> = 2.0 Hz, C<i>-ipso)</i>, 161.8 (d, <i>J</i> = 13.0 Hz, C-3), 170.7 (d, <i>J</i> = 5.0 Hz, CO), 171.6 (d, <i>J</i> = 11.0 Hz, CO). HRMS C<sub>23</sub>H<sub>24</sub>ClFN<sub>2</sub>O<sub>6</sub>P [M + H]<sup>+</sup> 509.1039; found, 509.1037. Anal. Calcd for C<sub>23</sub>H<sub>23</sub>ClFN<sub>2</sub>O<sub>6</sub>P: C, 54.29%; H, 4.56%; N, 5.51%. Found: C, 54.66%; H, 4.63%; N, 5.36%.</div></div><div id="sec4_1_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-1-Benzyl-4,6-dioxo-5-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>14c</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (8 mg, 0.05 mmol), <i>N</i>-phenylmaleimide (139 mg, 0.8 mmol), acetonitrile (6 mL), and diethyl α-benzylisocyanomethylphosphonate (213 mg, 0.8 mmol) gave <b>14c</b> (32 mg, 9%) as a yellowish oil, after column chromatography (EtOAc/hexane 1:1). IR (ATR) 3738, 2926, 2843, 1730, 1492, 1385, 1220, 1181, 1059, 1020, 782, 700 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.29 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.40 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.29 (dd, <i>J</i> = 15.0, 12.5 Hz, 1H, C<i>H</i><sub>2</sub>-Ar), 3.86 (dd, <i>J</i> = 15.0, 9.5 Hz, 1H, C<i>H</i><sub>2</sub>-Ar), 3.97 (dd, <i>J</i> = 19.0, 9.0 Hz, 1H, H-6a), 4.11–4.26 (m, 4H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.39 (dq, <i>J</i> = 9.0, 1.5 Hz, 1H, H-3a), 6.73–6.75 (m, 2H, ArH), 7.10–7.12 (m, 3H, ArH), 7.21–7.23 (m, 2H, ArH), 7.33–7.36 (m, 3H, ArH), 7.82 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.3 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.5 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 36.8 (d, <i>J</i> = 2.0 Hz, CH<sub>2</sub>–Ar), 45.9 (d, <i>J</i> = 3.0 Hz, C-6a), 59.9 (C-3a), 63.4 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.0 (d, <i>J</i> = 6.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 83.7 (d, <i>J</i> = 158.0 Hz, C-1), 126.5 (2CHAr), 126.7 (CHAr), 127.8 (2CHAr), 128.7 (CHAr), 128.8 (2CHAr), 131.0 (C-<i>ipso</i>), 131.8 (2CHAr), 134.9 (d, <i>J</i> = 12.0 Hz, C-<i>ipso</i>), 161.3 (d, <i>J</i> = 13.0 Hz, C-3), 171.1 (d, <i>J</i> = 6.0 Hz, CO), 173.1 (d, <i>J</i> = 8.0 Hz, CO). HRMS C<sub>23</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 441.1574; found, 441.1580. Additional column chromatography led to sample for testing. Purity 95.7% (<i>t</i><sub>R</sub> = 4.50 min).</div></div><div id="sec4_1_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-1-(4-Fluorobenzyl)-4,6-dioxo-5-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>15c</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (12 mg, 0.07 mmol), <i>N</i>-phenylmaleimide (121 mg, 0.7 mmol), acetonitrile (5 mL) and diethyl α-(4-fluorobenzyl)isocyanomethylphosphonate (200 mg, 0.7 mmol) gave <b>15c</b> (67 mg, 21%) as an oil, after column chromatography (EtOAc). IR (ATR) 3471, 2924, 2853, 1780, 1711, 1509, 1378, 1221, 1049, 1017, 968, 691 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.30 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.40 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.25 (dd, <i>J</i> = 14.5, 12.5 Hz, 1H, C<i>H</i><sub>2</sub>-Ar), 3.81 (dd, <i>J</i> = 14.5, 9.0 Hz, 1H, C<i>H</i><sub>2</sub>-Ar), 3.96 (dd, <i>J</i> = 19.0, 9.5 Hz, 1H, H-6a), 4.11–4.27 (m, 4H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.39 (ddd, <i>J</i> = 9.5, 3.5, 1.5 Hz, 1H, H-3a), 6.76–6.82 (m, 3H, ArH), 7.14–7.19 (m, 2H, ArH), 7.33–7.47 (m, 4H, ArH), 7.82 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.3 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.5 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 36.0 (CH<sub>2</sub>Ar), 45.9 (d, <i>J</i> = 2.5 Hz, C-6a), 59.9 (C-3a), 63.4 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.4 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 83.7 (d, <i>J</i> = 159.5 Hz, C-1), 114.5 (d, <i>J</i> = 2.0 Hz, 2CHAr), 126.3 (2CHAr), 128.9 (CHAr), 129.0 (2CHAr), 130.5 (d, <i>J</i> = 12.5. Hz, C-<i>ipso</i>), 130.9 (C-<i>ipso</i>), 133.4 (d, <i>J</i> = 8.0 Hz, 2CHAr), 161.5 (d, <i>J</i> = 12.5 Hz, C-3), 161.8 (d, <i>J</i> = 245.5 Hz, C-<i>ipso</i>), 171.0 (d, <i>J</i> = 6.0 Hz, CO), 173.2 (d, <i>J</i> = 12.5 Hz, CO). HRMS C<sub>23</sub>H<sub>25</sub>FN<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 459.1480; found, 459.1483. Purity 96.4% (<i>t</i><sub>R</sub> = 4.56 min).</div></div><div id="sec4_1_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-Ethyl-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9f</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (11 mg, 0.07 mmol), <i>N</i>-ethylmaleimide (213 mg, 1.7 mmol), acetonitrile (8 mL), and diethyl α-phenylisocyanomethylphosphonate (279 mg, 1.1 mmol) gave <b>9f</b> (130 mg, 31%) as a yellowish oil, after column chromatography (EtOAc). IR (ATR) 3476, 2981, 2929, 1780, 1698, 1626, 1396, 1251, 1055, 1026, 968, 766 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 0.75 (t, <i>J</i> = 7.0 Hz, 3H, NCH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.15 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.25 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.21–3.27 (m, 2H, NC<i>H</i><sub>2</sub>CH<sub>3</sub>), 3.88 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.06–4.15 (m, 4H, C<i>H</i><sub>2</sub>CH<sub>3</sub> and H-6a), 4.29 (ddd, <i>J</i> = 8.5, 3.5, 1.5 Hz, 1H, H-3a), 7.31–7.34 (m, 3H, ArH), 7.65 (dbr, <i>J</i> = 11.6 Hz, 2H, ArH), 7.96 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 12.6 (NCH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 34.0 (N<i>C</i>H<sub>2</sub>CH<sub>3</sub>), 47.9 (d, <i>J</i> = 2.0 Hz, C-6a), 60.5 (C-3a), 63.6 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.8 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 85.8 (d, <i>J</i> = 155.0 Hz, C-1), 127.9 (d, <i>J</i> = 1.0 Hz, 2CHAr), 128.6 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.6 (CHAr), 133.6 (d, <i>J</i> = 4.0 Hz, C<i>-ipso</i>), 162.7 (d, <i>J</i> = 12.0 Hz, C-3), 171.0 (d, <i>J</i> = 6.0 Hz, CO), 172.5 (d, <i>J</i> = 12.0 Hz, CO). HRMS C<sub>18</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 379.1417; found, 379.1418. Additional column chromatography led to sample for testing. Purity 95.5% (<i>t</i><sub>R</sub> = 4.06 min).</div></div><div id="sec4_1_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-4,6-Dioxo-1-phenyl-5-propyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9g</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (8 mg, 0.05 mmol), <i>N</i>-propylmaleimide (200 mg, 1.4 mmol), acetonitrile (7 mL), and diethyl α-phenylisocyanomethylphosphonate (228 mg, 0.9 mmol) gave <b>9g</b> (314 mg, 89%) as a yellowish oil, after column chromatography (EtOAc/hexane 1:1 to 3:2). IR (ATR) 3464, 2976, 2928, 1719, 1631, 1451, 1402, 1202, 1056, 1027, 963, 705, 583 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 0.59 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.13–1.19 (m, 2H, CH<sub>2</sub>C<i>H</i><sub>2</sub>CH<sub>3</sub>), 1.14 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.25 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.16 (m, 2H, C<i>H</i><sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 3.85 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.02–4.14 (m, 4H, C<i>H</i><sub>2</sub>CH<sub>3</sub> and H-6a), 4.30 (ddd, <i>J</i> = 8.5, 3.5, 1.5 Hz, 1H, H-3a), 7.29–7.34 (m, 3H, ArH), 7.65 (br d, <i>J</i> = 8.0 Hz, 2H, ArH), 7.95 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 11.0 (CH<sub>2</sub>CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.3 (d, <i>J</i> = 4.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.4 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 20.7 (CH<sub>2</sub><i>C</i>H<sub>2</sub>CH<sub>3</sub>), 40.6 (<i>C</i>H<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 47.8 (d, <i>J</i> = 3.0 Hz, C-6a), 60.5 (C-3a), 63.5 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.7 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 85.9 (d, <i>J</i> = 154.0 Hz, C-1), 127.8 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.5 (d, <i>J</i> = 3.0 Hz, CHAr), 128.6 (d, <i>J</i> = 6.0 Hz, 2CHAr), 133.5 (d, <i>J</i> = 4.0 Hz, C<i>-ipso</i>), 162.8 (d, <i>J</i> = 12.0 Hz, C-3), 172.2 (d, <i>J</i> = 6.0 Hz, CO), 172.7 (d, <i>J</i> = 12.0 Hz, CO). HRMS C<sub>19</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 393.1574; found, 393.1572. Additional column chromatography led to sample for testing. Purity 95.6% (<i>t</i><sub>R</sub> = 4.24 min).</div></div><div id="sec4_1_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(<i>tert</i>-Butyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9h</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (9 mg, 0.05 mmol), <i>N</i>-<i>tert</i>-butylmaleimide (215 mg, 1.4 mmol), acetonitrile (7 mL), and diethyl α-phenylisocyanomethylphosphonate (229 mg, 0.9 mmol) gave <b>9h</b> (202 mg, 55%) as a yellowish oil, after column chromatography (EtOAc). IR (ATR) 3454, 2981, 2923, 1777, 1709, 1348, 1265, 1241, 1173, 1061, 973, 744, 710, 588 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.13 [s, 9H, C(C<i>H</i><sub>3</sub>)<sub>3</sub>], 1.17 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.24 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.88–3.95 (m, 2H, C<i>H</i><sub>2</sub>CH<sub>3</sub> and H-6a), 4.07–4.15 (m, 4H, C<i>H</i><sub>2</sub>CH<sub>3</sub> and H-3a), 7.28–7.33 (m, 3H, ArH), 7.59 (dbr, <i>J</i> = 8.0 Hz, 2H, ArH), 7.93 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.4 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.4 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 27.7 (C(<i>C</i>H<sub>3</sub>)<sub>3</sub>), 48.1 (d, <i>J</i> = 2.0 Hz, C-6a), 58.6 [<i>C</i>(CH<sub>3</sub>)<sub>3</sub>], 60.2 (C-3a), 63.5 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.6 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.6 (d, <i>J</i> = 158.0 Hz, C-1), 127.9 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.4 (d, <i>J</i> = 2.0 Hz, CHAr), 128.5 (d, <i>J</i> = 6.0 Hz, 2CHAr), 134.1 (d, <i>J</i> = 4.0 Hz, C<i>-ipso</i>), 163.3 (d, <i>J</i> = 12.0 Hz, C-3), 172.6 (d, <i>J</i> = 5.0 Hz, CO), 173.6 (d, <i>J</i> = 10.0 Hz, CO). HRMS C<sub>20</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 407.1730; found, 407.1733. Additional column chromatography led to sample for testing. Purity 98.3% (<i>t</i><sub>R</sub> = 4.46 min).</div></div><div id="sec4_1_2_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(Adamantan-1-yl)methyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9i</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (12 mg, 0.07 mmol), <i>N</i>-(adamantan-1-methylphenyl)maleimide (270 mg, 1.1 mmol), acetonitrile (5 mL), and diethyl α-phenylisocyanomethylphosphonate (177 mg, 0.7 mmol) gave <b>9i</b> (220 mg, 63%) as a white solid, after column chromatography (EtOAc/hexane 7:3). Mp 107–108 °C (EtOAc). IR (ATR) 3469, 2908, 2850, 1714, 1446, 1392, 1226, 1158, 1012, 978, 758, 700, 573 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 0.95 (dd, <i>J</i> = 52.0, 12.0 Hz, 6H, 3CH<sub>2</sub>), 1.12 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.25 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.47 (dd, <i>J</i> = 53.0, 12.0 Hz, 6H, 3CH<sub>2</sub>), 1.72 (s, 3H, 3CH), 2.95 (s, 2H, NCH<sub>2</sub>), 3.81 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 3.99–3.15 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.11 (dd, <i>J</i> = 19.0, 8.5 Hz, 1H, H-6a), 4.29 (ddd, <i>J</i> = 8.5, 3.0, 1.0 Hz, 1H, H-3a), 7.25–7.33 (m, 3H, ArH), 7.72 (d, <i>J</i> = 7.0 Hz, 2H, ArH), 7.95 (dd, <i>J</i> = 5.0, 1.0 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.3 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.4 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 28.1 (3CH), 34.9 (C), 36.5 (3CH<sub>2</sub>), 40.0 (3CH<sub>2</sub>), 47.7 (d, <i>J</i> = 2.0 Hz, C-6a), 50.2 (NCH<sub>2</sub>), 60.6 (C-3a), 63.6 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.7 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.0 (d, <i>J</i> = 155.0 Hz, C-1), 127.8 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.5 (d, <i>J</i> = 3.0 Hz, CHAr), 129.0 (d, <i>J</i> = 4.5 Hz, 2CHAr), 133.5 (d, <i>J</i> = 5.0 Hz, C-<i>ipso</i>), 162.6 (d, <i>J</i> = 12.0 Hz, C-3), 172.7 (d, <i>J</i> = 5.0 Hz, CO), 173.2 (d, <i>J</i> = 13.0 Hz, CO); HRMS C<sub>27</sub>H<sub>36</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 499.2356; found, 499.2359. Purity 97.8% (<i>t</i><sub>R</sub>= 5.27 min).</div></div><div id="sec4_1_2_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-Benzyl-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9j</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (4 mg, 0.02 mmol), <i>N</i>-benzylmaleimide (112 mg, 0.6 mmol), acetonitrile (3 mL), and diethyl α-phenylisocyanomethylphosphonate (101 mg, 0.4 mmol) gave <b>9j</b> (139 mg, 79%) as a yellowish oil, after column chromatography (EtOAc/hexane 9:1). IR (NaCl) 3472, 3068, 2984, 1778, 1698, 1632, 1495, 1249, 1172, 1021, 750, 615 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.14 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.25 (t, <i>J</i> = 7.0 Hz, 3H CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.86 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.00–4.18 (m, 4H, C<i>H</i><sub>2</sub>CH<sub>3</sub> and H-6a), 4.33 (ddd, <i>J</i> = 8.5, 3.5, 1.5 Hz, 1H, H-3a), 4.36 (dd, <i>J</i> = 53.5, 14.5 Hz, 2H, CH<sub>2</sub>Ar), 6.94–6.96 (m, 2H, ArH), 7.14–7.22 (m, 3H, ArH), 7.23–7.30 (m, 3H, ArH), 7.61–7.63 (m, 2H, ArH), 7.92 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.1 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.2 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 42.4 (CH<sub>2</sub>Ar), 47.8 (d, <i>J</i> = 2.0 Hz, C-6a), 60.4 (C-3a), 63.4 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.6 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 85.7 (d, <i>J</i> = 155.0 Hz, C-1), 127.7 (d, <i>J</i> = 1.0 Hz, 2CHAr), 127.8 (CHAr), 128.3 (br s, 4CHAr), 128.4 (CHAr), 128.5 (2CHAr), 133.2 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i>), 135.0 (C-<i>ipso</i>), 162.3 (d, <i>J</i> = 11.5 Hz, C-3), 171.6 (d, <i>J</i> = 5.5 Hz, CO), 172.2 (d, <i>J</i> = 13.5 Hz, CO). HRMS C<sub>23</sub>H<sub>25</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 441.1574; found, 441.1579. Additional column chromatography led to sample for testing. Purity 95.4% (<i>t</i><sub>R</sub> = 4.43 min).</div></div><div id="sec4_1_2_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-4,6-Dioxo-5-phenethyl-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9k</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (7 mg, 0.04 mmol), <i>N</i>-phenethylmaleimide (200 mg, 1.0 mmol), acetonitrile (5 mL), and diethyl α-phenylisocyanomethylphosphonate (170 mg, 0.7 mmol) gave <b>9k</b> (110 mg, 36%) as an oil, after column chromatography (EtOAc/hexane 1:1). IR (NaCl) 3468, 3027, 2981, 1709, 1627, 1394, 1250, 1162, 1052, 1025, 968, 792, 750 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.14 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.25 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 2.40–2.53 (m, 2H, CH<sub>2</sub>), 3.46 (t, <i>J</i> = 7.5 Hz, 2H, CH<sub>2</sub>), 3.83 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 3.99–4.16 (m, 4H, C<i>H</i><sub>2</sub>CH<sub>3</sub> and H-6a), 4.24 (ddd, <i>J</i> = 8.5, 4.0, 1.0 Hz, 1H, H-3a), 6.97–6.99 (m, 2H, ArH), 7.16–7.25 (m, 3H, ArH), 7.30–7.38 (m, 3H, ArH), 7.68–7.70 (m, 2H, ArH), 7.85 (dd, <i>J</i> = 5.0, 1.0 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.1 (d, <i>J</i> = 4.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.2 (d, <i>J</i> = 4.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 33.0 (CH<sub>2</sub>), 39.9 (CH<sub>2</sub>), 47.5 (d, <i>J</i> = 2.5 Hz, C-6a), 60.2 (C-3a), 63.4 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.6 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 126.6 (CHAr), 127.6 (CHAr), 127.7 (CHAr), 128.4 (d, <i>J</i> = 2.5 Hz, CHAr), 128.5 (2CHAr), 128.6 (CHAr), 128.7 (CHAr), 128.8 (2CHAr), 133.2 (d, <i>J</i> = 4.5 Hz, C-<i>ipso</i>), 137.1 (C-<i>ipso</i>), 162.6 (d, <i>J</i> = 11.5 Hz, C-3), 171.6 (d, <i>J</i> = 5.5 Hz, CO), 172.3 (d, <i>J</i> = 13.5 Hz, CO). HMRS C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 455.1730; found, 455.1731. Additional column chromatography led to sample for testing. Purity 98.0% (<i>t</i><sub>R</sub> = 4.54 min).</div></div><div id="sec4_1_2_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(4-Fluorophenethyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9l</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (8 mg, 0.05 mmol), <i>N</i>-(4-fluorophenethyl)maleimide (263 mg, 1.2 mmol), acetonitrile (6 mL), and diethyl α-phenylisocyanomethylphosphonate (202 mg, 0.8 mmol) gave <b>9l</b> (201 mg, 53%) as a white solid, after column chromatography (EtOAc). Mp 94–95 °C (EtOAc). IR (NaCl) 3466, 3050, 2976, 1779, 1702, 1632, 1507, 1257, 1153, 1013, 763, 583 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.23 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.25 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 2.40–2.52 (m, 2H, CH<sub>2</sub>), 3.41–3.46 (m, 2H, CH<sub>2</sub>), 3.80 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 3.97–4.15 (m, 4H, C<i>H</i><sub>2</sub>CH<sub>3</sub> and H-6a), 4.24 (ddd, <i>J</i> = 8.0, 4.0, 1.5 Hz, 1H, H-3a), 6.86–6.92 (m, 4H, ArH), 7.31–7.37 (m, 3H, ArH), 7.67 (m, 2H, ArH), 7.83 (dd, <i>J</i> = 5.5, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.1 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.2 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 32.1 (CH<sub>2</sub>), 39.9 (CH<sub>2</sub>), 47.5 (d, <i>J</i> = 2.0 Hz, C-6a), 60.3 (C-3a), 63.4 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.6 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 85.7 (d, <i>J</i> = 153.0 Hz, C-1), 115.3 (d, <i>J</i> = 2.0 Hz, 2CHAr), 127.6 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.4 (d, <i>J</i> = 3.0 Hz, CHAr), 128.6 (d, <i>J</i> = 6.0 Hz, 2CHAr), 130.1 (d, <i>J</i> = 8.0 Hz, 2CHAr), 132.7 (d, <i>J</i> = 3.0 Hz, C-<i>ipso</i>), 133.1 (d, <i>J</i> = 5.0 Hz, C-<i>ipso</i>), 160.4 (d, <i>J</i> = 244.5 Hz, C-<i>ipso</i>), 162.5 (d, <i>J</i> = 12.0 Hz, C-3), 171.6 (d, <i>J</i> = 6.0 Hz, CO), 172.3 (d, <i>J</i> = 14.0 Hz, CO). HRMS C<sub>24</sub>H<sub>27</sub>FN<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 473.1636; found, 473.1640. Anal. Calcd for C<sub>24</sub>H<sub>26</sub>FN<sub>2</sub>O<sub>5</sub>P: C, 61.01%; H, 5.55%; N, 5.93%. Found: C, 61.14%; H, 5.74%; N, 5.83%.</div></div><div id="sec4_1_2_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(2,3-Dihydro-1<i>H</i>-inden-2-yl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9m</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (7 mg, 0.04 mmol), <i>N-</i>(2,3-dihydro-1<i>H</i>-inden-2-yl)maleimide (126 mg, 0.6 mmol), acetonitrile (3 mL), and diethyl α-phenylisocyanomethylphosphonate (100 mg, 0.4 mmol) gave <b>9m</b> (158 mg, 85%) as a beige solid, after column chromatography (EtOAc). Mp 124–126 °C (EtOAc). IR (ATR) 3457, 2986, 2943, 2866, 1766, 1698, 1623, 1377, 1252, 1170, 1055, 1021, 790, 704, 574 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.18 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.26 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 2.69 (dd, <i>J</i> = 15.0, 9.0 Hz, 1H, CH<sub>2</sub>), 2.75 (dd, <i>J</i> = 15.0, 9.0 Hz, 1H, CH<sub>2</sub>), 2.77 (dd, <i>J</i> = 15.0, 9.0 Hz, 1H, CH<sub>2</sub>), 3.23 (dd, <i>J</i> = 15.0, 9.0 Hz, 1H, CH<sub>2</sub>), 3.92 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.08–4.17 (m, 4H, C<i>H</i><sub>2</sub>CH<sub>3</sub> and H-6a), 4.31 (ddd, <i>J</i> = 9.0, 3.0, 1.5 Hz, 1H, H-3a), 4.62 (qu, <i>J</i> = 9,2 Hz, 1H, C<i>H</i>), 7.09 (m, 1 H, ArH), 7.07–7.11 (m, 3H, ArH), 7.32–7.37 (m, 3H, ArH), 7.64 (br d, <i>J</i> = 7.5 Hz, 2H, ArH), 8.00 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.4 (d, <i>J</i> = 2.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.5 (d, <i>J</i> = 3.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 34.6 (CH<sub>2</sub>), 35.1 (CH<sub>2</sub>), 48.0 (d, <i>J</i> = 2.0 Hz, C-6a), 50.8 (CH), 60.2 (C-3a), 63.6 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.7 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.1 (d, <i>J</i> = 157.0 Hz, C-1), 124.4 (d, <i>J</i> = 2.0 Hz, 2CHAr), 126.8 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.0 (d, <i>J</i> = 1.0 Hz, 2CHAr), 128.5 (d, <i>J</i> = 8.0 Hz, 2CHAr), 128.6 (CHAr), 133.7 (C<i>-ipso</i>), 133.8 (C<i>-ipso)</i>, 140.5 (d, <i>J</i> = 9.0 Hz, C<i>-ipso</i>), 162.7 (d, <i>J</i> = 12.0 Hz, C-3), 172.1 (d, <i>J</i> = 5.0 Hz, CO), 172.7 (d, <i>J</i> = 12.0 Hz, CO). HRMS C<sub>25</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 467.1730; found, 467.1728. Anal. Calcd for C<sub>25</sub>H<sub>27</sub>N<sub>2</sub>O<sub>5</sub>P: C, 64.37%; H, 5.83%; N, 6.01%. Found: C,64.55%; H,6.11%; N,5.76%.</div></div><div id="sec4_1_2_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-4,6-Dioxo-1-phenyl-5-[4-(trifluoromethyl)phenyl]-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9n</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (4 mg, 0.03 mmol), <i>N</i>-(4-trifluoromethylphenyl)maleimide (144 mg, 0.6 mmol), acetonitrile (3 mL), and diethyl α-phenylisocyanomethylphosphonate (101 mg, 0.4 mmol) gave <b>9n</b> (133 mg, 67%) as a white solid, after column chromatography (EtOAc). Mp 184–185 °C (EtOAc). IR (NaCl) 3492, 3050, 2984, 1723, 1616, 1378, 1326, 1249, 1170, 1067, 758, 580 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.19 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.95 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.10–4.20 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.28 (dd, <i>J</i> = 18.0, 9.0, 1H, H-6a), 4.51 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a), 6.85–6.87 (m, 2H, ArH), 7.34–7.38 (m, 3H, ArH), 7.54–7.56 (m, 2H, ArH), 7.67–7.69 (m, 2H, ArH), 8.05 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.2 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.3 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.3 (d, <i>J</i> = 3.0 Hz, C-6a), 60.1 (C-3a), 63.6 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.7 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.3 (d, <i>J</i> = 157.0 Hz, C-1), 123.5 (q, <i>J</i> = 272.5 Hz, CF<sub>3</sub>), 126.0 (q, <i>J</i> = 4.0 Hz, 2CHAr), 126.3 (2CHAr), 128.0 (d, <i>J</i> = 1.0 Hz, 2CHAr), 128.4 (d, <i>J</i> = 6.0 Hz, 2CHAr), 128.7 (d, <i>J</i> = 2.0 Hz, CHAr), 137.5 (q, <i>J</i> = 33.0 Hz, <i>C</i>CF<sub>3</sub>), 133.4 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i>), 134.1 (d, <i>J</i> = 1.5 Hz, C-<i>ipso</i>), 162.0 (d, <i>J</i> = 13.0 Hz, C-3), 170.4 (d, <i>J</i> = 5.0 Hz, CO), 171.2 (d, <i>J</i> = 12.0 Hz, CO). HRMS C<sub>23</sub>H<sub>23</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 495.1291; found, 495.1288. Anal. Calcd for C<sub>23</sub>H<sub>22</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>P: C, 55.88%; H, 4.49%; N, 5.67%. Found: C, 56.04%; H, 4.71%; N, 5.56%.</div></div><div id="sec4_1_2_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-4,6-Dioxo-1-phenyl-5-[3-(trifluoromethyl)phenyl]-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9o</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (10 mg, 0.06 mmol), <i>N</i>-(3-trifluoromethylphenyl)maleimide (362 mg, 1.5 mmol), acetonitrile (8 mL), and diethyl α-phenylisocyanomethylphosphonate (253 mg, 1.0 mmol) gave <b>9o</b> (218 mg, 44%) as a white solid, after column chromatography (EtOAc). Mp 179–180 °C (EtOAc). IR (ATR) 3483, 3084, 2957, 2036, 1719, 1446, 1382, 1329, 1168, 1027, 978, 739, 573 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.21 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.98 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.11–4.20 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.27 (dd, <i>J</i> = 18.0, 9.0 Hz, 1H, H-6a), 4.50 (ddd, <i>J</i> = 9.0, 2.5, 1.5 Hz, 1H, H-3a), 6.86 (s, 1H, ArH), 6.96 (d, <i>J</i> = 9.5 Hz, 1H, ArH), 7.36–7.39 (m, 3H, ArH), 7.42 (t, 7.5 Hz, 1H, ArH), 7.53 (d, <i>J</i> = 8.0 Hz, 1H, ArH), 7.67 (br d, <i>J</i> = 7.0 Hz, 2H, ArH), 8.06 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.6 (d, <i>J</i> = 2.0 Hz, C-6a), 60.2 (C-3a), 63.8 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.9 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.4 (d, <i>J</i> = 158.0 Hz, C-1), 123.3 (q, <i>J</i> = 4.0 Hz, CHAr), 123.4 (q, <i>J</i> = 272.5 Hz, CF<sub>3</sub>), 125.6 (q, <i>J</i> = 4.0 Hz, CHAr), 128.2 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.5 (d, <i>J</i> = 6.0 Hz, 2CHAr), 128.9 (d, <i>J</i> = 2.0 Hz, CHAr), 129.5 (d, <i>J</i> = 1.0 Hz, CHAr), 129.7 (CHAr), 131.6 (q, <i>J</i> = 33.5 Hz, <i>C</i>CF<sub>3</sub>), 131.7 (C<i>-ipso</i>), 133.5 (d, <i>J</i> = 4.0 Hz, C<i>-ipso</i>), 162.1 (d, <i>J</i> = 12.0 Hz, C-3), 170.6 (d, <i>J</i> = 5.0 Hz, CO), 171.5 (d, <i>J</i> = 11.0 Hz, CO). HRMS C<sub>23</sub>H<sub>23</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 495.1291; found, 495.1287. Anal. Calcd for C<sub>23</sub>H<sub>22</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>P: C, 55.88%; H, 4.49%; N, 5.67%. Found: C, 56.00%; H, 4.63%; N, 5.46%.</div></div><div id="sec4_1_2_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(4-Fluorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9p</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (7 mg, 0.04 mmol), <i>N</i>-(4-fluorophenyl)maleimide (211 mg, 1.1 mmol), acetonitrile (5 mL), and diethyl α-phenylisocyanomethylphosphonate (177 mg, 0.7 mmol) gave 9p (198 mg, 64%) as a white solid, after column chromatography (EtOAc). Mp 200–201 °C (EtOAc). IR (NaCl) 3481, 3061, 2980, 1787, 1717, 1511, 1385, 1245, 1017, 969, 700, 583 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.19 (t, <i>J</i> = 7.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.93 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.10–4.20 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.26 (dd, <i>J</i> = 18.0, 9.0, 1H, H-6a), 4.48 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a), 6.67–6.72 (m, 2H, ArH), 6.96–7.00 (m, 2H, ArH), 7.33–7.39 (m, 3H, ArH), 7.68–7.70 (m, 2H, ArH), 8.05 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.2 (d, <i>J</i> = 4.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.3 (d, <i>J</i> = 4.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.2 (d, <i>J</i> = 3.0 Hz, C-6a), 60.1 (C-3a), 63.6 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 63.7 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.2 (d, <i>J</i> = 157.0 Hz, C-1), 116.1 (d, <i>J</i> = 23.0 Hz, 2CHAr), 126.9 (d, <i>J</i> = 3.0 Hz, C-<i>ipso</i>), 127.9 (2CHAr), 128.0 (2CHAr), 128.4 (d, <i>J</i> = 6.0 Hz, 2CHAr), 128.6 (d, <i>J</i> = 2.0 Hz, CHAr), 133.4 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i>), 160.9 (d, <i>J</i> = 248.5 Hz, C-<i>ipso</i>), 162.2 (d, <i>J</i> = 12.0 Hz, C-3), 170.9 (d, <i>J</i> = 5.0 Hz, CO), 171.6 (d, <i>J</i> = 11.0 Hz, CO). HRMS C<sub>22</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup>445.1323; found, 445.1322. Anal. Calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>5</sub>P: C, 59.46%; H, 4.99%; N, 6.30%. Found: C, 59.73%; H, 5.13%; N, 6.19%.</div></div><div id="sec4_1_2_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(4-Chlorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9q</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (5 mg, 0.03 mmol), <i>N-</i>(4-chlorophenyl)maleimide (150 mg, 0.7 mmol), acetonitrile (4 mL), and diethyl α-phenylisocyanomethylphosphonate (118 mg, 0.5 mmol) gave <b>9q</b> (136 mg, 59%) as a white solid, after column chromatography (EtOAc). Mp 211–212 °C (EtOAc). IR (ATR) 3078, 2981, 2923, 2855, 1713, 1499, 1377, 1187, 1022, 773, 583 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.19 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.94 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.11–4.19 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.25 (dd, <i>J</i> = 18.0, 9.0 Hz, 1H, H-6a), 4.47 (ddd, <i>J</i> = 8.5, 3.0, 1.0 Hz, 1H, H-3a), 6.65–6.67 (m, 2H, ArH), 7.24–7.27 (m, 2H, ArH), 7.33–7.37 (m, 3H, ArH), 7.67 (br d, <i>J</i> = 7.5 Hz, 2H, ArH), 8.04 (dd, <i>J</i> = 5.5, 1.0 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.4 (d, <i>J</i> = 3.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.4 (d, <i>J</i> = 4.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.4 (d, <i>J</i> = 2.0 Hz, C-6a), 60.2 (C-3a), 63.7 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.8 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.4 (d, <i>J</i> = 157.0 Hz, C-1), 127.4 (2CHAr), 128.1 (d, <i>J</i> = 1.0 Hz, 2CHAr), 128.5 (d, <i>J</i> = 6.0 Hz, 2CHAr), 128.7 (d, <i>J</i> = 2.0 Hz, CHAr), 129.4 (2CHAr), 129.6 (C<i>-ipso</i>), 133.6 (d, <i>J</i> = 4.0 Hz, C<i>-ipso</i>), 134.7 (C<i>-ipso</i>), 162.2 (d, <i>J</i> = 12.0 Hz, C-3), 170.8 (d, <i>J</i> = 5.0 Hz, CO), 171.5 (d, <i>J</i> = 12.0 Hz, CO). HRMS C<sub>22</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 461.1028; found, 461.1026. Anal. Calcd for C<sub>22</sub>H<sub>22</sub>ClN<sub>2</sub>O<sub>5</sub>P: C, 57.34%; H, 4.81%; N, 6.08%. Found: C, 57.71%; H, 4.92%; N, 5.96%.</div></div><div id="sec4_1_2_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(2-Chlorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9r</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (6 mg, 0.04 mmol), <i>N-</i>(2-chlorophenyl)maleimide (180 mg, 0.9 mmol), acetonitrile (5 mL), and diethyl α-phenylisocyanomethylphosphonate (152 mg, 0.6 mmol) gave <b>9r</b> (200 mg, 72%) as a white solid, after column chromatography (EtOAc/hexane 7:3). Mp 172–174 °C (EtOAc). IR (ATR) 3496, 2981, 2866, 1790, 1718, 1482, 1386, 1237, 1194, 1045, 1021, 973, 757, 579 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.14 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>-rotamer A), 1.19 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>-rotamer B), 1.29 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>-rotamer A), 1.30 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>-rotamer B), 3.82 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>-rotamer A), 3.93 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>-rotamer B), 4.05–4.20 (m, 6H, C<i>H</i><sub>2</sub>CH<sub>3</sub>-rotamer A and B), 4.35 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a rotamer A), 4.36 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a rotamer B), 4.52 (ddd, <i>J</i> = 8.5, 4.5, 1.5 Hz, 1H, H-3a rotamer A), 4.56 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a rotamer B), 6.30 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H, ArH rotamer B), 7.10 (m, 1H, ArH rotamer B), 7.13 (ddd, <i>J</i> = 16.0, 8.0, 2.0 Hz, 1H, ArH rotamer A), 7.25–7.43 (m, 10H, 6ArH rotamer A and 4ArH rotamer B), 7.42 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H, ArH rotamer B), 7.71 (d, <i>J</i> = 8.0 Hz, 2H, ArH rotamer B), 7.78 (d, <i>J</i> = 8.0 Hz, 2H, ArH rotamer A), 8.03 (dd, <i>J</i> = 5.5 Hz, 1.5 Hz, 1H, H-3 rotamer A), 8.08 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3 rotamer B). <sup>13</sup>C NMR (100.6 MHz) δ 16.2 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer A or B), 16.2 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer A or B), 16.3 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer A or B), 16.3 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer A or B), 48.0 (d, <i>J</i> = 2.5 Hz, C-6a rotamer A), 48.6 (d, <i>J</i> = 2.5 Hz, C-6a rotamer B), 60.3 (C-3a rotamer B), 60.1 (C-3a rotamer A), 63.5 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer A), 63.6 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer B), 64.7 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer B), 64.8 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer A), 86.0 (d, <i>J</i> = 157.5, C-1 rotamer A), 86.6 (d, <i>J</i> = 153.5, C-1 rotamer B), 127.6 (CHAr rotamer A or B), 127.7 (d, <i>J</i> = 2.0 Hz, CHAr rotamer A or B), 127.8 (CHAr rotamer A), 127.9 (CHAr rotamer A or B), 128.0 (CHAr rotamer A or B), 128.4 (d, <i>J</i> = 5.0 Hz, 2CHAr rotamer B), 128.5 (2CHAr rotamer A or B), 128.6 (d, <i>J</i> = 2.0 Hz, CHAr rotamer A or B), 128.9 (d, <i>J</i> = 6.0 Hz, CHAr rotamer A), 129.1 (C-<i>ipso</i> rotamer A), 129.2 (C-<i>ipso</i> rotamer B), 129.3 (CHAr rotamer B), 129.6 (CHAr rotamer A), 130.2 (CHAr rotamer B), 130.3 (CHAr rotamer A or B), 130.7 (CHAr rotamer A or B), 130.9 (CHAr rotamer A or B), 132.0 (C-<i>ipso</i> rotamer A), 132.2 (C-<i>ipso</i> rotamer B), 132.9 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i> rotamer A), 133.5 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i> rotamer B), 162.0 (d, <i>J</i> = 11.5 Hz, C-3 rotamer A), 162.2 (d, <i>J</i> = 12.5 Hz, C-3 rotamer B), 170.2 (d, <i>J</i> = 5.0 Hz, CO rotamer B), 170.3 (d, <i>J</i> = 5.5 Hz, CO rotamer A), 170.7 (d, <i>J</i> = 11.5 Hz, CO rotamer A or B), 170.8 (d, <i>J</i> = 15.0 Hz, CO rotamer B). HRMS C<sub>22</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 461.1028; found, 461.1025. Anal. Calcd for C<sub>22</sub>H<sub>22</sub>ClN<sub>2</sub>O<sub>5</sub>P: C, 57.34%; H, 4.81%; N, 6.08%. Found: C,57.18%; H,4.86%; N,5.88%.</div></div><div id="sec4_1_2_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(3-Chlorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9s</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (8 mg, 0.05 mmol), <i>N</i>-(3-chlorophenyl)maleimide (250 mg, 1.2 mmol), acetonitrile (6 mL), and diethyl α-phenylisocyanomethylphosphonate (203 mg, 0.8 mmol) gave <b>9s</b> (167 mg, 45%) as a white solid, after column chromatography (EtOAc). Mp 186–187 °C (EtOAc). IR (ATR) 3488, 3084, 2962, 2928, 1709, 1587, 1475, 1382, 1241, 1183, 1051, 1022, 948, 705 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.19 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.94 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.10–4.19 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.26 (dd, <i>J</i> = 18.0, 9.0 Hz, 1H, H-6a), 4.48 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a), 6.63–6.68 (m, 2H, ArH), 7.22 (m, 1H, ArH), 7.26 (m, 1H, ArH), 7.35–7.39 (m, 3H, ArH), 7.68 (br d, <i>J</i> = 7.5 Hz, 2H, ArH), 8.05 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.5 (d, <i>J</i> = 3.0 Hz, C-6a), 60.2 (C-3a), 63.7 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.8 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.4 (d, <i>J</i> = 157.0 Hz, C-1), 124.4 (CHAr), 126.5 (CHAr), 128.2 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.5 (d, <i>J</i> = 6.0 Hz, 2CHAr), 128.9 (d, <i>J</i> = 2.0 Hz, CHAr), 129.0 (CHAr), 130.1 (CHAr), 132.2 (C<i>-ipso</i>), 133.5 (d, <i>J</i> = 4.0 Hz, C<i>-ipso</i>), 134.7 (C-<i>ipso</i>), 162.3 (d, <i>J</i> = 12.0 Hz, C-3), 170.6 (d, <i>J</i> = 5.0 Hz, CO), 171.4 (d, <i>J</i> = 12.0 Hz, CO). HRMS C<sub>22</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 461.1028; found, 461.1029. Anal. Calcd for C<sub>22</sub>H<sub>22</sub>ClN<sub>2</sub>O<sub>5</sub>P: C, 57.34%; H, 4.81%; N, 6.08%. Found: C, 57.70%; H, 4.96%; N, 5.59%.</div></div><div id="sec4_1_2_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(4-Bromophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9t</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (7 mg, 0.04 mmol), <i>N-</i>(4-bromophenyl)maleimide (275 mg, 1.1 mmol), acetonitrile (5 mL), and diethyl α-phenylisocyanomethylphosphonate (177 mg, 0.7 mmol) gave <b>9t</b> (181 mg, 51%) as a white solid, after column chromatography (EtOAc/hexane 1:1). Mp 180–182 °C (EtOAc). IR (ATR) 3478, 2918, 2845, 1797, 1714, 1480, 1387, 1236, 1187, 1158, 1022, 973, 744, 578 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.19 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.93 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.10–4.19 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.25 (dd, <i>J</i> = 18.0, 9.0 Hz, 1H, H-6a), 4.47 (ddd, <i>J</i> = 9.0, 3.0, 1.5 Hz, 1H, H-3a), 6.59–6.61 (m, 2H, ArH), 7.34–7.36 (m, 3H, ArH), 7.40–7.42 (m, 2H, ArH), 7.67 (br s, <i>J</i> = 7.5 Hz, 2H, ArH), 8.04 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.4 (d, <i>J</i> = 3.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.4 (d, <i>J</i> = 4.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.4 (d, <i>J</i> = 3.0 Hz, C-6a), 60.3 (C-3a), 63.7 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.8 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.4 (d, <i>J</i> = 157.0 Hz, C-1), 122.7 (C<i>-ipso</i>), 127.7 (2CHAr), 128.1 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.5 (d, <i>J</i> = 6.0 Hz, 2CHAr), 128.8 (d, <i>J</i> = 2.0 Hz, CHAr), 130.2 (C<i>-ipso</i>), 132.4 (2CHAr), 133.6 (d, <i>J</i> = 4.0 Hz, C<i>-ipso</i>), 162.2 (d, <i>J</i> = 12.0 Hz, C-3), 170.7 (d, <i>J</i> = 5.0 Hz, CO), 171.4 (d, <i>J</i> = 11.0 Hz, CO). HRMS C<sub>22</sub>H<sub>23</sub>BrN<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 505.0522; found, 505.0522. Anal. Calcd for C<sub>22</sub>H<sub>22</sub>BrN<sub>2</sub>O<sub>5</sub>P: C, 52.99%; H, 4.90%; N, 5.24%. Found: C, 53.30%; H, 4.61%; N, 5.10%.</div></div><div id="sec4_1_2_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(3,5-Dichlorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9u</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (12 mg, 0.07 mmol), <i>N</i>-(3,5-dichlorophenyl)maleimide (267 mg, 1.1 mmol), acetonitrile (5 mL), and diethyl α-phenylisocyanomethylphosphonate (177 mg, 0.7 mmol) gave <b>9u</b> (190 mg, 55%) as a white solid, after column chromatography (EtOAc/hexane 8:2). Mp 207–209 °C (EtOAc). IR (ATR) 3483, 3079, 2952, 2928, 1719, 1573, 1441, 1373, 1226, 1183, 1027, 973, 763, 734, 727, 588 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.20 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.94 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.10–4.19 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.25 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a), 4.47 (ddd, <i>J</i> = 9.0, 2.5, 1.5 Hz, 1H, H-3a), 6.60 (d, <i>J</i> = 2.0 Hz, 2H, ArH), 7.27 (m, 1H, ArH), 7.37–7.40 (m, 3H, ArH), 7.65 (br d, <i>J</i> = 5.0 Hz, 2H, ArH), 8.04 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.3 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.6 (d, <i>J</i> = 3.0 Hz, C-6a), 60.9 (C-3a), 63.8 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.9 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.5 (d, <i>J</i> = 158.0 Hz, C-1), 124.8 (2CHAr), 128.3 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.5 (d, <i>J</i> = 5.0 Hz, 2CHAr), 129.0 (d, <i>J</i> = 2.0 Hz, CHAr), 129.1 (CHAr), 132.8 (C<i>-ipso</i>), 133.5 (d, <i>J</i> = 3.0 Hz, C<i>-ipso)</i>, 135.3 (2C<i>-ipso</i>), 162.0 (d, <i>J</i> = 13.0 Hz, C-3), 170.2 (d, <i>J</i> = 5.0 Hz, CO), 171.1 (d, <i>J</i> = 11.0 Hz, CO). HRMS C<sub>22</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 495.0638; found, 495.0638. Anal. Calcd for C<sub>22</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>5</sub>P: C, 53.35%; H, 4.27%; N, 5.66%. Found: C, 53.69%; H, 4.35%; N, 5.42%.</div></div><div id="sec4_1_2_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(3,4-Dichlorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9v</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (8 mg, 0.05 mmol), <i>N</i>-(3-chloro-4-chlorophenyl)maleimide (288 mg, 1.2 mmol), acetonitrile (6 mL), and diethyl α-phenylisocyanomethylphosphonate (202 mg, 0.8 mmol) gave <b>9v</b> (210 mg, 53%) as a white solid, after column chromatography (EtOAc/hexane 1:1). Mp 172–174 °C (EtOAc). IR (ATR) 3480, 3075, 2957, 1790, 1716, 1464, 1251, 1187, 1058, 1024, 737, 579 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.20 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.95 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.10–4.20 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.26 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a), 4.47 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a), 6.61 (dd, <i>J</i> = 9.0, 2.5 Hz, 1H, ArH), 6.78 (d, <i>J</i> = 2.5 Hz, 1H, ArH), 7.35–7.38 (m, 4H, ArH), 7.65–7.68 (m, 2H, ArH), 8.04 (dd, <i>J</i> = 4.5, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.2 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.3 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.4 (d, <i>J</i> = 3.0 Hz, C-6a), 60.0 (C-3a), 63.6 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.7 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.2 (d, <i>J</i> = 157.0 Hz, C-1), 125.2 (CHAr), 127.9 (CHAr), 128.0 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128,3 (d, <i>J</i> = 6.0 Hz, 2CHAr), 128.7 (d, <i>J</i> = 2.0 Hz, CHAr), 130.2 (C-<i>ipso</i>), 130.6 (CHAr), 132.9 (C-<i>ipso</i>), 133.0 (C-<i>ipso</i>), 133.3 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i>), 161.9 (d, <i>J</i> = 13.0 Hz, C-3), 170.2 (d, <i>J</i> = 5.0 Hz, CO), 171.1 (d, <i>J</i> = 12.0 Hz, CO). HRMS C<sub>22</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 495.0638; found, 495.0637. Anal. Calcd for C<sub>22</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>5</sub>P: C, 53.35%; H, 4.27%; N, 5.66%. Found: C, 53.42%; H, 4.30%; N, 5.48%.</div></div><div id="sec4_1_2_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-4,6-Dioxo-1-phenyl-5-(2,4,6-trichlorophenyl)-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9w</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (8.3 mg, 0.05 mmol), <i>N-</i>(2,4,6-trichlorophenyl)maleimide (194 mg, 0.7 mmol), acetonitrile (4 mL), and diethyl α-phenylisocyanomethylphosphonate (127 mg, 0.5 mmol) gave <b>9w</b> (215 mg, 81%) as a yellowish solid, after column chromatography (EtOAc). Mp 146–148 °C (EtOAc). IR (ATR) 3501, 2976, 2854, 1786, 1727, 1471, 1361, 1253, 1043, 1322, 961, 704 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.14 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.84 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.03–4.17 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.41 (dd, <i>J</i> = 18.0, 9.0 Hz, 1H, H-6a), 4.57 (ddd, <i>J</i> = 8.5, 4.0, 1.0 Hz, 1H, H-3a), 7.26 (d, <i>J</i> = 3.0 Hz, 1H, ArH), 7.28–7.34 (m, 3H, ArH), 7.36 (d, <i>J</i> = 2.0 Hz, 1H, ArH), 7.75 (br d, <i>J</i> = 8.0 Hz, 2H, ArH), 8.02 (dd, <i>J</i> = 5.0, 1.0 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.3 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.4 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.3 (d, <i>J</i> = 3.0 Hz, C-6a), 61.0 (C-3a), 63.7 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.9 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.7 (d, <i>J</i> = 152.0 Hz, C-1), 126.6 (C<i>-ipso</i>), 127.8 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.6 (CHAr), 128.7 (CHAr), 128.8 (CHAr), 129.0 (d, <i>J</i> = 5.0 Hz, 2CHAr), 133.0 (d, <i>J</i> = 5.0 Hz, C<i>-ipso</i>), 135.1 (d, <i>J</i> = 10.0 Hz, C<i>-ipso</i>), 136.8 (2C<i>-ipso</i>), 161.8 (d, <i>J</i> = 11.0 Hz, C-3), 169.3 (d, <i>J</i> = 5.0 Hz, CO), 169.8 (d, <i>J</i> = 14.0 Hz, CO). HRMS C<sub>22</sub>H<sub>21</sub>Cl<sub>3</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 529.0248; found, 529.0242. Purity 98% (<i>t</i><sub>R</sub> = 5.06 min).</div></div><div id="sec4_1_2_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(3-Nitrophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9x</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (4 mg, 0.02 mmol), <i>N</i>-(3-nitrophenyl)maleimide (131 mg, 0.6 mmol), acetonitrile (3 mL), and diethyl α-phenylisocyanomethylphosphonate (101 mg, 0.4 mmol) gave <b>9x</b> (101 mg, 54%) as a white solid, after column chromatography (EtOAc). Mp 192–195 °C (EtOAc). IR (NaCl) 2984, 1724, 1537, 1351, 1248, 1176, 1050, 971, 758, 674 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.21 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.29 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.98 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.10–4.24 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.30 (dd, <i>J</i> = 18.0, 9.0 Hz, 1H, H-6a), 4.53 (ddd, <i>J</i> = 9.0, 3.0, 1.0 Hz, H-3a), 7.11 (dq, <i>J</i> = 8.0, 1.0 Hz, 1H, ArH), 7.38–7.41 (m, 3H, ArH), 7.49 (t, <i>J</i> = 8.0 Hz, 1H, ArH), 7.58 (t, <i>J</i> = 2.0 Hz, 1H, ArH), 7.67–7.69 (m, 2H, ArH), 8.07 (dd, <i>J</i> = 5.0, 1.0 Hz, 1H, H-3), 8.14 (ddd, <i>J</i> = 8.5, 2.5, 1.0 Hz, 1H, ArH). <sup>13</sup>C NMR (100.6 MHz) δ 16.2 (d, <i>J</i> = 3.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.3 (d, <i>J</i> = 3.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.5 (d, <i>J</i> = 2.0 Hz, C-6a), 60.0 (C-3a), 63.6 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.7 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.2 (d, <i>J</i> = 158.0 Hz, C-1), 121.4 (CHAr), 123.3 (CHAr), 128.1 (2CHAr), 128.2 (CHAr), 128.3 (CHAr), 128.9 (d, <i>J</i> = 1.5 Hz, CHAr), 129.8 (CHAr), 131.9 (CHAr), 132.0 (C-<i>ipso</i>), 133.2 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i>), 148.3 (C-<i>ipso</i>), 161.7 (d, <i>J</i> = 12.0 Hz, C-3), 170.2 (d, <i>J</i> = 5.5 Hz, CO), 171.1 (d, <i>J</i> = 11.0 Hz, CO). HRMS C<sub>22</sub>H<sub>23</sub>N<sub>3</sub>O<sub>7</sub>P [M + H]<sup>+</sup> 472.1268; found, 472.1276. Anal. Calcd for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>7</sub>P: C, 56.05%; H, 4.70%; N, 8.91%. Found: C, 55.73%; H, 4.74%; N, 8.85%.</div></div><div id="sec4_1_2_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(2-Methyl-5-nitrophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9y</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (5 mg, 0.03 mmol), <i>N-</i>(2-methyl-5-nitrophenyl)maleimide (138 mg, 0.6 mmol), acetonitrile (3 mL), and diethyl α-phenylisocyanomethylphosphonate (101 mg, 0.4 mmol) gave <b>9y</b> (111 mg, 57%) as a white solid, after column chromatography (EtOAc). Mp 196–198 °C (EtOAc). IR (ATR) 3493, 3079, 2947, 2845, 1724, 1519, 1343, 1192, 1017, 739, 578 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.16 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer A), 1.22 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer B), 1.29 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer B), 1.30 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer A), 1.51 (s, 3H, CH<sub>3</sub> rotamer A), 2.15 (s, 3H, CH<sub>3</sub> rotamer B), 3.85 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub> rotamer A), 3.99 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub> rotamer B), 4.03–4.24 (m, 6H, C<i>H</i><sub>2</sub>CH<sub>3</sub> rotamer A and B), 4.35 (dd, <i>J</i> = 18.0, 9.0 Hz, 1H, H-6a rotamer B), 4.39 (dd, <i>J</i> = 18.5, 9.0 Hz, 1H, H-6a rotamer A), 4.55 (ddd, <i>J</i> = 10.0, 2.5, 1.5 Hz, 1H, H-3a rotamer B), 4.59 (ddd, <i>J</i> = 9.0, 3.5, 1.5 Hz, 1H, H-3a rotamer A), 6.88 (d, <i>J</i> = 2.5 Hz, 1H, ArH rotamer B), 7.47–7.19 (m, 8H, 4ArH rotamer A and 4ArH rotamer B), 7.69 (br s, 2H, ArH rotamer B), 7.77 (d, <i>J</i> = 7.5 Hz, 2H, ArH rotamer A), 7.91 (d, <i>J</i> = 2.5 Hz, 1H, ArH rotamer A), 8.05 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, C-3 rotamer A), 8.08 (dd, <i>J</i> = 5.5, 2.5 Hz, 1H, C-3 rotamer B), 8.08–8.11 (m, 2H, ArH rotamer A and rotamer B). <sup>13</sup>C NMR (100.6 MHz) δ 16.3 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer A), 16.3 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer B), 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer A), 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer B), 17.5 (CH<sub>3</sub> rotamer A), 18.2 (CH<sub>3</sub> rotamer B), 48.3 (d, <i>J</i> = 2.5 Hz, C-6a rotamer A), 49.2 (d, <i>J</i> = 2.5 Hz, C-6a rotamer B), 60.1 (C-3a rotamer B), 61.0 (C-3a rotamer A), 63.7 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer A), 63.8 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer B), 64.9 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer B), 65.0((d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer A), 86.3 (d, <i>J</i> = 159.0, C-1 rotamer B), 86.6 (d, <i>J</i> = 154.5, C-1 rotamer A), 123.5 (CHAr rotamer B), 123.7 (CHAr rotamer A), 124.3 (CHAr rotamer A), 124.5 (CHAr rotamer B), 127.9 (CHAr rotamer A), 128.0 (CHAr rotamer B), 128.3 (d, <i>J</i> = 5.5 Hz, 2CHAr rotamer B), 128.3 (CHAr rotamer A), 128.4 (CHAr rotamer B), 128.8 (d, <i>J</i> = 2.5 Hz, CHAr rotamer A), 128.9 (d, <i>J</i> = 6.5 Hz, 2CHAr rotamer A), 129.4 (d, <i>J</i> = 2.0 Hz, CHAr rotamer B), 131.1 (C-<i>ipso</i> rotamer A), 131.2 (C-<i>ipso</i> rotamer B), 131.8 (CHAr rotamer B), 131.9 (CHAr rotamer A), 133.3 (d, <i>J</i> = 4.5 Hz, C-<i>ipso</i> rotamer A), 133.4 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i> rotamer B), 143.8 (C-<i>ipso</i> rotamer A), 143.9 (C-<i>ipso</i> rotamer B), 146.6 (C-<i>ipso</i> rotamer A), 146.7 (C-<i>ipso</i> rotamer B), 161.8 (d, <i>J</i> = 12.5 Hz, C-3 rotamer B), 161.9 (d, <i>J</i> = 11.5 Hz, C-3 rotamer A), 170.4 (d, <i>J</i> = 5.0 Hz, CO rotamer B), 170.6 (d, <i>J</i> = 5.5 Hz, CO rotamer A), 171.0 (d, <i>J</i> = 13.5 Hz, CO rotamer A), 171.3 (d, <i>J</i> = 10.0 Hz, CO rotamer B). HRMS C<sub>23</sub>H<sub>25</sub>N<sub>3</sub>O<sub>7</sub>P [M + H]<sup>+</sup> 486.1425; found, 486.1424. Anal. Calcd for C<sub>23</sub>H<sub>24</sub>N<sub>3</sub>O<sub>7</sub>P: C, 56.91%; H, 4.98%; N, 8.66%. Found: C, 57.33%; H, 5.11%; N, 8.59%.</div></div><div id="sec4_1_2_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(1,1′-Biphenyl)-4-yl-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9z</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (5 mg, 0.03 mmol), <i>N</i>-(<i>p</i>-phenylphenyl)maleimide (200 mg, 0.8 mmol), acetonitrile (4 mL), and diethyl α-phenylisocyanomethylphosphonate (134 mg, 0.5 mmol) gave <b>9z</b> (129 mg, 49%) as a yellowish oil, after column chromatography (EtOAc). IR (NaCl) 3483, 2982, 2928, 1716, 1628, 1487, 1378, 1248, 1182, 1052, 1024, 969, 839, 792 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.20 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.29 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.97 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.09–4.23 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.30 (dd, <i>J</i> = 18.5, 9.0 Hz, 1H, H-6a), 4.51 (ddd, <i>J</i> = 9.0, 3.0, 1.5 Hz, 1H, H-3a), 6.80 (m, 2H, ArH), 7.31–7.42 (m, 6H, ArH), 7.47–7.51 (m, 4H, ArH), 7.71 (br d, <i>J</i> = 7.5 Hz, 2H, ArH), 8.08 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.2 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.3 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.2 (d, <i>J</i> = 2.5 Hz, C-6a), 60.2 (C-3a), 63.5 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.6 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.5 (d, <i>J</i> = 157.0 Hz, C-1), 126.3 (2CHAr), 127.1 (2CHAr), 127.7 (CHAr), 127.8 (2CHAr), 127.9 (d, <i>J</i> = 1.5 Hz, 2CHAr), 128.4 (d, <i>J</i> = 6.0 Hz, 2CHAr), 128.6 (d, <i>J</i> = 2.0 Hz, CHAr), 128.8 (2CHAr), 130.0 (C-<i>ipso</i>), 133.4 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i>), 140.0 (C-<i>ipso</i>), 141.7 (C-<i>ipso</i>), 162.3 (d, <i>J</i> = 12.0 Hz, C-3), 170.9 (d, <i>J</i> = 5.5 Hz, CO), 171.7 (d, <i>J</i> = 11.5 Hz, CO). HRMS C<sub>28</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup>503.1730; found, 503.1727. Purity 98.5% (<i>t</i><sub>R</sub> = 4.71 min).</div></div><div id="sec4_1_2_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-4,6-Dioxo-1-phenyl-5-(<i>p</i>-tolyl)-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9aa</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (6 mg, 0.04 mmol), <i>N</i>-(4-methylphenyl)maleimide (153 mg, 0.9 mmol), acetonitrile (4.5 mL), and diethyl α-phenylisocyanomethylphosphonate (168 mg, 0.6 mmol) gave <b>9aa</b> (199 mg, 75%) as a white solid, after column chromatography (EtOAc/hexane 3:2 to 9:1). Mp 156–158 °C (EtOAc). IR (ATR) 3476, 2936, 2863, 1711, 1632, 1520, 1368, 1240, 1181, 1025, 971, 740, 583 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.19 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.29 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 2.28 (s, 3H, CH<sub>3</sub>–Ar), 3.93 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.11–4.19 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.24 (dd, <i>J</i> = 16.5, 9.0, 1H, H-6a), 4.46 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a), 6.60 (m, 2H, ArH), 7.09 (m, 2H, ArH), 7.31–7.38 (m, 3H, ArH), 7.68–7.70 (m, 2H, ArH), 8.05 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.2 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.3 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 21.1 (CH<sub>3</sub>–Ar), 48.1 (d, <i>J</i> = 3.0 Hz, C-6a), 60.2 (C-3a), 63.5 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.6 (d, <i>J</i> = 8.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.2 (d, <i>J</i> = 156.0 Hz, C-1), 125.8 (2CHAr), 127.9 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.3 (CHAr), 128.4 (CHAr), 128.5 (d, <i>J</i> = 2.0 Hz, CHAr), 128.5 (C-<i>ipso</i>), 129.6 (2CHAr), 133.5 (d, <i>J</i> = 4.0 Hz, C<i>-ipso</i>), 138.8 (C<i>-ipso</i>), 162.4 (d, <i>J</i> = 12.0 Hz, C-3), 171.1 (d, <i>J</i> = 5.0 Hz, CO), 171.7 (d, <i>J</i> = 11.0 Hz, CO). HRMS C<sub>23</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 441.1574; found, 441.1572. Anal. Calcd for C<sub>23</sub>H<sub>25</sub>N<sub>2</sub>O<sub>5</sub>P: C, 62.72%; H, 5.72%; N, 6.36%. Found: C, 62.87%; H, 5.82%; N, 6.18%.</div></div><div id="sec4_1_2_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-4,6-Dioxo-5-(4-phenoxyphenyl)-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9ab</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (9 mg, 0.05 mmol), <i>N</i>-(4-phenoxyphenyl)maleimide (371 mg, 1.4 mmol), acetonitrile (7 mL), and diethyl α-phenylisocyanomethylphosphonate (228 mg, 0.9 mmol) gave <b>9ab</b> (302 mg, 65%) as a white solid, after column chromatography (EtOAc). Mp 165–167 °C (EtOAc). IR (NaCl) 3488, 3057, 2984, 1783, 1715, 1628, 1488, 1242, 1187, 1024, 700, 578 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.19 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 1.28 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub>), 3.95 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.10–4.19 (m, 3H, C<i>H</i><sub>2</sub>CH<sub>3</sub>), 4.25 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a), 4.46–4,49 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a), 6.64–6.67 (m, 2H, ArH), 6.87–6.89 (m, 2H, ArH), 6.96–6.98 (m, 2H, ArH), 7.12 (m, 1H, ArH), 7.30–7.38 (m, 5H, ArH), 7.69 (d, <i>J</i> = 8.0 Hz, 2H, ArH), 8.01 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3). <sup>13</sup>C NMR (100.6 MHz) δ 16.2 (d, <i>J</i> = 4.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 16.3 (d, <i>J</i> = 4.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub>), 48.2 (d, <i>J</i> = 3.0 Hz, C-6a), 60.1 (C-3a), 63.5 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 64.6 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub>), 86.2 (d, <i>J</i> = 157.0 Hz, C-1), 118.5 (2CHAr), 119.6 (2CHAr), 124.0 (2CHAr), 125.6 (C-<i>ipso</i>), 127.5 (2CHAr), 127.9 (d, <i>J</i> = 2.0 Hz, 2CHAr), 128.4 (d, <i>J</i> = 6.0 Hz, CHAr), 128.6 (d, <i>J</i> = 2.0. Hz, CHAr), 129.8 (2CHAr), 133.5 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i>), 156.2 (C-<i>ipso</i>), 157.6 (C-<i>ipso</i>), 162.2 (d, <i>J</i> = 12.0 Hz, C-3), 171.0 (d, <i>J</i> = 6.0 Hz, CO), 171.7 (d, <i>J</i> = 11.0 Hz, CO). HRMS C<sub>28</sub>H<sub>28</sub>N<sub>2</sub>O<sub>6</sub>P [M + H]<sup>+</sup> 519.1679; found, 519.1675. Anal. Calcd for C<sub>28</sub>H<sub>27</sub>N<sub>2</sub>O<sub>6</sub>P: C, 64.86%; H, 5.25%; N, 5.40%. Found: C, 65.12%; H, 5.26%; N, 5.41%.</div></div><div id="sec4_1_2_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(Naphth-1-yl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9ac</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (3 mg, 0.02 mmol), <i>N</i>-(naphth-1-yl)maleimide (100 mg, 0.5 mmol), acetonitrile (2 mL), and diethyl α-phenylisocyanomethylphosphonate (76 mg, 0.3 mmol) gave <b>9ac</b> (70 mg, 49%) as a white solid, after column chromatography (EtOAc/hexane 1:1 to 9:1). Mp 197–198 °C (EtOAc). IR (ATR) 3480, 2927, 2853, 1716, 1598, 1446, 1397, 1358, 1240, 1177, 1039, 1025, 961, 775, 706, 583 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.17 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer A), 1.20 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer B), 1.30 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer A), 1.31 (t, <i>J</i> = 7.0 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer B), 3.90 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub> rotamer A), 3.98 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub> rotamer B), 4.04–4.26 (m, 6H, C<i>H</i><sub>2</sub>CH<sub>3</sub> rotamer A and B), 4.43 (dd, <i>J</i> = 18.5, 9.0 Hz, 1H, H-6a rotamer A), 4.46 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a rotamer B), 4.63 (ddd, <i>J</i> = 9.0, 3.5, 1.5 Hz, 1H, H-3a rotamer A), 4.67 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a rotamer B), 6.33 (dd, <i>J</i> = 8.5, 1.0 Hz, 1H, ArH rotamer A), 6.39 (dd, <i>J</i> = 7.5, 1.0 Hz, 1H, ArH rotamer B), 7.12 (ddd, <i>J</i> = 8.5, 7.0, 1.5 Hz, 1H, ArH rotamer A), 7.21 (dd, <i>J</i> = 7.5, 1.0 Hz, 1H, ArH rotamer A), 7.28–7.49 (m, 12H, ArH rotamer A and B), 7.73–7.90 (m, 8H, ArH rotamer A and B), 8.12 (dd, <i>J</i> = 5.0 Hz, 1.5 Hz, 1H, H-3 rotamer B), 8.13 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3 rotamer A). <sup>13</sup>C NMR (100.6 MHz) δ 16.2 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer A or B), 16.3 (d, <i>J</i> = 5.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer A or B), 16.3 (d, <i>J</i> = 6.0 Hz, 2CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer A or B), 48.3 (d, <i>J</i> = 2.5 Hz, C-6a rotamer A), 48.6 (d, <i>J</i> = 2.5 Hz, C-6a rotamer B), 60.3 (C-3a rotamer B), 61.0 (C-3a rotamer A), 63.6 (d, <i>J</i> = 7.5 Hz, 2<i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer A and B), 64.7 (d, <i>J</i> = 7.0 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer B), 64.7 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer A), 86.2 (d, <i>J</i> = 157.5 Hz, C-1 rotamer B), 86.5 (d, <i>J</i> = 155.0 Hz, C-1 rotamer A), 121.2 (CHAr rotamer A), 121.6 (CHAr rotamer B), 125.0 (CHAr rotamer A), 125.1 (CHAr rotamer B), 125.7 (CHAr rotamer B), 126.0 (CHAr rotamer A), 126.3 (CHAr rotamer A), 126.5 (CHAr rotamer B), 127.0 (CHAr rotamer A), 127.2 (CHAr rotamer B), 127.6 (C-<i>ipso</i> rotamer A), 127.8 (C-<i>ipso</i> rotamer B), 127.9 (d, <i>J</i> = 2.0 Hz, 2CHAr rotamer A), 128.0 (d, <i>J</i> = 2.0 Hz, 2CHAr rotamer B), 128.3 (CHAr rotamer A), 128.4 (d, <i>J</i> = 6.0 Hz, CHAr rotamer B), 128.6 (d, <i>J</i> = 2.0 Hz, 2CHAr rotamer A), 128.7 (d, <i>J</i> = 2.5 Hz, 2CHAr rotamer B), 128.9 (CHAr rotamer B), 129.0 (CHAr rotamer A), 130.0 (CHAr rotamer A), 130.1 (CHAr rotamer B), 133.4 (d, <i>J</i> = 4.5 Hz, C-<i>ipso</i> rotamer A), 133.5 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i> rotamer B), 134.1 (C-<i>ipso</i> rotamer A), 134.2 (C-<i>ipso</i> rotamer B), 162.3 (d, <i>J</i> = 11.5 Hz, C-3 rotamer A), 162.4 (d, <i>J</i> = 12.0 Hz, C-3 rotamer B), 171.3 (d, <i>J</i> = 5.5 Hz, CO rotamer B), 171.4 (d, <i>J</i> = 5.5 Hz, CO rotamer A), 171.7 (d, <i>J</i> = 12.5 Hz, CO rotamer A), 171.9 (d, <i>J</i> = 11.5 Hz, CO rotamer B). HRMS C<sub>26</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 477.1574; found, 477.1571. Anal. Calcd For C<sub>26</sub>H<sub>25</sub>N<sub>2</sub>O<sub>5</sub>P: C, 65.54%; H, 5.29%; N, 5.88%. Found: C, 65.34%; H, 5.12%; N, 5.65%.</div></div><div id="sec4_1_2_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> Diethyl (1<i>RS</i>,3a<i>SR</i>,6a<i>SR</i>)-5-(2-Chloropyridin-3-yl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-1-phosphonate (<b>9ad</b>)</h5><div class="NLM_p last">Following the general procedure, AgOAc (12 mg, 0.07 mmol), <i>N</i>-(2-chloropyridin-3-yl)maleimide (250 mg, 1.2 mmol), acetonitrile (6 mL), and diethyl α-phenylisocyanomethylphosphonate (203 mg, 0.8 mmol) gave <b>9ad</b> (224 mg, 61%) as a white solid, after column chromatography (EtOAc). Mp 176–178 °C (EtOAc). IR (ATR) 3483, 2991, 2948, 1790, 1722, 1564, 1420, 1242, 1050, 752, 699, 574 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HETCOR) δ 1.14 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer A), 1.19 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer B), 1.28 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer A), 1.29 (td, <i>J</i> = 7.0, 0.5 Hz, 3H, CH<sub>2</sub>C<i>H</i><sub>3</sub> rotamer B), 3.82 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub> rotamer A), 3.95 (m, 1H, C<i>H</i><sub>2</sub>CH<sub>3</sub> rotamer B), 4.05–4.20 (m, 6H, C<i>H</i><sub>2</sub>CH<sub>3</sub> rotamer A and B), 4.36 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a rotamer A), 4.38 (dd, <i>J</i> = 18.0, 8.5 Hz, 1H, H-6a rotamer B), 4.53 (ddd, <i>J</i> = 8.5, 4.0, 1.5 Hz, 1H, H-3a rotamer A), 4.58 (ddd, <i>J</i> = 8.5, 3.0, 1.5 Hz, 1H, H-3a rotamer B), 6.59 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H, ArH rotamer B), 7.14 (dd, <i>J</i> = 8.0, 5.0 Hz, 1H, ArH rotamer B), 7.27 (dd, <i>J</i> = 8.0, 5.0 Hz, 1H, ArH rotamer A), 7.31–7.37 (m, 6H, 3ArH rotamer A and 3ArH rotamer B), 7.46 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H, ArH rotamer A), 7.69 (m, 2H, ArH rotamer A), 7.76 (m, 2H, ArH rotamer B), 8.02 (dd, <i>J</i> = 5.5 Hz, 1.5 Hz, 1H, H-3 rotamer A), 8.07 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H, H-3 rotamer B), 8.36 (dd, <i>J</i> = 5.0, 2.0 Hz, 2H, ArH rotamer A and rotamer B). <sup>13</sup>C NMR (100.6 MHz) δ 16.3 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer A), 16.4 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer B), 16.4 (d, <i>J</i> = 6.0 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer A), 16.5 (d, <i>J</i> = 5.5 Hz, CH<sub>2</sub><i>C</i>H<sub>3</sub> rotamer B), 48.4 (d, <i>J</i> = 2.5 Hz, C-6a rotamer A), 49.0 (d, <i>J</i> = 2.5 Hz, C-6a rotamer B), 60.4 (C-3a rotamer A), 61.0 (C-3a rotamer B), 63.7 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer A), 63.8 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer B), 64.9 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer B), 65.0 (d, <i>J</i> = 7.5 Hz, <i>C</i>H<sub>2</sub>CH<sub>3</sub> rotamer A), 86.1 (d, <i>J</i> = 158.0 Hz, C-1 rotamer A or B), 86.9 (d, <i>J</i> = 153.0 Hz, C-1 rotamer A or B), 123.0 (CHAr rotamer A), 123.2 (CHAr rotamer B), 126.4 (C-<i>ipso</i> rotamer A), 126.5 (C-<i>ipso</i> rotamer B), 127.9 (d, <i>J</i> = 2.0 Hz, 2CHAr rotamer A), 128.1 (d, <i>J</i> = 1.5 Hz, 2CHAr rotamer B), 128.6 (d, <i>J</i> = 5.5 Hz, 2CHAr rotamer B), 128.8 (d, <i>J</i> = 4.5 Hz, CHAr rotamer A or B), 128.8 (CHAr rotamer A or B), 128.9 (d, <i>J</i> = 5.5 Hz, 2CHAr rotamer A), 132.9 (d, <i>J</i> = 4.5 Hz, C-<i>ipso</i> rotamer A), 133.6 (d, <i>J</i> = 4.0 Hz, C-<i>ipso</i> rotamer B), 138.4 (CHAr rotamer B), 138.6 (CHAr rotamer A), 149.2 (C-<i>ipso</i> rotamer A), 149.5 (C-<i>ipso</i> rotamer B), 150.3 (CHAr rotamer A), 150.5 (CHAr rotamer B), 161.6 (d, <i>J</i> = 11.5 Hz, C-3 rotamer A), 162.0 (d, <i>J</i> = 12.5 Hz, C-3 rotamer B), 169.7 (d, <i>J</i> = 5.0 Hz, CO rotamer A), 169.8 (d, <i>J</i> = 5.5 Hz, CO rotamer B), 170.5 (d, <i>J</i> = 11.5 Hz, CO rotamer A), 170.6 (d, <i>J</i> = 14.5 Hz, CO rotamer B). HRMS C<sub>21</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>5</sub>P [M + H]<sup>+</sup> 462.0980; found, 462.0980. Anal. Calcd For C<sub>21</sub>H<sub>21</sub>ClN<sub>3</sub>O<sub>5</sub>P: C, 54.61%; H, 4.58%; N, 9.10%. Found: C, 55.01%; H, 4.67%; N, 8.86%.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Theoretical Calculations</h3><div class="NLM_p last">The study of the [3 + 2] cycloaddition reaction (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) was performed for model systems that include the reactants (dimethyl α-phenylisocyanomethylphosphonate and <i>N</i>-methylmaleimide) and a silver cation bound to acetonitrile as the catalytic moiety. Geometry optimizations were carried out using the B3LYP functional<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> and the 6-31+G(d) basis set<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> for all atoms but silver, which was treated with the LANL2DZ basis<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> in conjunction with the effective core potential for inner electrons. The nature of the stationary points (reactant, transition state, and products) was confirmed by inspection of the vibrational frequencies. Intrinsic reaction coordinate calculations<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> were carried out to check the connection between the transition states and the minimum energy structures. To further check the relative stabilities of transition states, geometry optimizations were also performed using the MN15L functional.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Finally, solvation calculations were performed with the SMD version<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> of the IEFPCM model to take into account the contribution due to solvation in acetonitrile. All calculations were performed with Gaussian 16.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Binding Studies</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Preparation of Cellular Membranes</h4><div class="NLM_p">Male Swiss mice (final age 8–10 weeks) and Sprague–Dawley rats weighting 250–300 g (Harlan Interfauna Iberica, Spain) were killed, and the brain cortex was dissected and stored at −70 °C until assays were performed. Kidneys were also obtained from male Sprague–Dawley rats. All animal experimental protocols were performed in agreement with European Union regulations (O.J. of E.C. L 358/1 18/12/1986).</div><div class="NLM_p">Human brain samples were obtained at autopsy in the Basque Institute of Legal Medicine, Bilbao, Spain. Samples from the prefrontal cortex (Brodmann’s area 9) were dissected at the time of autopsy and immediately stored at −70 °C until assay. The study was developed in compliance with policies of research and ethical review boards for post-mortem brain studies.</div><div class="NLM_p last">To obtain cellular membranes (P2 fraction), the different samples were homogenized using an ultraturrax in 30 volumes of homogenization buffer (0.25 M sucrose, 1 mM MgCl<sub>2</sub>, 5 mM Tris-HCl, pH 7.4). The crude homogenate was centrifuged for 5 min at 1000<i>g</i> (4 °C), and the supernatant was centrifuged again for 10 min at 40000<i>g</i> (4 °C). The resultant pellet was washed twice in 20 volumes of homogenization buffer and recentrifuged in similar conditions. Protein content was measured according to the method of Bradford using BSA as standard.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Competition Binding Assays</h4><div class="NLM_p">The pharmacological activity of the compounds was evaluated through competition binding studies against the I<sub>2</sub>-IR selective radioligand [<sup>3</sup>H]2-[(2-benzofuranyl)-2-imidazoline (2-BFI), the α<sub>2</sub>-adrenergic receptor selective radioligand [<sup>3</sup>H]RX821002 (2-methoxyidazoxan) or the I<sub>1</sub>-IR selective radioligand [<sup>3</sup>H]clonidine. Specific binding was measured in 0.25 mL aliquots (50 mM Tris-HCl, pH 7.5) containing 100 μg of membranes, which were incubated in 96-well plates either with [<sup>3</sup>H]2-BFI (2 nM) for 45 min at 25 °C, [<sup>3</sup>H]RX821002 (1 nM) for 30 min at 25 °C, or [<sup>3</sup>H]clonidine (5 nM) for 45 min at 22 °C, in the absence or presence of the competing compounds (10<sup>–12</sup> to 10<sup>–3</sup> M, 10 concentrations). [<sup>3</sup>H]Clonidine binding was performed in the presence of 10 μM adrenaline to preclude binding to α<sub>2</sub>-AR.</div><div class="NLM_p last">Incubations were terminated by separating free ligand from bound ligand by rapid filtration under vacuum (1450 Filter Mate Harvester, PerkinElmer) through GF/C glass fiber filters. The filters were then rinsed three times with 300 μL of binding buffer, air-dried (120 min), and counted for radioactivity by liquid scintillation spectrometry using a MicroBeta TriLux counter (PerkinElmer). Specific binding was determined and plotted as a function of the compound concentration. Nonspecific binding was determined in the presence of idazoxan (10<sup>–5</sup> M), a compound with well established affinity for I<sub>2</sub>-IR and α<sub>2</sub>-adrenergic receptors, in [<sup>3</sup>H]2-BFI and [<sup>3</sup>H]RX821002 assays or rilmenidine (10<sup>–5</sup> M) in [<sup>3</sup>H]clonidine experiments. Analyses of competition experiments to obtain the inhibition constant (<i>K</i><sub>i</sub>) were performed by nonlinear regression using the GraphPad Prism program. <i>K</i><sub>i</sub> values were normalized to p<i>K</i><sub>i</sub> values. I<sub>2</sub>-IR/α<sub>2</sub> selectivity index was calculated as the antilogarithm of the difference between p<i>K</i><sub>i</sub> values for I<sub>2</sub>-IR and p<i>K</i><sub>i</sub> values for α<sub>2</sub>-AR. For [<sup>3</sup>H]clonidine experiments, IC<sub>50</sub> values were calculated (the concentration of tested ligand that displaces 50% of specifically bound [<sup>3</sup>H]clonidine).</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> I<sub>1</sub>-Binding Site Assay</h3><div class="NLM_p">Kidneys were obtained from male Sprague–Dawley rats (250–280 g) and cellular membranes (P2 fractions) prepared according to established methods. [<sup>3</sup>H]RX821002 (2-methoxyidazoxan) binds to α<sub>2</sub>-adrenoceptor subtypes and a nonadrenoceptor imidazoline binding site in rat kidney.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div><div class="NLM_p">Competition binding assays were performed as previously reported with minor modifications.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> [<sup>3</sup>H]Clonidine (5 nM, Perkin–Elmer) was bound in the presence of 10 μM adrenaline to preclude binding to α<sub>2</sub>-adrenoceptors. The specific component was defined by 1 mM rilmenidine. Membrane aliquots (220 μL, 0.1–0.12 mg of protein) were incubated with 10 concentrations of the test compounds over the range 10<sup>–12</sup> to 10<sup>–3</sup> M.</div><div class="NLM_p last">Incubations were carried out in 96 well plates (final volume 250 μL/well) in 50 mM Tris–HCl buffer (pH 7.4) supplemented with 1 mM MgCl<sub>2</sub> at 22 °C for 45 min with agitation (400 rpm). Bound radioligand and free radioactivity were separated by rapid filtration through presoaked (0.5% polyethylenimine) glass-fiber filters (Whatman GFB). Trapped radioligand was determined by liquid scintillation counting, and the data were analyzed with GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, CA, USA) to yield IC<sub>50</sub> values (the concentration of tested ligand that displaces 50% of specifically bound [<sup>3</sup>H]clonidine).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 3D-QSAR Study</h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Data Set Preparation</h4><div class="NLM_p last">The data set composed of previously synthesized and in vitro tested bicyclic α-iminophosphonates with different affinities on I<sub>2</sub>-IR and α<sub>2</sub>-AR receptors was used for the creation of the 3D-QSAR models (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Additionally, to compare and validate our results, we have added four standards in both data sets, tracizoline, idazoxan, BU99008, and LSL60101. Examined compounds cover wide range of experimental activity (p<i>K</i><sub>i</sub> I<sub>2</sub>, 3.11–10.28; p<i>K</i><sub>i</sub> α<sub>2</sub>, 3.59–10.27) and structural diversity, which ensure good quality and applicability of the created 3D-QSAR models. Selection of dominant forms of studied ligands at physiological pH 7.4 was obtained by the Marvin Sketch 5.5.1.0 program.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Subsequently, they were initially preoptimized with semiempirical/PM3 (Parameterized Model revision 3) method<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73,74)</a> and then by ab initio Hartree–Fock/3-21G method<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> using Gaussian 09 software<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> included in Chem3D Ultra program.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Obtained ligands’ conformations were used for calculation of specific molecular descriptors (grid independent descriptors, GRIND)<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> and 3D-QSAR model building.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 3D-QSAR Study</h4><div class="NLM_p last">3D-QSAR models were created using Pentacle program,<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> which calculates GRID independent descriptors (GRIND and GRIND2) from molecular interaction fields (MIFs). Four different probes were used to calculate MIFs: O probe (hydrogen bond acceptor groups), N1 probe (hydrogen bond donor groups), DRY probe (hydrophobic interactions), and TIP probe (the shape of molecule). The grid spacing was set to 0.5. ALMOND algorithm was used for the extraction of the most relevant regions, which represent favorable interaction positions between ligand and probe. Consistently Large Auto and Cross Correlation (CLACC) algorithm was used to calculate GRIND descriptors using the correlation between same and different nodes. The smoothing window was set to 0.8 Å. Partial Least Square (PLS) regression was applied for 3D-QSAR model building. Initial number of descriptors was reduced using Fractional Factorial Design (FFD) to obtain most significant GRIND variables. The results of node–node energies between the same or a different probe were then presented as correlograms.<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79,80)</a></div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> <i>In vivo</i> studies in mice</h3><div class="NLM_p last">Studies and procedures involving mouse brain dissection and extractions followed the ARRIVE<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> and standard ethical guidelines (European Communities Council Directive 2010/63/EU and Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research, National Research Council 2003) and were approved by the respective Local Bioethical Committees (Universitat de les Illes Balears-CAIB and University of Barcelona-GenCat). All efforts were made to minimize the number of animals used and their suffering.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Hypothermia</h3><div class="NLM_p last">For this study a total of 35 adult CD-1 mice and 9 adult Sprague–Dawley rats bred and housed in standard cages under defined environmental conditions (22 °C, 70% humidity, and 12 h light/dark cycle, lights on at 8:00 AM, with free access to a standard diet and tap water) in the animal facility at the University of the Balearic Islands were used. Animals were habituated to the experimenter by being handled and weighed for 2 days prior to any experimental procedures. For the acute treatment, mice or rats received a single dose of <b>9d</b> (20 mg/kg, ip, <i>n</i> = 12 for mice, and 20 or 35 mg/kg, ip, <i>n</i> = 3 per dose for rats) or vehicle (1 mL/kg of DMSO, ip, <i>n</i> = 13 for mice and <i>n</i> = 3 for rats), while for the repeated treatment, mice were daily treated with <b>9d</b> (20 mg/kg, ip, <i>n</i> = 5) or vehicle (ip, <i>n</i> = 5) for 5 consecutive days. The possible hypothermic effect exerted by <b>9d</b> was evaluated by measuring changes in rectal temperature before any drug treatment (basal value) and 1 h (for mice) or 1, 2, and 3 h (for rats) after drug injection by a rectal probe connected to a digital thermometer (Compact LCD display thermometer, SA880-1M, RS, Corby, UK). Animals were sacrificed right after the last rectal temperature measurement, and the hippocampus was freshly dissected and kept at −80 °C for future biochemical analysis.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Western Blot Analysis for FADD Protein</h3><div class="NLM_p last">Hippocampal sample proteins (40 μg) were separated by sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) on 10% polyacrylamide minigels (Bio-Rad) and transferred onto nitrocellulose membranes by standard Western blot procedures as described previously.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The membranes were incubated overnight with anti-FADD (H-181) Ab, no. sc-5559 (Santa Cruz Biotechnology, Santa Cruz, CA) and then stripped and reprobed for β-actin (clone AC-15) Ab, no. A1978 (Sigma). Following secondary antibody (anti-rabbit or anti-mouse) incubation and ECL detection system (Amersham, Buckinghamshire, UK), proteins were visualized on autoradiographic films (Amersham ECL Hyperfilm). Upon densitometric scanning (GS-800 Imaging Densitometer, Bio-Rad) of immunoreactive bands (integrated optical density, IOD) the amount of FADD protein in brain samples of mice from different treatment groups was compared with that of vehicle-treated controls (100%) in the same gel. Quantification of β-actin contents served as a loading control (no differences between treatment groups, data not shown). Each brain sample (and target protein) was quantified in 2–4 gels, and the mean value was used as a final estimate.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 5xFAD <i>In Vivo</i> Experimental Design</h3><div class="NLM_p">Female 5xFAD and WT mice, 5-months-old (<i>n</i> = 51), were used to carry out cognitive and molecular analyses. The 5xFAD mouse is a double transgenic APP/PS1 that coexpresses five mutations associated with AD and that rapidly develops severe amyloid pathology with high levels of intraneuronal Aβ42 around 2 months of age. The model was generated by the introduction of human APP with the Swedish (K670N/M671L), Florida (I716V), and London (Val717Ile) mutations and the introduction of PS1 M146L and L286V. Moreover, 5xFAD mouse presents neuronal loss and cognitive deficits in spatial learning (at approximately four to five months).<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></div><div class="NLM_p">The animals were randomly allocated to three experimental groups: WT control (<i>n</i> = 12) and 5xFAD control (<i>n</i> = 14), animals administered vehicle (2-hydroxypropyl)-β-cyclodextrin 1.8%, and 5xFAD treated with <b>9d</b> 5 (mg/kg)/day (<i>n</i> = 25), diluted in 1.8% (2-hydroxypropyl)-β-cyclodextrin and administered through drinking water, up to euthanasia. Weight and water consumption were controlled each week, and the <b>9d</b> concentration was adjusted accordingly to reach the precise dose. Animals had free access to food and water and were kept under standard temperature conditions (22 ± 2 °C) and 12 h/12 h light–dark cycles (300 lx/0 lx).</div><div class="NLM_p last">After 4 weeks of treatment period, animals were subjected to cognitive tests to study the effect of treatment on learning and memory, including short- and long-term memory (NORT). Mice were euthanized 3 days after the behavioral test completion by cervical dislocation. Brains were immediately removed from the skull, and the hippocampus was then isolated and frozen on powdered dry ice. They were maintained at −80 °C for biochemical experiments.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Behavioral Testing: NORT</h3><div class="NLM_p last">In brief, mice were placed in a black L-shape maze consisting of two arms at 90°, 25 cm long, 20 cm high, and 5 cm wide. The mice were habituated to the apparatus for 10 min on 3 consecutive days in the habituation phase. Afterward, on day 4, the training session took place, in which two identical objects (A) were placed in the maze and the mice were allowed to explore freely for 10 min. Two hours after training sessions, one of the objects was replaced with a novel object (B) to assess short-term-memory. Again, the amount of time spent exploring each object was scored. During this second trial, objects A and B were placed in the maze, and the times that the animal took to explore the new object (TN) and the old object (TO) were recorded. A discrimination index (DI) was calculated, defined as (TN – TO)/(TN + TO). Twenty-four hours after the acquisition trial, the mice were tested again to assess long-term memory, with a new object substituting object B and a new DI calculated. Exploration of an object by a mouse was defined as pointing the nose toward the object at a distance ≤2 cm or touching it with the nose. Turning or sitting around the object was not considered exploration. To avoid object preference biases, objects A and B were counterbalanced so that one-half of the animals in each experimental group were first exposed to object A and then to object B, whereas the other half first saw object B and then object A. All sessions were videotaped, and the time spent with each object was manually recorded. The maze, the surface, and the objects were cleaned with 70% ethanol between the animal trials to eliminate olfactory cues.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Determination of Oxidative Stress</h3><div class="NLM_p last">Hydrogen peroxide from brain samples of 10 mice of each group was measured as an indicator of OS, and it was quantified using the Hydrogen Peroxide Assay Kit (Sigma-Aldrich, St. Louis, MI) according to the manufacturer’s instructions.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> RNA Extraction and Gene Expression Determination</h3><div class="NLM_p">Total RNA isolation was carried out using TRIzol reagent according to manufacturer’s instructions. The yield, purity, and quality of RNA were determined spectrophotometrically with a NanoDrop ND-1000 (Thermo Scientific) apparatus and an Agilent 2100B Bioanalyzer (Agilent Technologies). RNAs with 260/280 ratios and RNA integrity number (RIN) higher than 1.9 and 7.5, respectively, were selected. Reverse transcription-polymerase chain reaction (RT-PCR) was performed as follows: 2 μg of mRNA (mRNA) was reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time quantitative PCR (qPCR) from 48 mice of both strains (<i>n</i> = 4–6 per group) was used to quantify mRNA expression of OS and inflammatory genes.</div><div class="NLM_p">SYBR Green real-time PCR was performed on a Step One Plus Detection System (Applied-Biosystems) employing SYBR Green PCR Master Mix (Applied-Biosystems). Each reaction mixture contained 6.75 μL (2 μg) of complementary DNA (cDNA), 0.75 μL of each primer (of which concentration was 100 nM), and 6.75 μL of SYBR Green PCR Master Mix (2×).</div><div class="NLM_p">TaqMan-based real-time PCR (Applied Biosystems) was also performed in a Step One Plus Detection System (Applied-Biosystems). Each 20 μL of TaqMan reaction contained 9 μL (25 ng) of cDNA, 1 μL of 20× probe of TaqMan Gene Expression Assays, and 10 μL of 2× TaqMan Universal PCR Master Mix.</div><div class="NLM_p last">Data were analyzed utilizing the comparative cycle threshold (Ct) method (ΔΔCt), where the housekeeping gene level was used to normalize differences in sample loading and preparation.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Normalization of expression levels was performed with <i>β-actin</i> gene for SYBR Green-based real-time PCR and TATA-binding protein (<i>Tbp</i>) gene for TaqMan-based real-time PCR. Primers sequences and TaqMan probes used in this study are presented in <a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">Table S10</a>. Each sample was analyzed in duplicate, and the results represent the <i>n</i>-fold difference of the transcript levels among different groups.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82"><a href="/doi/suppl/10.1021/acs.jmedchem.9b02080" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b02080?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02080</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental procedures for synthesis of <b>10a</b>–<b>10c</b> and <b>11</b>, theoretical calculations, 3D-QSAR study, in vitro BBB assay, DMPK assays, receptor characterization panel, in vivo data, tables of <sup>1</sup>H and <sup>13</sup>C spectra, and X-ray crystallography data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf">jm9b02080_si_001.pdf (14.37 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_003.csv">jm9b02080_si_003.csv (3.77 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b02080" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76843" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76843" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carmen Escolano</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology,
Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences,
and Institute of Biomedicine (IBUB), University
of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9117-8239" title="Orcid link">http://orcid.org/0000-0002-9117-8239</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7f1c1a0c1c10131e11103f0a1d511a1b0a"><span class="__cf_email__" data-cfemail="6704021404080b06090827120549020312">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sònia Abás</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology,
Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences,
and Institute of Biomedicine (IBUB), University
of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sergio Rodríguez-Arévalo</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology,
Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences,
and Institute of Biomedicine (IBUB), University
of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Bagán</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology,
Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences,
and Institute of Biomedicine (IBUB), University
of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Griñán-Ferré</span> - <span class="hlFld-Affiliation affiliation">Pharmacology
Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and
Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Foteini Vasilopoulou</span> - <span class="hlFld-Affiliation affiliation">Pharmacology
Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and
Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Iria Brocos-Mosquera</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, and Centro de Investigación
Biomédica en Red de Salud Mental, CIBERSAM, University of the Basque Country, UPV/EHU, E-48940 Leioa, Bizkaia, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carolina Muguruza</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, and Centro de Investigación
Biomédica en Red de Salud Mental, CIBERSAM, University of the Basque Country, UPV/EHU, E-48940 Leioa, Bizkaia, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0477-5757" title="Orcid link">http://orcid.org/0000-0002-0477-5757</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Belén Pérez</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Therapeutic and Toxicology, Autonomous University of Barcelona, E-08193 Barcelona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elies Molins</span> - <span class="hlFld-Affiliation affiliation">Institut
de Ciència de Materials de Barcelona (CSIC), Campus UAB, E-08193 Cerdanyola, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1012-0551" title="Orcid link">http://orcid.org/0000-0003-1012-0551</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">F. Javier Luque</span> - <span class="hlFld-Affiliation affiliation">Department
of Nutrition, Food Sciences and Gastronomy, School of Pharmacy and
Food Sciences, Institute of Biomedicine (IBUB), and Institute of Theoretical
and Computational Chemistry (IQTCUB), University
of Barcelona, E-08921 Santa Coloma de Gramanet, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8049-3567" title="Orcid link">http://orcid.org/0000-0002-8049-3567</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pilar Pérez-Lozano</span> - <span class="hlFld-Affiliation affiliation">Unit
of Pharmaceutical Technology, Pharmacy and Pharmaceutical Technology,
and Physical Chemistry Department, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6899-066X" title="Orcid link">http://orcid.org/0000-0001-6899-066X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven de Jonghe</span> - <span class="hlFld-Affiliation affiliation">Rega
Institute for Medical Research, Katholieke
Universiteit Leuven, 3000 Leuven, Belgium</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3872-6558" title="Orcid link">http://orcid.org/0000-0002-3872-6558</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dirk Daelemans</span> - <span class="hlFld-Affiliation affiliation">Rega
Institute for Medical Research, Katholieke
Universiteit Leuven, 3000 Leuven, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lieve Naesens</span> - <span class="hlFld-Affiliation affiliation">Rega
Institute for Medical Research, Katholieke
Universiteit Leuven, 3000 Leuven, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">José Brea</span> - <span class="hlFld-Affiliation affiliation">Innopharma
screening platform, BioFarma research group, Centro de Investigación
en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidad de Santiago de Compostela, 15782 Santiago
de Compostela, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. Isabel Loza</span> - <span class="hlFld-Affiliation affiliation">Innopharma
screening platform, BioFarma research group, Centro de Investigación
en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidad de Santiago de Compostela, 15782 Santiago
de Compostela, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Hernández-Hernández</span> - <span class="hlFld-Affiliation affiliation">IUNICS
University of the Balearic Islands (UIB), and Health Research Institute
of the Balearic Islands (IdISBa), Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jesús A. García-Sevilla</span> - <span class="hlFld-Affiliation affiliation">IUNICS
University of the Balearic Islands (UIB), and Health Research Institute
of the Balearic Islands (IdISBa), Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. Julia García-Fuster</span> - <span class="hlFld-Affiliation affiliation">IUNICS
University of the Balearic Islands (UIB), and Health Research Institute
of the Balearic Islands (IdISBa), Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Milica Radan</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Teodora Djikic</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katarina Nikolic</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mercè Pallàs</span> - <span class="hlFld-Affiliation affiliation">Pharmacology
Section, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and
Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3095-4254" title="Orcid link">http://orcid.org/0000-0003-3095-4254</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luis F. Callado</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, and Centro de Investigación
Biomédica en Red de Salud Mental, CIBERSAM, University of the Basque Country, UPV/EHU, E-48940 Leioa, Bizkaia, Spain</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>S.A. and S.R.-A. contributed equally to this work. C.G.-F., J.A.G.-S., M.J.G.-F., M.P., and C.E. designed the study. S.A., S.R.-A., and A.B. synthesized, purified, and characterized the I2-IR ligands. C.G.-F., F.V., and M.P. carried out the behavior and cognition studies and cellular parameter determination. I.B.-M., C.M., and L.F.C. performed the binding experiments. B.P. performed the PAMPA–BBB permeation experiments. E.M. conducted the X-ray crystallographic analysis. F.J.L. was in charge of the theoretical studies. P.P.-L. performed the physicochemical studies. S.L., D.D., and L.N. carried out the cytotoxicity studies. J.B. and M.I.L. determined the ADMET parameters. E.H.-H., J.A.G.-S., and M.J.G.-S. performed the hypothermic studies and analysis of FADD protein content. M.R., T.D., and K.N. carried out the 3D-QSAR study. C.G.-F., F.J.L, P.P.-L., J.A.G.-S., M.J.G.-S., L.F.C., K.N., M.P., and C.E. contributed to writing the manuscript. All the authors have read and approved the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): C.E., M.P., C.G.-F., S.A., L.-F.C., and J.A.G.-S. are inventors of the patent application on I2 imidazoline receptor ligands, WO2019/121853 (reference 29).<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e12884-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i84">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82006" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82006" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We strongly acknowledge the advice of Dr. Andrés G. Fernández (our mentor in the CaixaImpulse 2018 program) for invaluable advice. This study was supported by the Ministerio de Economı́a y Competitividad of Spain (SAF2016-77703) and the Basque Government (IT1211-19). The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434) under agreement CI18-00002. This activity has received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union’s Horizon 2020 research and innovation programme. C.G.-F, F.V., C.E., S.R.-A., A.B., and M.P. belong to 2017SGR106 (Generalitat de Catalunya). J.A.G.-S. is a member emeritus of the Institut d’Estudis Catalans. Financial support was provided for F.V. (University of Barcelona, APIF_2017), S.R.-A. (Generalitat de Catalunya, 2018FI_B_00227), A.B. (Institute of Biomedicine UB_2018), C.M. (Marie Sklodowska-Curie Actions Individual Fellowships H2020-MSCA-IF-2016, ID747487), and E.H.-H. (Consejerı́a de Innovación, Investigación y Turismo del Gobierno de las Islas Baleares y del Fondo Social Europeo, FPI/2102/2018). F.J.L. acknowledges the financial support from the Spanish Ministerio de Economı́a, Industria y Competitividad (grant MDM-2017-0767; AEI/FEDER UE), and Generalitat de Catalunya (grant 2017SGR1746). M.R., T.D., and K.N. kindly acknowledge Ministry of Science and Technological Development of the Republic of Serbia, Project Contract No. 172033, and HORISON2020-COST-Action CA18133 ERNEST: European Research Network on Signal Transduction.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">α<sub>2</sub>-AR</td><td class="NLM_def"><p class="first last">α<sub>2</sub> adrenergic receptor</p></td></tr><tr><td class="NLM_term">2-BFI</td><td class="NLM_def"><p class="first last">2-[(2-benzofuranyl)-2-imidazoline]</p></td></tr><tr><td class="NLM_term">B3LYP</td><td class="NLM_def"><p class="first last">3-parameter hybrid Becke exchange/Lee–Yang–Parr correlation</p></td></tr><tr><td class="NLM_term">BU224</td><td class="NLM_def"><p class="first last">2-(4,5-dihydroimidazol-2-yl)quinoline</p></td></tr><tr><td class="NLM_term">CCK<sub>A</sub></td><td class="NLM_def"><p class="first last">cholecystokinin type A receptor</p></td></tr><tr><td class="NLM_term">CCK<sub>B</sub></td><td class="NLM_def"><p class="first last">cholecystokinin type B receptor</p></td></tr><tr><td class="NLM_term"><i>Cxcl10</i></td><td class="NLM_def"><p class="first last">C-X-C motif chemokine 10 gene</p></td></tr><tr><td class="NLM_term">DI</td><td class="NLM_def"><p class="first last">discrimination index</p></td></tr><tr><td class="NLM_term">5xFAD</td><td class="NLM_def"><p class="first last">mouse model of amyloid deposition expressing five familial AD (FAD) mutations</p></td></tr><tr><td class="NLM_term">FADD</td><td class="NLM_def"><p class="first last">Fas-associated protein with death domain</p></td></tr><tr><td class="NLM_term">GRIND</td><td class="NLM_def"><p class="first last">Grid-independent descriptors</p></td></tr><tr><td class="NLM_term">HeLa</td><td class="NLM_def"><p class="first last">human cervical carcinoma cell line</p></td></tr><tr><td class="NLM_term">4-HNE</td><td class="NLM_def"><p class="first last">4-hydroxy-2-nonenal</p></td></tr><tr><td class="NLM_term">Hmox1</td><td class="NLM_def"><p class="first last">heme oxygenase (decycling) 1</p></td></tr><tr><td class="NLM_term">H<sub>2</sub>O<sub>2</sub></td><td class="NLM_def"><p class="first last">hydrogen peroxide</p></td></tr><tr><td class="NLM_term">IR</td><td class="NLM_def"><p class="first last">imidazoline receptors</p></td></tr><tr><td class="NLM_term">I<sub>1</sub>-IRs</td><td class="NLM_def"><p class="first last">imidazoline I<sub>1</sub> receptors</p></td></tr><tr><td class="NLM_term">I<sub>2</sub>-IRs</td><td class="NLM_def"><p class="first last">imidazoline I<sub>2</sub> receptors</p></td></tr><tr><td class="NLM_term">I<sub>3</sub>-IRs</td><td class="NLM_def"><p class="first last">imidazoline I<sub>3</sub> receptors</p></td></tr><tr><td class="NLM_term">LANLD2DZ</td><td class="NLM_def"><p class="first last">Los Alamos National Laboratory 2-double-z (density functional theory)</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin-Darby canine kidney</p></td></tr><tr><td class="NLM_term">MT4</td><td class="NLM_def"><p class="first last">human T-lymphocyte</p></td></tr><tr><td class="NLM_term">MRC-5</td><td class="NLM_def"><p class="first last">human embryonic lung fibroblast</p></td></tr><tr><td class="NLM_term">NORT</td><td class="NLM_def"><p class="first last">novel object recognition test</p></td></tr><tr><td class="NLM_term">iNOS</td><td class="NLM_def"><p class="first last">inducible nitric oxide synthase</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">oxidative stress</p></td></tr><tr><td class="NLM_term">PhosMic</td><td class="NLM_def"><p class="first last">diethyl isocyanomethylphosphonate</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>e</sub></td><td class="NLM_def"><p class="first last">permeability</p></td></tr><tr><td class="NLM_term">p<i>K</i><sub>I</sub></td><td class="NLM_def"><p class="first last">antilog of <i>K</i><sub>i</sub></p></td></tr><tr><td class="NLM_term">p<i>K</i><sub>iL</sub></td><td class="NLM_def"><p class="first last">low p<i>K</i><sub>i</sub> binding site</p></td></tr><tr><td class="NLM_term">p<i>K</i><sub>iH</sub></td><td class="NLM_def"><p class="first last">high p<i>K</i><sub>i</sub> binding site</p></td></tr><tr><td class="NLM_term">3D-QSAR</td><td class="NLM_def"><p class="first last">three-dimensional quantitative structure–activity relationship</p></td></tr><tr><td class="NLM_term">QM</td><td class="NLM_def"><p class="first last">quantum mechanical</p></td></tr><tr><td class="NLM_term">[<sup>3</sup>H]-RX821002</td><td class="NLM_def"><p class="first last"><sup>3</sup>H-labeled 2-methoxyidazoxan</p></td></tr><tr><td class="NLM_term">SAMP8</td><td class="NLM_def"><p class="first last">senescence accelerated mouse-prone 8</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term"><i>Tnf-α</i></td><td class="NLM_def"><p class="first last">tumor necrosis factor α gene</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">Vero</td><td class="NLM_def"><p class="first last">African green monkey kidney cell line</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">WT mice</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 82 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.</span></span> <span> </span><span class="NLM_article-title">Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>230</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=6146707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL2cXkvVeqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=1984&pages=232-236&author=P.+Bousquetauthor=J.+Feldmanauthor=J.+Schwartz&title=Central+cardiovascular+effects+of+alpha+adrenergic+drugs%3A+differences+between+catecholamines+and+imidazolines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Central cardiovascular effects of alpha adrenergic drugs:  differences between catecholamines and imidazolines</span></div><div class="casAuthors">Bousquet, P.; Feldman, J.; Schwartz, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">232-6</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">To check whether the central hypotensive effect of α-adrenergic agonists is linked with the stimulation of α2-receptors, such drugs were administered directly to the nucleus reticularis lateralis, an important site for the hypotensive action of clonidine  [4205-90-7].  α-Methylnorepinephrine  [6539-57-7], a selective α2-agonist had no hypotensive effect in this region, whereas potent α1-agonists such as cirazoline  [59939-16-1] and ST 587  [15327-38-5] produced dose-dependent hypotensive effects.  Thus, α2 selective catecholamines are not active in the nucleus reticularis lateralis region, whereas imidazolines induce a hypotensive effect, whatever their ability for one subtype of α-adrenoreceptors.  There may be some form of structure-activity relation which would indicate the existence, in this particular region of the medulla oblongata, of sites preferring the imidazoline structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsdRB-jlBIiLVg90H21EOLACvtfcHk0lg9UZEzydBxxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkvVeqs7Y%253D&md5=1507c694fd361235a39a83c561525114</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBousquet%26aufirst%3DP.%26aulast%3DFeldman%26aufirst%3DJ.%26aulast%3DSchwartz%26aufirst%3DJ.%26atitle%3DCentral%2520cardiovascular%2520effects%2520of%2520alpha%2520adrenergic%2520drugs%253A%2520differences%2520between%2520catecholamines%2520and%2520imidazolines%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1984%26volume%3D230%26spage%3D232%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-X.</span></span> <span> </span><span class="NLM_article-title">Imidazoline receptor system: the past, the present, and the future</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1124/pr.118.016311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1124%2Fpr.118.016311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=31819014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BB3Mfotlamuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=50-79&author=P.+Bousquetauthor=A.+Hudsonauthor=J.+A.+Garc%C3%ADa-Sevillaauthor=J.-X.+Li&title=Imidazoline+receptor+system%3A+the+past%2C+the+present%2C+and+the+future&doi=10.1124%2Fpr.118.016311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline Receptor System: The Past, the Present, and the Future</span></div><div class="casAuthors">Bousquet Pascal; Hudson Alan; Garcia-Sevilla Jesus A; Li Jun-Xu</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Imidazoline receptors historically referred to a family of nonadrenergic binding sites that recognize compounds with an imidazoline moiety, although this has proven to be an oversimplification.  For example, none of the proposed endogenous ligands for imidazoline receptors contain an imidazoline moiety but they are diverse in their chemical structure.  Three receptor subtypes (I1, I2, and I3) have been proposed and the understanding of each has seen differing progress over the decades.  I1 receptors partially mediate the central hypotensive effects of clonidine-like drugs.  Moxonidine and rilmenidine have better therapeutic profiles (fewer side effects) than clonidine as antihypertensive drugs, thought to be due to their higher I1/α2-adrenoceptor selectivity.  Newer I1 receptor agonists such as LNP599 [3-chloro-2-methyl-phenyl)-(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)-amine hydrochloride] have little to no activity on α2-adrenoceptors and demonstrate promising therapeutic potential for hypertension and metabolic syndrome.  I2 receptors associate with several distinct proteins, but the identities of these proteins remain elusive.  I2 receptor agonists have demonstrated various centrally mediated effects including antinociception and neuroprotection.  A new I2 receptor agonist, CR4056 [2-phenyl-6-(1H-imidazol-1yl) quinazoline], demonstrated clear analgesic activity in a recently completed phase II clinical trial and holds great promise as a novel I2 receptor-based first-in-class nonopioid analgesic.  The understanding of I3 receptors is relatively limited.  Existing data suggest that I3 receptors may represent a binding site at the Kir6.2-subtype ATP-sensitive potassium channels in pancreatic β-cells and may be involved in insulin secretion.  Despite the elusive nature of their molecular identities, recent progress on drug discovery targeting imidazoline receptors (I1 and I2) demonstrates the exciting potential of these compounds to elicit neuroprotection and to treat various disorders such as hypertension, metabolic syndrome, and chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTRY03PZp08XO4gDb7JggCfW6udTcc2eYpve_qezj3xLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mfotlamuw%253D%253D&md5=2d041d87f8ad2616b25ed24296d65772</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fpr.118.016311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.118.016311%26sid%3Dliteratum%253Aachs%26aulast%3DBousquet%26aufirst%3DP.%26aulast%3DHudson%26aufirst%3DA.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DJ.-X.%26atitle%3DImidazoline%2520receptor%2520system%253A%2520the%2520past%252C%2520the%2520present%252C%2520and%2520the%2520future%26jtitle%3DPharmacol.%2520Rev.%26date%3D2020%26volume%3D72%26spage%3D50%26epage%3D79%26doi%3D10.1124%2Fpr.118.016311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. T.</span></span> <span> </span><span class="NLM_article-title">Significance of the imidazoline receptors in toxicology</span>. <i>Clin. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.3109/15563650.2014.898770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.3109%2F15563650.2014.898770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1Wisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2014&pages=454-469&author=J.+A.+Lowryauthor=J.+T.+Brown&title=Significance+of+the+imidazoline+receptors+in+toxicology&doi=10.3109%2F15563650.2014.898770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Significance of the imidazoline receptors in toxicology</span></div><div class="casAuthors">Lowry, J. A.; Brown, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">454-469</span>CODEN:
                <span class="NLM_cas:coden">CTPPA5</span>;
        ISSN:<span class="NLM_cas:issn">1556-3650</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction. The alpha-2 adrenergic (AA-2) receptor agonists and imidazolines are common exposures in the American Assocn. of Poison Control Centers (AAPCC) National Poison Data System (NPDS).  Although the interaction between the AA-2 receptor and imidazoline receptors has been extensively studied, it largely remains unknown to health-care professionals.  This review describes these interactions and mechanisms by which agonists affect physiol. responses binding to these receptors.  Presently, three distinct classes of imidazoline receptors, also known as imidazoline binding sites or imidazoline/guanidinium receptive sites, have been characterized.  Four endogenous compds. have been found to bind and include clonidine-displacing substance, agmatine, harmane, and imidazole acetic acid.  Knowledge of the imidazoline receptors may lead to new therapeutic agents and inform management of patients with imidazoline overdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpntTw_iGYdALVg90H21EOLACvtfcHk0ljiS5ClMrRMwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1Wisro%253D&md5=bea368009e52cd94cfaa9ee98a95a10c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3109%2F15563650.2014.898770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15563650.2014.898770%26sid%3Dliteratum%253Aachs%26aulast%3DLowry%26aufirst%3DJ.%2BA.%26aulast%3DBrown%26aufirst%3DJ.%2BT.%26atitle%3DSignificance%2520of%2520the%2520imidazoline%2520receptors%2520in%2520toxicology%26jtitle%3DClin.%2520Toxicol.%26date%3D2014%26volume%3D52%26spage%3D454%26epage%3D469%26doi%3D10.3109%2F15563650.2014.898770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regunathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, D. J.</span></span> <span> </span><span class="NLM_article-title">Imidazoline receptors and their endogenous ligands</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1146/annurev.pa.36.040196.002455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1146%2Fannurev.pa.36.040196.002455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8725400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK28Xis1eruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1996&pages=511-544&author=S.+Regunathanauthor=D.+J.+Reis&title=Imidazoline+receptors+and+their+endogenous+ligands&doi=10.1146%2Fannurev.pa.36.040196.002455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline receptors and their endogenous ligands</span></div><div class="casAuthors">Regunathan, S.; Reis, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">511-44</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review, with 168 refs.  Imidazoline(I) receptors constitute a family of nonadrenergic high-affinity binding sites for clonidine, idazoxan, and allied drugs.  One major subclass, the I1 receptors, whose subcellular distribution and signal transduction mechanisms are uncertain, partly mediates the central hypotensive actions of clonidine-like drugs.  The I2 receptors, another subclass, are mitochondrial, not G protein coupled, and have diversified functions.  Several endogenous ligands for I receptors, collectively termed clinidine-displacing substances (CDSs), have been detected in tissues and serum, but the structure of only one, agmatine (decarboxylated arginine), is known.  Agmatine, widely distributed and bioactive, binds, like clonidine, to α2-adrenergic and I receptors of all subclasses.  The presence of agmatine and its biosynthetic enzyme in synaptosomes and specific neuronal pathways as well as serum suggests that it may be a novel neurotransmitter/hormone.  Another CDS that binds to I receptors and to antibodies to imidazoline drugs has been detected, but its structure is unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgCImYjeLA_7Vg90H21EOLACvtfcHk0lh6TyCHXY3i3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xis1eruro%253D&md5=b555a3b491e375c3f67c41efa46b90b9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pa.36.040196.002455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pa.36.040196.002455%26sid%3Dliteratum%253Aachs%26aulast%3DRegunathan%26aufirst%3DS.%26aulast%3DReis%26aufirst%3DD.%2BJ.%26atitle%3DImidazoline%2520receptors%2520and%2520their%2520endogenous%2520ligands%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1996%26volume%3D36%26spage%3D511%26epage%3D544%26doi%3D10.1146%2Fannurev.pa.36.040196.002455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fenton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyseng-Williamson, K. A.</span></span> <span> </span><span class="NLM_article-title">Moxonidine: a review of its use in essential hypertension</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.2165/00003495-200666040-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.2165%2F00003495-200666040-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=16597164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVajsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=477-496&author=C.+Fentonauthor=G.+M.+Keatingauthor=K.+A.+Lyseng-Williamson&title=Moxonidine%3A+a+review+of+its+use+in+essential+hypertension&doi=10.2165%2F00003495-200666040-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Moxonidine: a review of its use in essential hypertension</span></div><div class="casAuthors">Fenton, Caroline; Keating, Gillian M.; Lyseng-Williamson, Katherine A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-496</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Moxonidine (Physiotens, Moxon, Cynt) is an orally administered imidazoline compd. with selective agonist activity at imidazoline I1 receptors and only minor activity at α2-adrenoceptors.  Moxonidine acts centrally to reduce peripheral sympathetic activity, thus decreasing peripheral vascular resistance.  In patients with mild to moderate hypertension, moxonidine reduces blood pressure (BP) as effectively as most first-line antihypertensives when used as monotherapy and is also an effective adjunctive therapy in combination with other antihypertensive agents.  It improves the metabolic profile in patients with hypertension and diabetes mellitus or impaired glucose tolerance, is well tolerated, has a low potential for drug interactions and may be administered once daily in most patients.  Thus, moxonidine is a good option in the treatment of patients with mild to moderate hypertension, particularly as adjunctive therapy in patients with the metabolic syndrome.  Pharmacol. Properties Moxonidine is a centrally acting selective agonist at imidazoline I1 receptors, for which it has an affinity >30-fold that for α2-adrenoceptors.  Moxonidine inhibits peripheral sympathetic activity, which decreases peripheral vascular resistance and results in significant decreases in systolic and diastolic BP (SBP and DBP).  Moxonidine has minimal effect on cardiac hemodynamics and reduces left ventricular mass.  Markers of endothelial dysfunction and end-organ damage, including microalbuminuria, improved in hypertensive patients who achieved BP control with moxonidine.  Moxonidine also improved the metabolic profile of patients with hypertension and type 2 diabetes or impaired glucose tolerance.  Oral moxonidine is rapidly absorbed, although the max. antihypertensive effect occurs 3-4 h after administration.  Oral bioavailability is 88% and is unaffected by food.  No first-pass metab. occurs and moxonidine is mostly excreted unchanged in the urine.  Therapeutic Efficacy In well designed, 8-wk trials, monotherapy with moxonidine 0.2-0.6 mg/day reduced sitting DBP to a significantly greater extent than placebo (mean change from baseline -10.7 to -13.2 vs -2.3 to -9mm Hg) in patients with mild to moderate essential hypertension.  Sitting SBP also improved from baseline to a significantly greater extent with moxonidine than with placebo (mean -19.5 to -24.9 vs -1.2 to -13mm Hg).  Redns. in sitting SBP and DBP with moxonidine 0.2-0.8 mg/day at 8 wk were similar to those with enalapril 5-20mg once daily, atenolol 50-100 mg/day (except in postmenopausal women where atenolol reduced BP to a greater extent than moxonidine), hydrochlorothiazide 25mg once daily and rilmenidine 1-2 mg/day.  At 26 wk, redns. in sitting SBP and DBP with moxonidine 0.2-0.4 mg/day were similar to those with nifedipine sustained release 20-40 mg/day.  Once-daily adjunctive moxonidine 0.4mg was also effective in patients with mild to moderate hypertension in well designed trials.  In patients who did not respond to moxonidine monotherapy, mean improvements in sitting DBP at 4 wk were -7.3mm Hg with moxonidine 0.4mg once daily plus amlodipine 5mg once daily, -4.8mm Hg with moxonidine 0.4mg once daily plus enalapril 10mg once daily and -3.2mm Hg with moxonidine 0.4mg once daily plus hydrochlorothiazide 12.5mg once daily.  In another trial, changes in sitting SBP and DBP after 8 wk' treatment were significantly greater with once-daily moxonidine 0.4mg plus hydrochlorothiazide 25mg than with the resp. monotherapies (-27 vs -20 and -22mm Hg and -16 vs -12 and -13mm Hg).  Moxonidine was generally well tolerated in clin. trials in patients with mild to moderate hypertension.  In placebo-controlled monotherapy trials, 36-43% of moxonidine recipients experienced treatment-emergent adverse events vs. 22-29% of placebo recipients and =32% and 35% of enalapril and hydrochlorothiazide recipients, resp.  Dry mouth was the most common adverse event with moxonidine monotherapy, affecting 11-20% of patient; other all-cause adverse events included diarrhea, headache, bronchitis, nausea, dizziness and back pain.  Other than dry mouth, asthenia and fatigue, adverse events in moxonidine monotherapy recipients were not generally related to α2-adrenoceptor inhibition.  No new adverse events were reported in combination therapy trials.  Moxonidine was also well tolerated in a pool anal. is postmarketing surveillance studies in 91 170 patients, about two-thirds of whom received moxonidine as monotherapy.  Adverse events affected 9.4% of patients, causing 1.8% to discontinue treatment, and were generally not related to dosage, treatment duration, sex or age; dry mouth affected 4.2% of patients aged >65 years vs. 2.7% of those aged <40 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9CoyjIGYbU7Vg90H21EOLACvtfcHk0lh6TyCHXY3i3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVajsLg%253D&md5=d5399532ca6221cb157cf4ff15e63f75</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2165%2F00003495-200666040-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200666040-00006%26sid%3Dliteratum%253Aachs%26aulast%3DFenton%26aufirst%3DC.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26aulast%3DLyseng-Williamson%26aufirst%3DK.%2BA.%26atitle%3DMoxonidine%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520essential%2520hypertension%26jtitle%3DDrugs%26date%3D2006%26volume%3D66%26spage%3D477%26epage%3D496%26doi%3D10.2165%2F00003495-200666040-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. L.</span></span> <span> </span><span class="NLM_article-title">Rilmenidine: a clinical overview</span>. <i>Am. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">106S</span>– <span class="NLM_lpage">111S</span>, <span class="refDoi"> DOI: 10.1016/S0895-7061(00)00226-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0895-7061%2800%2900226-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10921529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlOgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=106S-111S&author=J.+L.+Reid&title=Rilmenidine%3A+a+clinical+overview&doi=10.1016%2FS0895-7061%2800%2900226-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Rilmenidine: A clinical overview</span></div><div class="casAuthors">Reid, J. L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hypertension</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6, Pt. 2</span>),
    <span class="NLM_cas:pages">106S-111S</span>CODEN:
                <span class="NLM_cas:coden">AJHYE6</span>;
        ISSN:<span class="NLM_cas:issn">0895-7061</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 26 refs.  Rilmenidine is an antihypertensive agent with selectivity for I1 imidazoline receptors that acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+/H+ antiport.  Rilmenidine provides antihypertensive efficacy comparable with that of diuretics, β-blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors.  Experience from trials and clin. practice highlights rilmenidine's clin. and metabolic acceptability in hypertensive populations, including those at special risk because of old age, renal impairment, diabetes mellitus, or dyslipidemia.  In the at-risk hypertensive, rilmenidine reduces left ventricular hypertrophy to a similar degree to other ref. agents.  New studies show a significant improvement in glucose metab. in metabolic syndrome patients treated with rilmenidine, and a significant redn. in microalbuminuria during rilmenidine treatment of hypertensive type 2 diabetics.  Thus the efficacy/tolerance ratio of rilmenidine supports its role as a first-line antihypertensive option for all groups of hypertensive patient, with specific advantages in some at-risk populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF9Ve8mDpJv7Vg90H21EOLACvtfcHk0lh6TyCHXY3i3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlOgu74%253D&md5=7c8fd08a145e1845fcc70868ce9b2b6b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0895-7061%2800%2900226-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0895-7061%252800%252900226-0%26sid%3Dliteratum%253Aachs%26aulast%3DReid%26aufirst%3DJ.%2BL.%26atitle%3DRilmenidine%253A%2520a%2520clinical%2520overview%26jtitle%3DAm.%2520J.%2520Hypertens.%26date%3D2000%26volume%3D13%26spage%3D106S%26epage%3D111S%26doi%3D10.1016%2FS0895-7061%2800%2900226-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpello, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. G.</span></span> <span> </span><span class="NLM_article-title">The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I<sub>1</sub>- and I<sub>2</sub>-sites</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1065</span>– <span class="NLM_lpage">1070</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1994.tb13191.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1111%2Fj.1476-5381.1994.tb13191.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=7952865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2cXlsVyqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=1994&pages=1065-1070&author=S.+L.+Chanauthor=C.+A.+Brownauthor=K.+E.+Scarpelloauthor=N.+G.+Morgan&title=The+imidazoline+site+involved+in+control+of+insulin+secretion%3A+characteristics+that+distinguish+it+from+I1-+and+I2-sites&doi=10.1111%2Fj.1476-5381.1994.tb13191.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The imidazoline site involved in control of insulin secretion; characteristics that distinguish it from I1- and I2-sites</span></div><div class="casAuthors">Chan, Susan L. F.; Brown, Colin A.; Scarpello, Kay E.; Morgan, Noel G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1065-70</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">The nature of the binding site mediating the insulin secretagogue activity of certain imidazoline compds. remains unclear and the pharmacol. of the I1- and I2-imidazoline sites, described in many tissues, does not correlate with the obsd. responses to imidazolines in islets.  In the present paper, the authors describe further results which support the concept that the islet imidazoline site may represent a novel subtype of imidazoline receptor.  Culture of rat isolated islets in the presence of imidazoline secretagogues (either efaroxan or phentolamine) resulted in loss of responsiveness on subsequent re-exposure to these agents.  However, culture of islets with either idazoxan or UK 14,304 (imidazoline ligands that do not stimulate insulin secretion) did not lead to any loss of response when the islets were subsequently exposed to efaroxan.  By contrast, islets cultured with UK 14,304 (a potent α2-adrenoceptor agonist), displayed loss of sensitivity to noradrenaline, consistent with down-regulation of α2-adrenoceptors.  To characterize the imidazoline site further, radioligand binding studies were performed in membranes from RINm5F insulinoma cells using [3H]-RX821002, an imidazoline insulin secretagogue that does not interact significantly with imidazoline sites in other tissues.  [3H]-RX821002 labeled α2-adrenoceptors with high affinity (2.01 nM) but also labeled a second, non-adrenoceptor site with much lower affinity.  Under conditions of α2-adrenoceptor blockade (in the presence of adrenaline), efaroxan displaced [3H]-RX821002 binding to the low affinity site, in a dose-dependent manner.  Competition studies employing addnl. imidazoline compds. of varying secretagogue activity revealed that the pharmacol. profile of the low affinity site correlates well with that obsd. in secretion expts.  The results obtained from the down-regulation expts. with isolated islets and from the radioligand binding studies suggest that the low affinity [3H]-RX821002 binding site may represent the functional receptor responsive for the secretagogue activity of imidazole compds. in the endocrine pancreas and that it has a pharmacol. profile distinct from those of I2- and I2-sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrog6sMKnpanLVg90H21EOLACvtfcHk0lgMKVdYOlJ6FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsVyqt7o%253D&md5=edce0bacb9d33e93d7c7cbcccf0ed133</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1994.tb13191.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1994.tb13191.x%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BL.%26aulast%3DBrown%26aufirst%3DC.%2BA.%26aulast%3DScarpello%26aufirst%3DK.%2BE.%26aulast%3DMorgan%26aufirst%3DN.%2BG.%26atitle%3DThe%2520imidazoline%2520site%2520involved%2520in%2520control%2520of%2520insulin%2520secretion%253A%2520characteristics%2520that%2520distinguish%2520it%2520from%2520I1-%2520and%2520I2-sites%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1994%26volume%3D112%26spage%3D1065%26epage%3D1070%26doi%3D10.1111%2Fj.1476-5381.1994.tb13191.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. X.</span></span> <span> </span><span class="NLM_article-title">Imidazoline I<sub>2</sub> receptors: an update</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.pharmthera.2017.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=28322973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksFChsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2017&pages=48-56&author=J.+X.+Li&title=Imidazoline+I2+receptors%3A+an+update&doi=10.1016%2Fj.pharmthera.2017.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline I2 receptors: An update</span></div><div class="casAuthors">Li, Jun-Xu</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-56</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Since first introduced more than two decades ago, the research in imidazoline I2 receptors has been steadily increasing.  This review provides an update on the current status of I2 receptor pharmacol.  Imidazoline I2 receptors or I2 binding sites refer to several (at least four) different proteins that bind to [3H]-idazoxan and [3H]-2-BFI with high affinity.  The mol. identities of the proteins remain elusive.  One of the proteins (45 kD) seems to be consistent with the identity of brain creatine kinase.  The biol. functions of I2 receptors have been primarily unveiled by the studies of selective I2 receptor ligands.  Accumulating evidence suggests that I2 receptor ligands are effective analgesics for persistent and chronic painful conditions such as inflammatory, neuropathic and postoperative pain.  One selective I2 receptor ligand, CR4056, has been advanced to phase II clin. trial with the therapeutic indication of chronic inflammatory pain (osteoarthritis).  The expansion to the treatment of other chronic pain conditions should be expected if CR4056 could eventually be approved as a new drug.  I2 receptor ligands also demonstrate robust discriminative stimulus activity and induce a characteristic discriminative cue in animals.  Biochem. and preclin. in vivo investigations also suggest that I2 receptor ligands have neuroprotective activity and modulate body temp.  The emerging discrepancies of a range of purported selective I2 receptor ligands suggest different pharmacol. effects mediated by discrete I2 receptor components which likely attribute to the I2 receptor-related proteins.  It is proposed that the I2 receptors represent an emerging drug target for the treatment of neurol. disorders such as pain and stroke, and deserve more research attention to translate preclin. findings to pharmacotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJxeU1YaY8KLVg90H21EOLACvtfcHk0lgMKVdYOlJ6FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksFChsLw%253D&md5=a6c968a86e34ae2446f7bbf4b3f1ccea</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BX.%26atitle%3DImidazoline%2520I2%2520receptors%253A%2520an%2520update%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D178%26spage%3D48%26epage%3D56%26doi%3D10.1016%2Fj.pharmthera.2017.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Imidazoline I<sub>2</sub> receptors: target for new analgesics?</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>658</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.02.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.ejphar.2011.02.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=21371460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktF2itrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=658&publication_year=2011&pages=49-56&author=J.+X.+Liauthor=Y.+Zhang&title=Imidazoline+I2+receptors%3A+target+for+new+analgesics%3F&doi=10.1016%2Fj.ejphar.2011.02.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline I2 receptors: Target for new analgesics?</span></div><div class="casAuthors">Li, Jun-Xu; Zhang, Yanan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">658</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">49-56</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pain remains a major clin. challenge because there are no effective analgesics for some pain conditions and the mainstay analgesics for severe pain, opioids, have serious unwanted effects.  There is a dire need for novel analgesics in the clinic.  Imidazoline receptors are a family of three receptors (I1, I2 and I3) that all can recognize compds. with an imidazoline structure.  Accumulating evidence suggests that I2 receptors are involved in pain modulation.  Ligands acting at I2 receptors are effective for tonic inflammatory and neuropathic pain but are much less effective for acute phasic pain.  When studied in combination, I2 receptor ligands enhance the analgesic effects of opioids in both acute phasic and chronic tonic pain.  During chronic use, patients can develop tolerance to and dependence on opioids.  Imidazoline I2 receptor ligands can attenuate the development of tolerance to opioid analgesia and inhibit drug withdrawal or antagonist pptn. induced abstinence syndrome in animals.  Taken together, drugs acting on I2 receptors may be useful as a monotherapy or combined with opioids as an adjuvant for treating pain.  Future studies should focus on understanding the relative efficacy of I2 receptor ligands and developing new compds. to fill the gap in intrinsic efficacy continuum of I2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9uQD_LTPxDbVg90H21EOLACvtfcHk0lgMKVdYOlJ6FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktF2itrc%253D&md5=a96e237169e6a42b4fa5b5921ee3c287</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.02.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.02.038%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BX.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DImidazoline%2520I2%2520receptors%253A%2520target%2520for%2520new%2520analgesics%253F%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D658%26spage%3D49%26epage%3D56%26doi%3D10.1016%2Fj.ejphar.2011.02.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regunathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feinstein, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, D. J.</span></span> <span> </span><span class="NLM_article-title">Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved?</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>881</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1999.tb09389.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1111%2Fj.1749-6632.1999.tb09389.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10415945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK1MXkslelsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=881&publication_year=1999&pages=410-419&author=S.+Regunathanauthor=D.+L.+Feinsteinauthor=D.+J.+Reis&title=Anti-proliferative+and+anti-inflammatory+actions+of+imidazoline+agents.+Are+imidazoline+receptors+involved%3F&doi=10.1111%2Fj.1749-6632.1999.tb09389.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved?</span></div><div class="casAuthors">Regunathan, S.; Feinstein, D. L.; Reis, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">881</span>
        (<span class="NLM_cas:issue">Imidazoline Receptors and Their Endogenous Ligands</span>),
    <span class="NLM_cas:pages">410-419</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">We have shown that cultured vascular smooth muscle cells (VSMC) and brain astroglial cells express I-receptors of the I2 subtype.  While imidazoline agents are anti-proliferative in smooth muscle cells, they increase the expression of glial fibrillary acidic protein (GFAP) in astrocytes.  Because increases in GFAP suppress the induction of calcium-independent, inducible nitric oxide synthase (NOS-2), we measured whether idazoxan and related imidazolines and agmatine would also suppress the expression of NOS-2.  Cultured astrocytes and macrophages, RAW 264.7 cell line, were incubated with lipopolysaccharide (LPS, 1 μg/mL) or cytokine mixt. in the presence of 1-100 μM of idazoxan, agmatine, or other imidazoline agents.  Idazoxan potently (IC50, 10 μM) decreased the activity of NOS-2 in astrocytes, but was less potent in RAW 264.7 cells.  By contrast, agmatine was most potent in RAW 264.7 cells (IC50, 10 μM) but less potent in glial cells and VSMC.  Both idazoxan and agmatine decreased the activity of NOS-2 by reducing the levels of enzyme protein as measured by immunoblot and immunocytochem.  No specific binding of [3H]-idazoxan was obsd. in RAW 264.7 cell membranes.  We conclude that idazoxan, agmatine, and selected imidazoline agents inhibit the expression of NOS-2 and proliferation in primary glial cells and VSMC.  While the antiproliferative actions appear mediated by I-receptors of the I2 type, the anti-inflammatory response is probably not mediated by I-receptors but possibly by direct actions on signal transduction enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvuNl8TXpR77Vg90H21EOLACvtfcHk0lgMKVdYOlJ6FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkslelsr4%253D&md5=9ce35919240def895c8e20e765aea8e2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1999.tb09389.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1999.tb09389.x%26sid%3Dliteratum%253Aachs%26aulast%3DRegunathan%26aufirst%3DS.%26aulast%3DFeinstein%26aufirst%3DD.%2BL.%26aulast%3DReis%26aufirst%3DD.%2BJ.%26atitle%3DAnti-proliferative%2520and%2520anti-inflammatory%2520actions%2520of%2520imidazoline%2520agents.%2520Are%2520imidazoline%2520receptors%2520involved%253F%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D881%26spage%3D410%26epage%3D419%26doi%3D10.1111%2Fj.1749-6632.1999.tb09389.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessop, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, D. P.</span></span> <span> </span><span class="NLM_article-title">Modulation of stress by imidazoline binding sites: implications for psychiatric disorders</span>. <i>Stress</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1080/10253890802302908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1080%2F10253890802302908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=19006007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1ektrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=97-114&author=K.+L.+Smithauthor=D.+S.+Jessopauthor=D.+P.+Finn&title=Modulation+of+stress+by+imidazoline+binding+sites%3A+implications+for+psychiatric+disorders&doi=10.1080%2F10253890802302908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of stress by imidazoline binding sites: Implications for psychiatric disorders</span></div><div class="casAuthors">Smith, Karen L.; Jessop, David S.; Finn, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Stress (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-114</span>CODEN:
                <span class="NLM_cas:coden">STREFR</span>;
        ISSN:<span class="NLM_cas:issn">1025-3890</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">In this review, we present evidence for the involvement of imidazoline binding sites (IBS) in modulating responses to stress, through central control of monoaminergic and hypothalamo-pituitary-adrenal (HPA) axis activity.  Pharmacol. and physiol. evidence is presented for differential effects of different IBS subtypes on serotoninergic and catecholaminergic pathways involved in control of basal and stress-stimulated HPA axis activity.  IBS ligands can modulate behavioral and neuroendocrine responses in animal models of stress, depression and anxiety, and a body of evidence exists for alterations in central IBS expression in psychiatric patients, which can be normalized partially or fully by treatment with antidepressants.  Dysfunction in monoaminergic systems and the HPA axis under basal and stress-induced activation has been extensively reported in psychiatric illnesses.  On the basis of the literature, we suggest a potential therapeutic role for selective IBS ligands in the treatment of depression and anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCG9rU5LdfPrVg90H21EOLACvtfcHk0lh6uY_ZuPS5UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1ektrw%253D&md5=c837e6ae48707b312bd220414063091a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1080%2F10253890802302908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10253890802302908%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DK.%2BL.%26aulast%3DJessop%26aufirst%3DD.%2BS.%26aulast%3DFinn%26aufirst%3DD.%2BP.%26atitle%3DModulation%2520of%2520stress%2520by%2520imidazoline%2520binding%2520sites%253A%2520implications%2520for%2520psychiatric%2520disorders%26jtitle%3DStress%26date%3D2009%26volume%3D12%26spage%3D97%26epage%3D114%26doi%3D10.1080%2F10253890802302908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Gómez, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruíz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garibi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguinaco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barturen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span> <span> </span><span class="NLM_article-title">Increased density of I<sub>2</sub>-imidazoline receptors in human gliobastomas</span>. <i>NeuroReport</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1396</span>, <span class="refDoi"> DOI: 10.1097/00001756-199605310-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1097%2F00001756-199605310-00013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8856683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2sXhslWltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=1393-1396&author=J.+I.+Mart%C3%ADn-G%C3%B3mezauthor=J.+Ru%C3%ADzauthor=L.+F.+Calladoauthor=J.+M.+Garibiauthor=L.+Aguinacoauthor=F.+Barturenauthor=J.+J.+Meana&title=Increased+density+of+I2-imidazoline+receptors+in+human+gliobastomas&doi=10.1097%2F00001756-199605310-00013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Increased density of I2-imidazoline receptors in human glioblastomas</span></div><div class="casAuthors">Martin-Gomez, J. Ignacio; Ruiz, Javier; Callado, Luis F.; Garibi, Jesus M.; Aguinaco, Luis; Barturen, Fernando; Meana, J. Javier</div><div class="citationInfo"><span class="NLM_cas:title">NeuroReport</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1393-1396</span>CODEN:
                <span class="NLM_cas:coden">NERPEZ</span>;
        ISSN:<span class="NLM_cas:issn">0959-4965</span>.
    
            (<span class="NLM_cas:orgname">Rapid Science Publishers</span>)
        </div><div class="casAbstract">A glial location has been proposed for the non-adrenoceptor [3H]idazoxan-binding site termed the I2-imidazoline receptor.  The specific binding of [3H]idazoxan in the presence of (-)adrenaline was measured in membranes from excised human glioblastomas, meningiomas and normal brains.  The pharmacol. profile of the [3H]idazoxan binding in astrocytic tumors was similar to that in normal brain, compatible with the presence of I2-imidazoline receptors.  There was a higher d. of I2-imidazoline receptors in astrocytic tumors (Bmax = 266 fmol mg-1 protein) than in normal brain (Bmax = 54 fmol mg-1 protein), with no differences in affinity values.  Almost no [3H]idazoxan-specific binding was shown in meningiomas.  The results suggest that I2-imidazoline receptors may be a selective marker for glial tumors in the evaluation of intracranial neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRjlQBz8r9dLVg90H21EOLACvtfcHk0lh6uY_ZuPS5UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhslWltLo%253D&md5=e82aae3988886b2778b7e3c952c20cfe</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1097%2F00001756-199605310-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001756-199605310-00013%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADn-G%25C3%25B3mez%26aufirst%3DJ.%2BI.%26aulast%3DRu%25C3%25ADz%26aufirst%3DJ.%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DGaribi%26aufirst%3DJ.%2BM.%26aulast%3DAguinaco%26aufirst%3DL.%26aulast%3DBarturen%26aufirst%3DF.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26atitle%3DIncreased%2520density%2520of%2520I2-imidazoline%2520receptors%2520in%2520human%2520gliobastomas%26jtitle%3DNeuroReport%26date%3D1996%26volume%3D7%26spage%3D1393%26epage%3D1396%26doi%3D10.1097%2F00001756-199605310-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Gómez, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garibi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span> <span> </span><span class="NLM_article-title">Imidazoline I<sub>2</sub> receptors density increases with the malignancy of human gliomas</span>. <i>J. Neurol., Neurosurg. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1136/jnnp.2003.020446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1136%2Fjnnp.2003.020446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=15090584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BD2c7pslCqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2004&pages=785-787&author=L.+F.+Calladoauthor=J.+I.+Mart%C3%ADn-G%C3%B3mezauthor=J.+Ruizauthor=J.+M.+Garibiauthor=J.+J.+Meana&title=Imidazoline+I2+receptors+density+increases+with+the+malignancy+of+human+gliomas&doi=10.1136%2Fjnnp.2003.020446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline I(2) receptor density increases with the malignancy of human gliomas</span></div><div class="casAuthors">Callado L F; Martin-Gomez J I; Ruiz J; Garibi J M; Meana J J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurology, neurosurgery, and psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">785-7</span>
        ISSN:<span class="NLM_cas:issn">0022-3050</span>.
    </div><div class="casAbstract">BACKGROUND:  Current glioma grading schemes are limited by subjective histological criteria.  Imidazoline I(2) receptors are principally expressed on glial cells.  OBJECTIVE:  To investigate the feasibility of using the measurement of imidazoline I(2) receptor expression to differentiate glial tumours from other types of brain tumours and for grading the different gliomas.  METHODS:  The specific binding of [(3)H]idazoxan to imidazoline I(2) receptors was measured in homogenates from human gliomas of different grades.  RESULTS:  The density of imidazoline I(2) receptors was significantly greater in the three types of malignant glial tumours than in postmortem control brain or non-glial tumours.  The increase in density correlated with the malignancy grade of the gliomas.  No significant differences in affinity values were observed.  CONCLUSION:  These results suggest that the density of imidazoline I(2) receptors may be a useful radioligand parameter for the differentiation of glial tumours from other types of brain tumours and for grading the different gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9dE_E2AERb7JzI8owOhpDfW6udTcc2eaG-HwLU4DTNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7pslCqtQ%253D%253D&md5=ee3c9eeb65915e694404db86f11bc80f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1136%2Fjnnp.2003.020446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjnnp.2003.020446%26sid%3Dliteratum%253Aachs%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DMart%25C3%25ADn-G%25C3%25B3mez%26aufirst%3DJ.%2BI.%26aulast%3DRuiz%26aufirst%3DJ.%26aulast%3DGaribi%26aufirst%3DJ.%2BM.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26atitle%3DImidazoline%2520I2%2520receptors%2520density%2520increases%2520with%2520the%2520malignancy%2520of%2520human%2520gliomas%26jtitle%3DJ.%2520Neurol.%252C%2520Neurosurg.%2520Psychiatry%26date%3D2004%26volume%3D75%26spage%3D785%26epage%3D787%26doi%3D10.1136%2Fjnnp.2003.020446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span> <span> </span><span class="NLM_article-title">Imidazoline binding sites in Huntington’s and Parkinson’s disease putamen</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>301</i></span>,  <span class="NLM_fpage">R19</span>– <span class="NLM_lpage">R21</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00196-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0014-2999%2896%2900196-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8773473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK28XjtFaqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=1996&pages=R19-R21&author=G.+P.+Reynoldsauthor=R.+M.+Boultonauthor=S.+J.+Pearsonauthor=A.+L.+Hudsonauthor=D.+J.+Nutt&title=Imidazoline+binding+sites+in+Huntington%E2%80%99s+and+Parkinson%E2%80%99s+disease+putamen&doi=10.1016%2F0014-2999%2896%2900196-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline binding sites in Huntington's and Parkinson's disease putamen</span></div><div class="casAuthors">Reynolds, Gavin P.; Boulton, Ruth M.; Pearson, Sally J.; Hudson, Alan L.; Nutt, David J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">R19-R21</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Binding of [3H]2-(2-benzofuranyl)-2-imidazoline ([3H]BFI) to the imidazoline I2 receptor was detd. in putamen taken post mortem from patients with two extrapyramidal motor disorders, Parkinson's and Huntington's diseases, and age-matched control subjects.  No deficit of binding was apparent in Parkinson's disease, indicating that the receptors are not present on nigrostriatal terminals.  A significant loss (by 56%) in imidazoline I2 receptor binding was obsd. in Huntington's disease, consistent with the receptors being sited on degenerating neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopwlnDGo-2wLVg90H21EOLACvtfcHk0lgsQLp-elvVOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtFaqtb0%253D&md5=5191aa938cf58399e6bef53a6999df75</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900196-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900196-3%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DG.%2BP.%26aulast%3DBoulton%26aufirst%3DR.%2BM.%26aulast%3DPearson%26aufirst%3DS.%2BJ.%26aulast%3DHudson%26aufirst%3DA.%2BL.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26atitle%3DImidazoline%2520binding%2520sites%2520in%2520Huntington%25E2%2580%2599s%2520and%2520Parkinson%25E2%2580%2599s%2520disease%2520putamen%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D301%26spage%3DR19%26epage%3DR21%26doi%3D10.1016%2F0014-2999%2896%2900196-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gargalidis-Moudanos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzinat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javoy-Agid, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remaury, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parini, A.</span></span> <span> </span><span class="NLM_article-title">I<sub>2</sub>-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson’s disease</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1016/S0197-0186(96)00035-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0197-0186%2896%2900035-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9116585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADyaK2s7ntVWhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1997&pages=31-36&author=C.+Gargalidis-Moudanosauthor=N.+Pizzinatauthor=F.+Javoy-Agidauthor=A.+Remauryauthor=A.+Parini&title=I2-imidazoline+binding+sites+and+monoamine+oxidase+activity+in+human+postmortem+brain+from+patients+with+Parkinson%E2%80%99s+disease&doi=10.1016%2FS0197-0186%2896%2900035-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease</span></div><div class="casAuthors">Gargalidis-Moudanos C; Pizzinat N; Javoy-Agid F; Remaury A; Parini A</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry international</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-6</span>
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    </div><div class="casAbstract">I2-imidazoline binding site (I2BS) has been identified with a regulatory site located on a sub-population of monoamine oxidase (MAO)-A and -B.  Previous studies showed a modification of MAO and I2BS in the elderly and in neurodegenerative processes such as Alzheimer's disease.  In the present study, we studied the potential modification of I2 binding sites and monoamine oxidases in Parkinson's disease.  Putamen and cerebral cortex were collected from 17 normal subjects (79 +/- 12 yr) and 16 patients (76 +/- 9 yr) affected by Parkinson's disease.  In mitochondrial preparations, radioligand binding studies with [3H]idazoxan showed that putamen and frontal cortex express equivalent amount of I2BS.  The density and affinity of I2BS were similar in normal subjects (putamen: Bmax = 207 +/- 58 fmol/mg of protein, Kd = 10.1 +/- 3.4 nM; cerebral cortex: Bmax = 193 +/- 54 fmol/mg of protein, Kd = 12.8 +/- 6.8 nM) and Parkinson's disease patients (putamen: Bmax = 193 +/- 60 fmol/mg of protein, Kd = 9.8 +/- 4.6 nM; cerebral cortex: Bmax = 199 +/- 49 fmol/mg of protein, Kd = 15.9 +/- 8.1 nM).  The activity of total monoamine oxidase and monoamine oxidase B, measured by [14C]tyramine and [14C]phenylethylamine oxidation, respectively, were higher in putamen than in cerebral cortex.  No differences have been detected in the enzyme activity between normal and pathological subjects.  These data suggest that, although MAO and I2BS may play a role in the development of Parkinson's disease, they are not altered in the chronic phase of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQE1BPAKWlxLO3MPKNEWB5RfW6udTcc2eYDkX0YSIgsCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7ntVWhsw%253D%253D&md5=1a8976c96852e3f68d384fbd4249759d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0197-0186%2896%2900035-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0197-0186%252896%252900035-6%26sid%3Dliteratum%253Aachs%26aulast%3DGargalidis-Moudanos%26aufirst%3DC.%26aulast%3DPizzinat%26aufirst%3DN.%26aulast%3DJavoy-Agid%26aufirst%3DF.%26aulast%3DRemaury%26aufirst%3DA.%26aulast%3DParini%26aufirst%3DA.%26atitle%3DI2-imidazoline%2520binding%2520sites%2520and%2520monoamine%2520oxidase%2520activity%2520in%2520human%2520postmortem%2520brain%2520from%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurochem.%2520Int.%26date%3D1997%26volume%3D30%26spage%3D31%26epage%3D36%26doi%3D10.1016%2FS0197-0186%2896%2900035-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barturen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">Evidence of increased non-adrenoreceptor [<sup>3</sup>H]idazoxan binding sites in the frontal cortex of depressed suicide victims</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1016/0006-3223(93)90243-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0006-3223%2893%2990243-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8268335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2cXhvVykt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1993&pages=498-501&author=J.+J.+Meanaauthor=F.+Barturenauthor=I.+Mart%C3%ADnauthor=J.+A.+Garc%C3%ADa-Sevilla&title=Evidence+of+increased+non-adrenoreceptor+%5B3H%5Didazoxan+binding+sites+in+the+frontal+cortex+of+depressed+suicide+victims&doi=10.1016%2F0006-3223%2893%2990243-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence of increased non-adrenoceptor [3H]idazoxan binding sites in the frontal cortex of depressed suicide victims</span></div><div class="casAuthors">Meana, J. Javier; Barturen, Fernando; Martin, Inaki; Garcia-Sevilla, Jesus A.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">498-501</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    </div><div class="casAbstract">This is the first demonstration of an increased d. of binding sites for [3H]idazoxan distinct from α2-adrenoceptors in the frontal cortex of depressed suicide victims.  Moreover, an unchanged binding of the antagonist [3H]idazoxan to the α2-adrenoceptor is also shown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Njo4vl215bVg90H21EOLACvtfcHk0lgsQLp-elvVOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvVykt7c%253D&md5=911efecd8a29c024e6f51da8655551a5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2F0006-3223%2893%2990243-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-3223%252893%252990243-7%26sid%3Dliteratum%253Aachs%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26aulast%3DBarturen%26aufirst%3DF.%26aulast%3DMart%25C3%25ADn%26aufirst%3DI.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DEvidence%2520of%2520increased%2520non-adrenoreceptor%2520%255B3H%255Didazoxan%2520binding%2520sites%2520in%2520the%2520frontal%2520cortex%2520of%2520depressed%2520suicide%2520victims%26jtitle%3DBiol.%2520Psychiatry%26date%3D1993%26volume%3D34%26spage%3D498%26epage%3D501%26doi%3D10.1016%2F0006-3223%2893%2990243-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-
Sevilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribá, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busquets, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaquet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimón, J.</span></span> <span> </span><span class="NLM_article-title">Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.1996.01830090049008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1001%2Farchpsyc.1996.01830090049008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8792757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADyaK28zosVyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1996&pages=803-810&author=J.+Garc%C3%ADa-%0ASevillaauthor=P.+V.+Escrib%C3%A1author=M.+Sastreauthor=C.+Walzerauthor=X.+Busquetsauthor=G.+Jaquetauthor=D.+J.+Reisauthor=J.+Guim%C3%B3n&title=Immunodetection+and+quantitation+of+imidazoline+receptor+proteins+in+platelets+of+patients+with+major+depression+and+in+brains+of+suicide+victims&doi=10.1001%2Farchpsyc.1996.01830090049008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims</span></div><div class="casAuthors">Garcia-Sevilla J A; Escriba P V; Sastre M; Walzer C; Busquets X; Jaquet G; Reis D J; Guimon J</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">803-10</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">BACKGROUND:  Imidazoline receptors are a newly discovered family of receptors, some of which, like alpha 2-adrenoceptors, have a presynaptic inhibitory effect on the release of norepinephrine.  The aim of this study was to identify by immunodetection imidazoline receptor proteins in human platelets and the brain to assess their status in depression and suicide.  METHODS:  Platelets were collected from 26 drug-free depressed patients and 26 controls.  Specimens of frontal cortex (Brodmann area 9) were collected from 13 suicide victims and 11 controls.  Levels of imidazoline receptor proteins were assessed by immunoblotting techniques.  Solubilized imidazoline receptors were separated by gel electrophoresis, transferred to nitrocellulose membranes, labeled with a specific anti-imidazoline receptor antiserum, and quantitated by image analysis.  RESULTS:  Platelet and brain membranes expressed similar 45-kd imidazoline receptor proteins, and their mean +/- SEM immunoreactivities were found to be increased in depressed patients (platelets, 40% +/- 5%) and suicide victims (brain, 51% +/- 14%).  Platelets also expressed a 35-kd imidazoline receptor protein that was also found to be up-regulated in depressed patients (21% +/- 4%).  In contrast, brain membranes did not express this 35-kd protein but revealed a 29/30-kd imidazoline receptor protein that was found to be down-regulated in suicide victims (19% +/- 3%).  In a subset of depressed patients who underwent antidepressant treatment, a change in the immunoreactivity of the up-regulated 45-kd platelet imidazoline receptor protein (-35% +/- 5%), but not of the 35-kd protein, was observed.  CONCLUSION:  The results support a role for the newly discovered imidazoline receptors (mainly the 45-kd receptor expressed in the brain and platelets) in the pathogenesis of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlQEHGUcd1PwaK-_ZudimnfW6udTcc2eamh9wNXa2zerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28zosVyqtQ%253D%253D&md5=75c7ada01afb6b7f31dd2197b6b52d75</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.1996.01830090049008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.1996.01830090049008%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-%2BSevilla%26aufirst%3DJ.%26aulast%3DEscrib%25C3%25A1%26aufirst%3DP.%2BV.%26aulast%3DSastre%26aufirst%3DM.%26aulast%3DWalzer%26aufirst%3DC.%26aulast%3DBusquets%26aufirst%3DX.%26aulast%3DJaquet%26aufirst%3DG.%26aulast%3DReis%26aufirst%3DD.%2BJ.%26aulast%3DGuim%25C3%25B3n%26aufirst%3DJ.%26atitle%3DImmunodetection%2520and%2520quantitation%2520of%2520imidazoline%2520receptor%2520proteins%2520in%2520platelets%2520of%2520patients%2520with%2520major%2520depression%2520and%2520in%2520brains%2520of%2520suicide%2520victims%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D1996%26volume%3D53%26spage%3D803%26epage%3D810%26doi%3D10.1001%2Farchpsyc.1996.01830090049008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruíz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barturen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">Non-adrenoreceptor [<sup>3</sup>H]idazoxan binding sites (I<sub>2</sub>-imidazoline sites) are increased in postmortem brain from patients with Alzheimer’s disease</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/0304-3940(93)90925-B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0304-3940%2893%2990925-B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=7902542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADyaK2c%252FmslGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1993&pages=109-112&author=J.+Ru%C3%ADzauthor=I.+Mart%C3%ADnauthor=L.+F.+Calladoauthor=J.+J.+Meanaauthor=F.+Barturenauthor=J.+A.+Garc%C3%ADa-Sevilla&title=Non-adrenoreceptor+%5B3H%5Didazoxan+binding+sites+%28I2-imidazoline+sites%29+are+increased+in+postmortem+brain+from+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1016%2F0304-3940%2893%2990925-B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Non-adrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease</span></div><div class="casAuthors">Ruiz J; Martin I; Callado L F; Meana J J; Barturen F; Garcia-Sevilla J A</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience letters</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-12</span>
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    </div><div class="casAbstract">The I2-imidazoline site (a non-adrenergic mitochondrial site for which a glial location has been proposed and that is associated with the B-form of the enzyme monoamine oxidase) was evaluated in postmortem cortical membranes from 9 subjects with Alzheimer's disease (AD) and 9 matched-controls by using [3H]idazoxan (0.6-30 nM) in the presence of 10(-6) M (-)-adrenaline to prevent binding to alpha 2-adrenoceptors.  In AD the density (Bmax) of I2-imidazoline sites was significantly higher (+63%) than in controls whereas no differences were apparent in affinity values (Kd).  The results support the hypothesis that the I2 imidazoline site has a major location on glial (astrocyte) cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvuMd4yNs05TQLBVDQn4bCfW6udTcc2eamh9wNXa2zerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252FmslGnsg%253D%253D&md5=6c064f8501729c47d4a02e86e8a174df</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0304-3940%2893%2990925-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3940%252893%252990925-B%26sid%3Dliteratum%253Aachs%26aulast%3DRu%25C3%25ADz%26aufirst%3DJ.%26aulast%3DMart%25C3%25ADn%26aufirst%3DI.%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26aulast%3DBarturen%26aufirst%3DF.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DNon-adrenoreceptor%2520%255B3H%255Didazoxan%2520binding%2520sites%2520%2528I2-imidazoline%2520sites%2529%2520are%2520increased%2520in%2520postmortem%2520brain%2520from%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurosci.%2520Lett.%26date%3D1993%26volume%3D160%26spage%3D109%26epage%3D112%26doi%3D10.1016%2F0304-3940%2893%2990925-B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribá, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouras, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimón, J.</span></span> <span> </span><span class="NLM_article-title">Imidazoline receptor proteins in brains of patients with Alzheimer’s disease</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/S0304-3940(98)00265-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0304-3940%2898%2900265-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9655601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK1cXis1yjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1998&pages=95-98&author=J.+A.+Garc%C3%ADa-Sevillaauthor=P.+V.+Escrib%C3%A1author=C.+Walzerauthor=C.+Bourasauthor=J.+Guim%C3%B3n&title=Imidazoline+receptor+proteins+in+brains+of+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0304-3940%2898%2900265-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline receptor proteins in brains of patients with Alzheimer's disease</span></div><div class="casAuthors">Garcia-Sevilla, Jesus A.; Escriba, Pablo V.; Walzer, Claude; Bouras, Constantin; Guimon, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">2,3</span>),
    <span class="NLM_cas:pages">95-98</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Imidazoline receptors (29/30- and 45-kDa proteins) were quantitated in postmortem brains of patients with Alzheimer's disease (AD) by using immunoblotting techniques and a specific antiserum.  Increased levels of the 29/30-kDa protein (30%), 45-kDa protein (36%) and glial fibrillary acidic protein (88%) were found in the frontal cortex of AD patients.  These findings are in line with the reported higher d. of imidazoline receptors labeled by [3H]idazoxan in AD brains, suggesting that these imidazoline receptor proteins are related to the I2-imidazoline receptor located in mitochondria of glial (astrocyte) cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGophkoEHIqMybVg90H21EOLACvtfcHk0liIXyCDhUPkiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1yjtbg%253D&md5=fe8ceb13ca9328478de26d3aee4d6f8f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0304-3940%2898%2900265-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3940%252898%252900265-1%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26aulast%3DEscrib%25C3%25A1%26aufirst%3DP.%2BV.%26aulast%3DWalzer%26aufirst%3DC.%26aulast%3DBouras%26aufirst%3DC.%26aulast%3DGuim%25C3%25B3n%26aufirst%3DJ.%26atitle%3DImidazoline%2520receptor%2520proteins%2520in%2520brains%2520of%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurosci.%2520Lett.%26date%3D1998%26volume%3D247%26spage%3D95%26epage%3D98%26doi%3D10.1016%2FS0304-3940%2898%2900265-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauri, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caselli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovati, L. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.2147/JPR.S132026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.2147%2FJPR.S132026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=28496359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWksLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=1033-1043&author=E.+Comiauthor=M.+Lanzaauthor=F.+Ferrariauthor=V.+Mauriauthor=G.+Caselliauthor=L.+C.+Rovati&title=Efficacy+of+CR4056%2C+a+first-in-class+imidazoline-2+analgesic+drug%2C+in+comparison+with+naproxen+in+two+rat+models+of+osteoarthritis&doi=10.2147%2FJPR.S132026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis</span></div><div class="casAuthors">Comi, Eleonora; Lanza, Marco; Ferrari, Flora; Mauri, Valeria; Caselli, Gianfranco; Rovati, Lucio Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1033-1043</span>CODEN:
                <span class="NLM_cas:coden">JPROEV</span>;
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Purpose: CR4056, (2-phenyl-6-(1H-imidazol-1yl) quinazoline), an imidazoline-2 (I2) receptor ligand, is a promising analgesic drug that has been reported to be effective in several animal models of pain.  The aim of this study was to evaluate the effects of CR4056 in two well-established rat models of osteoarthritis (OA), mimicking the painful and structural components of human OA.  Methods: Knee OA was induced either by single intra-articular injection of monoiodoacetate (MIA) or by medial meniscal tear (MMT) in the right knee of male rats.  In the MIA model, allodynia and hyperalgesia were measured as paw withdrawal threshold to mech. stimulation.  In the MMT model, pain behavior was analyzed as wt.-bearing asymmetry (i.e. difference in hind paw wt. distribution, HPWD) between the injured and the contralateral limbs.  Results: Acute oral administration of CR4056, 14 days after MIA injection, significantly and dose-dependently reduced allodynia and hyperalgesia 90 min after treatment, whereas acute naproxen administration significantly reduced allodynia but not hyperalgesia.  After 7 days of repeated treatment, both CR4056 and naproxen showed significant anti-allodynic and anti-hyperalgesic effects in the MIA model.  Rats undergoing MMT surgery developed a significant and progressive asymmetry in HPWD compared with sham-operated animals.  Repeated treatment with CR4056 significantly reduced the progression of the pain behavior, whereas naproxen had no effects.  Conclusion: The data presented here show that the I2 ligand CR4056 could be a new effective treatment for OA pain.  The compd. is currently under Phase II clin. evaluation for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpANu0GScmmFrVg90H21EOLACvtfcHk0lg9EOkYJjEbcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWksLzN&md5=7fbb8cd6ca7b7bbc647ad4cbd6cacda7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2147%2FJPR.S132026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S132026%26sid%3Dliteratum%253Aachs%26aulast%3DComi%26aufirst%3DE.%26aulast%3DLanza%26aufirst%3DM.%26aulast%3DFerrari%26aufirst%3DF.%26aulast%3DMauri%26aufirst%3DV.%26aulast%3DCaselli%26aufirst%3DG.%26aulast%3DRovati%26aufirst%3DL.%2BC.%26atitle%3DEfficacy%2520of%2520CR4056%252C%2520a%2520first-in-class%2520imidazoline-2%2520analgesic%2520drug%252C%2520in%2520comparison%2520with%2520naproxen%2520in%2520two%2520rat%2520models%2520of%2520osteoarthritis%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2017%26volume%3D10%26spage%3D1033%26epage%3D1043%26doi%3D10.2147%2FJPR.S132026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rovati, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blicharski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonazzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacovelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girolami, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of the firts-in-classs imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and desease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial</span>. <i>Osteoarthritis and Cartilage</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.joca.2019.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.joca.2019.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=31526875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BB3MrptlGgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=22&author=L.+C.+Rovatiauthor=N.+Brambillaauthor=T.+Blicharskiauthor=J.+Connellauthor=C.+Vitaliniauthor=A.+Bonazziauthor=G.+Giacovelliauthor=F.+Girolamiauthor=M.+D%E2%80%99Amato&title=Efficacy+and+safety+of+the+firts-in-classs+imidazoline-2+receptor+ligand+CR4056+in+pain+from+knee+osteoarthritis+and+desease+phenotypes%3A+a+randomized%2C+double-blind%2C+placebo-controlled+phase+2+trial&doi=10.1016%2Fj.joca.2019.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial</span></div><div class="casAuthors">Rovati L C; Brambilla N; Vitalini C; Bonazzi A; Giacovelli G; Girolami F; D'Amato M; Blicharski T; Connell J</div><div class="citationInfo"><span class="NLM_cas:title">Osteoarthritis and cartilage</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  CR4056 is a selective imidazoline-2 (I2) receptor ligand with potent analgesic activity in animal pain models.  This proof-of-concept study tested CR4056 efficacy and safety in patients with knee osteoarthritis (OA) and different phenotypes.  DESIGN:  This is a multicenter, randomized, double-blind, placebo-controlled trial.  Knee OA patients with moderate to severe pain received CR4056 (women 100 mg bid; men 200 mg bid) or placebo (both genders) for 14 days.  The primary outcome was the change in WOMAC pain score (0-100 scale) compared to placebo, analyzed in the intention-to-treat population and pre-defined OA phenotypes.  RESULTS:  213 patients were treated with CR4056 (92 women; 52 men) or placebo (69 overall).  After 14 days, median WOMAC pain improvements were 10 points on placebo and 14, 20 and 16 in women, men, and pooled CR4056 groups (P = 0.184, 0.030 and 0.070 vs placebo, respectively).  Pre-specified subgroup analysis in the metabolic OA phenotype (BMI ≥ 27.5 kg/m(2), N = 156) showed statistically significant differences in all CR4056-treated groups vs placebo of 12-18 points.  Conversely, there were too few patients with a neuropathic or inflammatory phenotype for a meaningful analysis.  CR4056 was well tolerated; the most common adverse event was mild headache.  CONCLUSIONS:  Although the primary endpoint was met in males only, this exploratory phase 2 trial shows that CR4056 might be an effective analgesic against knee OA pain, especially in overweight patients representing the metabolic OA phenotype.  These findings, along with the broad-spectrum analgesic activity of CR4056 in animal models, warrant further clinical investigation in OA and other pain conditions.  CLINICAL TRIAL REGISTRATION NUMBER:  EudraCT 2015-001136-37.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-_ap8hyM_J0loaUqgkFHkfW6udTcc2eaDc6w9FX2R0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrptlGgtw%253D%253D&md5=2dfafb5acb63d759bb79f95369a9f948</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.joca.2019.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joca.2019.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DRovati%26aufirst%3DL.%2BC.%26aulast%3DBrambilla%26aufirst%3DN.%26aulast%3DBlicharski%26aufirst%3DT.%26aulast%3DConnell%26aufirst%3DJ.%26aulast%3DVitalini%26aufirst%3DC.%26aulast%3DBonazzi%26aufirst%3DA.%26aulast%3DGiacovelli%26aufirst%3DG.%26aulast%3DGirolami%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520the%2520firts-in-classs%2520imidazoline-2%2520receptor%2520ligand%2520CR4056%2520in%2520pain%2520from%2520knee%2520osteoarthritis%2520and%2520desease%2520phenotypes%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25202%2520trial%26jtitle%3DOsteoarthritis%2520and%2520Cartilage%26date%3D2020%26volume%3D28%26spage%3D22%26doi%3D10.1016%2Fj.joca.2019.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyacke, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mick, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passchier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of <sup>11</sup>C-BU99008, a PET ligand for the imidazoline<sub>2</sub> binding site in human brain</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1597</span>– <span class="NLM_lpage">1602</span>, <span class="refDoi"> DOI: 10.2967/jnumed.118.208009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.2967%2Fjnumed.118.208009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=29523627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktVajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=1597-1602&author=R.+J.+Tyackeauthor=J.+F.+M.+Myersauthor=A.+V.+Venkataramanauthor=I.+Mickauthor=S.+Turtonauthor=J.+Passchierauthor=S.+M.+Husbandsauthor=E.+A.+Rabinerauthor=R.+N.+Gunnauthor=P.+S.+Murphyauthor=C.+A.+Parkerauthor=D.+J.+Nutt&title=Evaluation+of+11C-BU99008%2C+a+PET+ligand+for+the+imidazoline2+binding+site+in+human+brain&doi=10.2967%2Fjnumed.118.208009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of 11C-BU99008, a PET ligand for the Imidazoline2 binding site in human brain</span></div><div class="casAuthors">Tyacke, Robin J.; Myers, Jim F. M.; Venkataraman, Ashwin; Mick, Inge; Turton, Samuel; Passchier, Jan; Husbands, Stephen M.; Rabiner, Eugenii A.; Gunn, Roger N.; Murphy, Philip S.; Parker, Christine A.; Nutt, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1597-1602</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The imidazoline2 binding site (I2BS) is thought to be expressed in glia and implicated in the regulation of glial fibrillary acidic protein.  A PET ligand for this target would be important for the investigation of neurodegenerative and neuroinflammatory diseases. 11C-BU99008 has previously been identified as a putative PET radioligand.  Here, we present the first in vivo characterization of this PET radioligand in humans and assess its test-retest reproducibility.  Methods: Fourteen healthy male volunteers underwent dynamic PET imaging with 11C-BU99008 and arterial sampling.  Six subjects were used in a test-retest assessment, and 8 were used in a pharmacol. evaluation, undergoing a second or third heterologous competition scan with the mixed I2BS/α2-adrenoceptor drug idazoxan (n = 8; 20, 40, 60, and 80 mg) and the mixed irreversible monoamine oxidase type A/B inhibitor isocarboxazid (n = 4; 50 mg).  Regional time-activity data were generated from arterial plasma input functions cor. for metabolites using the most appropriate model to derive the outcome measure VT (regional distribution vol.).  All image processing and kinetic analyses were performed in MIAKAT.  Results: Brain uptake of 11C-BU99008 was good, with reversible kinetics and a heterogeneous distribution consistent with known I2BS expression.  Model selection criteria indicated that the 2-tissue-compartment model was preferred.  VT ests. were high in the striatum (105 ± 21 mL·cm-3), medium in the cingulate cortex (62 ± 10 mL·cm-3), and low in the cerebellum (41 ± 7 mL·cm-3).  Test-retest reliability was reasonable.  The uptake was dose-dependently reduced throughout the brain by pretreatment with idazoxan, with an av. block across all regions of about 60% (VT, ∼30 mL·cm-3) at the highest dose (80 mg).  The median ED for idazoxan was 28 mg.  Uptake was not blocked by pretreatment with the monoamine oxidase inhibitor isocarboxazid.  Conclusion: 11C-BU99008 in human PET studies demonstrates good brain delivery, reversible kinetics, heterogeneous distribution, specific binding signal consistent with I2BS distribution, and good test-retest reliability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK69AF7SLNorVg90H21EOLACvtfcHk0lg9EOkYJjEbcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktVajtrY%253D&md5=49ef228fd095cac95ce9d8edc1d10339</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.208009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.208009%26sid%3Dliteratum%253Aachs%26aulast%3DTyacke%26aufirst%3DR.%2BJ.%26aulast%3DMyers%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DVenkataraman%26aufirst%3DA.%2BV.%26aulast%3DMick%26aufirst%3DI.%26aulast%3DTurton%26aufirst%3DS.%26aulast%3DPasschier%26aufirst%3DJ.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26aulast%3DGunn%26aufirst%3DR.%2BN.%26aulast%3DMurphy%26aufirst%3DP.%2BS.%26aulast%3DParker%26aufirst%3DC.%2BA.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26atitle%3DEvaluation%2520of%252011C-BU99008%252C%2520a%2520PET%2520ligand%2520for%2520the%2520imidazoline2%2520binding%2520site%2520in%2520human%2520brain%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D1597%26epage%3D1602%26doi%3D10.2967%2Fjnumed.118.208009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dervenoulas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyacke, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polychronis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politis, M.</span></span> <span> </span><span class="NLM_article-title">Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s disease: an <i>in vivo</i> <sup>11</sup>C-BU99008 PET study</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">3116</span>, <span class="refDoi"> DOI: 10.1093/brain/awz260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1093%2Fbrain%2Fawz260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=31504212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BB3MrntV2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2019&pages=3116&author=H.+Wilsonauthor=G.+Dervenoulasauthor=G.+Paganoauthor=R.+J.+Tyackeauthor=S.+Polychronisauthor=J.+Myersauthor=R.+N.+Gunnauthor=E.+A.+Rabinerauthor=D.+Nuttauthor=M.+Politis&title=Imidazoline+2+binding+sites+reflecting+astroglia+pathology+in+Parkinson%E2%80%99s+disease%3A+an+in+vivo+11C-BU99008+PET+study&doi=10.1093%2Fbrain%2Fawz260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study</span></div><div class="casAuthors">Wilson Heather; Dervenoulas George; Pagano Gennaro; Polychronis Sotirios; Politis Marios; Tyacke Robin J; Myers Jim; Nutt David; Gunn Roger N; Gunn Roger N; Rabiner Eugenii A; Rabiner Eugenii A</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3116-3128</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Astroglia are multifunctional cells that regulate neuroinflammation and maintain homeostasis within the brain.  Astroglial α-synuclein-positive cytoplasmic accumulations have been shown post-mortem in patients with Parkinson's disease and therefore astroglia may play an important role in the initiation and progression of Parkinson's disease.  Imidazoline 2 binding sites are expressed on activated astroglia in the cortex, hippocampus, basal ganglia and brainstem; therefore, by measuring imidazoline 2 binding site levels we can indirectly evaluate astrogliosis in patients with Parkinson's disease.  Here, we aimed to evaluate the role of astroglia activation in vivo in patients with Parkinson's disease using 11C-BU99008 PET, a novel radioligand with high specificity and selectivity for imidazoline 2 binding sites.  Twenty-two patients with Parkinson's disease and 14 healthy control subjects underwent 3 T MRI and a 120-min 11C-BU99008 PET scan with volume of distribution (VT) estimated using a two-tissue compartmental model with a metabolite corrected arterial plasma input function.  Parkinson's disease patients were stratified into early (n = 8) and moderate/advanced (n = 14) groups according to disease stage.  In early Parkinson's disease, increased 11C-BU99008 VT uptake was observed in frontal (P = 0.022), temporal (P = 0.02), parietal (P = 0.026) and occipital (P = 0.047) cortical regions compared with healthy controls.  The greatest 11C-BU99008 VT increase in patients with early Parkinson's disease was observed in the brainstem (52%; P = 0.018).  In patients with moderate/advanced Parkinson's disease, loss of 11C-BU99008 VT was observed across frontal (P = 0.002), temporal (P < 0.001), parietal (P = 0.039), occipital (P = 0.024), and insula (P < 0.001) cortices; and in the subcortical regions of caudate (P < 0.001), putamen (P < 0.001) and thalamus (P < 0.001); and in the brainstem (P = 0.018) compared with healthy controls.  In patients with Parkinson's disease, loss of 11C-BU99008 VT in cortical regions, striatum, thalamus and brainstem correlated with longer disease duration (P < 0.05) and higher disease burden scores, measured with Movement Disorder Society Unified Parkinson's Disease Rating Scale (P < 0.05).  In the subgroup of patients with moderate/advanced Parkinson's disease, loss of 11C-BU99008 VT in the frontal (r = 0.79; P = 0.001), temporal (r = 0.74; P = 0.002) and parietal (r = 0.89; P < 0.001) cortex correlated with global cognitive impairment.  This study demonstrates in vivo the role of astroglia in the initiation and progression of Parkinson's disease.  Reactive astroglia observed early in Parkinson's disease could reflect a neuroprotective compensatory mechanisms and pro-inflammatory upregulation in response to α-synuclein accumulation.  However, as the disease progresses and significant neurodegeneration occurs, astroglia lose their reactive function and such loss in the cortex has clinical relevance in the development of cognitive impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNZ2xJM2Tbm79KldV63DuefW6udTcc2eakhMlHw1cUNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrntV2iug%253D%253D&md5=c3c0ba77344dd469deeb0787f8bf41c9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawz260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawz260%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DH.%26aulast%3DDervenoulas%26aufirst%3DG.%26aulast%3DPagano%26aufirst%3DG.%26aulast%3DTyacke%26aufirst%3DR.%2BJ.%26aulast%3DPolychronis%26aufirst%3DS.%26aulast%3DMyers%26aufirst%3DJ.%26aulast%3DGunn%26aufirst%3DR.%2BN.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26aulast%3DNutt%26aufirst%3DD.%26aulast%3DPolitis%26aufirst%3DM.%26atitle%3DImidazoline%25202%2520binding%2520sites%2520reflecting%2520astroglia%2520pathology%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520an%2520in%2520vivo%252011C-BU99008%2520PET%2520study%26jtitle%3DBrain%26date%3D2019%26volume%3D142%26spage%3D3116%26doi%3D10.1093%2Fbrain%2Fawz260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dardonville, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozas, I.</span></span> <span> </span><span class="NLM_article-title">Imidazoline binding sites and their ligands: an overview of the different chemical structures</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1002/med.20007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fmed.20007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=15224384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Witb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=639-661&author=C.+Dardonvilleauthor=I.+Rozas&title=Imidazoline+binding+sites+and+their+ligands%3A+an+overview+of+the+different+chemical+structures&doi=10.1002%2Fmed.20007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline binding sites and their ligands: an overview of the different chemical structures</span></div><div class="casAuthors">Dardonville, Christophe; Rozas, Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-661</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Since Bousquet et al. discovered the imidazoline binding sites (IBS) two decades ago, when they realized that the antihypertensive drug clonidine interacts not only with the α2-adrenoceptors (α2-AR) but also with a distinct imidazoline preferring binding site, these receptors have been paid a great deal of attention.  At least two subtypes, I1 and I2, have been characterized based on their binding affinity for different radioligands, but their structures still remain unknown.  The pharmacol. profile of these IBSs has been the objective of several and very thorough reviews.  However, a medicinal chem. overview of the different lBS ligands prepd. to date has never been attempted.  In this study, the authors attempt to compile all the different chem. structures reported to date as IBS ligands and classify them in function of their chem. structure and binding affinity for the different IBS subtypes.  Thus, the authors comment on the different endogenous IBS ligands known as well as the drugs described to interact with the I1-IBS which have found application as antihypertensive drugs.  Then, the authors review those compds. described in the literature to interact with the I2-IBS, classifying them by their chem. families (imidazolines, guanidines, 2-aminoimidazolines, 3-carbolines).  Finally, some conclusions are drawn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRNIrzXSLExbVg90H21EOLACvtfcHk0lhpY2GHLi9ntg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Witb7N&md5=0fe33c62d6d3e897434ddc37ceacc294</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fmed.20007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20007%26sid%3Dliteratum%253Aachs%26aulast%3DDardonville%26aufirst%3DC.%26aulast%3DRozas%26aufirst%3DI.%26atitle%3DImidazoline%2520binding%2520sites%2520and%2520their%2520ligands%253A%2520an%2520overview%2520of%2520the%2520different%2520chemical%2520structures%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2004%26volume%3D24%26spage%3D639%26epage%3D661%26doi%3D10.1002%2Fmed.20007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abás, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdozain, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Arévalo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escolano, C.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of a structurally new family of high affinity imidazoline I<sub>2</sub> receptors ligands</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00426</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00426" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGqsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=737-742&author=S.+Ab%C3%A1sauthor=A.+M.+Erdozainauthor=B.+Kellerauthor=S.+Rodr%C3%ADguez-Ar%C3%A9valoauthor=L.+F.+Calladoauthor=J.+A.+Garc%C3%ADa-Sevillaauthor=C.+Escolano&title=Neuroprotective+effects+of+a+structurally+new+family+of+high+affinity+imidazoline+I2+receptors+ligands&doi=10.1021%2Facschemneuro.6b00426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective Effects of a Structurally New Family of High Affinity Imidazoline I2 Receptor Ligands</span></div><div class="casAuthors">Abas, Sonia; Erdozain, Amaia M.; Keller, Benjamin; Rodriguez-Arevalo, Sergio; Callado, Luis F.; Garcia-Sevilla, Jesus A.; Escolano, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">737-742</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The imidazoline I2 receptors (I2-IRs) are widely distributed in the brain, and I2-IR ligands may have therapeutic potential as neuroprotective agents.  Since structural data for I2-IR remains unknown, the discovery of selective I2-IR ligands devoid of α2-adrenoceptor (α2-AR) affinity is likely to provide valuable tools in defining the pharmacol. characterization of these receptors.  We report the pharmacol. characterization of a new family of (2-imidazolin-4-yl)phosphonates.  Radioligand binding studies showed that they displayed a higher affinity for I2-IRs than idazoxan, and high I2/α2 selectivity.  In vivo studies in mice showed that acute treatments with 1b and 2c significantly increased p-FADD/FADD ratio (an index of cell survival) in the hippocampus when compared with vehicle-treated controls.  Addnl., acute and repeated treatments with 2c, but not with 1b, markedly reduced hippocampal p35 cleavage into neurotoxic p25.  The present results indicate a neuroprotective potential of (2-imidazolin-4-yl)phosphonates acting at I2-IRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgccGN_OMgMrVg90H21EOLACvtfcHk0lhpY2GHLi9ntg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGqsrjJ&md5=6726444171cfbc3c8adab1437fdb34cd</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00426%26sid%3Dliteratum%253Aachs%26aulast%3DAb%25C3%25A1s%26aufirst%3DS.%26aulast%3DErdozain%26aufirst%3DA.%2BM.%26aulast%3DKeller%26aufirst%3DB.%26aulast%3DRodr%25C3%25ADguez-Ar%25C3%25A9valo%26aufirst%3DS.%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26aulast%3DEscolano%26aufirst%3DC.%26atitle%3DNeuroprotective%2520effects%2520of%2520a%2520structurally%2520new%2520family%2520of%2520high%2520affinity%2520imidazoline%2520I2%2520receptors%2520ligands%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D737%26epage%3D742%26doi%3D10.1021%2Facschemneuro.6b00426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abás, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estarellas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escolano, C.</span></span> <span> </span><span class="NLM_article-title">Easy access to (2-imidazolin-4-yl)phosphonates by a microwave assisted multicomponent reaction</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2872</span>– <span class="NLM_lpage">2881</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2015.03.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.tet.2015.03.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVKgu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=2872-2881&author=S.+Ab%C3%A1sauthor=C.+Estarellasauthor=F.+J.+Luqueauthor=C.+Escolano&title=Easy+access+to+%282-imidazolin-4-yl%29phosphonates+by+a+microwave+assisted+multicomponent+reaction&doi=10.1016%2Fj.tet.2015.03.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Easy access to (2-imidazolin-4-yl)phosphonates by a microwave assisted multicomponent reaction</span></div><div class="casAuthors">Abas, Sonia; Estarellas, Carolina; Javier Luque, F.; Escolano, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2872-2881</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An efficient and user-friendly synthetic process involving the combination of multicomponent reaction methodol. and microwave heating generates unprecedented (2-imidazolin-4-yl)phosphonates 1-18.  E.g., reaction of phenethylamine with acetone and di-Et isocyanomethylphosphonate in the presence of 10 mol% AgNO3 in a microwave oven at 40° gave a 91% yield of di-Et [5,5-dimethyl-1-(1-phenethyl)-4,5-dihydro-1H-imidazol-4-yl]phosphonate.  This strategy presents a Ag-catalyzed, operationally simple and environmentally friendly transformation without the need of anhyd. atm. or addnl. solvents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosd6_Cw0V1b7Vg90H21EOLACvtfcHk0lj0rUN3Qe6wYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVKgu7Y%253D&md5=6437e89b25680b0d9368f6801fa642a2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2015.03.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2015.03.065%26sid%3Dliteratum%253Aachs%26aulast%3DAb%25C3%25A1s%26aufirst%3DS.%26aulast%3DEstarellas%26aufirst%3DC.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DEscolano%26aufirst%3DC.%26atitle%3DEasy%2520access%2520to%2520%25282-imidazolin-4-yl%2529phosphonates%2520by%2520a%2520microwave%2520assisted%2520multicomponent%2520reaction%26jtitle%3DTetrahedron%26date%3D2015%26volume%3D71%26spage%3D2872%26epage%3D2881%26doi%3D10.1016%2Fj.tet.2015.03.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griñán-Ferré, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasilopoulou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abás, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Arévalo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagán, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sureda, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Fuster, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escolano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallàs, M.</span></span> <span> </span><span class="NLM_article-title">Behavioral and cognitive improvement induced by novel imidazoline I<sub>2</sub> receptor ligands in female SAMP8 mice</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1007/s13311-018-00681-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1007%2Fs13311-018-00681-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=30460457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlShtr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=416-431&author=C.+Gri%C3%B1%C3%A1n-Ferr%C3%A9author=F.+Vasilopoulouauthor=S.+Ab%C3%A1sauthor=S.+Rodr%C3%ADguez-Ar%C3%A9valoauthor=A.+Bag%C3%A1nauthor=F.+X.+Suredaauthor=B.+P%C3%A9rezauthor=L.+F.+Calladoauthor=J.+A.+Garc%C3%ADa-Sevillaauthor=M.+J.+Garc%C3%ADa-Fusterauthor=C.+Escolanoauthor=M.+Pall%C3%A0s&title=Behavioral+and+cognitive+improvement+induced+by+novel+imidazoline+I2+receptor+ligands+in+female+SAMP8+mice&doi=10.1007%2Fs13311-018-00681-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral and Cognitive Improvement Induced by Novel Imidazoline I2 Receptor Ligands in Female SAMP8 Mice</span></div><div class="casAuthors">Grinan-Ferre, Christian; Vasilopoulou, Foteini; Abas, Sonia; Rodriguez-Arevalo, Sergio; Bagan, Andrea; Sureda, Francesc X.; Perez, Belen; Callado, Luis F.; Garcia-Sevilla, Jesus A.; Garcia-Fuster, M. Julia; Escolano, Carmen; Pallas, Merce</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">416-431</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">As populations increase their life expectancy, age-related neurodegenerative disorders such as Alzheimer's disease have become more common.  I2-Imidazoline receptors (I2-IR) are widely distributed in the central nervous system, and dysregulation of I2-IR in patients with neurodegenerative diseases has been reported, suggesting their implication in cognitive impairment.  This evidence indicates that high-affinity selective I2-IR ligands potentially contribute to the delay of neurodegeneration.  In vivo studies in the female senescence accelerated mouse-prone 8 mice have shown that treatment with I2-IR ligands, MCR5 and MCR9, produce beneficial effects in behavior and cognition.  Changes in mol. pathways implicated in oxidative stress, inflammation, synaptic plasticity, and apoptotic cell death were also studied.  Furthermore, treatments with these I2-IR ligands diminished the amyloid precursor protein processing pathway and increased Aβ degrading enzymes in the hippocampus of SAMP8 mice.  These results collectively demonstrate the neuroprotective role of these new I2-IR ligands in a mouse model of brain aging through specific pathways and suggest their potential as therapeutic agents in brain disorders and age-related neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpll-tgGobyQbVg90H21EOLACvtfcHk0lj0rUN3Qe6wYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlShtr%252FK&md5=422a2e7ff722c4dce09dd7ac3a8366f0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs13311-018-00681-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-018-00681-5%26sid%3Dliteratum%253Aachs%26aulast%3DGri%25C3%25B1%25C3%25A1n-Ferr%25C3%25A9%26aufirst%3DC.%26aulast%3DVasilopoulou%26aufirst%3DF.%26aulast%3DAb%25C3%25A1s%26aufirst%3DS.%26aulast%3DRodr%25C3%25ADguez-Ar%25C3%25A9valo%26aufirst%3DS.%26aulast%3DBag%25C3%25A1n%26aufirst%3DA.%26aulast%3DSureda%26aufirst%3DF.%2BX.%26aulast%3DP%25C3%25A9rez%26aufirst%3DB.%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26aulast%3DGarc%25C3%25ADa-Fuster%26aufirst%3DM.%2BJ.%26aulast%3DEscolano%26aufirst%3DC.%26aulast%3DPall%25C3%25A0s%26aufirst%3DM.%26atitle%3DBehavioral%2520and%2520cognitive%2520improvement%2520induced%2520by%2520novel%2520imidazoline%2520I2%2520receptor%2520ligands%2520in%2520female%2520SAMP8%2520mice%26jtitle%3DNeurotherapeutics%26date%3D2019%26volume%3D16%26spage%3D416%26epage%3D431%26doi%3D10.1007%2Fs13311-018-00681-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arróniz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abás, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanera, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escolano, C.</span></span> <span> </span><span class="NLM_article-title">First diastereoselective [3 + 2] cycloaddition reaction of diethyl isocyanomethylphosphonate and maleimides</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1640</span>– <span class="NLM_lpage">1649</span>, <span class="refDoi"> DOI: 10.1039/c3ob26766k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1039%2Fc3ob26766k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=23358611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisVKqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=1640-1649&author=C.+Arr%C3%B3nizauthor=J.+Molinaauthor=S.+Ab%C3%A1sauthor=E.+Molinsauthor=J.+M.+Campaneraauthor=F.+J.+Luqueauthor=C.+Escolano&title=First+diastereoselective+%5B3+%2B+2%5D+cycloaddition+reaction+of+diethyl+isocyanomethylphosphonate+and+maleimides&doi=10.1039%2Fc3ob26766k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">First diastereoselective [3 + 2] cycloaddition reaction of diethyl isocyanomethylphosphonate and maleimides</span></div><div class="casAuthors">Arroniz, Carlos; Molina, Juan; Abas, Sonia; Molins, Elies; Campanera, Josep M.; Luque, F. Javier; Escolano, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1640-1649</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Bicyclic α-iminophosphonates were prepd. via the first diastereoselective silver catalyzed [3 + 2] cycloaddn. reaction of di-Et isocyanomethylphosphonate and diversely N-substituted maleimides.  The redn. of the resulting imine by catalytic hydrogenation led to cyclic α-aminophosphonates, which are α-aminoester surrogates.  The relative stereochem. of the adducts was confirmed by x-ray crystallog. anal. of di-Et (1RS,3aRS,6aRS)-4,6-dioxo-5-phenyl-1,3a,4,5,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate 4.  The diastereoselectivity of the cycloaddn. reaction was rationalized by theor. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1ExSqAVZBT7Vg90H21EOLACvtfcHk0lj0rUN3Qe6wYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisVKqsbg%253D&md5=9b9c92129362823b987555431ed6aad8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2Fc3ob26766k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3ob26766k%26sid%3Dliteratum%253Aachs%26aulast%3DArr%25C3%25B3niz%26aufirst%3DC.%26aulast%3DMolina%26aufirst%3DJ.%26aulast%3DAb%25C3%25A1s%26aufirst%3DS.%26aulast%3DMolins%26aufirst%3DE.%26aulast%3DCampanera%26aufirst%3DJ.%2BM.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DEscolano%26aufirst%3DC.%26atitle%3DFirst%2520diastereoselective%2520%255B3%2520%252B%25202%255D%2520cycloaddition%2520reaction%2520of%2520diethyl%2520isocyanomethylphosphonate%2520and%2520maleimides%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D1640%26epage%3D1649%26doi%3D10.1039%2Fc3ob26766k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escolano, C.</span>; <span class="NLM_string-name">Pallás, M.</span>; <span class="NLM_string-name">Griñán-Ferré, C.</span>; <span class="NLM_string-name">Abás, S.</span>; <span class="NLM_string-name">Callado, L.-F.</span>; <span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthetic I<sub>2</sub> Imidazoline Receptor Ligands for Prevention or Treatment of Human Brain Disorders</span>. <span class="NLM_patent">WO 2019/121853 A1</span>, June 27, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Escolano&author=M.+Pall%C3%A1s&author=C.+Gri%C3%B1%C3%A1n-Ferr%C3%A9&author=S.+Ab%C3%A1s&author=L.-F.+Callado&author=J.+A.+Garc%C3%ADa-Sevilla&title=Synthetic+I2+Imidazoline+Receptor+Ligands+for+Prevention+or+Treatment+of+Human+Brain+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEscolano%26aufirst%3DC.%26atitle%3DSynthetic%2520I2%2520Imidazoline%2520Receptor%2520Ligands%2520for%2520Prevention%2520or%2520Treatment%2520of%2520Human%2520Brain%2520Disorders%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grijalba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazos, A.</span></span> <span> </span><span class="NLM_article-title">α<sub>2</sub>-Adrenoceptor subtypes in the human brain: a phamacological delineation of [<sup>3</sup>H]RX-821002 binding to membranes and tissue sections</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00381-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0014-2999%2896%2900381-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8880071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK28Xlt1KjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=1996&pages=83-93&author=B.+Grijalbaauthor=L.+F.+Calladoauthor=J.+J.+Meanaauthor=J.+A.+Garc%C3%ADa-Sevillaauthor=A.+Pazos&title=%CE%B12-Adrenoceptor+subtypes+in+the+human+brain%3A+a+phamacological+delineation+of+%5B3H%5DRX-821002+binding+to+membranes+and+tissue+sections&doi=10.1016%2F0014-2999%2896%2900381-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">α2-Adrenoceptor subtypes in the human brain: a pharmacological delineation of [3H]RX-821002 binding to membranes and tissue sections</span></div><div class="casAuthors">Grijalba, Bernardo; Callado, Luis F.; Meana, J. Javier; Garcia-Sevilla, Jesus A.; Pazos, Angel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-93</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In order to study the characterization and localization of [3H]RX-821002 (2-methoxy-idazoxan) binding to α2-adrenoceptor subtypes in several regions of the human brain, we have carried out competition studies using both autoradiog. and membrane binding assays.  The α2A-adrenoceptor subtype was found to be predominant in the different layers of the frontal cortex, cerebellum and hippocampal formation, while in the neostriatum it was the non-α2A- (α2B- and α2C-) adrenoceptor subtype.  In the frontal cortex, in addn. to binding to the α2A-adrenoceptor subtype, [3H]RX-821002 bound also to a small portion of α2B- and α2C-adrenoceptors in layer III, and to an unidentified binding site in the external layers.  In the hippocampus, both α2A- and non-α2A- (α2B- and α2C-) adrenoceptors were labeled in the dentate gyrus and the CA1 field, together with 5-HT1A receptors. 5-HT1A receptors were labeled predominantly in the stratum pyramidale layer.  These results, in addn. to delineate the relative presence of α2-adrenoceptor subtypes, indicate that caution is needed when analyzing RX 821002 binding to human brain tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr01_lWikhGyLVg90H21EOLACvtfcHk0lj5_JSSAFvLtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xlt1KjtL4%253D&md5=74ad82e678a1bc11a028e5236926eea2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900381-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900381-0%26sid%3Dliteratum%253Aachs%26aulast%3DGrijalba%26aufirst%3DB.%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26aulast%3DPazos%26aufirst%3DA.%26atitle%3D%25CE%25B12-Adrenoceptor%2520subtypes%2520in%2520the%2520human%2520brain%253A%2520a%2520phamacological%2520delineation%2520of%2520%255B3H%255DRX-821002%2520binding%2520to%2520membranes%2520and%2520tissue%2520sections%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D310%26spage%3D83%26epage%3D93%26doi%3D10.1016%2F0014-2999%2896%2900381-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeztu, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutiérrez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span> <span> </span><span class="NLM_article-title">Differential [<sup>3</sup>H]idazoxan and [<sup>3</sup>H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) binding to imidazoline I<sub>2</sub> receptors in human postmortem frontal cortex</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(01)01097-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0014-2999%2801%2901097-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=11448473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltVGjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2001&pages=109-114&author=L.+F.+Calladoauthor=A.+I.+Maeztuauthor=J.+Ballesterosauthor=M.+Guti%C3%A9rrezauthor=J.+J.+Meana&title=Differential+%5B3H%5Didazoxan+and+%5B3H%5D2-%282-benzofuranyl%29-2-imidazoline+%282-BFI%29+binding+to+imidazoline+I2+receptors+in+human+postmortem+frontal+cortex&doi=10.1016%2FS0014-2999%2801%2901097-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Differential [3H]idazoxan and [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) binding to imidazoline I2 receptors in human postmortem frontal cortex</span></div><div class="casAuthors">Callado, L. F.; Maeztu, A. I.; Ballesteros, J.; Gutierrez, M.; Javier Meana, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">109-114</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">[3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) and [3H]idazoxan are the most used tools to characterize imidazoline I2 receptors.  We evaluated the binding of both radioligands to human postmortem frontal cortex membranes.  Satn. binding analyses revealed that [3H]idazoxan (in the presence of 2 μM efaroxan to avoid radioligand binding to α2-adrenoceptors and imidazoline I1 receptors) and [3H]2-BFI bound with high affinity to an apparent single population of sites.  However, in competition studies whereas [3H]idazoxan (10 nM) binding was displaced monophasically by idazoxan and 2-BFI, both drugs displayed biphasic curves for [3H]2-BFI (1 nM).  The proportion of the low-affinity binding site increased from 17% to 25% when 10 nM [3H]2-BFI was displaced by idazoxan.  Amiloride inhibited [3H]2-BFI (10 nM) binding with low affinity and in a monophasic way.  These data indicate that [3H]2-BFI recognizes in human postmortem brain membranes a second binding site different from the imidazoline I2 receptors labeled by [3H]idazoxan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8wS7zlfj4E7Vg90H21EOLACvtfcHk0lj5_JSSAFvLtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltVGjsrg%253D&md5=a1c7b1a2b2a354d79546801271be96fb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901097-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901097-4%26sid%3Dliteratum%253Aachs%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DMaeztu%26aufirst%3DA.%2BI.%26aulast%3DBallesteros%26aufirst%3DJ.%26aulast%3DGuti%25C3%25A9rrez%26aufirst%3DM.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26atitle%3DDifferential%2520%255B3H%255Didazoxan%2520and%2520%255B3H%255D2-%25282-benzofuranyl%2529-2-imidazoline%2520%25282-BFI%2529%2520binding%2520to%2520imidazoline%2520I2%2520receptors%2520in%2520human%2520postmortem%2520frontal%2520cortex%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D423%26spage%3D109%26epage%3D114%26doi%3D10.1016%2FS0014-2999%2801%2901097-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span> BU99008 was
prepared
according to the literature procedure:<span class="NLM_contrib-group"><span class="NLM_string-name">Tyacke, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, E. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation and initial in vitro and in vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1<i>H</i>-imidazol-2-yl)-1-methyl-1<i>H</i>-indole), for the imidazoline<sub>2</sub> binding site</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1002/syn.21541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fsyn.21541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=22290740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFyjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2012&pages=542-551&author=R.+J.+Tyackeauthor=A.+Fisherauthor=E.+S.+J.+Robinsonauthor=P.+Grundtauthor=E.+M.+Turnerauthor=S.+M.+Husbandsauthor=A.+L.+Hudsonauthor=C.+A.+Parkerauthor=D.+J.+Nutt&title=Evaluation+and+initial+in+vitro+and+in+vivo+characterization+of+the+potential+positron+emission+tomography+ligand%2C+BU99008+%282-%284%2C5-dihydro-1H-imidazol-2-yl%29-1-methyl-1H-indole%29%2C+for+the+imidazoline2+binding+site&doi=10.1002%2Fsyn.21541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-Dihydro-1H-imidazol-2-yl)-1- methyl-1H-indole), for the imidazoline2 binding site</span></div><div class="casAuthors">Tyacke, Robin J.; Fisher, Amy; Robinson, Emma S. J.; Grundt, Peter; Turner, Emma M.; Husbands, Stephen M.; Hudson, Alan L.; Parker, Christine A.; Nutt, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">542-551</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The d. of the Imidazoline2 binding site (I2BS) has been shown to change in psychiatric conditions such as depression and addiction, along with neurodegenerative disorders such as Alzheimer's disease and Huntington's chorea.  The presence of I2BS on glial cells and the possibility that they may in some way regulate glial fibrillary acidic protein has led to increased interest into the role of I2BS and I2BS ligands in conditions characterized by marked gliosis.  In addn., it has been suggested that I2BS may be a marker for human glioblastomas.  Therefore, the development of a positron emission tomog. (PET) radioligand for the I2BS would be of major benefit in our understanding of these conditions.  We now report the successful synthesis and initial pharmacol. evaluation of potential PET radioligands for the I2BS as well as the tritiation and characterization of the most favorable of the series, BU99008 (6), both in vitro and ex vivo in rat.  The series as a whole demonstrated excellent affinity and selectivity for the I2BS, with BU99008 (6) selected as the lead candidate to be taken forward for in vivo assessment.  BU99008 (6) showed very good affinity for the I2BS (Ki of 1.4 nM; Kd = 1.3 nM), good selectivity compared with the α2-adrenoceptor (909-fold).  In addn., following peripheral administration, [3H]BU99008 demonstrated a heterogenous uptake into the rat brain consistent with the known distribution of the I2BS in vivo.  This, and the amenability of BU99008 (6) to radiolabeling with a positron-emitting radioisotope, indicates its potential as a PET radioligand for imaging the I2BS in vivo.  Synapse, 2012. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK29aH8onmobVg90H21EOLACvtfcHk0lhGbKl24dwqhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFyjtr0%253D&md5=fa51bf0a89bd4411472a2c3c6223c770</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fsyn.21541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.21541%26sid%3Dliteratum%253Aachs%26aulast%3DTyacke%26aufirst%3DR.%2BJ.%26aulast%3DFisher%26aufirst%3DA.%26aulast%3DRobinson%26aufirst%3DE.%2BS.%2BJ.%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DTurner%26aufirst%3DE.%2BM.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DHudson%26aufirst%3DA.%2BL.%26aulast%3DParker%26aufirst%3DC.%2BA.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26atitle%3DEvaluation%2520and%2520initial%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520the%2520potential%2520positron%2520emission%2520tomography%2520ligand%252C%2520BU99008%2520%25282-%25284%252C5-dihydro-1H-imidazol-2-yl%2529-1-methyl-1H-indole%2529%252C%2520for%2520the%2520imidazoline2%2520binding%2520site%26jtitle%3DSynapse%26date%3D2012%26volume%3D66%26spage%3D542%26epage%3D551%26doi%3D10.1002%2Fsyn.21541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span>CR4056
was prepared according to the literature procedure: <span class="NLM_contrib-group"><span class="NLM_string-name">Giordani, A.</span>; <span class="NLM_string-name">Mandelli, S.</span>; <span class="NLM_string-name">Verpilio, I.</span>; <span class="NLM_string-name">Zanzola, S.</span>; <span class="NLM_string-name">Tarchino, F.</span>; <span class="NLM_string-name">Caselli, G.</span>; <span class="NLM_string-name">Piepoli, T.</span>; <span class="NLM_string-name">Mazzari, S.</span>; <span class="NLM_string-name">Makovec, F.</span>; <span class="NLM_string-name">Rovati, L. C.</span></span> <span> </span><span class="NLM_article-title">6–1H-Imidazo-quinazoline and Quinolines Derivatives, New Potent Analgesics and Anti-inflammatory Agents</span>. <span class="NLM_patent">US 8,193,353 B2</span>, June 5, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+Giordani&author=S.+Mandelli&author=I.+Verpilio&author=S.+Zanzola&author=F.+Tarchino&author=G.+Caselli&author=T.+Piepoli&author=S.+Mazzari&author=F.+Makovec&author=L.+C.+Rovati&title=6%E2%80%931H-Imidazo-quinazoline+and+Quinolines+Derivatives%2C+New+Potent+Analgesics+and+Anti-inflammatory+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGiordani%26aufirst%3DA.%26atitle%3D6%25E2%2580%25931H-Imidazo-quinazoline%2520and%2520Quinolines%2520Derivatives%252C%2520New%2520Potent%2520Analgesics%2520and%2520Anti-inflammatory%2520Agents%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lione, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A. L.</span></span> <span> </span><span class="NLM_article-title">[<sup>3</sup>H]-2-(2-benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I<sub>2</sub> receptors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00131-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0014-2999%2896%2900131-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8813605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK28Xjs1WnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=1996&pages=221-229&author=L.+A.+Lioneauthor=D.+J.+Nuttauthor=A.+L.+Hudson&title=%5B3H%5D-2-%282-benzofuranyl%29-2-imidazoline%3A+a+new+selective+high+affinity+radioligand+for+the+study+of+rabbit+brain+imidazoline+I2+receptors&doi=10.1016%2F0014-2999%2896%2900131-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">[3H]2-(2-Benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors</span></div><div class="casAuthors">Lione, Lisa A.; Nutt, David J.; Hudson, Alan L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">221-229</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">This is the first study characterizing the binding of the new imidazoline I2 receptor selective radioligand [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) to rabbit brain membranes. [3H]2-BFI binding was found to be saturable and of high affinity identifying two binding sites with KD1 = 0.27 nM, Bmax = 111.2 fmol mg-1 protein and KD2 = 8.97 nM, Bmax = 268 fmol mg-1 protein.  Specific binding represented greater than 90% of total binding.  Kinetic studies revealed that the binding was rapid and reversible and also showed [3H]2-BFI interacted with these two sites or two affinity states.  In competition binding studies against [3H]2-BFI, idazoxan, 2-BFI, cirazoline, guanabenz, naphazoline, amiloride and BU224 (2-(4,5-dihydroimidaz-2-yl-quinoline)) displaced [3H]2-BFI with high affinity.  In contrast the α2-adrenoceptor antagonists efaroxan and rauwolscine, the I1 site selective drug moxonidine, the monoamine oxidase-A inhibitor clorgyline and the proposed endogenous imidazoline receptor ligand, agmatine, were weak at displacing [3H]2-BFI binding.  These findings are consistent with [3H]2-BFI recognizing imidazoline receptors of the I2 subtype in rabbit brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1OiDjhS1mSbVg90H21EOLACvtfcHk0lhGbKl24dwqhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjs1WnsrY%253D&md5=6bab1d0772a2dd4271161b22e445ad64</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900131-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900131-8%26sid%3Dliteratum%253Aachs%26aulast%3DLione%26aufirst%3DL.%2BA.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26aulast%3DHudson%26aufirst%3DA.%2BL.%26atitle%3D%255B3H%255D-2-%25282-benzofuranyl%2529-2-imidazoline%253A%2520a%2520new%2520selective%2520high%2520affinity%2520radioligand%2520for%2520the%2520study%2520of%2520rabbit%2520brain%2520imidazoline%2520I2%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D304%26spage%3D221%26epage%3D229%26doi%3D10.1016%2F0014-2999%2896%2900131-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alemany, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">Labelling I<sub>2B</sub>-imidazoline receptors by [<sup>3</sup>H]-2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes</span>. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1007/PL00005026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1007%2FPL00005026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9228188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1Cisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=1997&pages=39-47&author=R.+Alemanyauthor=G.+Olmosauthor=J.+A.+Garc%C3%ADa-Sevilla&title=Labelling+I2B-imidazoline+receptors+by+%5B3H%5D-2-%282-benzofuranyl%29-2-imidazoline+%282-BFI%29+in+rat+brain+and+liver%3A+characterization%2C+regulation+and+relation+to+monoamine+oxidase+enzymes&doi=10.1007%2FPL00005026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Labeling of I2B-imidazoline receptors by [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes</span></div><div class="casAuthors">Alemany, Regina; Olmos, Gabriel; Garcia-Sevilla, Jesus A.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-47</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The novel selective imidazoline radioligand [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) was used to characterize and assess further the nature of I2-imidazoline receptors in rat brain and liver.  In the cerebral cortex, 2-BFI displayed high affinity (Ki= 9.8 nM) for a single class of [3H]2-BFI binding sites.  Other imidazoline/guanidine compds. (e.g. aganodine, cirazoline and idazoxan) displayed biphasic competition curves, indicating the existence of high (KiH= 2.9-78 nM; RH= 61-83%) and low (KiL= 4.7-158 μM) affinity sites.  The pharmacol. profile for [3H]2-BFI binding (aganodine > cirazoline > 2-BFI » clonidine > amiloride » efaroxan) was typical of that for I2-sites.  This profile was almost identical to that obtained against [3H]idazoxan (correlation between pKi values, r = 0.97) which indicated that the sites characterized with [3H]2-BFI in brain corresponded to I2-imidazoline receptors.  The low affinity of amiloride against [3H]2-BFI (Ki= 900 nM) further indicated that these brain I2-sites belong to the I2B-subtype.  [3H]2-BFI binding sites (Bmax= 72 fmol/mg protein) in brain were differentially modulated by treatment (7 days) with cirazoline (up-regulation: 25%) and the MAO inhibitor phenelzine (down-regulation: 31%), indicating that these I2-sites are regulated in vivo, as is the case for those labeled by [3H]idazoxan.  Chronic treatment with 2-phenylethylamine, a phenelzine metabolite and endogenous amine, did not alter the d. of brain of I2-imidazoline receptors labeled by [3H]idazoxan.  Preincubation of liver membranes with the MAO inhibitor clorgyline (10-7 M) abolished the binding of [3H]Ro 41-1049 (N-(2-aminoethyl)-5-(m-fluorophenyl)-4-thiazole carboxamide) to MAO-A, but it die not alter the binding of [3H]Ro 19-6327 (N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide) to MAO-B or that of [3H]2-BFI to I2-sites.  At 10-4 M it also abolished MAO-B sites, but a substantial proportion of I2-sites (40%) remained intact.  Preincubation of liver membranes at 60° also abolished MAO-A/B sites, whereas still 22% of I2-sites remained.  The results indicate that [3H]2-BFI is a good tool for the identification of I2-imidazoline receptors and suggest further that certain I2-sites and MAO are different proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDZh0VOVNH-rVg90H21EOLACvtfcHk0lg0B8hA3SIPOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1Cisbk%253D&md5=2a2c118e0fbf26ba1e4db935bf9cba66</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2FPL00005026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00005026%26sid%3Dliteratum%253Aachs%26aulast%3DAlemany%26aufirst%3DR.%26aulast%3DOlmos%26aufirst%3DG.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DLabelling%2520I2B-imidazoline%2520receptors%2520by%2520%255B3H%255D-2-%25282-benzofuranyl%2529-2-imidazoline%2520%25282-BFI%2529%2520in%2520rat%2520brain%2520and%2520liver%253A%2520characterization%252C%2520regulation%2520and%2520relation%2520to%2520monoamine%2520oxidase%2520enzymes%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D1997%26volume%3D356%26spage%3D39%26epage%3D47%26doi%3D10.1007%2FPL00005026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lione, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A. L.</span></span> <span> </span><span class="NLM_article-title">Characterisation and localisation of [<sup>3</sup>H]-2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I<sub>2</sub> receptors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(98)00389-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0014-2999%2898%2900389-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9721049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK1cXltFWkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=1998&pages=123-135&author=L.+A.+Lioneauthor=D.+J.+Nuttauthor=A.+L.+Hudson&title=Characterisation+and+localisation+of+%5B3H%5D-2-%282-benzofuranyl%29-2-imidazoline+binding+in+rat+brain%3A+a+selective+ligand+for+imidazoline+I2+receptors&doi=10.1016%2FS0014-2999%2898%2900389-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization and localization of [3H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors</span></div><div class="casAuthors">Lione, Lisa A.; Nutt, David J.; Hudson, Alan L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">123-135</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">In rat whole brain homogenates, satn. binding anal. revealed that both [3H]2-BFI (2-(2-benzofuranyl)-2-imidazoline) and [3H]idazoxan (in the presence of 5 μM rauwolscine) bound with high affinity to an apparent single population of sites.  However, the Kd for [3H]2-BFI (1.74 nM) was significantly less than that for [3H]idazoxan (10.4 nM).  In competition studies idazoxan, 2-BFI, BU 224 (2-(4,5-dihydroimidaz-2-yl)-quinoline), amiloride and guanabenz displayed high affinity (Ki values=7.32, 1.71, 2.08, 21.80 and 14.90 nM, resp.) for 70-80% of sites, and low μM affinity for the remaining 20-30% of sites labeled by [3H]2-BFI.  In contrast, several α2-adrenoceptor, imidazoline I1 receptor and histamine receptor ligands exhibited only micromolar affinity for the [3H]2-BFI labeled site.  Quant. receptor autoradiog. revealed high binding by [3H]2-BFI to discrete brain nuclei, notably the area postrema, interpeduncular nucleus, arcuate nucleus, mammillary peduncle, ependyma and pineal gland.  These data indicate that [3H]2-BFI recognizes imidazoline I2 receptors in rat brain with higher affinity and selectivity than [3H]idazoxan and thus represents a superior radioligand to [3H]idazoxan for the study of imidazoline I2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2a9GddMzRyrVg90H21EOLACvtfcHk0lg0B8hA3SIPOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltFWkurs%253D&md5=481f07df94cc3e16a3ec0407c4fd6b00</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2898%2900389-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252898%252900389-6%26sid%3Dliteratum%253Aachs%26aulast%3DLione%26aufirst%3DL.%2BA.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26aulast%3DHudson%26aufirst%3DA.%2BL.%26atitle%3DCharacterisation%2520and%2520localisation%2520of%2520%255B3H%255D-2-%25282-benzofuranyl%2529-2-imidazoline%2520binding%2520in%2520rat%2520brain%253A%2520a%2520selective%2520ligand%2520for%2520imidazoline%2520I2%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D353%26spage%3D123%26epage%3D135%26doi%3D10.1016%2FS0014-2999%2898%2900389-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quaglia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dontenwill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentili, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maranca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piergentili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasili, L.</span></span> <span> </span><span class="NLM_article-title">2-(2-Phenylcyclopropyl)imidazolines: reversed enantioselective interaction at I<sub>1</sub> and I<sub>2</sub> imidazoline receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2737</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm991049m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm991049m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK1MXktlKkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=2737-2740&author=W.+Quagliaauthor=P.+Bousquetauthor=M.+Piginiauthor=A.+Carottiauthor=A.+Carrieriauthor=M.+Dontenwillauthor=F.+Gentiliauthor=M.+Giannellaauthor=F.+Marancaauthor=A.+Piergentiliauthor=L.+Brasili&title=2-%282-Phenylcyclopropyl%29imidazolines%3A+reversed+enantioselective+interaction+at+I1+and+I2+imidazoline+receptors&doi=10.1021%2Fjm991049m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">2-(2-Phenylcyclopropyl)imidazolines: Reversed Enantioselective Interaction at I1 and I2 Imidazoline Receptors</span></div><div class="casAuthors">Quaglia, Wilma; Bousquet, Pascal; Pigini, Maria; Carotti, Angelo; Carrieri, Antonio; Dontenwill, Monique; Gentili, Francesco; Giannella, Mario; Maranca, Francoise; Piergentili, Alessandro; Brasili, Livio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2737-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Depending of the stereochem., replacement of the double bond in Tracizoline structure, which is 10-fold selective for the I2 imidazoline receptor subtype, by a cyclopropyl ring provides ligands selective for either I1 or I2 subtype, with a 6-fold increase of I2 selectivity and a 100-fold increase (reversed) of I1 selectivity.  Thus, the imidazoline I1 and I2 receptor binding sites have stereospecific requirements, the two subtypes showing a reversal of enantioselectivity, which may offer leads to the development of selective imidazoline receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGldzb64JdabVg90H21EOLACvtfcHk0lg0B8hA3SIPOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktlKkurs%253D&md5=2fca66d374abfb0426d70455cc2a7dc0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm991049m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm991049m%26sid%3Dliteratum%253Aachs%26aulast%3DQuaglia%26aufirst%3DW.%26aulast%3DBousquet%26aufirst%3DP.%26aulast%3DPigini%26aufirst%3DM.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DCarrieri%26aufirst%3DA.%26aulast%3DDontenwill%26aufirst%3DM.%26aulast%3DGentili%26aufirst%3DF.%26aulast%3DGiannella%26aufirst%3DM.%26aulast%3DMaranca%26aufirst%3DF.%26aulast%3DPiergentili%26aufirst%3DA.%26aulast%3DBrasili%26aufirst%3DL.%26atitle%3D2-%25282-Phenylcyclopropyl%2529imidazolines%253A%2520reversed%2520enantioselective%2520interaction%2520at%2520I1%2520and%2520I2%2520imidazoline%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D2737%26epage%3D2740%26doi%3D10.1021%2Fjm991049m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alemany, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribá, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menargues, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">LSL60101, a selective ligand for imidazoline I<sub>2</sub> receptors, on glial fibrillary acidic protein concentration</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(95)00214-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0014-2999%2895%2900214-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=7589187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2MXmvVenurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=1995&pages=205-210&author=R.+Alemanyauthor=G.+Olmosauthor=P.+V.+Escrib%C3%A1author=A.+Menarguesauthor=R.+Obachauthor=J.+A.+Garc%C3%ADa-Sevilla&title=LSL60101%2C+a+selective+ligand+for+imidazoline+I2+receptors%2C+on+glial+fibrillary+acidic+protein+concentration&doi=10.1016%2F0014-2999%2895%2900214-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">LSL 60101, a selective ligand for imidazoline I2 receptors, on glial fibrillary acidic protein concentration</span></div><div class="casAuthors">Alemany, Regina; Olmos, Gabriel; Escriba, Pablo V.; Menargues, Angel; Obach, Rossend; Garcia-Sevilla, Jesus A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-10</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The concn. of the astrocytic marker, glial fibrillary acidic protein (GFAP) was quantitated by immunoblotting (Western blotting) in the rat brain after treatment with the novel ligand for imidazoline I2 receptors LSL 60101 [2-(2-benzofuranyl)imidazole] and its 6-methoxy deriv. LSL 60125.  Chronic (7-21 days), but not acute (1 day) or short-term (3 days), treatment with LSL 60101 (10 mg/kg i.p.) markedly increased (44-49%) GFAP immunoreactivity in the rat cerebral cortex.  In contrast, chronic (7 days) treatment with LSL 60125 (10 mg/kg i.p.) did not significantly modify GFAP concns.  In vitro, both drugs displayed moderate high affinity and high selectivity for imidazoline I2 receptors vs. α2-adrenoceptors; however, only chronic treatment with LSL 60101 (10 mg/kg i.p.) but not with LSL 60125 (10 mg/kg i.p.) was assocd. with an up-regulation of imidazoline I2 receptors.  These data indicate that glial imidazoline I2 receptors may have a direct physiol. function related to GFAP expression and that LSL 60101 could be a good tool for the study of the implication of these receptors on astrocyte activation and neuronal regeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9GvqhLzzkvrVg90H21EOLACvtfcHk0lg0B8hA3SIPOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvVenurs%253D&md5=23df74e2d55e94e471c91612bd98dd11</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2895%2900214-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252895%252900214-6%26sid%3Dliteratum%253Aachs%26aulast%3DAlemany%26aufirst%3DR.%26aulast%3DOlmos%26aufirst%3DG.%26aulast%3DEscrib%25C3%25A1%26aufirst%3DP.%2BV.%26aulast%3DMenargues%26aufirst%3DA.%26aulast%3DObach%26aufirst%3DR.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DLSL60101%252C%2520a%2520selective%2520ligand%2520for%2520imidazoline%2520I2%2520receptors%252C%2520on%2520glial%2520fibrillary%2520acidic%2520protein%2520concentration%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D280%26spage%3D205%26epage%3D210%26doi%3D10.1016%2F0014-2999%2895%2900214-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennuni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caselli, G.</span></span> <span> </span><span class="NLM_article-title">Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.2147/JPR.S18353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.2147%2FJPR.S18353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=21647215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Sgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=111-115&author=F.+Ferrariauthor=S.+Fiorentinoauthor=L.+Mennuniauthor=P.+Garofaloauthor=O.+Letariauthor=S.+Mandelliauthor=A.+Giordaniauthor=M.+Lanzaauthor=G.+Caselli&title=Analgesic+efficacy+of+CR4056%2C+a+novel+imidazoline-2+receptor+ligand%2C+in+rat+models+of+inflammatory+and+neuropathic+pain&doi=10.2147%2FJPR.S18353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain</span></div><div class="casAuthors">Ferrari, Flora; Fiorentino, Simonetta; Mennuni, Laura; Garofalo, Paolo; Letari, Ornella; Mandelli, Stefano; Giordani, Antonio; Lanza, Marco; Caselli, Gianfranco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-125</span>CODEN:
                <span class="NLM_cas:coden">JPROEV</span>;
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Two decades of investigations have failed to unequivocally clarify the functions and the mol. nature of imidazoline-2 receptors (I2R).  However, there is robust pharmacol. evidence for the functional modulation of monoamino oxidase (MAO) and other important enzyme activities by I2 site ligands.  Some compds. of this class proved to be active exptl. tools in preventing both exptl. pain and opioid tolerance and dependence.  Unfortunately, even though these compds. bind with high potency to central I2 sites, they fail to represent a valid clin. opportunity due to their pharmacokinetic, selectivity or side-effects profile.  This paper presents the preclin. profile of a novel I2 ligand (2-phenyl-6-(1H-imidazol-1yl)quinazoline; [CR4056]) that selectively inhibits the activity of human recombinant MAO-A in a concn.-dependent manner.  A sub-chronic four day oral treatment of CR4056 increased norepinephrine (NE) tissue levels both in the rat cerebral cortex (63.1% ± 4.2%; P<0.05) and lumbar spinal cord (51.3% ± 6.7%; P<0.05).  In the complete Freund's adjuvant (CFA) rat model of inflammatory pain, CR4056 was found to be orally active (ED50 = 5.8 mg/kg, by mouth [p.o.]).  In the acute capsaicin model, CR4056 completely blocked mech. hyperalgesia in the injured hind paw (ED50 = 4.1 mg/kg, p.o.; ED100 = 17.9 mg/kg, p.o.).  This effect was dose-dependently antagonized by the non-selective imidazoline I2/α2 antagonist idazoxan.  In rat models of neuropathic pain, oral administration of CR4056 significantly attenuated mech. hyperalgesia and allodynia.  In summary, the present study suggests a novel pharmacol. opportunity for inflammatory and/or neuropathic pain treatment based on selective interaction with central imidazoline-2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ByEw6EQAb7Vg90H21EOLACvtfcHk0ljnEk1CppFpTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Sgtbo%253D&md5=40c74f3a352a79bae53566311a89bc91</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2147%2FJPR.S18353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S18353%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DF.%26aulast%3DFiorentino%26aufirst%3DS.%26aulast%3DMennuni%26aufirst%3DL.%26aulast%3DGarofalo%26aufirst%3DP.%26aulast%3DLetari%26aufirst%3DO.%26aulast%3DMandelli%26aufirst%3DS.%26aulast%3DGiordani%26aufirst%3DA.%26aulast%3DLanza%26aufirst%3DM.%26aulast%3DCaselli%26aufirst%3DG.%26atitle%3DAnalgesic%2520efficacy%2520of%2520CR4056%252C%2520a%2520novel%2520imidazoline-2%2520receptor%2520ligand%252C%2520in%2520rat%2520models%2520of%2520inflammatory%2520and%2520neuropathic%2520pain%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2011%26volume%3D4%26spage%3D111%26epage%3D115%26doi%3D10.2147%2FJPR.S18353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span> <i>Pentacle</i>, version 1.0.6, <span class="NLM_publisher-name">Molecular
Discovery Ltd.</span>, <span class="NLM_publisher-loc">Perugia, Italy</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Pentacle%2C+version+1.0.6%2C+Molecular%0ADiscovery+Ltd.%2C+Perugia%2C+Italy%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPentacle%26pub%3DMolecular%250ADiscovery%2520Ltd%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawless, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gombar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraczkiewicz, R.</span></span> <span> </span><span class="NLM_article-title">Modeling ADMET</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1425</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-3609-0_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1007%2F978-1-4939-3609-0_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=27311462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsleru7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1425&publication_year=2016&pages=63-83&author=J.+Ghoshauthor=M.+S.+Lawlessauthor=M.+Waldmanauthor=V.+Gombarauthor=R.+Fraczkiewicz&title=Modeling+ADMET&doi=10.1007%2F978-1-4939-3609-0_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling admet</span></div><div class="casAuthors">Ghosh, Jayeeta; Lawless, Michael S.; Waldman, Marvin; Gombar, Vijay; Fraczkiewicz, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1425</span>
        (<span class="NLM_cas:issue">In Silico Methods for Predicting Drug Toxicity</span>),
    <span class="NLM_cas:pages">63-83</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Drug discovery and development is a costly and time-consuming endeavor.  Over the last two decades, computational tools and in silico models to predict ADMET (Adsorption, Distribution, Metab., Excretion, and Toxicity) profiles of mols. have been incorporated into the drug discovery process mainly in an effort to avoid late-stage failures due to poor pharmacokinetics and toxicity.  It is now widely recognized that ADMET issues should be addressed as early as possible in drug discovery.  Here, we describe in detail how ADMET models can be developed and applied using a com. available package, ADMET Predictor 7.2 (ADMET Predictor v7.2. Simulations Plus, Inc., Lancaster, CA, USA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfUDnl_gEbCbVg90H21EOLACvtfcHk0ljnEk1CppFpTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsleru7fO&md5=0b4ca6adb95de007f55cc4b2c5a8c59a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3609-0_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-3609-0_4%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DJ.%26aulast%3DLawless%26aufirst%3DM.%2BS.%26aulast%3DWaldman%26aufirst%3DM.%26aulast%3DGombar%26aufirst%3DV.%26aulast%3DFraczkiewicz%26aufirst%3DR.%26atitle%3DModeling%2520ADMET%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2016%26volume%3D1425%26spage%3D63%26epage%3D83%26doi%3D10.1007%2F978-1-4939-3609-0_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span>ADMET Predictor, v. 9.5, <span class="NLM_publisher-name">Simulations Plus
Inc.</span>, <span class="NLM_publisher-loc">Lancaster, CA, USA</span>, <span class="NLM_year">2019</span>, <a href="https://www.simulations-plus.com" class="extLink">https://www.simulations-plus.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ADMET+Predictor%2C+v.+9.5%2C+Simulations+Plus%0AInc.%2C+Lancaster%2C+CA%2C+USA%2C+2019%2C+https%3A%2F%2Fwww.simulations-plus.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26pub%3DSimulations%2520Plus%250AInc%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">Swiss ADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small mol</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">42717</span>, <span class="refDoi"> DOI: 10.1038/srep42717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1038%2Fsrep42717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=28256516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42717&author=A.+Dainaauthor=O.+Michielinauthor=V.+Zoete&title=Swiss+ADME%3A+a+free+web+tool+to+evaluate+pharmacokinetics%2C+drug-likeness+and+medicinal+chemistry+friendliness+of+small+mol&doi=10.1038%2Fsrep42717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span></div><div class="casAuthors">Daina Antoine; Michielin Olivier; Zoete Vincent; Michielin Olivier; Michielin Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42717</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.  Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited.  In that context, computer models constitute valid alternatives to experiments.  Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar.  Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch.  Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl_Uk5dOMKs6qcneEtCi92fW6udTcc2ea_qONn2aFW4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D&md5=9715b8cb8a34b17c4c73ff69a5a8cc50</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fsrep42717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42717%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DSwiss%2520ADME%253A%2520a%2520free%2520web%2520tool%2520to%2520evaluate%2520pharmacokinetics%252C%2520drug-likeness%2520and%2520medicinal%2520chemistry%2520friendliness%2520of%2520small%2520mol%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42717%26doi%3D10.1038%2Fsrep42717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span> </span><span class="NLM_article-title">Biopharmaceutics classification system-based biowaivers, International
council for harmonisation of technical requirements for pharmaceutical
for human use</span>. <a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M9/M9EWG_DraftGuideline_Step2_2018_0606.pdf" class="extLink">https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M9/M9EWG_DraftGuideline_Step2_2018_0606.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Biopharmaceutics+classification+system-based+biowaivers%2C+International%0Acouncil+for+harmonisation+of+technical+requirements+for+pharmaceutical%0Afor+human+use.+https%3A%2F%2Fwww.ich.org%2Ffileadmin%2FPublic_Web_Site%2FICH_Products%2FGuidelines%2FMultidisciplinary%2FM9%2FM9EWG_DraftGuideline_Step2_2018_0606.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DBiopharmaceutics%2520classification%2520system-based%2520biowaivers%252C%2520International%250Acouncil%2520for%2520harmonisation%2520of%2520technical%2520requirements%2520for%2520pharmaceutical%250Afor%2520human%2520use" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span>International
council on harmonisation
of technical requirements for registration of pharmaceuticals for
human use. ICH harmonized tripartite guideline. “Stability
testing of new drug substance and products”. Q1A (R2), <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=International%0Acouncil+on+harmonisation%0Aof+technical+requirements+for+registration+of+pharmaceuticals+for%0Ahuman+use.+ICH+harmonized+tripartite+guideline.+%E2%80%9CStability%0Atesting+of+new+drug+substance+and+products%E2%80%9D.+Q1A+%28R2%29%2C+2003."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span>For information
on the Eurofins Lead Profiling Screen, see <a href="http://www.eurofins.com" class="extLink">http://www.eurofins.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+information%0Aon+the+Eurofins+Lead+Profiling+Screen%2C+see+http%3A%2F%2Fwww.eurofins.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cawston, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">1009</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00489.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1111%2Fj.1476-5381.2009.00489.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=19922535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1ektrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2010&pages=1009-1021&author=E.+E.+Cawstonauthor=L.+J.+Miller&title=Therapeutic+potential+for+novel+drugs+targeting+the+type+1+cholecystokinin+receptor&doi=10.1111%2Fj.1476-5381.2009.00489.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor</span></div><div class="casAuthors">Cawston, Erin E.; Miller, Laurence J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1009-1021</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Cholecystokinin (CCK) is a physiol. important gastrointestinal and neuronal peptide hormone, with roles in stimulating gallbladder contraction, pancreatic secretion, gastrointestinal motility and satiety.  CCK exerts its effects via interactions with two structurally related class I guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs), the CCK1 receptor and the CCK2 receptor.  Here, we focus on the CCK1 receptor, with particular relevance to the broad spectrum of signaling initiated by activation with the natural full agonist peptide ligand, CCK.  Distinct ligand-binding pockets have been defined for the natural peptide ligand and for some non-peptidyl small mol. ligands.  While many CCK1 receptor ligands have been developed and have had their pharmacol. well described, their clin. potential has not yet been fully explored.  The case is built for the potential importance of developing more selective partial agonists and allosteric modulators of this receptor that could have important roles in the treatment of common clin. syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtyv1BtMA3crVg90H21EOLACvtfcHk0lhBGeUDhBe1dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1ektrg%253D&md5=5226f315676918d3a345674bdb60eb5f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00489.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00489.x%26sid%3Dliteratum%253Aachs%26aulast%3DCawston%26aufirst%3DE.%2BE.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26atitle%3DTherapeutic%2520potential%2520for%2520novel%2520drugs%2520targeting%2520the%2520type%25201%2520cholecystokinin%2520receptor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D159%26spage%3D1009%26epage%3D1021%26doi%3D10.1111%2Fj.1476-5381.2009.00489.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effects of imidazoline receptor ligands on basal and kainic acid-induced neurotoxic signalling in mice</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">886</span>, <span class="refDoi"> DOI: 10.1177/0269881116652579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1177%2F0269881116652579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=27302941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWmur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=875-886&author=B.+Kellerauthor=J.+A.+Garc%C3%ADa-Sevilla&title=Inhibitory+effects+of+imidazoline+receptor+ligands+on+basal+and+kainic+acid-induced+neurotoxic+signalling+in+mice&doi=10.1177%2F0269881116652579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effects of imidazoline receptor ligands on basal and kainic acid-induced neurotoxic signalling in mice</span></div><div class="casAuthors">Keller, Benjamin; Garcia-Sevilla, Jesus A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">875-886</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">This in vivo study assessed the potential of the imidazoline receptor (IR) ligands moxonidine (selective I1-IR), BU224 (selective I2-IR) and LSL61122 (mixed I1/I2-IR) to dampen excitotoxic signalling induced by kainic acid (KA; 45 mg/kg) in the mouse brain (hippocampus and cerebral cortex).  KA triggered a strong behavioral syndrome (seizures; maximal at 60-90 min) and sustained stimulation (at 72 h with otherwise normal mouse behavior) of pro-apoptotic c-Jun-N-terminal kinases (JNK) and calpain with increased cleavage of p35 into neurotoxic p25 (cyclin-dependent kinase 5 [Cdk5] activators) in mouse hippocampus.  Pretreatment (five days) with LSL61122 (10 mg/kg), but not moxonidine (1 mg/kg) or BU224 (20 mg/kg), attenuated the KA-induced behavioral syndrome, and all three IR ligands inhibited JNK and calpain activation, as well as p35/p25 cleavage after KA in the hippocampus (effects also obsd. after acute IR drug treatments).  Efaroxan (I1-IR, 10 mg/kg) and idazoxan (I2-IR, 10 mg/kg), postulated IR antagonists, did not antagonize the effects of moxonidine and LSL61122 on KA targets (these IR ligands showed agonistic properties inhibiting pro-apoptotic JNK).  Brain subcellular prepns. revealed reduced synaptosomal postsynaptic d.-95 protein contents (a mediator of JNK activation) and indicated increased p35/Cdk5 complexes (with pro-survival functions) after treatment with moxonidine, BU224 and LSL61122.  These results showed that I1- and I2-IR ligands (moxonidine and BU224), and esp. the mixed I1/I2-IR ligand LSL61122, are partly neuroprotective against KA-induced excitotoxic signalling.  These findings suggest a therapeutic potential of IR drugs in disorders assocd. with glutamate-mediated neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqp6nvNi5b37Vg90H21EOLACvtfcHk0lhBGeUDhBe1dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWmur%252FF&md5=10fc8def3fa26dd5d175dbb8d857eacd</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F0269881116652579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881116652579%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DB.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DInhibitory%2520effects%2520of%2520imidazoline%2520receptor%2520ligands%2520on%2520basal%2520and%2520kainic%2520acid-induced%2520neurotoxic%2520signalling%2520in%2520mice%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2016%26volume%3D30%26spage%3D875%26epage%3D886%26doi%3D10.1177%2F0269881116652579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorn, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. X.</span></span> <span> </span><span class="NLM_article-title">Characterization of the hypothermic effects of imidazoline I<sub>2</sub> receptor agonists in rats</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">1936</span>– <span class="NLM_lpage">1945</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.01894.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1111%2Fj.1476-5381.2012.01894.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=22324428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOrsr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=1936-1945&author=D.+A.+Thornauthor=X.+F.+Anauthor=Y.+Zhangauthor=M.+Piginiauthor=J.+X.+Li&title=Characterization+of+the+hypothermic+effects+of+imidazoline+I2+receptor+agonists+in+rats&doi=10.1111%2Fj.1476-5381.2012.01894.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the hypothermic effects of imidazoline I2 receptor agonists in rats</span></div><div class="casAuthors">Thorn, David A.; An, Xiao-Fei; Zhang, Yanan; Pigini, Maria; Li, Jun-Xu</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1936-1945</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Imidazoline I2 receptors have been implicated in several CNS disorders.  Although several I2 receptor agonists have been described, no simple and sensitive in vivo bioassay is available for studying I2 receptor ligands.  This study examd. I2 receptor agonist-induced hypothermia as a functional in vivo assay of I2 receptor agonism.  Different groups of rats were used to examine the effects of I2 receptor agonists on the rectal temp. and locomotion.  The pharmacol. mechanisms were investigated by combining I2 receptor ligands and different antagonists.  All the selective I2 receptor agonists examd. (2-BFI, diphenyzoline, phenyzoline, CR4056, tracizoline, BU224 and S22687, 3.2-56 mg·kg-1, i.p.) dose-dependently and markedly decreased the rectal temp. (hypothermia) in rats, with varied duration of action.  Pharmacol. mechanism of the obsd. hypothermia was studied by combining the I2 receptor agonists (2-BFI, BU224, tracizoline and diphenyzoline) with imidazoline I2 receptor/ α2 adrenoceptor antagonist idazoxan, selective I1 receptor antagonist efaroxan, α2 adrenoceptor antagonist/5-HT1A receptor agonist yohimbine.  Idazoxan but not yohimbine or efaroxan attenuated the hypothermic effects of 2-BFI, BU224, tracizoline and diphenyzoline, supporting the I2 receptor mechanism.  In contrast, both idazoxan and yohimbine attenuated hypothermia induced by the α2 adrenoceptor agonist clonidine.  Among all the I2 receptor agonists studied, only S22687 markedly increased the locomotor activity in rats.  Imidazoline I2 receptor agonists can produce hypothermic effects, which are primarily mediated by I2 receptors.  These data suggest that I2 receptor agonist-induced hypothermia is a simple and sensitive in vivo assay for studying I2 receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-o3Cxi8jkyLVg90H21EOLACvtfcHk0ljSOLZ-GbuArw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOrsr7P&md5=95ae5d105c505d90702aee3952f3e4a7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01894.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01894.x%26sid%3Dliteratum%253Aachs%26aulast%3DThorn%26aufirst%3DD.%2BA.%26aulast%3DAn%26aufirst%3DX.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPigini%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BX.%26atitle%3DCharacterization%2520of%2520the%2520hypothermic%2520effects%2520of%2520imidazoline%2520I2%2520receptor%2520agonists%2520in%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D1936%26epage%3D1945%26doi%3D10.1111%2Fj.1476-5381.2012.01894.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craven, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, E. L.</span></span> <span> </span><span class="NLM_article-title">Effects of alpha 2-adrenoceptor antagonists and imidazoline 2-receptor ligands on neuronal damage in global ischaemia in the rat</span>. <i>Clin. Exp. Pharmacol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1111/j.1440-1681.1997.tb01808.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1111%2Fj.1440-1681.1997.tb01808.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9075597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2sXis1Knur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1997&pages=204-207&author=J.+A.+Cravenauthor=E.+L.+Conway&title=Effects+of+alpha+2-adrenoceptor+antagonists+and+imidazoline+2-receptor+ligands+on+neuronal+damage+in+global+ischaemia+in+the+rat&doi=10.1111%2Fj.1440-1681.1997.tb01808.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of α2-adrenoceptor antagonists and imidazoline2-receptor ligands on neuronal damage in global ischemia in the rat</span></div><div class="casAuthors">Craven, John A.; Conway, Elizabeth L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Pharmacology and Physiology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">204-207</span>CODEN:
                <span class="NLM_cas:coden">CEXPB9</span>;
        ISSN:<span class="NLM_cas:issn">0305-1870</span>.
    
            (<span class="NLM_cas:orgname">Blackwell</span>)
        </div><div class="casAbstract">The neuroprotective effects of 3 mg idazoxan/kg, both an α2-adrenoceptor antagonist and imidazoline2-receptor (I2-receptor) ligand, 3 mg methoxyidazoxan/kg, a specific α2-adrenoceptor antagonist, and 0.6 and 3 mg BU224/kg, a selective I2-receptor ligand, were evaluated following 10 min of global ischemia in rats.  Neuronal cell counts in the CA1 region of the hippocampus 8 days postischemia indicated 46-96% cell loss compared with controls and a 320% increase in [3H]-PK11195 binding, used as a marker of gliosis.  No significant neuroprotective effect on these markers of neuronal damage could be detected in the drug-treated groups.  However, in 1 subset of idazoxan-treated rats, neuronal loss and gliosis were minimal.  Mean body temp. during 3 h postischemia was lower in idazoxan-treated rats than in the other treated groups, and there was a correlation between mean body temp. and cell counts and mean body temp. and gliosis in this group.  These results indicate that at the doses used neither BU224 nor methoxyidazoxan is neuroprotective in this ischemia model and they raise the possibility that any neuroprotective effect of idazoxan may be related to hypothermic effects of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_DbikVKDTDbVg90H21EOLACvtfcHk0ljSOLZ-GbuArw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1Knur0%253D&md5=e9bb9d97aff36a51e0e874d563ebae84</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1681.1997.tb01808.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1681.1997.tb01808.x%26sid%3Dliteratum%253Aachs%26aulast%3DCraven%26aufirst%3DJ.%2BA.%26aulast%3DConway%26aufirst%3DE.%2BL.%26atitle%3DEffects%2520of%2520alpha%25202-adrenoceptor%2520antagonists%2520and%2520imidazoline%25202-receptor%2520ligands%2520on%2520neuronal%2520damage%2520in%2520global%2520ischaemia%2520in%2520the%2520rat%26jtitle%3DClin.%2520Exp.%2520Pharmacol.%2520Physiol.%26date%3D1997%26volume%3D24%26spage%3D204%26epage%3D207%26doi%3D10.1111%2Fj.1440-1681.1997.tb01808.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marion, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penrod, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obrist, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochanek, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeKosky, S. T.</span></span> <span> </span><span class="NLM_article-title">Treatment of traumatic brain injury with moderate hypothermia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>336</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1056/NEJM199702203360803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1056%2FNEJM199702203360803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9023090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADyaK2s7msVOgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=1997&pages=540-546&author=D.+W.+Marionauthor=L.+E.+Penrodauthor=S.+F.+Kelseyauthor=W.+D.+Obristauthor=P.+M.+Kochanekauthor=A.+M.+Palmerauthor=S.+R.+Wisniewskiauthor=S.+T.+DeKosky&title=Treatment+of+traumatic+brain+injury+with+moderate+hypothermia&doi=10.1056%2FNEJM199702203360803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of traumatic brain injury with moderate hypothermia</span></div><div class="casAuthors">Marion D W; Penrod L E; Kelsey S F; Obrist W D; Kochanek P M; Palmer A M; Wisniewski S R; DeKosky S T</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">540-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Traumatic brain injury initiates several metabolic processes that can exacerbate the injury.  There is evidence that hypothermia may limit some of these deleterious metabolic responses.  METHODS:  In a randomized, controlled trial, we compared the effects of moderate hypothermia and normothermia in 82 patients with severe closed head injuries (a score of 3 to 7 on the Glasgow Coma Scale).  The patients assigned to hypothermia were cooled to 33 degrees C a mean of 10 hours after injury, kept at 32 degrees to 33 degrees C for 24 hours, and then rewarmed.  A specialist in physical medicine and rehabilitation who was unaware of the treatment assignments evaluated the patients 3, 6, and 12 months later with the use of the Glasgow Outcome Scale.  RESULTS:  The demographic characteristics and causes and severity of injury were similar in the hypothermia and normothermia groups.  At 12 months, 62 percent of the patients in the hypothermia group and 38 percent of those in the normothermia group had good outcomes (moderate, mild, or no disabilities).  The adjusted risk ratio for a bad outcome in the hypothermia group was 0.5 (95 percent confidence interval, 0.2 to 1.2).  Hypothermia did not improve the outcomes in the patients with coma scores of 3 or 4 on admission.  Among the patients with scores of 5 to 7, hypothermia was associated with significantly improved outcomes at 3 and 6 months (adjusted risk ratio for a bad outcome, 0.2; 95 percent confidence interval, 0.1 to 0.9 at both intervals), although not at 12 months (risk ratio, 0.3; 95 percent confidence interval, 0.1 to 1.0).  CONCLUSIONS:  Treatment with moderate hypothermia for 24 hours in patients with severe traumatic brain injury and coma scores of 5 to 7 on admission hastened neurologic recovery and may have improved the outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkDoz6qOFQI8ScOqQTSkOffW6udTcc2eZ_DNfUK5YvRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7msVOgsQ%253D%253D&md5=4e2ccf1ae3413c12c3e72d2381fbf18f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1056%2FNEJM199702203360803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199702203360803%26sid%3Dliteratum%253Aachs%26aulast%3DMarion%26aufirst%3DD.%2BW.%26aulast%3DPenrod%26aufirst%3DL.%2BE.%26aulast%3DKelsey%26aufirst%3DS.%2BF.%26aulast%3DObrist%26aufirst%3DW.%2BD.%26aulast%3DKochanek%26aufirst%3DP.%2BM.%26aulast%3DPalmer%26aufirst%3DA.%2BM.%26aulast%3DWisniewski%26aufirst%3DS.%2BR.%26aulast%3DDeKosky%26aufirst%3DS.%2BT.%26atitle%3DTreatment%2520of%2520traumatic%2520brain%2520injury%2520with%2520moderate%2520hypothermia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1997%26volume%3D336%26spage%3D540%26epage%3D546%26doi%3D10.1056%2FNEJM199702203360803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maier, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahern, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yenari, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, G. K.</span></span> <span> </span><span class="NLM_article-title">Optimal depth and duration of mild hypothermia in focal model of transient cerebral ischemia: effects on neurologic outcome, infarct size, apopotosis, and inflammation</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2171</span>– <span class="NLM_lpage">2180</span>, <span class="refDoi"> DOI: 10.1161/01.STR.29.10.2171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1161%2F01.STR.29.10.2171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9756600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADyaK1cvivFKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1998&pages=2171-2180&author=C.+M.+Maierauthor=K.+V.+Ahernauthor=M.+L.+Chengauthor=J.+E.+Leeauthor=M.+A.+Yenariauthor=G.+K.+Steinberg&title=Optimal+depth+and+duration+of+mild+hypothermia+in+focal+model+of+transient+cerebral+ischemia%3A+effects+on+neurologic+outcome%2C+infarct+size%2C+apopotosis%2C+and+inflammation&doi=10.1161%2F01.STR.29.10.2171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia: effects on neurologic outcome, infarct size, apoptosis, and inflammation</span></div><div class="casAuthors">Maier C M; Ahern K v; Cheng M L; Lee J E; Yenari M A; Steinberg G K</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2171-80</span>
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Mild hypothermia is possibly the single most effective method of cerebroprotection developed to date.  However, many questions regarding mild hypothermia remain to be addressed before its potential implementation in the treatment of human stroke.  Here we report the results of 2 studies designed to determine the optimal depth and duration of mild hypothermia in focal stroke and its effects on infarct size, neurological outcome, programmed cell death, and inflammation.  METHODS:  Rats underwent a 2-hour occlusion of the left middle cerebral artery.  In the first study (I) animals were kept (intraischemically) at either 37 degreesC (n=8), 33 degreesC (n=8), or 30 degreesC (n=8).  Study II consisted of 4 groups: (1) controls (37 degreesC, n=10), (2) 30 minutes of hypothermia started at ischemic onset (33 degreesC, n=9), (3)1 hour (33 degreesC, n=8), and (4) 2 hours (33 degreesC, n=8).  Brain temperature was measured by a thermocouple probe placed in the contralateral cortex.  After suture removal, all animals were rewarmed and reperfused for 22 hours (I) or 70 hours (II).  RESULTS:  Mild hypothermia to 33 degreesC or 30 degreesC was neuroprotective (17+/-7% and 27+/-6%, respectively) relative to controls (53+/-8%, P<0.02), but 33 degreesC was better tolerated and recovery from anesthesia was faster.  The neurological score of hypothermic animals was significantly better than that of controls (I & II) at both 24 and 72 hours postischemia except for the 30-minute group (II), which showed no improvement.  In Study II, 2 hours of hypothermia reduced injury by 59%, 1 hour reduced injury by 84% whereas 30 minutes did not reduce injury.  Normalized for infarct size, 2 hours of mild hypothermia decreased neutrophil accumulation by 57% whereas both 1 hour and 30 minutes had no effect.  At 72 hours, 1 and 2 hours of mild hypothermia decreased transferase dUTP nick-end labeling (TUNEL) staining by 78% and 99%, respectively, and 30 minutes of hypothermia had no effect.  CONCLUSIONS:  Intraischemic mild hypothermia must be maintained for 1 to 2 hours to obtain optimal neuroprotection against ischemic cell death due to necrosis and apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcokX7KntZvnELvajU9pjPfW6udTcc2ebtQtQRIsPsfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1cvivFKktg%253D%253D&md5=4311bf2c122c068734121571ae2ba626</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1161%2F01.STR.29.10.2171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.STR.29.10.2171%26sid%3Dliteratum%253Aachs%26aulast%3DMaier%26aufirst%3DC.%2BM.%26aulast%3DAhern%26aufirst%3DK.%2BV.%26aulast%3DCheng%26aufirst%3DM.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DYenari%26aufirst%3DM.%2BA.%26aulast%3DSteinberg%26aufirst%3DG.%2BK.%26atitle%3DOptimal%2520depth%2520and%2520duration%2520of%2520mild%2520hypothermia%2520in%2520focal%2520model%2520of%2520transient%2520cerebral%2520ischemia%253A%2520effects%2520on%2520neurologic%2520outcome%252C%2520infarct%2520size%252C%2520apopotosis%252C%2520and%2520inflammation%26jtitle%3DStroke%26date%3D1998%26volume%3D29%26spage%3D2171%26epage%3D2180%26doi%3D10.1161%2F01.STR.29.10.2171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Hernández, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Fuster, M. J.</span></span> <span> </span><span class="NLM_article-title">Improved age-related deficits in cognitive performance and affective-like behavior following acute, but not repeated , 8-OH-DPAT treatments in rats: regulation of hippocampal FADD</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2018.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.neurobiolaging.2018.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=30138765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=115-126&author=E.+Hern%C3%A1ndez-Hern%C3%A1ndezauthor=A.+Mirallesauthor=S.+Estebanauthor=M.+J.+Garc%C3%ADa-Fuster&title=Improved+age-related+deficits+in+cognitive+performance+and+affective-like+behavior+following+acute%2C+but+not+repeated+%2C+8-OH-DPAT+treatments+in+rats%3A+regulation+of+hippocampal+FADD&doi=10.1016%2Fj.neurobiolaging.2018.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Improved age-related deficits in cognitive performance and affective-like behavior following acute, but not repeated, 8-OH-DPAT treatments in rats: regulation of hippocampal FADD</span></div><div class="casAuthors">Hernandez-Hernandez, Elena; Miralles, Antonio; Esteban, Susana; Garcia-Fuster, M. Julia</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-126</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The aims of this study were (1) to behaviorally phenotype rats at different ages for both cognitive performance and affect, (2) to evaluate the possible beneficial effects of 8-OH-DPAT (a 5-HT1A receptor agonist) treatments on improving age-related behavioral deficits, and (3) to uncover putative key brain targets (e.g., Fas-assocd. protein with death domain [FADD] and related partners) that might contribute to the obsd. age-related behavioral changes.  The principal results showed that acute, but not repeated, 8-OH-DPAT treatments improved age-related deficits in cognitive performance and affect while induced hypothermia.  Moreover, multifunctional FADD protein decreased with age specifically in the hippocampus (as compared to the prefrontal cortex) and was further decreased following acute 8-OH-DPAT.  The major conclusions indicate a parallelism between the beneficial effects obsd. following acute 8-OH-DPAT on improving the neg. consequences of aging on cognition and affect, together with the acute induction of hypothermia and hippocampal FADD regulation.  Because these effects were not obsd. following repeated treatment (i.e., obsd. tolerance to acute hypothermia), the results suggest 5-HT1A receptors desensitization and/or the activation of compensatory adaptive mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquC2U2RVr0fbVg90H21EOLACvtfcHk0ljnaBN5zWSPmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgsL%252FN&md5=cad916a633c8cfb6a20581fef14cbefd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2018.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2018.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DHern%25C3%25A1ndez-Hern%25C3%25A1ndez%26aufirst%3DE.%26aulast%3DMiralles%26aufirst%3DA.%26aulast%3DEsteban%26aufirst%3DS.%26aulast%3DGarc%25C3%25ADa-Fuster%26aufirst%3DM.%2BJ.%26atitle%3DImproved%2520age-related%2520deficits%2520in%2520cognitive%2520performance%2520and%2520affective-like%2520behavior%2520following%2520acute%252C%2520but%2520not%2520repeated%2520%252C%25208-OH-DPAT%2520treatments%2520in%2520rats%253A%2520regulation%2520of%2520hippocampal%2520FADD%26jtitle%3DNeurobiol.%2520Aging%26date%3D2018%26volume%3D71%26spage%3D115%26epage%3D126%26doi%3D10.1016%2Fj.neurobiolaging.2018.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Hernández, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Fuster, M. J.</span></span> <span> </span><span class="NLM_article-title">Repeated treatment with the α2-adrenoceptor agonist UK-14304 improves cognitive performance in middle-age rats: role of hippocampal Fas-associated death domain</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1177/0269881117742667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1177%2F0269881117742667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=29207901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivVanurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=248-255&author=E.+Hern%C3%A1ndez-Hern%C3%A1ndezauthor=A.+Mirallesauthor=S.+Estebanauthor=M.+J.+Garcia-Fuster&title=Repeated+treatment+with+the+%CE%B12-adrenoceptor+agonist+UK-14304+improves+cognitive+performance+in+middle-age+rats%3A+role+of+hippocampal+Fas-associated+death+domain&doi=10.1177%2F0269881117742667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated treatment with the a2-adrenoceptor agonist UK-14304 improves cognitive performance in middle-age rats: Role of hippocampal Fas-associated death domain</span></div><div class="casAuthors">Hernandez-Hernandez, Elena; Miralles, Antonio; Esteban, Susana; Garcia-Fuster, M. Julia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">248-255</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">The cell fate regulator Fas-assocd. death domain (FADD) balances cell death with non-apoptotic actions via its phosphorylated form.  A recent study assocd. loss of cortical FADD with cognitive decline and increased risk of clin. dementia.  Since the activation of cortical α2A-adrenoceptors improved memory deficits in various animal models of working memory loss, the present study evaluated whether UK-14304, an α2-adrenoceptor agonist known to acutely regulate brain FADD forms, would improve cognitive function in middle-aged rats.  Sprague-Dawley rats were treated with UK-14304 (0.3 or 1 mg/kg) or saline (1 mL/kg) for seven days.  Cognitive performance was evaluated in the eight-arm radial maze.  FADD protein content was measured in the prefrontal cortex and hippocampus by Western blot anal.  The results showed that UK-14304 (1 mg/kg) improved cognitive performance (less time: -310±45 s, p=0.025 and fewer errors: -2.75±1.06, p=0.043 to complete the maze) and increased FADD selectively in the hippocampus (+35±11%, p=0.029).  Interestingly, hippocampal FADD content neg. correlated with the time (r=-0.651, p<0.01) needed to complete the maze.  Thus, better cognitive scores were assocd. with higher FADD hippocampal content.  These results support a role for α2-adrenoceptors in ameliorating cognition and suggest FADD protein content as a possible correlate for cognitive performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquOawyd4UagLVg90H21EOLACvtfcHk0ljnaBN5zWSPmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivVanurs%253D&md5=42f6ba8731dd93e02bbb47fde4f9e77a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1177%2F0269881117742667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881117742667%26sid%3Dliteratum%253Aachs%26aulast%3DHern%25C3%25A1ndez-Hern%25C3%25A1ndez%26aufirst%3DE.%26aulast%3DMiralles%26aufirst%3DA.%26aulast%3DEsteban%26aufirst%3DS.%26aulast%3DGarcia-Fuster%26aufirst%3DM.%2BJ.%26atitle%3DRepeated%2520treatment%2520with%2520the%2520%25CE%25B12-adrenoceptor%2520agonist%2520UK-14304%2520improves%2520cognitive%2520performance%2520in%2520middle-age%2520rats%253A%2520role%2520of%2520hippocampal%2520Fas-associated%2520death%2520domain%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2018%26volume%3D32%26spage%3D248%26epage%3D255%26doi%3D10.1177%2F0269881117742667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bilkei-Gorzo, A.</span></span> <span> </span><span class="NLM_article-title">Genetic mouse models of brain ageing and Alzheimer’s disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2013.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.pharmthera.2013.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=24362083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2014&pages=244-257&author=A.+Bilkei-Gorzo&title=Genetic+mouse+models+of+brain+ageing+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.pharmthera.2013.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic mouse models of brain ageing and Alzheimer's disease</span></div><div class="casAuthors">Bilkei-Gorzo, Andras</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">244-257</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Progression of brain ageing is influenced by a complex interaction of genetic and environmental factors.  Anal. of genetically modified animals with uniform genetic backgrounds in a standardized, controlled environment enables the dissection of crit. determinants of brain ageing on a mol. level.  Human and animal studies suggest that increased load of damaged macromols., efficacy of DNA maintenance, mitochondrial activity, and cellular stress defences are crit. determinants of brain ageing.  Surprisingly, mouse lines with genetic impairment of anti-oxidative capacity generally did not show enhanced cognitive ageing but rather an increased sensitivity to oxidative challenge.  Mouse lines with impaired mitochondrial activity had critically short life spans or severe and rapidly progressing neurodegeneration.  Strains with impaired clearance in damaged macromols. or defects in the regulation of cellular stress defences showed alterations in the onset and progression of cognitive decline.  Importantly, reduced insulin/insulin-like growth factor signalling generally increased life span but impaired cognitive functions revealing a complex interaction between ageing of the brain and of the body.  Brain ageing is accompanied by an increased risk of developing Alzheimer's disease.  Transgenic mouse models expressing high levels of mutant human amyloid precursor protein showed a no. of symptoms and pathophysiol. processes typical for early phase of Alzheimer's disease.  Generally, therapeutic strategies effective against Alzheimer's disease in humans were also active in the Tg2576, APP23, APP/PS1 and 5xFAD lines, but a large no. of false pos. findings were also reported.  The 3xtg AD model likely has the highest face and construct validity but further studies are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR3CR6awT_MLVg90H21EOLACvtfcHk0lgRQ9wVBFhCxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1ehug%253D%253D&md5=50cbc54477a66f45648d574960c034ec</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2013.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2013.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DBilkei-Gorzo%26aufirst%3DA.%26atitle%3DGenetic%2520mouse%2520models%2520of%2520brain%2520ageing%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2014%26volume%3D142%26spage%3D244%26epage%3D257%26doi%3D10.1016%2Fj.pharmthera.2013.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antunes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biala, G.</span></span> <span> </span><span class="NLM_article-title">The novel object recognition memory: neurobiology, test procedure, and its modifications</span>. <i>Cogn. Process.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1007/s10339-011-0430-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1007%2Fs10339-011-0430-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=22160349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BC38zoslWlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=93-110&author=M.+Antunesauthor=G.+Biala&title=The+novel+object+recognition+memory%3A+neurobiology%2C+test+procedure%2C+and+its+modifications&doi=10.1007%2Fs10339-011-0430-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The novel object recognition memory: neurobiology, test procedure, and its modifications</span></div><div class="casAuthors">Antunes M; Biala G</div><div class="citationInfo"><span class="NLM_cas:title">Cognitive processing</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Animal models of memory have been considered as the subject of many scientific publications at least since the beginning of the twentieth century.  In humans, memory is often accessed through spoken or written language, while in animals, cognitive functions must be accessed through different kind of behaviors in many specific, experimental models of memory and learning.  Among them, the novel object recognition test can be evaluated by the differences in the exploration time of novel and familiar objects.  Its application is not limited to a field of research and enables that various issues can be studied, such as the memory and learning, the preference for novelty, the influence of different brain regions in the process of recognition, and even the study of different drugs and their effects.  This paper describes the novel object recognition paradigms in animals, as a valuable measure of cognition.  The purpose of this work was to review the neurobiology and methodological modifications of the test commonly used in behavioral pharmacology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQocv30hVI3YVf1XRtfYM0dfW6udTcc2eamRb-d8GCNyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zoslWlsQ%253D%253D&md5=4f73ed1bafb04056c5aef19b1b86c802</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs10339-011-0430-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10339-011-0430-z%26sid%3Dliteratum%253Aachs%26aulast%3DAntunes%26aufirst%3DM.%26aulast%3DBiala%26aufirst%3DG.%26atitle%3DThe%2520novel%2520object%2520recognition%2520memory%253A%2520neurobiology%252C%2520test%2520procedure%252C%2520and%2520its%2520modifications%26jtitle%3DCogn.%2520Process.%26date%3D2012%26volume%3D13%26spage%3D93%26epage%3D110%26doi%3D10.1007%2Fs10339-011-0430-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heneka, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">Inflammasome signalling in brain function and neurodegenerative disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1038/s41583-018-0055-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1038%2Fs41583-018-0055-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=30206330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSnt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=610-621&author=M.+T.+Henekaauthor=R.+M.+McManusauthor=E.+Latz&title=Inflammasome+signalling+in+brain+function+and+neurodegenerative+disease&doi=10.1038%2Fs41583-018-0055-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammasome signalling in brain function and neurodegenerative disease</span></div><div class="casAuthors">Heneka, Michael T.; McManus, Roisin M.; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The mammalian CNS is an intricate and fragile structure, which on one hand is open to change in order to store information, but on the other hand is vulnerable to damage from injury, pathogen invasion or neurodegeneration.  During senescence and neurodegeneration, activation of the innate immune system can occur.  Inflammasomes are signalling complexes that regulate cells of the immune system, which in the brain mainly includes microglial cells.  In microglia, the NLRP3 (NOD-, LRR- and pyrin domain-contg. 3) inflammasome becomes activated when these cells sense proteins such as misfolded or aggregated amyloid-β, α-synuclein and prion protein or superoxide dismutase, ATP and members of the complement pathway.  Several other inflammasomes have been described in microglia and the other cells of the brain, including astrocytes and neurons, where their activation and subsequent caspase 1 cleavage contribute to disease development and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNcYCoTzamKLVg90H21EOLACvtfcHk0ljydssAvw1MfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSnt7jO&md5=140aef541b7b1eaae9ca1b71b848c2ce</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fs41583-018-0055-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41583-018-0055-7%26sid%3Dliteratum%253Aachs%26aulast%3DHeneka%26aufirst%3DM.%2BT.%26aulast%3DMcManus%26aufirst%3DR.%2BM.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DInflammasome%2520signalling%2520in%2520brain%2520function%2520and%2520neurodegenerative%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2018%26volume%3D19%26spage%3D610%26epage%3D621%26doi%3D10.1038%2Fs41583-018-0055-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.-M.</span>; <span class="NLM_string-name">Zhou, H.</span>; <span class="NLM_string-name">Hong, J. S.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress, neuroinflammation, and neurodegeneration</span>. In  <i>Neuroinflammation and neurodegeneration</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, P. K.</span>, <span class="NLM_string-name">Toborek, M.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2014</span>; pp  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">104</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1007%2F978-1-4939-1071-7_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=81-104&author=H.-M.+Gao&author=H.+Zhou&author=J.+S.+Hongauthor=P.+K.+Peterson&author=M.+Toborek&title=Neuroinflammation+and+neurodegeneration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-1071-7_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-1071-7_5%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DH.-M.%26atitle%3DOxidative%2520stress%252C%2520neuroinflammation%252C%2520and%2520neurodegeneration%26btitle%3DNeuroinflammation%2520and%2520neurodegeneration%26aulast%3DPeterson%26aufirst%3DP.%2BK.%26pub%3DSpringer%26date%3D2014%26spage%3D81%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekert, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, R. J.</span></span> <span> </span><span class="NLM_article-title">TNF alpha inhibitors in Alzheimer’s disease: a systematic review</span>. <i>Int. J. Geriatr. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">688</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1002/gps.4871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fgps.4871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=29516540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BC1MrovVOjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=688-694&author=J.+O.+Ekertauthor=R.+L.+Gouldauthor=G.+Reynoldsauthor=R.+J.+Howard&title=TNF+alpha+inhibitors+in+Alzheimer%E2%80%99s+disease%3A+a+systematic+review&doi=10.1002%2Fgps.4871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">TNF alpha inhibitors in Alzheimer's disease: A systematic review</span></div><div class="casAuthors">Ekert Justyna O; Gould Rebecca L; Howard Robert J; Reynolds Gemma</div><div class="citationInfo"><span class="NLM_cas:title">International journal of geriatric psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">688-694</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The objective of this study was to evaluate the effect of tumour necrosis factor-alpha inhibitors (TNF-αI) on Alzheimer's disease-associated pathology.  DESIGN:  A literature search of PubMed, Embase, PsychINFO, Web of Science, Scopus, and the Cochrane Library databases for human and animal studies that evaluated the use of TNF-αI was performed on 26 October 2016.  RESULTS:  The main outcomes assessed were cognition and behaviour, reduction in brain tissue mass, presence of plaques and tangles, and synaptic function.  Risk of bias was assessed regarding blinding, statistical model, outcome reporting, and other biases.  Sixteen studies were included, 13 of which were animal studies and 3 of which were human.  All animal studies found that treatment with TNF-αI leads to an improvement in cognition and behaviour.  None of the studies measured change in brain tissue mass.  The majority of studies documented a beneficial effect in other areas, including the presence of plaques and tangles and synaptic function.  The amount of data from human studies was limited.  Two out of 3 studies concluded that TNF-αI are beneficial in Alzheimer's disease patients, with one being an observational study and the latter being a small pilot study, with a high risk of bias.  CONCLUSION:  It was concluded that a large-scale randomized controlled trial assessing the effectiveness of TNF-αI on humans is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwUdIMvEaLnTslzEEsg76ufW6udTcc2eamRb-d8GCNyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrovVOjug%253D%253D&md5=87fe8070b58d57832042842ad7d04ef4</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fgps.4871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgps.4871%26sid%3Dliteratum%253Aachs%26aulast%3DEkert%26aufirst%3DJ.%2BO.%26aulast%3DGould%26aufirst%3DR.%2BL.%26aulast%3DReynolds%26aufirst%3DG.%26aulast%3DHoward%26aufirst%3DR.%2BJ.%26atitle%3DTNF%2520alpha%2520inhibitors%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520systematic%2520review%26jtitle%3DInt.%2520J.%2520Geriatr.%2520Psychiatry%26date%3D2018%26volume%3D33%26spage%3D688%26epage%3D694%26doi%3D10.1002%2Fgps.4871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iadecola, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, M. E.</span></span> <span> </span><span class="NLM_article-title">Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">9157</span>– <span class="NLM_lpage">9164</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.17-23-09157.1997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1523%2FJNEUROSCI.17-23-09157.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9364062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2sXnsFWksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=9157-9164&author=C.+Iadecolaauthor=F.+Zhangauthor=R.+Caseyauthor=M.+Nagayamaauthor=M.+E.+Ross&title=Delayed+reduction+of+ischemic+brain+injury+and+neurological+deficits+in+mice+lacking+the+inducible+nitric+oxide+synthase+gene&doi=10.1523%2FJNEUROSCI.17-23-09157.1997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene</span></div><div class="casAuthors">Iadecola, Costantino; Zhang, Fangyi; Casey, Robyn; Nagayama, Masao; Ross, M. Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9157-9164</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Inducible nitric oxide synthase (iNOS), an enzyme that produces toxic amts. of nitric oxide, is expressed in a no. of brain pathologies, including cerebral ischemia.  The authors used mice with a null mutation of the iNOS gene to study the role of iNOS in ischemic brain damage.  Focal cerebral ischemia was produced by occlusion of the middle cerebral artery (MCA).  In wild-type mice, iNOS mRNA expression in the post-ischemic brain began between 24 and 48 h, peaked at 96 h and subsided 7 d after MCA occlusion.  INOS mRNA induction was assocd. with expression of iNOS protein and enzymic activity.  In contrast, mice lacking the iNOS gene did not express iNOS message or protein after MCA occlusion.  The infarct and the motor deficits produced by MCA occlusion were smaller in iNOS knockouts than in wild-type mice.  Such redn. in ischemic damage and neurol. deficits was obsd. 96 h after ischemia but not at 24 h, when iNOS is not yet expressed in wild-type mice.  The decreased susceptibility to cerebral ischemia in iNOS knockouts could not be attributed to differences in the degree of ischemia or vascular reactivity between wild-type and knockout mice.  These findings indicate that iNOS expression is one of the factors contributing to the expansion of the brain damage that occurs in the post-ischemic period.  INOS inhibition may provide a novel therapeutic strategy targeted specifically at the secondary progression of ischemic brain injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAQjGLMFFg3LVg90H21EOLACvtfcHk0lgq7xUlm_jq2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsFWksLs%253D&md5=2224c658f3fa78e7722efc27c0219944</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.17-23-09157.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.17-23-09157.1997%26sid%3Dliteratum%253Aachs%26aulast%3DIadecola%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DCasey%26aufirst%3DR.%26aulast%3DNagayama%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DM.%2BE.%26atitle%3DDelayed%2520reduction%2520of%2520ischemic%2520brain%2520injury%2520and%2520neurological%2520deficits%2520in%2520mice%2520lacking%2520the%2520inducible%2520nitric%2520oxide%2520synthase%2520gene%26jtitle%3DJ.%2520Neurosci.%26date%3D1997%26volume%3D17%26spage%3D9157%26epage%3D9164%26doi%3D10.1523%2FJNEUROSCI.17-23-09157.1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schipper, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavitian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cressatti, M.</span></span> <span> </span><span class="NLM_article-title">The sinister face of heme oxygenase-1 in brain aging and disease</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2018.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.pneurobio.2018.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=30009872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWhsrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=40-70&author=H.+M.+Schipperauthor=W.+Songauthor=A.+Tavitianauthor=M.+Cressatti&title=The+sinister+face+of+heme+oxygenase-1+in+brain+aging+and+disease&doi=10.1016%2Fj.pneurobio.2018.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The sinister face of heme oxygenase-1 in brain aging and disease</span></div><div class="casAuthors">Schipper, Hyman M.; Song, Wei; Tavitian, Ayda; Cressatti, Marisa</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-70</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Under stressful conditions, cellular heme catabolism to carbon monoxide, iron and biliverdin is mediated by the 32 kDa enzyme, heme oxygenase-1 (HO-1).  A wide range of pro-oxidant and inflammatory stimuli act on diverse consensus sequences within the Hmox1 promoter to rapidly induce the gene.  There is ample evidence attesting to the beneficial effects of HO-1 upregulation in brain.  By converting pro-oxidant heme to the antioxidants, biliverdin and bilirubin, HO-1/biliverdin reductase may help restore a more favorable tissue redox microenvironment.  Contrariwise, in some cell types and under certain circumstances, heme-derived carbon monoxide and iron may amplify intracellular oxidative stress and exacerbate the disease process.  This inimical side of neural HO-1 has often been ignored in biomedical literature promulgating interventions aimed at boosting central HO-1 expression for the management of diverse CNS conditions and is the focus of the current review.  A comprehensive model of astroglial stress is presented wherein sustained Hmox1 induction promotes oxidative mitochondrial membrane damage, iron sequestration and mitophagy (macroautophagy).  The HO-1 mediated gliopathy renders nearby neuronal constituents vulnerable to oxidative injury and recapitulates 'core' neuropathol. features of many aging-related neurodegenerative and some neurodevelopmental brain disorders.  A balanced literature should acknowledge that, in a host of chronic human CNS afflictions, the glial HO-1 response may serve as a robust transducer of noxious stimuli, an important driver of relevant neuropathol. and a potentially disease-modifying therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRgFe9imcJ3rVg90H21EOLACvtfcHk0lgq7xUlm_jq2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWhsrnL&md5=68c2e441383714dd479bc3acb64d618f</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2018.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2018.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DSchipper%26aufirst%3DH.%2BM.%26aulast%3DSong%26aufirst%3DW.%26aulast%3DTavitian%26aufirst%3DA.%26aulast%3DCressatti%26aufirst%3DM.%26atitle%3DThe%2520sinister%2520face%2520of%2520heme%2520oxygenase-1%2520in%2520brain%2520aging%2520and%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2019%26volume%3D172%26spage%3D40%26epage%3D70%26doi%3D10.1016%2Fj.pneurobio.2018.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griñán-Ferré, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarroca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puigoriol-Illamola, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguado, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfeliu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallàs, M.</span></span> <span> </span><span class="NLM_article-title">Epigenetic mechanisms underlying cognitive impairment and Alzheimer disease hallmarks in 5xFAD mice</span>. <i>Aging</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">664</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.18632/aging.100906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.18632%2Faging.100906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=27013617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVymtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=664-684&author=C.+Gri%C3%B1%C3%A1n-Ferr%C3%A9author=S.+Sarrocaauthor=A.+Ivanovaauthor=D.+Puigoriol-Illamolaauthor=F.+Aguadoauthor=A.+Caminsauthor=C.+Sanfeliuauthor=M.+Pall%C3%A0s&title=Epigenetic+mechanisms+underlying+cognitive+impairment+and+Alzheimer+disease+hallmarks+in+5xFAD+mice&doi=10.18632%2Faging.100906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic mechanisms underlying cognitive impairment and Alzheimer disease hallmarks in 5XFAD mice</span></div><div class="casAuthors">Grinan-Ferre, Christian; Sarroca, Sara; Ivanova, Aleksandra; Puigoriol-Illamola, Dolors; Aguado, Fernando; Camins, Antoni; Sanfeliu, Coral; Pallas, Merce</div><div class="citationInfo"><span class="NLM_cas:title">Aging</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">664-684</span>CODEN:
                <span class="NLM_cas:coden">AGINCN</span>;
        ISSN:<span class="NLM_cas:issn">1945-4589</span>.
    
            (<span class="NLM_cas:orgname">Impact Journals LLC</span>)
        </div><div class="casAbstract">5XFAD is an early-onset mouse transgenic model of Alzheimer disease (AD).  Up to now there are no studies that focus on the epigenetic changes produced as a result of Aβ-42 accumulation and the possible involvement in the different expression of related AD-genes.  Under several behavioral and cognition test, we found impairment in memory and psychoemotional changes in female 5XFAD mice in ref. to wild type that worsens with age.  Cognitive changes correlated with alterations on protein level anal. and gene expression of markers related with tau aberrant phosphorylation, amyloidogenic pathway (APP, BACE1), Oxidative Stress (iNOS, Aldh2) and inflammation (astrogliosis, TNF-α and IL-6); no changes were found in non-amyloidogenic pathway indicators such as ADAM10.  Epigenetics changes as higher CpG methylation and transcriptional changes in DNA methyltransferases (DNMTs) family were found.  Dnmt1 increases in younger 5XFAD and Dnmt3a and b high levels in the oldest transgenic mice.  Similar pattern was found with histone methyltransferases such as Jarid1a and G9a.  Histone deacetylase 2 (Hdac2) or Sirt6., both related with cognition and memory, presented a similar pattern.  Taken together, these hallmarks presented by the 5XFAD model prompted its use in assessing different potential therapeutic interventions based on epigenetic targets after earlier amyloid deposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy0gsGdoC1kbVg90H21EOLACvtfcHk0lgq7xUlm_jq2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVymtLg%253D&md5=a805b5c900563cec2dcb6d218192ed04</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.18632%2Faging.100906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Faging.100906%26sid%3Dliteratum%253Aachs%26aulast%3DGri%25C3%25B1%25C3%25A1n-Ferr%25C3%25A9%26aufirst%3DC.%26aulast%3DSarroca%26aufirst%3DS.%26aulast%3DIvanova%26aufirst%3DA.%26aulast%3DPuigoriol-Illamola%26aufirst%3DD.%26aulast%3DAguado%26aufirst%3DF.%26aulast%3DCamins%26aufirst%3DA.%26aulast%3DSanfeliu%26aufirst%3DC.%26aulast%3DPall%25C3%25A0s%26aufirst%3DM.%26atitle%3DEpigenetic%2520mechanisms%2520underlying%2520cognitive%2520impairment%2520and%2520Alzheimer%2520disease%2520hallmarks%2520in%25205xFAD%2520mice%26jtitle%3DAging%26date%3D2016%26volume%3D8%26spage%3D664%26epage%3D684%26doi%3D10.18632%2Faging.100906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becke, A. D.</span></span> <span> </span><span class="NLM_article-title">Density-functional thermochemistry. III. The role of exact exchange</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">5648</span>, <span class="refDoi"> DOI: 10.1063/1.464913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1063%2F1.464913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK3sXisVWgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1993&pages=5648&author=A.+D.+Becke&title=Density-functional+thermochemistry.+III.+The+role+of+exact+exchange&doi=10.1063%2F1.464913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Density-functional thermochemistry. III. The role of exact exchange</span></div><div class="casAuthors">Becke, Axel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5648-52</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Despite the remarkable thermochem. accuracy of Kohn-Sham d.-functional theories with gradient corrections for exchange-correlation, the author believes that further improvements are unlikely unless exact-exchange information is considered.  Arguments to support this view are presented, and a semiempirical exchange-correlation functional (contg. local-spin-d., gradient, and exact-exchange terms) is tested for 56 atomization energies, 42 ionization potentials, 8 proton affinities, and 10 total at. energies of first- and second-row systems.  This functional performs better than previous functionals with gradient corrections only, and fits expt. atomization energies with an impressively small av. abs. deviation of 2.4 kcal/mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3BqpycUTBwLVg90H21EOLACvtfcHk0ljAMKIIcU8WJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVWgtrw%253D&md5=291bbfc119095338bb1624f0c21c7ca8</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1063%2F1.464913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.464913%26sid%3Dliteratum%253Aachs%26aulast%3DBecke%26aufirst%3DA.%2BD.%26atitle%3DDensity-functional%2520thermochemistry.%2520III.%2520The%2520role%2520of%2520exact%2520exchange%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1993%26volume%3D98%26spage%3D5648%26doi%3D10.1063%2F1.464913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, R. G.</span></span> <span> </span><span class="NLM_article-title">Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density</span>. <i>Phys. Rev. B: Condens. Matter Mater. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">785</span>, <span class="refDoi"> DOI: 10.1103/PhysRevB.37.785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1103%2FPhysRevB.37.785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9944570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL1cXktFWrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1988&pages=785&author=C.+Leeauthor=W.+Yangauthor=R.+G.+Parr&title=Development+of+the+Colle-Salvetti+correlation-energy+formula+into+a+functional+of+the+electron+density&doi=10.1103%2FPhysRevB.37.785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density</span></div><div class="casAuthors">Lee, Chengteh; Yang, Weitao; Parr, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Physical Review B:  Condensed Matter and Materials Physics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">785-9</span>CODEN:
                <span class="NLM_cas:coden">PRBMDO</span>;
        ISSN:<span class="NLM_cas:issn">0163-1829</span>.
    </div><div class="casAbstract">A correlation-energy formula due to R. Colle and D. Salvetti (1975), in which the correlation energy d. is expressed in terms of the electron d. and a Laplacian of the 2nd-order Hartree-Fock d. matrix, is restated as a formula involving the d. and local kinetic-energy d.  On insertion of gradient expansions for the local kinetic-energy d., d.-functional formulas for the correlation energy and correlation potential are then obtained.  Through numerical calcns. on a no. of atoms, pos. ions, and mols., of both open- and closed-shell type, it is demonstrated that these formulas, like the original Colle-Salvetti formulas, give correlation energies within a few percent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8yJ1cBkpi67Vg90H21EOLACvtfcHk0ljAMKIIcU8WJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktFWrtbw%253D&md5=ee7b59267a2ff72e15171a481819ccf8</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1103%2FPhysRevB.37.785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1103%252FPhysRevB.37.785%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DParr%26aufirst%3DR.%2BG.%26atitle%3DDevelopment%2520of%2520the%2520Colle-Salvetti%2520correlation-energy%2520formula%2520into%2520a%2520functional%2520of%2520the%2520electron%2520density%26jtitle%3DPhys.%2520Rev.%2520B%253A%2520Condens.%2520Matter%2520Mater.%2520Phys.%26date%3D1988%26volume%3D37%26spage%3D785%26doi%3D10.1103%2FPhysRevB.37.785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitznagel, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleyer, P. v. R.</span></span> <span> </span><span class="NLM_article-title">Efficient diffuse function-augmented basis sets for anion calculations. III. The 3-21+G basis set for first-row elements, Li–F</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1002/jcc.540040303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fjcc.540040303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL3sXlt1ymsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1983&pages=294-301&author=T.+Clarkauthor=J.+Chandrasekharauthor=G.+W.+Spitznagelauthor=P.+v.+R.+Schleyer&title=Efficient+diffuse+function-augmented+basis+sets+for+anion+calculations.+III.+The+3-21%2BG+basis+set+for+first-row+elements%2C+Li%E2%80%93F&doi=10.1002%2Fjcc.540040303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient diffuse function-augmented basis sets for anion calculations.  III.  The 3-21 + G basis set for first-row elements, lithium to fluorine</span></div><div class="casAuthors">Clark, Timothy; Chandrasekhar, Jayaraman; Spitznagel, Guenther W.; Schleyer, Paul v. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">294-301</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    </div><div class="casAbstract">The relatively small diffuse function-augmented basis set, 3-21+G, describes anion geometries and proton affinities adequately.  The diffuse sp orbital exponents are recommended for general use to augment larger basis sets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAg8Jhz7uoELVg90H21EOLACvtfcHk0ljAMKIIcU8WJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlt1ymsb8%253D&md5=2c6dc9df839e5a23820c29db41ce68dc</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fjcc.540040303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.540040303%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DT.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DSpitznagel%26aufirst%3DG.%2BW.%26aulast%3DSchleyer%26aufirst%3DP.%2Bv.%2BR.%26atitle%3DEfficient%2520diffuse%2520function-augmented%2520basis%2520sets%2520for%2520anion%2520calculations.%2520III.%2520The%25203-21%252BG%2520basis%2520set%2520for%2520first-row%2520elements%252C%2520Li%25E2%2580%2593F%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1983%26volume%3D4%26spage%3D294%26epage%3D301%26doi%3D10.1002%2Fjcc.540040303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wadt, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, P. J.</span></span> <span> </span><span class="NLM_article-title">Ab initio effective core potentials for molecular calculations. Potentials for K to Au including the outermost core orbitals</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">284</span>, <span class="refDoi"> DOI: 10.1063/1.448800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1063%2F1.448800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL2MXht1SjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1985&pages=284&author=W.+R.+Wadtauthor=P.+J.+Hay&title=Ab+initio+effective+core+potentials+for+molecular+calculations.+Potentials+for+K+to+Au+including+the+outermost+core+orbitals&doi=10.1063%2F1.448800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Ab initio effective core potentials for molecular calculations.  Potentials for main group elements sodium to bismuth</span></div><div class="casAuthors">Wadt, Willard R.; Hay, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">284-98</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">A consistent set of ab initio effective core potentials (ECP) was generated for the main group elements from Na to Bi by using the procedure originally developed by Kahn (1976).  For Rb to Bi the ECP's are generated from the relativistic Hartree-Fock at. wave functions of Cowan which incorporate the Darwin and mass-velocity terms.  Energy-optimized valence basis sets of (3s3p) primitive Gaussians are presented for use with the ECP's.  Comparisons between all-electron and valence-electron ECP calcns. are presented for NaF, NaCl, Cl2, Cl2-, Br2, Br2-, and Xe2+.  The results show that the av. errors introduced by the ECP's are generally only a few percent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt2lGOejwqOLVg90H21EOLACvtfcHk0lh1axbm_9PLZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXht1SjtLk%253D&md5=16288166d7c3a65ba452c4673b7c7d2a</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1063%2F1.448800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.448800%26sid%3Dliteratum%253Aachs%26aulast%3DWadt%26aufirst%3DW.%2BR.%26aulast%3DHay%26aufirst%3DP.%2BJ.%26atitle%3DAb%2520initio%2520effective%2520core%2520potentials%2520for%2520molecular%2520calculations.%2520Potentials%2520for%2520K%2520to%2520Au%2520including%2520the%2520outermost%2520core%2520orbitals%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1985%26volume%3D82%26spage%3D284%26doi%3D10.1063%2F1.448800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, H. B.</span></span> <span> </span><span class="NLM_article-title">An improved algorithm for reaction path following</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">2154</span>, <span class="refDoi"> DOI: 10.1063/1.456010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1063%2F1.456010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL1MXhsVahtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1989&pages=2154&author=C.+Gonzalezauthor=H.+B.+Schlegel&title=An+improved+algorithm+for+reaction+path+following&doi=10.1063%2F1.456010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">An improved algorithm for reaction path following</span></div><div class="casAuthors">Gonzalez, Carlos; Schlegel, H. Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2154-61</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">A new algorithm is presented for obtaining points on a steepest descent path from the transition state of the reactants and products.  In mass-weighted coordinates, this path corresponds to the intrinsic reaction coordinate.  Points on the reaction path are found by constrained optimizations involving all internal degrees of freedom of the mol.  The points are optimized so that the segment of the reaction path between any two adjacent points is given by an arc of a circle, and so that the gradient at each point is tangent to the path.  Only the transition vector and the energy gradients are needed to construct the path.  The resulting path is continuous, differentiable and piecewise quadratic.  In the limit of small step size, the present algorithm is shown to take a step with the correct tangent vector and curvature vector; hence, it is a second order algorithm.  The method was tested on the following reactions: HCN → CNH, SiH2 + H2 → SiH4, CH4 + H → CH3 + H2, F- + CH3F → FCH3 + F-, and C2H5F → C2H4 + HF.  Reaction paths calcd. with a step size of 0.4 a.u. are almost identical to those computed with a step size of 0.1 a.u. or smaller.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpndb7Cg_0ZNbVg90H21EOLACvtfcHk0lh1axbm_9PLZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhsVahtbk%253D&md5=17e5199cc364324ce3c55c6701342b58</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1063%2F1.456010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.456010%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez%26aufirst%3DC.%26aulast%3DSchlegel%26aufirst%3DH.%2BB.%26atitle%3DAn%2520improved%2520algorithm%2520for%2520reaction%2520path%2520following%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1989%26volume%3D90%26spage%3D2154%26doi%3D10.1063%2F1.456010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, D. G.</span></span> <span> </span><span class="NLM_article-title">MN-15: A new local exchanged-correlation functional for Kohn-Sham density functional theory broad accuracy for atoms, molecules, and solids</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1280</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.5b01082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b01082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12qsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1280-1293&author=H.+S.+Yuauthor=X.+Heauthor=D.+G.+Truhlar&title=MN-15%3A+A+new+local+exchanged-correlation+functional+for+Kohn-Sham+density+functional+theory+broad+accuracy+for+atoms%2C+molecules%2C+and+solids&doi=10.1021%2Facs.jctc.5b01082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">MN15-L: A New Local Exchange-Correlation Functional for Kohn-Sham Density Functional Theory with Broad Accuracy for Atoms, Molecules, and Solids</span></div><div class="casAuthors">Yu, Haoyu S.; He, Xiao; Truhlar, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1280-1293</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kohn-Sham d. functional theory is widely used for applications of electronic structure theory in chem., materials science, and condensed-matter physics, but the accuracy depends on the quality of the exchange-correlation functional.  Here, we present a new local exchange-correlation functional called MN15-L that predicts accurate results for a broad range of mol. and solid-state properties including main-group bond energies, transition metal bond energies, reaction barrier heights, noncovalent interactions, at. excitation energies, ionization potentials, electron affinities, total at. energies, hydrocarbon thermochem., and lattice consts. of solids.  The MN15-L functional has the same math. form as a previous meta-nonseparable gradient approxn. exchange-correlation functional, MN12-L, but it is improved because we optimized it against a larger database, designated 2015A, and included smoothness restraints; the optimization has a much better representation of transition metals.  The mean unsigned error on 422 chem. energies is 2.32 kcal/mol, which is the best among all tested functionals, with or without nonlocal exchange.  The MN15-L functional also provides good results for test sets that are outside the training set.  A key issue is that the functional is local (no nonlocal exchange or nonlocal correlation), which makes it relatively economical for treating large and complex systems and solids.  Another key advantage is that medium-range correlation energy is built in so that one does not need to add damped dispersion by mol. mechanics in order to predict accurate noncovalent binding energies.  We believe that the MN15-L functional should be useful for a wide variety of applications in chem., physics, materials science, and mol. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbBt4RRpG2aLVg90H21EOLACvtfcHk0lh1axbm_9PLZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12qsQ%253D%253D&md5=009604f205a3b5524da28a9dd4beb8d4</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b01082%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BS.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DTruhlar%26aufirst%3DD.%2BG.%26atitle%3DMN-15%253A%2520A%2520new%2520local%2520exchanged-correlation%2520functional%2520for%2520Kohn-Sham%2520density%2520functional%2520theory%2520broad%2520accuracy%2520for%2520atoms%252C%2520molecules%252C%2520and%2520solids%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D1280%26epage%3D1293%26doi%3D10.1021%2Facs.jctc.5b01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marenich, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, D. G.</span></span> <span> </span><span class="NLM_article-title">Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">6378</span>– <span class="NLM_lpage">6396</span>, <span class="refDoi"> DOI: 10.1021/jp810292n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp810292n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksV2is74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=6378-6396&author=A.+V.+Marenichauthor=C.+J.+Cramerauthor=D.+G.+Truhlar&title=Universal+solvation+model+based+on+solute+electron+density+and+on+a+continuum+model+of+the+solvent+defined+by+the+bulk+dielectric+constant+and+atomic+surface+tensions&doi=10.1021%2Fjp810292n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Universal Solvation Model Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic Surface Tensions</span></div><div class="casAuthors">Marenich, Aleksandr V.; Cramer, Christopher J.; Truhlar, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6378-6396</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-6106</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a new continuum solvation model based on the quantum mech. charge d. of a solute mol. interacting with a continuum description of the solvent.  The model is called SMD, where the "D" stands for "d." to denote that the full solute electron d. is used without defining partial at. charges.  "Continuum" denotes that the solvent is not represented explicitly but rather as a dielec. medium with surface tension at the solute-solvent boundary.  SMD is a universal solvation model, where "universal" denotes its applicability to any charged or uncharged solute in any solvent or liq. medium for which a few key descriptors are known (in particular, dielec. const., refractive index, bulk surface tension, and acidity and basicity parameters).  The model separates the observable solvation free energy into two main components.  The first component is the bulk electrostatic contribution arising from a self-consistent reaction field treatment that involves the soln. of the nonhomogeneous Poisson equation for electrostatics in terms of the integral-equation-formalism polarizable continuum model (IEF-PCM).  The cavities for the bulk electrostatic calcn. are defined by superpositions of nuclear-centered spheres.  The second component is called the cavity-dispersion-solvent-structure term and is the contribution arising from short-range interactions between the solute and solvent mols. in the first solvation shell.  This contribution is a sum of terms that are proportional (with geometry-dependent proportionality consts. called at. surface tensions) to the solvent-accessible surface areas of the individual atoms of the solute.  The SMD model has been parametrized with a training set of 2821 solvation data including 112 aq. ionic solvation free energies, 220 solvation free energies for 166 ions in acetonitrile, methanol, and DMSO, 2346 solvation free energies for 318 neutral solutes in 91 solvents (90 nonaq. org. solvents and water), and 143 transfer free energies for 93 neutral solutes between water and 15 org. solvents.  The elements present in the solutes are H, C, N, O, F, Si, P, S, Cl, and Br.  The SMD model employs a single set of parameters (intrinsic at. Coulomb radii and at. surface tension coeffs.) optimized over six electronic structure methods: M05-2X/MIDI!6D, M05-2X/6-31G*, M05-2X/6-31+G**, M05-2X/cc-pVTZ, B3LYP/6-31G*, and HF/6-31G*.  Although the SMD model has been parametrized using the IEF-PCM protocol for bulk electrostatics, it may also be employed with other algorithms for solving the nonhomogeneous Poisson equation for continuum solvation calcns. in which the solute is represented by its electron d. in real space.  This includes, for example, the conductor-like screening algorithm.  With the 6-31G* basis set, the SMD model achieves mean unsigned errors of 0.6-1.0 kcal/mol in the solvation free energies of tested neutrals and mean unsigned errors of 4 kcal/mol on av. for ions with either Gaussian03 or GAMESS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrvm7K8c8dLVg90H21EOLACvtfcHk0lh1axbm_9PLZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksV2is74%253D&md5=54931a64c70d28445ee53876a8b1a4b9</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjp810292n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp810292n%26sid%3Dliteratum%253Aachs%26aulast%3DMarenich%26aufirst%3DA.%2BV.%26aulast%3DCramer%26aufirst%3DC.%2BJ.%26aulast%3DTruhlar%26aufirst%3DD.%2BG.%26atitle%3DUniversal%2520solvation%2520model%2520based%2520on%2520solute%2520electron%2520density%2520and%2520on%2520a%2520continuum%2520model%2520of%2520the%2520solvent%2520defined%2520by%2520the%2520bulk%2520dielectric%2520constant%2520and%2520atomic%2520surface%2520tensions%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2009%26volume%3D113%26spage%3D6378%26epage%3D6396%26doi%3D10.1021%2Fjp810292n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span></span>; <span class="NLM_etal"></span> <i>Gaussian 16</i>, revision B.01, <span class="NLM_publisher-name">Gaussian, Inc.</span>: <span class="NLM_publisher-loc">Wallingford, CT</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+J.+Frisch&title=Gaussian+16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26jtitle%3DGaussian%252016%26pub%3DGaussian%252C%2520Inc%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabilondo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span> <span> </span><span class="NLM_article-title">[<sup>3</sup>H] RX821002 (2-methoxyidazoxan) binds to α<sub>2</sub>-adrenoceptor subtypes and a non-adrenoceptor imidazoline binding site in rat kidney</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(96)00692-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0014-2999%2896%2900692-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8982708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK28Xnt1Krtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=1996&pages=359-368&author=L.+F.+Calladoauthor=A.+M.+Gabilondoauthor=J.+J.+Meana&title=%5B3H%5D+RX821002+%282-methoxyidazoxan%29+binds+to+%CE%B12-adrenoceptor+subtypes+and+a+non-adrenoceptor+imidazoline+binding+site+in+rat+kidney&doi=10.1016%2FS0014-2999%2896%2900692-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">[3H]RX 821002 (2-methoxyidazoxan) binds to α2-adrenoceptor subtypes and a non-adrenoceptor imidazoline binding site in rat kidney</span></div><div class="casAuthors">Callado, Luis F.; Gabilondo, Ane M.; Meana, J. Javier</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">359-368</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The binding of [3H]RX 821002 was evaluated in rat kidney membranes.  [3H]RX 821002 (0.13-16 nM) recognized a single, saturable binding site with high affinity.  Different binding site densities were calcd. depending on non-specific binding as defined by (-)-adrenaline or RX 821002 (10 μM).  Competition assays using (-)-adrenaline and the subtype-selective drugs ARC 239 (2-[2-[4-(o-methoxyphenyl)-piperazin-1-yl]-ethyl]-4,4-dimethyl-1,3(2H,4H)-isoquinolindione), BRL 44408 (2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole), oxymetazoline or prazosin for [3H]RX 821002 binding sites revealed the presence of α2B-adrenoceptors (33-51%), α2D-adrenoceptors (15-28%) and an adrenaline-insensitive population (34-40%), sensitive to imidazolines.  After the addn. of (-)-adrenaline (3 μM) to mask α2-adrenoceptors, [3H]RX 821002 specifically identified a saturable binding site with high affinity (Kd = 4.9 nM).  The pharmacol. profile of this non-adrenoceptor, [3H]RX 821002 binding site (potencies: efaroxan>clonidine>guanabenz>BRL 44408>ARC 239>BU 224 (2-(4,5-dihydroimidaz-2-yl)quinoline)>moxonidine>(-)-noradrenaline>cimetidine) is different to that of imidazoline I1 or imidazoline I2 binding sites.  Alternative incubation in the presence of ARC 239 (50 nM) to mask α2B-adrenoceptors or BRL 44408 (100 nM) to mask α2D-adrenoceptors confirmed the existence of both α2-adrenoceptor subtypes and a non-adrenoceptor imidazoline binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_fNrKA8UDdbVg90H21EOLACvtfcHk0ljhpVgVD9df8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt1Krtrw%253D&md5=a9c19d6fc068713870455004efe28674</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2896%2900692-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252896%252900692-9%26sid%3Dliteratum%253Aachs%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DGabilondo%26aufirst%3DA.%2BM.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26atitle%3D%255B3H%255D%2520RX821002%2520%25282-methoxyidazoxan%2529%2520binds%2520to%2520%25CE%25B12-adrenoceptor%2520subtypes%2520and%2520a%2520non-adrenoceptor%2520imidazoline%2520binding%2520site%2520in%2520rat%2520kidney%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D316%26spage%3D359%26epage%3D368%26doi%3D10.1016%2FS0014-2999%2896%2900692-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span>MarvinSketch 5.5.1.0. <span class="NLM_publisher-name">ChemAxon</span>, <span class="NLM_publisher-loc">Budapest, Hungary</span>, <span class="NLM_year">2011</span>; software available
at <a href="https://www.chemaxon.com" class="extLink">https://www.chemaxon.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MarvinSketch+5.5.1.0.+ChemAxon%2C+Budapest%2C+Hungary%2C+2011%3B+software+available%0Aat+https%3A%2F%2Fwww.chemaxon.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26pub%3DChemAxon%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. J. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of parameters for semiempirical methods I. Method</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/jcc.540100208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fjcc.540100208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL1MXkt1ylu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1989&pages=209-220&author=J.+J.+P.+Stewart&title=Optimization+of+parameters+for+semiempirical+methods+I.+Method&doi=10.1002%2Fjcc.540100208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of parameters for semiempirical methods.  I.  Method</span></div><div class="casAuthors">Stewart, James J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-20</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    </div><div class="casAbstract">A new method for obtaining optimized parameters for semiempirical methods is developed and applied to the MNDO method.  The method uses derivs. of calcd. values for properties with respect to adjustable parameters to obtain the optimized values of parameters.  The large increase in speed is a result of using a simple series expression for calcd. values of properties rather than employing full semiempirical calcns.  With this optimization procedure, the rate-detg. step for parameterizing elements changes from the mechanics of parameterization to the assembling of exptl. ref. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwG85ot7_Rq7Vg90H21EOLACvtfcHk0ljhpVgVD9df8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkt1ylu70%253D&md5=cbf1b7604277340a97e061539b65af71</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1002%2Fjcc.540100208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.540100208%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DJ.%2BJ.%2BP.%26atitle%3DOptimization%2520of%2520parameters%2520for%2520semiempirical%2520methods%2520I.%2520Method%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1989%26volume%3D10%26spage%3D209%26epage%3D220%26doi%3D10.1002%2Fjcc.540100208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. J. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of parameters for semiempirical methods II.Method</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1002/jcc.540100209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fjcc.540100209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL1MXkt1ylu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1989&pages=221-264&author=J.+J.+P.+Stewart&title=Optimization+of+parameters+for+semiempirical+methods+II.Method&doi=10.1002%2Fjcc.540100209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of parameters for semiempirical methods.  II.  Applications</span></div><div class="casAuthors">Stewart, James J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-64</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    </div><div class="casAbstract">MNDO/AM1-type parameters for 12 elements were optimized using a newly developed method for optimizing parameters for semiempirical methods.  With the new method, MNDO-PM3, the av. difference between the predicted heats of formation and exptl. values for 657 compds. is 7.8 kcal/mol, and for 106 hypervalent compds., 13.6 kcal/mol.  For MNDO the equiv. differences are 13.9 and 75.8 kcal/mol, while those for AM1, in which MNDO parameters are used for Al, P, and S, are 12.7 and 83.1 kcal/mol, resp.  Av. errors for ionization potentials, bond angles, and dipole moments are intermediate between those for MINDO and AM1, while errors on bond lengths are slightly reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofaR7BHv7vB7Vg90H21EOLACvtfcHk0lhAo1bO2COMqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkt1ylu7o%253D&md5=b94fa02ec95f5b1b2d62c2014ac4c288</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fjcc.540100209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.540100209%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DJ.%2BJ.%2BP.%26atitle%3DOptimization%2520of%2520parameters%2520for%2520semiempirical%2520methods%2520II.Method%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1989%26volume%3D10%26spage%3D221%26epage%3D264%26doi%3D10.1002%2Fjcc.540100209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hehre, W. J.</span>; <span class="NLM_string-name">Radom, L.</span>; <span class="NLM_string-name">Schleyer, PvR.</span>; <span class="NLM_string-name">Pople, J. A.</span></span> <i>Ab initio molecular orbital theory</i>; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1986</span>; Vol  <span class="NLM_volume">1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&author=W.+J.+Hehre&author=L.+Radom&author=PvR.+Schleyer&author=J.+A.+Pople&title=Ab+initio+molecular+orbital+theory"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHehre%26aufirst%3DW.%2BJ.%26btitle%3DAb%2520initio%2520molecular%2520orbital%2520theory%26pub%3DWiley%26date%3D1986%26volume%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span>; <span class="NLM_string-name">Trucks, G. W.</span>; <span class="NLM_string-name">Schlegel, H. B.</span>; <span class="NLM_string-name">Scuseria, G. E.</span>; <span class="NLM_string-name">Robb, M. A.</span>; <span class="NLM_string-name">Cheeseman, J. R.</span>; <span class="NLM_string-name">Scalmani, G.</span>; <span class="NLM_string-name">Barone, V.</span>; <span class="NLM_string-name">Mennucci, B.</span>; <span class="NLM_string-name">Petersson, G. A.</span>; <span class="NLM_string-name">Nakatsuji, H.</span>; <span class="NLM_string-name">Caricato, M.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Hratchian, H. P.</span>; <span class="NLM_string-name">Izmaylov, A. F.</span>; <span class="NLM_string-name">Bloino, J.</span>; <span class="NLM_string-name">Zheng, G.</span>; <span class="NLM_string-name">Sonnenberg, J. L.</span>; <span class="NLM_string-name">Hada, M.</span>; <span class="NLM_string-name">Ehara, M.</span>; <span class="NLM_string-name">Toyota, K.</span>; <span class="NLM_string-name">Fukuda, R.</span>; <span class="NLM_string-name">Hasegawa, J.</span>; <span class="NLM_string-name">Ishida, M.</span>; <span class="NLM_string-name">Nakajima, T.</span>; <span class="NLM_string-name">Honda, Y.</span>; <span class="NLM_string-name">Kitao, O.</span>; <span class="NLM_string-name">Nakai, H.</span>; <span class="NLM_string-name">Vreven, T.</span>; <span class="NLM_string-name">Montgomery, J. A.,  Jr.</span>; <span class="NLM_string-name">Peralta, J. E.</span>; <span class="NLM_string-name">Ogliaro, F.</span>; <span class="NLM_string-name">Bearpark, M.</span>; <span class="NLM_string-name">Heyd, J. J.</span>; <span class="NLM_string-name">Brothers, E.</span>; <span class="NLM_string-name">Kudin, K. N.</span>; <span class="NLM_string-name">Staroverov, V. N.</span>; <span class="NLM_string-name">Kobayashi, R.</span>; <span class="NLM_string-name">Normand, J.</span>; <span class="NLM_string-name">Raghavachari, K.</span>; <span class="NLM_string-name">Rendell, A.</span>; <span class="NLM_string-name">Burant, J. C.</span>; <span class="NLM_string-name">Iyengar, S. S.</span>; <span class="NLM_string-name">Tomasi, J.</span>; <span class="NLM_string-name">Cossi, M.</span>; <span class="NLM_string-name">Rega, N.</span>; <span class="NLM_string-name">Millam, J. M.</span>; <span class="NLM_string-name">Klene, M.</span>; <span class="NLM_string-name">Knox, J. E.</span>; <span class="NLM_string-name">Cross, J. B.</span>; <span class="NLM_string-name">Bakken, V.</span>; <span class="NLM_string-name">Adamo, C.</span>; <span class="NLM_string-name">Jaramillo, J.</span>; <span class="NLM_string-name">Gomperts, R.</span>; <span class="NLM_string-name">Stratmann, R. E.</span>; <span class="NLM_string-name">Yazyev, O.</span>; <span class="NLM_string-name">Austin, A. J.</span>; <span class="NLM_string-name">Cammi, R.</span>; <span class="NLM_string-name">Pomelli, C.</span>; <span class="NLM_string-name">Ochterski, J. W.</span>; <span class="NLM_string-name">Martin, R. L.</span>; <span class="NLM_string-name">Morokuma, K.</span>; <span class="NLM_string-name">Zakrzewski, V. G.</span>; <span class="NLM_string-name">Voth, G. A.</span>; <span class="NLM_string-name">Salvador, P.</span>; <span class="NLM_string-name">Dannenberg, J. J.</span>; <span class="NLM_string-name">Dapprich, S.</span>; <span class="NLM_string-name">Daniels, A. D.</span>; <span class="NLM_string-name">Farkas, O.</span>; <span class="NLM_string-name">Foresman, J. B.</span>; <span class="NLM_string-name">Ortiz, J. V.</span>; <span class="NLM_string-name">Cioslowski, J.</span>; <span class="NLM_string-name">Fox, D. J.</span></span> <i>Gaussian 09</i>, revision D.01, <span class="NLM_publisher-name">Gaussian Inc.</span>: <span class="NLM_publisher-loc">Wallingford, CT</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+J.+Frisch&author=G.+W.+Trucks&author=H.+B.+Schlegel&author=G.+E.+Scuseria&author=M.+A.+Robb&author=J.+R.+Cheeseman&author=G.+Scalmani&author=V.+Barone&author=B.+Mennucci&author=G.+A.+Petersson&author=H.+Nakatsuji&author=M.+Caricato&author=X.+Li&author=H.+P.+Hratchian&author=A.+F.+Izmaylov&author=J.+Bloino&author=G.+Zheng&author=J.+L.+Sonnenberg&author=M.+Hada&author=M.+Ehara&author=K.+Toyota&author=R.+Fukuda&author=J.+Hasegawa&author=M.+Ishida&author=T.+Nakajima&author=Y.+Honda&author=O.+Kitao&author=H.+Nakai&author=T.+Vreven&author=J.+A.+Montgomery&author=J.+E.+Peralta&author=F.+Ogliaro&author=M.+Bearpark&author=J.+J.+Heyd&author=E.+Brothers&author=K.+N.+Kudin&author=V.+N.+Staroverov&author=R.+Kobayashi&author=J.+Normand&author=K.+Raghavachari&author=A.+Rendell&author=J.+C.+Burant&author=S.+S.+Iyengar&author=J.+Tomasi&author=M.+Cossi&author=N.+Rega&author=J.+M.+Millam&author=M.+Klene&author=J.+E.+Knox&author=J.+B.+Cross&author=V.+Bakken&author=C.+Adamo&author=J.+Jaramillo&author=R.+Gomperts&author=R.+E.+Stratmann&author=O.+Yazyev&author=A.+J.+Austin&author=R.+Cammi&author=C.+Pomelli&author=J.+W.+Ochterski&author=R.+L.+Martin&author=K.+Morokuma&author=V.+G.+Zakrzewski&author=G.+A.+Voth&author=P.+Salvador&author=J.+J.+Dannenberg&author=S.+Dapprich&author=A.+D.+Daniels&author=O.+Farkas&author=J.+B.+Foresman&author=J.+V.+Ortiz&author=J.+Cioslowski&author=D.+J.+Fox&title=Gaussian+09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26jtitle%3DGaussian%252009%26pub%3DGaussian%2520Inc%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">CambridgeSoft Corporation</span>.  <i>ChemBio3D
Ultra</i>, version 13.0; <span class="NLM_publisher-name">CambridgeSoft</span>, <span class="NLM_publisher-loc">Cambridge, MA, USA</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=CambridgeSoft+Corporation&title=ChemBio3D%0AUltra"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DChemBio3D%250AUltra%26pub%3DCambridgeSoft%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durán, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamora, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, M.</span></span> <span> </span><span class="NLM_article-title">Suitability of GRIND-Based principal properties for the description of molecular similarity and ligand-based virtual screening</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2138</span>, <span class="refDoi"> DOI: 10.1021/ci900228x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900228x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2jsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2129-2138&author=%C3%81.+Dur%C3%A1nauthor=I.+Zamoraauthor=M.+Pastor&title=Suitability+of+GRIND-Based+principal+properties+for+the+description+of+molecular+similarity+and+ligand-based+virtual+screening&doi=10.1021%2Fci900228x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Suitability of GRIND-Based Principal Properties for the Description of Molecular Similarity and Ligand-Based Virtual Screening</span></div><div class="casAuthors">Duran, Angel; Zamora, Ismael; Pastor, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2129-2138</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The information provided by the alignment-independent GRid Independent Descriptors (GRIND) can be condensed by the application of principal component anal., obtaining a small no. of principal properties (GRIND-PP), which is more suitable for describing mol. similarity.  The objective of the present study is to optimize diverse parameters involved in the obtaining of the GRIND-PP and validate their suitability for applications, requiring a biol. relevant description of the mol. similarity.  With this aim, GRIND-PP computed with a collection of diverse settings were used to carry out ligand-based virtual screening (LBVS) on std. conditions.  The quality of the results obtained was remarkable and comparable with other LBVS methods, and their detailed statistical anal. allowed to identify the method settings more determinant for the quality of the results and their optimum.  Remarkably, some of these optimum settings differ significantly from those used in previously published applications, revealing their unexplored potential.  Their applicability in large compd. database was also explored by comparing the equivalence of the results obtained using either computed or projected principal properties.  In general, the results of the study confirm the suitability of the GRIND-PP for practical applications and provide useful hints about how they should be computed for obtaining optimum results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphtRXLhSV-07Vg90H21EOLACvtfcHk0lhAo1bO2COMqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2jsbfL&md5=72cd0eb456ccecf5ae7a9270abc1f158</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fci900228x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900228x%26sid%3Dliteratum%253Aachs%26aulast%3DDur%25C3%25A1n%26aufirst%3D%25C3%2581.%26aulast%3DZamora%26aufirst%3DI.%26aulast%3DPastor%26aufirst%3DM.%26atitle%3DSuitability%2520of%2520GRIND-Based%2520principal%2520properties%2520for%2520the%2520description%2520of%2520molecular%2520similarity%2520and%2520ligand-based%2520virtual%2520screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D2129%26epage%3D2138%26doi%3D10.1021%2Fci900228x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durán, Á.</span>; <span class="NLM_string-name">Pastor, M.</span></span> <i>Pentacle, An advanced tool for computing and handling grid-independent descriptors</i>. User Manual Version 1.06; <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=%C3%81.+Dur%C3%A1n&author=M.+Pastor&title=Pentacle%2C+An+advanced+tool+for+computing+and+handling+grid-independent+descriptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DDur%25C3%25A1n%26aufirst%3D%25C3%2581.%26jtitle%3DPentacle%252C%2520An%2520advanced%2520tool%2520for%2520computing%2520and%2520handling%2520grid-independent%2520descriptors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, K.</span></span> <span> </span><span class="NLM_article-title">Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection</span>. <i>Chemom. Intell. Lab. Syst.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.chemolab.2011.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.chemolab.2011.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVamsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2011&pages=146-161&author=P.+K.+Ojhaauthor=K.+Roy&title=Comparative+QSARs+for+antimalarial+endochins%3A+Importance+of+descriptor-thinning+and+noise+reduction+prior+to+feature+selection&doi=10.1016%2Fj.chemolab.2011.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection</span></div><div class="casAuthors">Ojha, Probir Kumar; Roy, Kunal</div><div class="citationInfo"><span class="NLM_cas:title">Chemometrics and Intelligent Laboratory Systems</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-161</span>CODEN:
                <span class="NLM_cas:coden">CILSEN</span>;
        ISSN:<span class="NLM_cas:issn">0169-7439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The emergence of multidrug resistance of the currently available antimalarial drugs has led to the need of the discovery and development of new antimalarial compds.  In the present study, we have selected a series of 53 endochin analogs with antimalarial activity against the clin. relevant multidrug resistant malarial strain TM-90-C2B to develop robust QSAR models using different chemometric tools such as stepwise regression, factor anal. followed by multiple linear regression (FA-MLR), factor anal. followed by partial least squares (FA-PLS) anal., genetic function approxn. (GFA) and genetic partial least squares (G/PLS) techniques.  We have tried to emphasize on importance of descriptor-thinning prior to feature selection step.  For this purpose, we have partitioned the total pool of descriptors into three categories followed by running stepwise regression sep. for all three categories of descriptors for selection of variables.  Then we have applied genetic methods of model development on the selected pool of descriptors.  We have validated the models using different validation parameters to check the statistical quality and reliability of the models.  It has been found that models developed from variable selection by stepwise regression followed by GFA and G/PLS are the best two models.  This study reflects the importance of descriptor-thinning and noise redn. prior to feature selection for the development of QSAR models.  According to the best two models, we interpreted that substitutions with rotatable bond contg. groups (e.g., long alkyl chains), limited vol. of the mols., absence of ≡ C-R group, presence of electroneg. (like -Br) fragments, absence of cycles or rings in the mols. are important for the antimalarial activity.  The developed models are believed to comply with the OECD guidelines for QSAR models.  The results also confirmed that the QSAR models developed from the reduced pool of descriptors were better than those obtained from the entire pool of descriptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-k6pitRvJF7Vg90H21EOLACvtfcHk0liuB5ANtPqQVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVamsb7E&md5=348f7175dfd99da4e2eb3a0914223d93</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.chemolab.2011.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemolab.2011.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DOjha%26aufirst%3DP.%2BK.%26aulast%3DRoy%26aufirst%3DK.%26atitle%3DComparative%2520QSARs%2520for%2520antimalarial%2520endochins%253A%2520Importance%2520of%2520descriptor-thinning%2520and%2520noise%2520reduction%2520prior%2520to%2520feature%2520selection%26jtitle%3DChemom.%2520Intell.%2520Lab.%2520Syst.%26date%3D2011%26volume%3D109%26spage%3D146%26epage%3D161%26doi%3D10.1016%2Fj.chemolab.2011.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kilkenny, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuthill, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, D. G.</span></span> <span> </span><span class="NLM_article-title">Improving biocesce research reporting: the ARRIVE guidelines for reporting animal research</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e1000412</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.1000412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1371%2Fjournal.pbio.1000412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=20613859" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=e1000412&author=C.+Kilkennyauthor=W.+J.+Browneauthor=I.+C.+Cuthillauthor=M.+Emersonauthor=D.+G.+Altman&title=Improving+biocesce+research+reporting%3A+the+ARRIVE+guidelines+for+reporting+animal+research&doi=10.1371%2Fjournal.pbio.1000412"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1000412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1000412%26sid%3Dliteratum%253Aachs%26aulast%3DKilkenny%26aufirst%3DC.%26aulast%3DBrowne%26aufirst%3DW.%2BJ.%26aulast%3DCuthill%26aufirst%3DI.%2BC.%26aulast%3DEmerson%26aufirst%3DM.%26aulast%3DAltman%26aufirst%3DD.%2BG.%26atitle%3DImproving%2520biocesce%2520research%2520reporting%253A%2520the%2520ARRIVE%2520guidelines%2520for%2520reporting%2520animal%2520research%26jtitle%3DPLoS%2520Biol.%26date%3D2010%26volume%3D8%26spage%3De1000412%26doi%3D10.1371%2Fjournal.pbio.1000412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oakley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillozet-Bongaarts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disterhoft, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s desease mutations: potential factors in amyloid plaque formation</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">10129</span>– <span class="NLM_lpage">10140</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1202-06.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1523%2FJNEUROSCI.1202-06.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=17021169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVymurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=10129-10140&author=H.+Oakleyauthor=S.+L.+Coleauthor=S.+Loganauthor=E.+Mausauthor=P.+Shaoauthor=J.+Craftauthor=A.+Guillozet-Bongaartsauthor=M.+Ohnoauthor=J.+Disterhoftauthor=L.+Van+Eldikauthor=R.+Berryauthor=R.+Vassar&title=Intraneuronal+beta-amyloid+aggregates%2C+neurodegeneration%2C+and+neuron+loss+in+transgenic+mice+with+five+familial+Alzheimer%E2%80%99s+desease+mutations%3A+potential+factors+in+amyloid+plaque+formation&doi=10.1523%2FJNEUROSCI.1202-06.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation</span></div><div class="casAuthors">Oakley, Holly; Cole, Sarah L.; Logan, Sreemathi; Maus, Erika; Shao, Pei; Craft, Jeffery; Guillozet-Bongaarts, Angela; Ohno, Masuo; Disterhoft, John; Van Eldik, Linda; Berry, Robert; Vassar, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">10129-10140</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Mutations in the genes for amyloid precursor protein (APP) and presenilins (PS1, PS2) increase prodn. of β-amyloid 42 (Aβ42) and cause familial Alzheimer's disease (FAD).  Transgenic mice that express FAD mutant APP and PS1 overproduce Aβ42 and exhibit amyloid plaque pathol. similar to that found in AD, but most transgenic models develop plaques slowly.  To accelerate plaque development and investigate the effects of very high cerebral Aβ42 levels, we generated APP/PS1 double transgenic mice that coexpress five FAD mutations (5XFAD mice) and additively increase Aβ42 prodn.  5XFAD mice generate Aβ42 almost exclusively and rapidly accumulate massive cerebral Aβ42 levels.  Amyloid deposition (and gliosis) begins at 2 mo and reaches a very large burden, esp. in subiculum and deep cortical layers.  Intraneuronal Aβ42 accumulates in 5XFAD brain starting at 1.5 mo of age (before plaques form), is aggregated (as detd. by thioflavin S staining), and occurs within neuron soma and neurites.  Some amyloid deposits originate within morphol. abnormal neuron soma that contain intraneuronal Aβ.  Synaptic markers synaptophysin, syntaxin, and postsynaptic d.-95 decrease with age in 5XFAD brain, and large pyramidal neurons in cortical layer 5 and subiculum are lost.  In addn., levels of the activation subunit of cyclin-dependent kinase 5, p25, are elevated significantly at 9 mo in 5XFAD brain, although an upward trend is obsd. by 3 mo of age, before significant neurodegeneration or neuron loss.  Finally, 5XFAD mice have impaired memory in the Y-maze.  Thus, 5XFAD mice rapidly recapitulate major features of AD amyloid pathol. and may be useful models of intraneuronal Aβ42-induced neurodegeneration and amyloid plaque formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIhU1MNDa0RrVg90H21EOLACvtfcHk0liuB5ANtPqQVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVymurbK&md5=a47a3bedd25b37812f9172ebca81fb1d</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1202-06.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1202-06.2006%26sid%3Dliteratum%253Aachs%26aulast%3DOakley%26aufirst%3DH.%26aulast%3DCole%26aufirst%3DS.%2BL.%26aulast%3DLogan%26aufirst%3DS.%26aulast%3DMaus%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DP.%26aulast%3DCraft%26aufirst%3DJ.%26aulast%3DGuillozet-Bongaarts%26aufirst%3DA.%26aulast%3DOhno%26aufirst%3DM.%26aulast%3DDisterhoft%26aufirst%3DJ.%26aulast%3DVan%2BEldik%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DR.%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DIntraneuronal%2520beta-amyloid%2520aggregates%252C%2520neurodegeneration%252C%2520and%2520neuron%2520loss%2520in%2520transgenic%2520mice%2520with%2520five%2520familial%2520Alzheimer%25E2%2580%2599s%2520desease%2520mutations%253A%2520potential%2520factors%2520in%2520amyloid%2520plaque%2520formation%26jtitle%3DJ.%2520Neurosci.%26date%3D2006%26volume%3D26%26spage%3D10129%26epage%3D10140%26doi%3D10.1523%2FJNEUROSCI.1202-06.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergio  Rodriguez-Arévalo</span>, <span class="hlFld-ContribAuthor ">Andrea  Bagán</span>, <span class="hlFld-ContribAuthor ">Christian  Griñán-Ferré</span>, <span class="hlFld-ContribAuthor ">Foteini  Vasilopoulou</span>, <span class="hlFld-ContribAuthor ">Mercè  Pallàs</span>, <span class="hlFld-ContribAuthor ">Iria  Brocos-Mosquera</span>, <span class="hlFld-ContribAuthor ">Luis F.  Callado</span>, <span class="hlFld-ContribAuthor ">M. Isabel  Loza</span>, <span class="hlFld-ContribAuthor ">Antón L.  Martínez</span>, <span class="hlFld-ContribAuthor ">José  Brea</span>, <span class="hlFld-ContribAuthor ">Belén  Pérez</span>, <span class="hlFld-ContribAuthor ">Elies  Molins</span>, <span class="hlFld-ContribAuthor ">Steven  De Jonghe</span>, <span class="hlFld-ContribAuthor ">Dirk  Daelemans</span>, <span class="hlFld-ContribAuthor ">Milica  Radan</span>, <span class="hlFld-ContribAuthor ">Teodora  Djikic</span>, <span class="hlFld-ContribAuthor ">Katarina  Nikolic</span>, <span class="hlFld-ContribAuthor ">Elena  Hernández-Hernández</span>, <span class="hlFld-ContribAuthor ">M. Julia  García-Fuster</span>, <span class="hlFld-ContribAuthor ">Jesús A.  García-Sevilla</span>, <span class="hlFld-ContribAuthor ">Carmen  Escolano</span>. </span><span class="cited-content_cbyCitation_article-title">Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113540. <a href="https://doi.org/10.1016/j.ejmech.2021.113540" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113540</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113540%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBenzofuranyl-2-imidazoles%252Bas%252Bimidazoline%252BI2%252Breceptor%252Bligands%252Bfor%252BAlzheimer%252527s%252Bdisease%26aulast%3DRodriguez-Ar%25C3%25A9valo%26aufirst%3DSergio%26date%3D2021%26volume%3D222%26spage%3D113540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Foteini  Vasilopoulou</span>, <span class="hlFld-ContribAuthor ">Sergio  Rodríguez‐Arévalo</span>, <span class="hlFld-ContribAuthor ">Andrea  Bagán</span>, <span class="hlFld-ContribAuthor ">Carmen  Escolano</span>, <span class="hlFld-ContribAuthor ">Christian  Griñán‐Ferré</span>, <span class="hlFld-ContribAuthor ">Mercè  Pallàs</span>. </span><span class="cited-content_cbyCitation_article-title">Disease‐modifying treatment with I
              2
              imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: a comparative study with donepezil. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2021,</strong> <em>178 </em>
                                    (15)
                                     , 3017-3033. <a href="https://doi.org/10.1111/bph.15478" title="DOI URL">https://doi.org/10.1111/bph.15478</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.15478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.15478%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DDisease%2525E2%252580%252590modifying%252Btreatment%252Bwith%252BI%252B2%252Bimidazoline%252Breceptor%252Bligand%252BLSL60101%252Bin%252Ban%252BAlzheimer%252527s%252Bdisease%252Bmouse%252Bmodel%25253A%252Ba%252Bcomparative%252Bstudy%252Bwith%252Bdonepezil%26aulast%3DVasilopoulou%26aufirst%3DFoteini%26date%3D2021%26date%3D2021%26volume%3D178%26issue%3D15%26spage%3D3017%26epage%3D3033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Hernández-Hernández</span>, <span class="hlFld-ContribAuthor ">M. Julia  García-Fuster</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluating the effects of 2-BFI and tracizoline, two potent I2-imidazoline receptor agonists, on cognitive performance and affect in middle-aged rats. </span><span class="cited-content_cbyCitation_journal-name">Naunyn-Schmiedeberg's Archives of Pharmacology</span><span> <strong>2021,</strong> <em>394 </em>
                                    (5)
                                     , 989-996. <a href="https://doi.org/10.1007/s00210-020-02042-6" title="DOI URL">https://doi.org/10.1007/s00210-020-02042-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00210-020-02042-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00210-020-02042-6%26sid%3Dliteratum%253Aachs%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Archives%2520of%2520Pharmacology%26atitle%3DEvaluating%252Bthe%252Beffects%252Bof%252B2-BFI%252Band%252Btracizoline%25252C%252Btwo%252Bpotent%252BI2-imidazoline%252Breceptor%252Bagonists%25252C%252Bon%252Bcognitive%252Bperformance%252Band%252Baffect%252Bin%252Bmiddle-aged%252Brats%26aulast%3DHern%25C3%25A1ndez-Hern%25C3%25A1ndez%26aufirst%3DElena%26date%3D2021%26date%3D2021%26volume%3D394%26issue%3D5%26spage%3D989%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Foteini  Vasilopoulou</span>, <span class="hlFld-ContribAuthor ">Christian  Griñán-Ferré</span>, <span class="hlFld-ContribAuthor ">Sergio  Rodríguez-Arévalo</span>, <span class="hlFld-ContribAuthor ">Andrea  Bagán</span>, <span class="hlFld-ContribAuthor ">Sònia  Abás</span>, <span class="hlFld-ContribAuthor ">Carmen  Escolano</span>, <span class="hlFld-ContribAuthor ">Mercè  Pallàs</span>. </span><span class="cited-content_cbyCitation_article-title">I2 imidazoline receptor modulation protects aged SAMP8 mice against cognitive decline by suppressing the calcineurin pathway. </span><span class="cited-content_cbyCitation_journal-name">GeroScience</span><span> <strong>2021,</strong> <em>43 </em>
                                    (2)
                                     , 965-983. <a href="https://doi.org/10.1007/s11357-020-00281-2" title="DOI URL">https://doi.org/10.1007/s11357-020-00281-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11357-020-00281-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11357-020-00281-2%26sid%3Dliteratum%253Aachs%26jtitle%3DGeroScience%26atitle%3DI2%252Bimidazoline%252Breceptor%252Bmodulation%252Bprotects%252Baged%252BSAMP8%252Bmice%252Bagainst%252Bcognitive%252Bdecline%252Bby%252Bsuppressing%252Bthe%252Bcalcineurin%252Bpathway%26aulast%3DVasilopoulou%26aufirst%3DFoteini%26date%3D2021%26date%3D2020%26volume%3D43%26issue%3D2%26spage%3D965%26epage%3D983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Hernández-Hernández</span>, <span class="hlFld-ContribAuthor ">Jesús A.  García-Sevilla</span>, <span class="hlFld-ContribAuthor ">M. Julia  García-Fuster</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the antidepressant-like potential of the selective I2-imidazoline receptor ligand LSL 60101 in adult male rats. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reports</span><span> <strong>2021,</strong> <em>73 </em>
                                    (1)
                                     , 288-295. <a href="https://doi.org/10.1007/s43440-020-00148-5" title="DOI URL">https://doi.org/10.1007/s43440-020-00148-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s43440-020-00148-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs43440-020-00148-5%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reports%26atitle%3DExploring%252Bthe%252Bantidepressant-like%252Bpotential%252Bof%252Bthe%252Bselective%252BI2-imidazoline%252Breceptor%252Bligand%252BLSL%252B60101%252Bin%252Badult%252Bmale%252Brats%26aulast%3DHern%25C3%25A1ndez-Hern%25C3%25A1ndez%26aufirst%3DElena%26date%3D2021%26date%3D2020%26volume%3D73%26issue%3D1%26spage%3D288%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nandkishor  Kotagale</span>, <span class="hlFld-ContribAuthor ">Madhura  Dixit</span>, <span class="hlFld-ContribAuthor ">Harshal  Garmelwar</span>, <span class="hlFld-ContribAuthor ">Shraddha  Bhondekar</span>, <span class="hlFld-ContribAuthor ">Milind  Umekar</span>, <span class="hlFld-ContribAuthor ">Brijesh  Taksande</span>. </span><span class="cited-content_cbyCitation_article-title">Agmatine reverses memory deficits induced by Aβ1–42 peptide in mice: A key role of imidazoline receptors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology Biochemistry and Behavior</span><span> <strong>2020,</strong> <em>196 </em>, 172976. <a href="https://doi.org/10.1016/j.pbb.2020.172976" title="DOI URL">https://doi.org/10.1016/j.pbb.2020.172976</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pbb.2020.172976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pbb.2020.172976%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520Biochemistry%2520and%2520Behavior%26atitle%3DAgmatine%252Breverses%252Bmemory%252Bdeficits%252Binduced%252Bby%252BA%2525CE%2525B21%2525E2%252580%25259342%252Bpeptide%252Bin%252Bmice%25253A%252BA%252Bkey%252Brole%252Bof%252Bimidazoline%252Breceptors%26aulast%3DKotagale%26aufirst%3DNandkishor%26date%3D2020%26volume%3D196%26spage%3D172976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Foteini  Vasilopoulou</span>, <span class="hlFld-ContribAuthor ">Andrea  Bagan</span>, <span class="hlFld-ContribAuthor ">Sergio  Rodriguez-Arevalo</span>, <span class="hlFld-ContribAuthor ">Carmen  Escolano</span>, <span class="hlFld-ContribAuthor ">Christian  Griñán-Ferré</span>, <span class="hlFld-ContribAuthor ">Mercè  Pallàs</span>. </span><span class="cited-content_cbyCitation_article-title">Amelioration of BPSD-Like Phenotype and Cognitive Decline in SAMP8 Mice Model Accompanied by Molecular Changes after Treatment with I2-Imidazoline Receptor Ligand MCR5. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2020,</strong> <em>12 </em>
                                    (5)
                                     , 475. <a href="https://doi.org/10.3390/pharmaceutics12050475" title="DOI URL">https://doi.org/10.3390/pharmaceutics12050475</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics12050475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics12050475%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DAmelioration%252Bof%252BBPSD-Like%252BPhenotype%252Band%252BCognitive%252BDecline%252Bin%252BSAMP8%252BMice%252BModel%252BAccompanied%252Bby%252BMolecular%252BChanges%252Bafter%252BTreatment%252Bwith%252BI2-Imidazoline%252BReceptor%252BLigand%252BMCR5%26aulast%3DVasilopoulou%26aufirst%3DFoteini%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D5%26spage%3D475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative I<sub>2</sub>-IR ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. (a) General Structure of Bicyclic α-Iminophosphonates <b>Ia</b> (Previously Reported) and <b>Ib</b> (Reported Herein),<sup>a</sup> (b) Chemical Structures of <b>8a</b> and <b>8c</b>, and (c) Chemical Structure of MCR5 (<b>7</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: <i>N</i>-substituted maleimide derivative (1.5 mmol), PhosMic (1 mmol), AgOAc (0.06 mmol), acetonitrile, room temperature, overnight.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. α-Substituted PhosMic derivatives used in this work.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Procedure for the Synthesis of Bicyclic α-Iminophosphonates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Compounds prepared in previous work (R = H)<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and compounds prepared in this work (R = Ph, 4FPh, 4-MeOPh, PhCH<sub>2</sub>, 4FPhCH<sub>2</sub>). Reagents and conditions: (a) <i>N</i>-substituted maleimide derivative (1.5 mmol), α-substituted PhosMic (<b>10a</b>, <b>10b</b>, <b>10c</b>, <b>10d</b>, <b>10e</b>, 1 mmol), AgOAc (0.06 mmol), acetonitrile, room temperature, overnight.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0013.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Second Round of Compounds Synthesized, Featuring Modified <i>N</i>-Maleimide Substituents Inspired by Compounds <b>9a</b> and <b>9b</b>, R′ = Alkyl, and <b>9c</b> and <b>9d</b>, R′ = Aryl<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>-alkyl- or <i>N</i>-aryl-substituted maleimide derivative (1.5 mmol), α-PhenylPhosMic (<b>10a</b>, 1 mmol), AgOAc (0.06 mmol), acetonitrile, room temperature, overnight.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structures of <b>9b</b>, <b>9c</b>, <b>9d</b>, <b>9v</b>, and <b>9ab</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representation of the transition states for the <i>cis</i> and <i>trans</i> [3 + 2] cycloaddition between <i>N</i>-methylmaleimide and α-phenylPhosMic (ethyl groups substituted by methyl) located from B3LYP calculations (C···C distances in Å; C–N–C angle in deg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representation of positive (in red) interactions of <b>9c</b> (A) and <b>13d</b> (B) in I<sub>2</sub>-IR 3D-QSAR model. The steric hot spots (TIP) are presented in green and hydrophobic regions (DRY) in yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representation of negative (in blue) interactions of <b>9m</b> (A) and <b>9ac</b> (B) in I<sub>2</sub>-IR 3D-QSAR model. The steric hot spots (TIP) are presented in green, hydrophobic regions (DRY) in yellow, and H-bond acceptor regions (N1) in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Hypothermic effects of <b>9d</b> (B06) in rodents. (A) Acute effect of <b>9d</b> (20 mg/kg, ip) in mice. Columns are means ± SEM of the difference (Δ, 1 h minus basal value) in body temperature (°C) for each treatment group. ***<i>p</i> < 0.001 vs control group (Student’s <i>t</i>-test). (B) Acute effect of <b>9d</b> (20 or 35 mg/kg, ip) in rats. Columns are means ± SEM of the difference (Δ, 1, 2, or 3 h minus basal value) in body temperature (°C) for each treatment group. #<i>p</i> < 0.05 for dose of 20 mg/kg and **<i>p</i> < 0.01 and ***<i>p</i> < 0.001 for dose of 35 mg/kg vs control group (repeated measures ANOVA followed by Sidak’s comparison test). (C) Repeated (5 days) effect of <b>9d</b> (20 mg/kg, ip) in mice. Circles are means ± SEM of the daily difference (Δ, 1 h minus basal value) in body temperature (°C) for each treatment group. *<i>p</i> < 0.05 vs control group (repeated measures ANOVA followed by Sidak’s comparison test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of acute (20 mg/kg, ip) and repeated (20 mg/kg, ip, 5 days) treatments with <b>9d</b> (B06) on the contents of FADD protein in the hippocampus of mice. Columns are means ± SEM of FADD in <b>9d</b>- and vehicle-treated groups. *<i>p</i> < 0.05 vs control group (Student’s <i>t</i>-test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. DI of NORT in 6-month-old (WT C, <i>n</i> = 12), 5xFAD (C, <i>n</i> = 14) control mice and 5xFAD mice after treatment with <b>9d</b> (B06) at 5 mg/kg for 4 weeks (<i>n</i> = 25). Summary from (A) Short-Term Memory and (B) Long-Term Memory. Values represented are mean ± standard error of the mean (SEM). One-way ANOVA followed by (Tukey post hoc test); <i>P</i>-value: *<i>p</i> < 0.05 vs WT-Control, <sup>$</sup><i>p</i> < 0.05; <sup>$$</sup><i>p</i> < 0.01 vs 5xFAD-Control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/medium/jm9b02080_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Gene expression of inflammatory markers, <i>Cxcl10</i> and <i>Tnf-α</i>, and OS markers, <i>iNOS</i> and <i>Hmox1</i> (<i>n</i> = 4 for each group). (B) H<sub>2</sub>O<sub>2</sub> concentration (<i>n</i> = 10 for each group) and (C) representative Western blot and bar chart sAPPα and sAPPβ (<i>n</i> = 4–6 for each group) in the hippocampus of 6-month-old female WT, 5xFAD Control mice, and 5xFAD mice after treatment with <b>9d</b> (B06) at 5 mg/kg for 4 weeks. Bars represent mean ± standard error of the mean (SEM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02080/20200402/images/large/jm9b02080_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02080&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13076" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13076" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 82 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.</span></span> <span> </span><span class="NLM_article-title">Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>230</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=6146707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL2cXkvVeqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=1984&pages=232-236&author=P.+Bousquetauthor=J.+Feldmanauthor=J.+Schwartz&title=Central+cardiovascular+effects+of+alpha+adrenergic+drugs%3A+differences+between+catecholamines+and+imidazolines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Central cardiovascular effects of alpha adrenergic drugs:  differences between catecholamines and imidazolines</span></div><div class="casAuthors">Bousquet, P.; Feldman, J.; Schwartz, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">232-6</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">To check whether the central hypotensive effect of α-adrenergic agonists is linked with the stimulation of α2-receptors, such drugs were administered directly to the nucleus reticularis lateralis, an important site for the hypotensive action of clonidine  [4205-90-7].  α-Methylnorepinephrine  [6539-57-7], a selective α2-agonist had no hypotensive effect in this region, whereas potent α1-agonists such as cirazoline  [59939-16-1] and ST 587  [15327-38-5] produced dose-dependent hypotensive effects.  Thus, α2 selective catecholamines are not active in the nucleus reticularis lateralis region, whereas imidazolines induce a hypotensive effect, whatever their ability for one subtype of α-adrenoreceptors.  There may be some form of structure-activity relation which would indicate the existence, in this particular region of the medulla oblongata, of sites preferring the imidazoline structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsdRB-jlBIiLVg90H21EOLACvtfcHk0ljLEI6wWQ-UGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkvVeqs7Y%253D&md5=1507c694fd361235a39a83c561525114</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBousquet%26aufirst%3DP.%26aulast%3DFeldman%26aufirst%3DJ.%26aulast%3DSchwartz%26aufirst%3DJ.%26atitle%3DCentral%2520cardiovascular%2520effects%2520of%2520alpha%2520adrenergic%2520drugs%253A%2520differences%2520between%2520catecholamines%2520and%2520imidazolines%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1984%26volume%3D230%26spage%3D232%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-X.</span></span> <span> </span><span class="NLM_article-title">Imidazoline receptor system: the past, the present, and the future</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1124/pr.118.016311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1124%2Fpr.118.016311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=31819014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BB3Mfotlamuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=50-79&author=P.+Bousquetauthor=A.+Hudsonauthor=J.+A.+Garc%C3%ADa-Sevillaauthor=J.-X.+Li&title=Imidazoline+receptor+system%3A+the+past%2C+the+present%2C+and+the+future&doi=10.1124%2Fpr.118.016311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline Receptor System: The Past, the Present, and the Future</span></div><div class="casAuthors">Bousquet Pascal; Hudson Alan; Garcia-Sevilla Jesus A; Li Jun-Xu</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Imidazoline receptors historically referred to a family of nonadrenergic binding sites that recognize compounds with an imidazoline moiety, although this has proven to be an oversimplification.  For example, none of the proposed endogenous ligands for imidazoline receptors contain an imidazoline moiety but they are diverse in their chemical structure.  Three receptor subtypes (I1, I2, and I3) have been proposed and the understanding of each has seen differing progress over the decades.  I1 receptors partially mediate the central hypotensive effects of clonidine-like drugs.  Moxonidine and rilmenidine have better therapeutic profiles (fewer side effects) than clonidine as antihypertensive drugs, thought to be due to their higher I1/α2-adrenoceptor selectivity.  Newer I1 receptor agonists such as LNP599 [3-chloro-2-methyl-phenyl)-(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)-amine hydrochloride] have little to no activity on α2-adrenoceptors and demonstrate promising therapeutic potential for hypertension and metabolic syndrome.  I2 receptors associate with several distinct proteins, but the identities of these proteins remain elusive.  I2 receptor agonists have demonstrated various centrally mediated effects including antinociception and neuroprotection.  A new I2 receptor agonist, CR4056 [2-phenyl-6-(1H-imidazol-1yl) quinazoline], demonstrated clear analgesic activity in a recently completed phase II clinical trial and holds great promise as a novel I2 receptor-based first-in-class nonopioid analgesic.  The understanding of I3 receptors is relatively limited.  Existing data suggest that I3 receptors may represent a binding site at the Kir6.2-subtype ATP-sensitive potassium channels in pancreatic β-cells and may be involved in insulin secretion.  Despite the elusive nature of their molecular identities, recent progress on drug discovery targeting imidazoline receptors (I1 and I2) demonstrates the exciting potential of these compounds to elicit neuroprotection and to treat various disorders such as hypertension, metabolic syndrome, and chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTRY03PZp08XO4gDb7JggCfW6udTcc2eYy2pjzRe3hw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mfotlamuw%253D%253D&md5=2d041d87f8ad2616b25ed24296d65772</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fpr.118.016311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.118.016311%26sid%3Dliteratum%253Aachs%26aulast%3DBousquet%26aufirst%3DP.%26aulast%3DHudson%26aufirst%3DA.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DJ.-X.%26atitle%3DImidazoline%2520receptor%2520system%253A%2520the%2520past%252C%2520the%2520present%252C%2520and%2520the%2520future%26jtitle%3DPharmacol.%2520Rev.%26date%3D2020%26volume%3D72%26spage%3D50%26epage%3D79%26doi%3D10.1124%2Fpr.118.016311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. T.</span></span> <span> </span><span class="NLM_article-title">Significance of the imidazoline receptors in toxicology</span>. <i>Clin. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.3109/15563650.2014.898770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.3109%2F15563650.2014.898770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1Wisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2014&pages=454-469&author=J.+A.+Lowryauthor=J.+T.+Brown&title=Significance+of+the+imidazoline+receptors+in+toxicology&doi=10.3109%2F15563650.2014.898770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Significance of the imidazoline receptors in toxicology</span></div><div class="casAuthors">Lowry, J. A.; Brown, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">454-469</span>CODEN:
                <span class="NLM_cas:coden">CTPPA5</span>;
        ISSN:<span class="NLM_cas:issn">1556-3650</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction. The alpha-2 adrenergic (AA-2) receptor agonists and imidazolines are common exposures in the American Assocn. of Poison Control Centers (AAPCC) National Poison Data System (NPDS).  Although the interaction between the AA-2 receptor and imidazoline receptors has been extensively studied, it largely remains unknown to health-care professionals.  This review describes these interactions and mechanisms by which agonists affect physiol. responses binding to these receptors.  Presently, three distinct classes of imidazoline receptors, also known as imidazoline binding sites or imidazoline/guanidinium receptive sites, have been characterized.  Four endogenous compds. have been found to bind and include clonidine-displacing substance, agmatine, harmane, and imidazole acetic acid.  Knowledge of the imidazoline receptors may lead to new therapeutic agents and inform management of patients with imidazoline overdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpntTw_iGYdALVg90H21EOLACvtfcHk0lih5-t45eRgig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1Wisro%253D&md5=bea368009e52cd94cfaa9ee98a95a10c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3109%2F15563650.2014.898770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15563650.2014.898770%26sid%3Dliteratum%253Aachs%26aulast%3DLowry%26aufirst%3DJ.%2BA.%26aulast%3DBrown%26aufirst%3DJ.%2BT.%26atitle%3DSignificance%2520of%2520the%2520imidazoline%2520receptors%2520in%2520toxicology%26jtitle%3DClin.%2520Toxicol.%26date%3D2014%26volume%3D52%26spage%3D454%26epage%3D469%26doi%3D10.3109%2F15563650.2014.898770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regunathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, D. J.</span></span> <span> </span><span class="NLM_article-title">Imidazoline receptors and their endogenous ligands</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1146/annurev.pa.36.040196.002455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1146%2Fannurev.pa.36.040196.002455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8725400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK28Xis1eruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1996&pages=511-544&author=S.+Regunathanauthor=D.+J.+Reis&title=Imidazoline+receptors+and+their+endogenous+ligands&doi=10.1146%2Fannurev.pa.36.040196.002455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline receptors and their endogenous ligands</span></div><div class="casAuthors">Regunathan, S.; Reis, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">511-44</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review, with 168 refs.  Imidazoline(I) receptors constitute a family of nonadrenergic high-affinity binding sites for clonidine, idazoxan, and allied drugs.  One major subclass, the I1 receptors, whose subcellular distribution and signal transduction mechanisms are uncertain, partly mediates the central hypotensive actions of clonidine-like drugs.  The I2 receptors, another subclass, are mitochondrial, not G protein coupled, and have diversified functions.  Several endogenous ligands for I receptors, collectively termed clinidine-displacing substances (CDSs), have been detected in tissues and serum, but the structure of only one, agmatine (decarboxylated arginine), is known.  Agmatine, widely distributed and bioactive, binds, like clonidine, to α2-adrenergic and I receptors of all subclasses.  The presence of agmatine and its biosynthetic enzyme in synaptosomes and specific neuronal pathways as well as serum suggests that it may be a novel neurotransmitter/hormone.  Another CDS that binds to I receptors and to antibodies to imidazoline drugs has been detected, but its structure is unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgCImYjeLA_7Vg90H21EOLACvtfcHk0lih5-t45eRgig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xis1eruro%253D&md5=b555a3b491e375c3f67c41efa46b90b9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pa.36.040196.002455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pa.36.040196.002455%26sid%3Dliteratum%253Aachs%26aulast%3DRegunathan%26aufirst%3DS.%26aulast%3DReis%26aufirst%3DD.%2BJ.%26atitle%3DImidazoline%2520receptors%2520and%2520their%2520endogenous%2520ligands%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1996%26volume%3D36%26spage%3D511%26epage%3D544%26doi%3D10.1146%2Fannurev.pa.36.040196.002455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fenton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyseng-Williamson, K. A.</span></span> <span> </span><span class="NLM_article-title">Moxonidine: a review of its use in essential hypertension</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.2165/00003495-200666040-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.2165%2F00003495-200666040-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=16597164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVajsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=477-496&author=C.+Fentonauthor=G.+M.+Keatingauthor=K.+A.+Lyseng-Williamson&title=Moxonidine%3A+a+review+of+its+use+in+essential+hypertension&doi=10.2165%2F00003495-200666040-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Moxonidine: a review of its use in essential hypertension</span></div><div class="casAuthors">Fenton, Caroline; Keating, Gillian M.; Lyseng-Williamson, Katherine A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-496</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Moxonidine (Physiotens, Moxon, Cynt) is an orally administered imidazoline compd. with selective agonist activity at imidazoline I1 receptors and only minor activity at α2-adrenoceptors.  Moxonidine acts centrally to reduce peripheral sympathetic activity, thus decreasing peripheral vascular resistance.  In patients with mild to moderate hypertension, moxonidine reduces blood pressure (BP) as effectively as most first-line antihypertensives when used as monotherapy and is also an effective adjunctive therapy in combination with other antihypertensive agents.  It improves the metabolic profile in patients with hypertension and diabetes mellitus or impaired glucose tolerance, is well tolerated, has a low potential for drug interactions and may be administered once daily in most patients.  Thus, moxonidine is a good option in the treatment of patients with mild to moderate hypertension, particularly as adjunctive therapy in patients with the metabolic syndrome.  Pharmacol. Properties Moxonidine is a centrally acting selective agonist at imidazoline I1 receptors, for which it has an affinity >30-fold that for α2-adrenoceptors.  Moxonidine inhibits peripheral sympathetic activity, which decreases peripheral vascular resistance and results in significant decreases in systolic and diastolic BP (SBP and DBP).  Moxonidine has minimal effect on cardiac hemodynamics and reduces left ventricular mass.  Markers of endothelial dysfunction and end-organ damage, including microalbuminuria, improved in hypertensive patients who achieved BP control with moxonidine.  Moxonidine also improved the metabolic profile of patients with hypertension and type 2 diabetes or impaired glucose tolerance.  Oral moxonidine is rapidly absorbed, although the max. antihypertensive effect occurs 3-4 h after administration.  Oral bioavailability is 88% and is unaffected by food.  No first-pass metab. occurs and moxonidine is mostly excreted unchanged in the urine.  Therapeutic Efficacy In well designed, 8-wk trials, monotherapy with moxonidine 0.2-0.6 mg/day reduced sitting DBP to a significantly greater extent than placebo (mean change from baseline -10.7 to -13.2 vs -2.3 to -9mm Hg) in patients with mild to moderate essential hypertension.  Sitting SBP also improved from baseline to a significantly greater extent with moxonidine than with placebo (mean -19.5 to -24.9 vs -1.2 to -13mm Hg).  Redns. in sitting SBP and DBP with moxonidine 0.2-0.8 mg/day at 8 wk were similar to those with enalapril 5-20mg once daily, atenolol 50-100 mg/day (except in postmenopausal women where atenolol reduced BP to a greater extent than moxonidine), hydrochlorothiazide 25mg once daily and rilmenidine 1-2 mg/day.  At 26 wk, redns. in sitting SBP and DBP with moxonidine 0.2-0.4 mg/day were similar to those with nifedipine sustained release 20-40 mg/day.  Once-daily adjunctive moxonidine 0.4mg was also effective in patients with mild to moderate hypertension in well designed trials.  In patients who did not respond to moxonidine monotherapy, mean improvements in sitting DBP at 4 wk were -7.3mm Hg with moxonidine 0.4mg once daily plus amlodipine 5mg once daily, -4.8mm Hg with moxonidine 0.4mg once daily plus enalapril 10mg once daily and -3.2mm Hg with moxonidine 0.4mg once daily plus hydrochlorothiazide 12.5mg once daily.  In another trial, changes in sitting SBP and DBP after 8 wk' treatment were significantly greater with once-daily moxonidine 0.4mg plus hydrochlorothiazide 25mg than with the resp. monotherapies (-27 vs -20 and -22mm Hg and -16 vs -12 and -13mm Hg).  Moxonidine was generally well tolerated in clin. trials in patients with mild to moderate hypertension.  In placebo-controlled monotherapy trials, 36-43% of moxonidine recipients experienced treatment-emergent adverse events vs. 22-29% of placebo recipients and =32% and 35% of enalapril and hydrochlorothiazide recipients, resp.  Dry mouth was the most common adverse event with moxonidine monotherapy, affecting 11-20% of patient; other all-cause adverse events included diarrhea, headache, bronchitis, nausea, dizziness and back pain.  Other than dry mouth, asthenia and fatigue, adverse events in moxonidine monotherapy recipients were not generally related to α2-adrenoceptor inhibition.  No new adverse events were reported in combination therapy trials.  Moxonidine was also well tolerated in a pool anal. is postmarketing surveillance studies in 91 170 patients, about two-thirds of whom received moxonidine as monotherapy.  Adverse events affected 9.4% of patients, causing 1.8% to discontinue treatment, and were generally not related to dosage, treatment duration, sex or age; dry mouth affected 4.2% of patients aged >65 years vs. 2.7% of those aged <40 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9CoyjIGYbU7Vg90H21EOLACvtfcHk0lhP3mU9XD9rTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVajsLg%253D&md5=d5399532ca6221cb157cf4ff15e63f75</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2165%2F00003495-200666040-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200666040-00006%26sid%3Dliteratum%253Aachs%26aulast%3DFenton%26aufirst%3DC.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26aulast%3DLyseng-Williamson%26aufirst%3DK.%2BA.%26atitle%3DMoxonidine%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520essential%2520hypertension%26jtitle%3DDrugs%26date%3D2006%26volume%3D66%26spage%3D477%26epage%3D496%26doi%3D10.2165%2F00003495-200666040-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. L.</span></span> <span> </span><span class="NLM_article-title">Rilmenidine: a clinical overview</span>. <i>Am. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">106S</span>– <span class="NLM_lpage">111S</span>, <span class="refDoi"> DOI: 10.1016/S0895-7061(00)00226-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0895-7061%2800%2900226-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10921529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlOgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=106S-111S&author=J.+L.+Reid&title=Rilmenidine%3A+a+clinical+overview&doi=10.1016%2FS0895-7061%2800%2900226-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Rilmenidine: A clinical overview</span></div><div class="casAuthors">Reid, J. L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hypertension</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6, Pt. 2</span>),
    <span class="NLM_cas:pages">106S-111S</span>CODEN:
                <span class="NLM_cas:coden">AJHYE6</span>;
        ISSN:<span class="NLM_cas:issn">0895-7061</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 26 refs.  Rilmenidine is an antihypertensive agent with selectivity for I1 imidazoline receptors that acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+/H+ antiport.  Rilmenidine provides antihypertensive efficacy comparable with that of diuretics, β-blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors.  Experience from trials and clin. practice highlights rilmenidine's clin. and metabolic acceptability in hypertensive populations, including those at special risk because of old age, renal impairment, diabetes mellitus, or dyslipidemia.  In the at-risk hypertensive, rilmenidine reduces left ventricular hypertrophy to a similar degree to other ref. agents.  New studies show a significant improvement in glucose metab. in metabolic syndrome patients treated with rilmenidine, and a significant redn. in microalbuminuria during rilmenidine treatment of hypertensive type 2 diabetics.  Thus the efficacy/tolerance ratio of rilmenidine supports its role as a first-line antihypertensive option for all groups of hypertensive patient, with specific advantages in some at-risk populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF9Ve8mDpJv7Vg90H21EOLACvtfcHk0lhP3mU9XD9rTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlOgu74%253D&md5=7c8fd08a145e1845fcc70868ce9b2b6b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0895-7061%2800%2900226-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0895-7061%252800%252900226-0%26sid%3Dliteratum%253Aachs%26aulast%3DReid%26aufirst%3DJ.%2BL.%26atitle%3DRilmenidine%253A%2520a%2520clinical%2520overview%26jtitle%3DAm.%2520J.%2520Hypertens.%26date%3D2000%26volume%3D13%26spage%3D106S%26epage%3D111S%26doi%3D10.1016%2FS0895-7061%2800%2900226-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpello, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. G.</span></span> <span> </span><span class="NLM_article-title">The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I<sub>1</sub>- and I<sub>2</sub>-sites</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1065</span>– <span class="NLM_lpage">1070</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1994.tb13191.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1111%2Fj.1476-5381.1994.tb13191.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=7952865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2cXlsVyqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=1994&pages=1065-1070&author=S.+L.+Chanauthor=C.+A.+Brownauthor=K.+E.+Scarpelloauthor=N.+G.+Morgan&title=The+imidazoline+site+involved+in+control+of+insulin+secretion%3A+characteristics+that+distinguish+it+from+I1-+and+I2-sites&doi=10.1111%2Fj.1476-5381.1994.tb13191.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The imidazoline site involved in control of insulin secretion; characteristics that distinguish it from I1- and I2-sites</span></div><div class="casAuthors">Chan, Susan L. F.; Brown, Colin A.; Scarpello, Kay E.; Morgan, Noel G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1065-70</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">The nature of the binding site mediating the insulin secretagogue activity of certain imidazoline compds. remains unclear and the pharmacol. of the I1- and I2-imidazoline sites, described in many tissues, does not correlate with the obsd. responses to imidazolines in islets.  In the present paper, the authors describe further results which support the concept that the islet imidazoline site may represent a novel subtype of imidazoline receptor.  Culture of rat isolated islets in the presence of imidazoline secretagogues (either efaroxan or phentolamine) resulted in loss of responsiveness on subsequent re-exposure to these agents.  However, culture of islets with either idazoxan or UK 14,304 (imidazoline ligands that do not stimulate insulin secretion) did not lead to any loss of response when the islets were subsequently exposed to efaroxan.  By contrast, islets cultured with UK 14,304 (a potent α2-adrenoceptor agonist), displayed loss of sensitivity to noradrenaline, consistent with down-regulation of α2-adrenoceptors.  To characterize the imidazoline site further, radioligand binding studies were performed in membranes from RINm5F insulinoma cells using [3H]-RX821002, an imidazoline insulin secretagogue that does not interact significantly with imidazoline sites in other tissues.  [3H]-RX821002 labeled α2-adrenoceptors with high affinity (2.01 nM) but also labeled a second, non-adrenoceptor site with much lower affinity.  Under conditions of α2-adrenoceptor blockade (in the presence of adrenaline), efaroxan displaced [3H]-RX821002 binding to the low affinity site, in a dose-dependent manner.  Competition studies employing addnl. imidazoline compds. of varying secretagogue activity revealed that the pharmacol. profile of the low affinity site correlates well with that obsd. in secretion expts.  The results obtained from the down-regulation expts. with isolated islets and from the radioligand binding studies suggest that the low affinity [3H]-RX821002 binding site may represent the functional receptor responsive for the secretagogue activity of imidazole compds. in the endocrine pancreas and that it has a pharmacol. profile distinct from those of I2- and I2-sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrog6sMKnpanLVg90H21EOLACvtfcHk0lhP3mU9XD9rTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsVyqt7o%253D&md5=edce0bacb9d33e93d7c7cbcccf0ed133</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1994.tb13191.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1994.tb13191.x%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BL.%26aulast%3DBrown%26aufirst%3DC.%2BA.%26aulast%3DScarpello%26aufirst%3DK.%2BE.%26aulast%3DMorgan%26aufirst%3DN.%2BG.%26atitle%3DThe%2520imidazoline%2520site%2520involved%2520in%2520control%2520of%2520insulin%2520secretion%253A%2520characteristics%2520that%2520distinguish%2520it%2520from%2520I1-%2520and%2520I2-sites%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1994%26volume%3D112%26spage%3D1065%26epage%3D1070%26doi%3D10.1111%2Fj.1476-5381.1994.tb13191.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. X.</span></span> <span> </span><span class="NLM_article-title">Imidazoline I<sub>2</sub> receptors: an update</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.pharmthera.2017.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=28322973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksFChsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2017&pages=48-56&author=J.+X.+Li&title=Imidazoline+I2+receptors%3A+an+update&doi=10.1016%2Fj.pharmthera.2017.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline I2 receptors: An update</span></div><div class="casAuthors">Li, Jun-Xu</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-56</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Since first introduced more than two decades ago, the research in imidazoline I2 receptors has been steadily increasing.  This review provides an update on the current status of I2 receptor pharmacol.  Imidazoline I2 receptors or I2 binding sites refer to several (at least four) different proteins that bind to [3H]-idazoxan and [3H]-2-BFI with high affinity.  The mol. identities of the proteins remain elusive.  One of the proteins (45 kD) seems to be consistent with the identity of brain creatine kinase.  The biol. functions of I2 receptors have been primarily unveiled by the studies of selective I2 receptor ligands.  Accumulating evidence suggests that I2 receptor ligands are effective analgesics for persistent and chronic painful conditions such as inflammatory, neuropathic and postoperative pain.  One selective I2 receptor ligand, CR4056, has been advanced to phase II clin. trial with the therapeutic indication of chronic inflammatory pain (osteoarthritis).  The expansion to the treatment of other chronic pain conditions should be expected if CR4056 could eventually be approved as a new drug.  I2 receptor ligands also demonstrate robust discriminative stimulus activity and induce a characteristic discriminative cue in animals.  Biochem. and preclin. in vivo investigations also suggest that I2 receptor ligands have neuroprotective activity and modulate body temp.  The emerging discrepancies of a range of purported selective I2 receptor ligands suggest different pharmacol. effects mediated by discrete I2 receptor components which likely attribute to the I2 receptor-related proteins.  It is proposed that the I2 receptors represent an emerging drug target for the treatment of neurol. disorders such as pain and stroke, and deserve more research attention to translate preclin. findings to pharmacotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJxeU1YaY8KLVg90H21EOLACvtfcHk0liU2EP0dz23Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksFChsLw%253D&md5=a6c968a86e34ae2446f7bbf4b3f1ccea</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BX.%26atitle%3DImidazoline%2520I2%2520receptors%253A%2520an%2520update%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D178%26spage%3D48%26epage%3D56%26doi%3D10.1016%2Fj.pharmthera.2017.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Imidazoline I<sub>2</sub> receptors: target for new analgesics?</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>658</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.02.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.ejphar.2011.02.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=21371460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktF2itrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=658&publication_year=2011&pages=49-56&author=J.+X.+Liauthor=Y.+Zhang&title=Imidazoline+I2+receptors%3A+target+for+new+analgesics%3F&doi=10.1016%2Fj.ejphar.2011.02.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline I2 receptors: Target for new analgesics?</span></div><div class="casAuthors">Li, Jun-Xu; Zhang, Yanan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">658</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">49-56</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pain remains a major clin. challenge because there are no effective analgesics for some pain conditions and the mainstay analgesics for severe pain, opioids, have serious unwanted effects.  There is a dire need for novel analgesics in the clinic.  Imidazoline receptors are a family of three receptors (I1, I2 and I3) that all can recognize compds. with an imidazoline structure.  Accumulating evidence suggests that I2 receptors are involved in pain modulation.  Ligands acting at I2 receptors are effective for tonic inflammatory and neuropathic pain but are much less effective for acute phasic pain.  When studied in combination, I2 receptor ligands enhance the analgesic effects of opioids in both acute phasic and chronic tonic pain.  During chronic use, patients can develop tolerance to and dependence on opioids.  Imidazoline I2 receptor ligands can attenuate the development of tolerance to opioid analgesia and inhibit drug withdrawal or antagonist pptn. induced abstinence syndrome in animals.  Taken together, drugs acting on I2 receptors may be useful as a monotherapy or combined with opioids as an adjuvant for treating pain.  Future studies should focus on understanding the relative efficacy of I2 receptor ligands and developing new compds. to fill the gap in intrinsic efficacy continuum of I2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9uQD_LTPxDbVg90H21EOLACvtfcHk0liU2EP0dz23Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktF2itrc%253D&md5=a96e237169e6a42b4fa5b5921ee3c287</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.02.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.02.038%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BX.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DImidazoline%2520I2%2520receptors%253A%2520target%2520for%2520new%2520analgesics%253F%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D658%26spage%3D49%26epage%3D56%26doi%3D10.1016%2Fj.ejphar.2011.02.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regunathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feinstein, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, D. J.</span></span> <span> </span><span class="NLM_article-title">Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved?</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>881</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1999.tb09389.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1111%2Fj.1749-6632.1999.tb09389.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10415945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK1MXkslelsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=881&publication_year=1999&pages=410-419&author=S.+Regunathanauthor=D.+L.+Feinsteinauthor=D.+J.+Reis&title=Anti-proliferative+and+anti-inflammatory+actions+of+imidazoline+agents.+Are+imidazoline+receptors+involved%3F&doi=10.1111%2Fj.1749-6632.1999.tb09389.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved?</span></div><div class="casAuthors">Regunathan, S.; Feinstein, D. L.; Reis, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">881</span>
        (<span class="NLM_cas:issue">Imidazoline Receptors and Their Endogenous Ligands</span>),
    <span class="NLM_cas:pages">410-419</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">We have shown that cultured vascular smooth muscle cells (VSMC) and brain astroglial cells express I-receptors of the I2 subtype.  While imidazoline agents are anti-proliferative in smooth muscle cells, they increase the expression of glial fibrillary acidic protein (GFAP) in astrocytes.  Because increases in GFAP suppress the induction of calcium-independent, inducible nitric oxide synthase (NOS-2), we measured whether idazoxan and related imidazolines and agmatine would also suppress the expression of NOS-2.  Cultured astrocytes and macrophages, RAW 264.7 cell line, were incubated with lipopolysaccharide (LPS, 1 μg/mL) or cytokine mixt. in the presence of 1-100 μM of idazoxan, agmatine, or other imidazoline agents.  Idazoxan potently (IC50, 10 μM) decreased the activity of NOS-2 in astrocytes, but was less potent in RAW 264.7 cells.  By contrast, agmatine was most potent in RAW 264.7 cells (IC50, 10 μM) but less potent in glial cells and VSMC.  Both idazoxan and agmatine decreased the activity of NOS-2 by reducing the levels of enzyme protein as measured by immunoblot and immunocytochem.  No specific binding of [3H]-idazoxan was obsd. in RAW 264.7 cell membranes.  We conclude that idazoxan, agmatine, and selected imidazoline agents inhibit the expression of NOS-2 and proliferation in primary glial cells and VSMC.  While the antiproliferative actions appear mediated by I-receptors of the I2 type, the anti-inflammatory response is probably not mediated by I-receptors but possibly by direct actions on signal transduction enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvuNl8TXpR77Vg90H21EOLACvtfcHk0liU2EP0dz23Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkslelsr4%253D&md5=9ce35919240def895c8e20e765aea8e2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1999.tb09389.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1999.tb09389.x%26sid%3Dliteratum%253Aachs%26aulast%3DRegunathan%26aufirst%3DS.%26aulast%3DFeinstein%26aufirst%3DD.%2BL.%26aulast%3DReis%26aufirst%3DD.%2BJ.%26atitle%3DAnti-proliferative%2520and%2520anti-inflammatory%2520actions%2520of%2520imidazoline%2520agents.%2520Are%2520imidazoline%2520receptors%2520involved%253F%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D881%26spage%3D410%26epage%3D419%26doi%3D10.1111%2Fj.1749-6632.1999.tb09389.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessop, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, D. P.</span></span> <span> </span><span class="NLM_article-title">Modulation of stress by imidazoline binding sites: implications for psychiatric disorders</span>. <i>Stress</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1080/10253890802302908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1080%2F10253890802302908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=19006007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1ektrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=97-114&author=K.+L.+Smithauthor=D.+S.+Jessopauthor=D.+P.+Finn&title=Modulation+of+stress+by+imidazoline+binding+sites%3A+implications+for+psychiatric+disorders&doi=10.1080%2F10253890802302908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of stress by imidazoline binding sites: Implications for psychiatric disorders</span></div><div class="casAuthors">Smith, Karen L.; Jessop, David S.; Finn, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Stress (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-114</span>CODEN:
                <span class="NLM_cas:coden">STREFR</span>;
        ISSN:<span class="NLM_cas:issn">1025-3890</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">In this review, we present evidence for the involvement of imidazoline binding sites (IBS) in modulating responses to stress, through central control of monoaminergic and hypothalamo-pituitary-adrenal (HPA) axis activity.  Pharmacol. and physiol. evidence is presented for differential effects of different IBS subtypes on serotoninergic and catecholaminergic pathways involved in control of basal and stress-stimulated HPA axis activity.  IBS ligands can modulate behavioral and neuroendocrine responses in animal models of stress, depression and anxiety, and a body of evidence exists for alterations in central IBS expression in psychiatric patients, which can be normalized partially or fully by treatment with antidepressants.  Dysfunction in monoaminergic systems and the HPA axis under basal and stress-induced activation has been extensively reported in psychiatric illnesses.  On the basis of the literature, we suggest a potential therapeutic role for selective IBS ligands in the treatment of depression and anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCG9rU5LdfPrVg90H21EOLACvtfcHk0liU2EP0dz23Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1ektrw%253D&md5=c837e6ae48707b312bd220414063091a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1080%2F10253890802302908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10253890802302908%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DK.%2BL.%26aulast%3DJessop%26aufirst%3DD.%2BS.%26aulast%3DFinn%26aufirst%3DD.%2BP.%26atitle%3DModulation%2520of%2520stress%2520by%2520imidazoline%2520binding%2520sites%253A%2520implications%2520for%2520psychiatric%2520disorders%26jtitle%3DStress%26date%3D2009%26volume%3D12%26spage%3D97%26epage%3D114%26doi%3D10.1080%2F10253890802302908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Gómez, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruíz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garibi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguinaco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barturen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span> <span> </span><span class="NLM_article-title">Increased density of I<sub>2</sub>-imidazoline receptors in human gliobastomas</span>. <i>NeuroReport</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1396</span>, <span class="refDoi"> DOI: 10.1097/00001756-199605310-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1097%2F00001756-199605310-00013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8856683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2sXhslWltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=1393-1396&author=J.+I.+Mart%C3%ADn-G%C3%B3mezauthor=J.+Ru%C3%ADzauthor=L.+F.+Calladoauthor=J.+M.+Garibiauthor=L.+Aguinacoauthor=F.+Barturenauthor=J.+J.+Meana&title=Increased+density+of+I2-imidazoline+receptors+in+human+gliobastomas&doi=10.1097%2F00001756-199605310-00013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Increased density of I2-imidazoline receptors in human glioblastomas</span></div><div class="casAuthors">Martin-Gomez, J. Ignacio; Ruiz, Javier; Callado, Luis F.; Garibi, Jesus M.; Aguinaco, Luis; Barturen, Fernando; Meana, J. Javier</div><div class="citationInfo"><span class="NLM_cas:title">NeuroReport</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1393-1396</span>CODEN:
                <span class="NLM_cas:coden">NERPEZ</span>;
        ISSN:<span class="NLM_cas:issn">0959-4965</span>.
    
            (<span class="NLM_cas:orgname">Rapid Science Publishers</span>)
        </div><div class="casAbstract">A glial location has been proposed for the non-adrenoceptor [3H]idazoxan-binding site termed the I2-imidazoline receptor.  The specific binding of [3H]idazoxan in the presence of (-)adrenaline was measured in membranes from excised human glioblastomas, meningiomas and normal brains.  The pharmacol. profile of the [3H]idazoxan binding in astrocytic tumors was similar to that in normal brain, compatible with the presence of I2-imidazoline receptors.  There was a higher d. of I2-imidazoline receptors in astrocytic tumors (Bmax = 266 fmol mg-1 protein) than in normal brain (Bmax = 54 fmol mg-1 protein), with no differences in affinity values.  Almost no [3H]idazoxan-specific binding was shown in meningiomas.  The results suggest that I2-imidazoline receptors may be a selective marker for glial tumors in the evaluation of intracranial neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRjlQBz8r9dLVg90H21EOLACvtfcHk0ligqSdMDS8Lng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhslWltLo%253D&md5=e82aae3988886b2778b7e3c952c20cfe</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1097%2F00001756-199605310-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001756-199605310-00013%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADn-G%25C3%25B3mez%26aufirst%3DJ.%2BI.%26aulast%3DRu%25C3%25ADz%26aufirst%3DJ.%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DGaribi%26aufirst%3DJ.%2BM.%26aulast%3DAguinaco%26aufirst%3DL.%26aulast%3DBarturen%26aufirst%3DF.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26atitle%3DIncreased%2520density%2520of%2520I2-imidazoline%2520receptors%2520in%2520human%2520gliobastomas%26jtitle%3DNeuroReport%26date%3D1996%26volume%3D7%26spage%3D1393%26epage%3D1396%26doi%3D10.1097%2F00001756-199605310-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Gómez, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garibi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span> <span> </span><span class="NLM_article-title">Imidazoline I<sub>2</sub> receptors density increases with the malignancy of human gliomas</span>. <i>J. Neurol., Neurosurg. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1136/jnnp.2003.020446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1136%2Fjnnp.2003.020446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=15090584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BD2c7pslCqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2004&pages=785-787&author=L.+F.+Calladoauthor=J.+I.+Mart%C3%ADn-G%C3%B3mezauthor=J.+Ruizauthor=J.+M.+Garibiauthor=J.+J.+Meana&title=Imidazoline+I2+receptors+density+increases+with+the+malignancy+of+human+gliomas&doi=10.1136%2Fjnnp.2003.020446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline I(2) receptor density increases with the malignancy of human gliomas</span></div><div class="casAuthors">Callado L F; Martin-Gomez J I; Ruiz J; Garibi J M; Meana J J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurology, neurosurgery, and psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">785-7</span>
        ISSN:<span class="NLM_cas:issn">0022-3050</span>.
    </div><div class="casAbstract">BACKGROUND:  Current glioma grading schemes are limited by subjective histological criteria.  Imidazoline I(2) receptors are principally expressed on glial cells.  OBJECTIVE:  To investigate the feasibility of using the measurement of imidazoline I(2) receptor expression to differentiate glial tumours from other types of brain tumours and for grading the different gliomas.  METHODS:  The specific binding of [(3)H]idazoxan to imidazoline I(2) receptors was measured in homogenates from human gliomas of different grades.  RESULTS:  The density of imidazoline I(2) receptors was significantly greater in the three types of malignant glial tumours than in postmortem control brain or non-glial tumours.  The increase in density correlated with the malignancy grade of the gliomas.  No significant differences in affinity values were observed.  CONCLUSION:  These results suggest that the density of imidazoline I(2) receptors may be a useful radioligand parameter for the differentiation of glial tumours from other types of brain tumours and for grading the different gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9dE_E2AERb7JzI8owOhpDfW6udTcc2eZ3tH4VBnjeVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7pslCqtQ%253D%253D&md5=ee3c9eeb65915e694404db86f11bc80f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1136%2Fjnnp.2003.020446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjnnp.2003.020446%26sid%3Dliteratum%253Aachs%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DMart%25C3%25ADn-G%25C3%25B3mez%26aufirst%3DJ.%2BI.%26aulast%3DRuiz%26aufirst%3DJ.%26aulast%3DGaribi%26aufirst%3DJ.%2BM.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26atitle%3DImidazoline%2520I2%2520receptors%2520density%2520increases%2520with%2520the%2520malignancy%2520of%2520human%2520gliomas%26jtitle%3DJ.%2520Neurol.%252C%2520Neurosurg.%2520Psychiatry%26date%3D2004%26volume%3D75%26spage%3D785%26epage%3D787%26doi%3D10.1136%2Fjnnp.2003.020446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span> <span> </span><span class="NLM_article-title">Imidazoline binding sites in Huntington’s and Parkinson’s disease putamen</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>301</i></span>,  <span class="NLM_fpage">R19</span>– <span class="NLM_lpage">R21</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00196-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0014-2999%2896%2900196-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8773473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK28XjtFaqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=1996&pages=R19-R21&author=G.+P.+Reynoldsauthor=R.+M.+Boultonauthor=S.+J.+Pearsonauthor=A.+L.+Hudsonauthor=D.+J.+Nutt&title=Imidazoline+binding+sites+in+Huntington%E2%80%99s+and+Parkinson%E2%80%99s+disease+putamen&doi=10.1016%2F0014-2999%2896%2900196-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline binding sites in Huntington's and Parkinson's disease putamen</span></div><div class="casAuthors">Reynolds, Gavin P.; Boulton, Ruth M.; Pearson, Sally J.; Hudson, Alan L.; Nutt, David J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">R19-R21</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Binding of [3H]2-(2-benzofuranyl)-2-imidazoline ([3H]BFI) to the imidazoline I2 receptor was detd. in putamen taken post mortem from patients with two extrapyramidal motor disorders, Parkinson's and Huntington's diseases, and age-matched control subjects.  No deficit of binding was apparent in Parkinson's disease, indicating that the receptors are not present on nigrostriatal terminals.  A significant loss (by 56%) in imidazoline I2 receptor binding was obsd. in Huntington's disease, consistent with the receptors being sited on degenerating neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopwlnDGo-2wLVg90H21EOLACvtfcHk0ligqSdMDS8Lng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtFaqtb0%253D&md5=5191aa938cf58399e6bef53a6999df75</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900196-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900196-3%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DG.%2BP.%26aulast%3DBoulton%26aufirst%3DR.%2BM.%26aulast%3DPearson%26aufirst%3DS.%2BJ.%26aulast%3DHudson%26aufirst%3DA.%2BL.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26atitle%3DImidazoline%2520binding%2520sites%2520in%2520Huntington%25E2%2580%2599s%2520and%2520Parkinson%25E2%2580%2599s%2520disease%2520putamen%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D301%26spage%3DR19%26epage%3DR21%26doi%3D10.1016%2F0014-2999%2896%2900196-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gargalidis-Moudanos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzinat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javoy-Agid, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remaury, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parini, A.</span></span> <span> </span><span class="NLM_article-title">I<sub>2</sub>-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson’s disease</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1016/S0197-0186(96)00035-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0197-0186%2896%2900035-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9116585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADyaK2s7ntVWhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1997&pages=31-36&author=C.+Gargalidis-Moudanosauthor=N.+Pizzinatauthor=F.+Javoy-Agidauthor=A.+Remauryauthor=A.+Parini&title=I2-imidazoline+binding+sites+and+monoamine+oxidase+activity+in+human+postmortem+brain+from+patients+with+Parkinson%E2%80%99s+disease&doi=10.1016%2FS0197-0186%2896%2900035-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease</span></div><div class="casAuthors">Gargalidis-Moudanos C; Pizzinat N; Javoy-Agid F; Remaury A; Parini A</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry international</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-6</span>
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    </div><div class="casAbstract">I2-imidazoline binding site (I2BS) has been identified with a regulatory site located on a sub-population of monoamine oxidase (MAO)-A and -B.  Previous studies showed a modification of MAO and I2BS in the elderly and in neurodegenerative processes such as Alzheimer's disease.  In the present study, we studied the potential modification of I2 binding sites and monoamine oxidases in Parkinson's disease.  Putamen and cerebral cortex were collected from 17 normal subjects (79 +/- 12 yr) and 16 patients (76 +/- 9 yr) affected by Parkinson's disease.  In mitochondrial preparations, radioligand binding studies with [3H]idazoxan showed that putamen and frontal cortex express equivalent amount of I2BS.  The density and affinity of I2BS were similar in normal subjects (putamen: Bmax = 207 +/- 58 fmol/mg of protein, Kd = 10.1 +/- 3.4 nM; cerebral cortex: Bmax = 193 +/- 54 fmol/mg of protein, Kd = 12.8 +/- 6.8 nM) and Parkinson's disease patients (putamen: Bmax = 193 +/- 60 fmol/mg of protein, Kd = 9.8 +/- 4.6 nM; cerebral cortex: Bmax = 199 +/- 49 fmol/mg of protein, Kd = 15.9 +/- 8.1 nM).  The activity of total monoamine oxidase and monoamine oxidase B, measured by [14C]tyramine and [14C]phenylethylamine oxidation, respectively, were higher in putamen than in cerebral cortex.  No differences have been detected in the enzyme activity between normal and pathological subjects.  These data suggest that, although MAO and I2BS may play a role in the development of Parkinson's disease, they are not altered in the chronic phase of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQE1BPAKWlxLO3MPKNEWB5RfW6udTcc2ebcT6-DEd77mLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7ntVWhsw%253D%253D&md5=1a8976c96852e3f68d384fbd4249759d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0197-0186%2896%2900035-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0197-0186%252896%252900035-6%26sid%3Dliteratum%253Aachs%26aulast%3DGargalidis-Moudanos%26aufirst%3DC.%26aulast%3DPizzinat%26aufirst%3DN.%26aulast%3DJavoy-Agid%26aufirst%3DF.%26aulast%3DRemaury%26aufirst%3DA.%26aulast%3DParini%26aufirst%3DA.%26atitle%3DI2-imidazoline%2520binding%2520sites%2520and%2520monoamine%2520oxidase%2520activity%2520in%2520human%2520postmortem%2520brain%2520from%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurochem.%2520Int.%26date%3D1997%26volume%3D30%26spage%3D31%26epage%3D36%26doi%3D10.1016%2FS0197-0186%2896%2900035-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barturen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">Evidence of increased non-adrenoreceptor [<sup>3</sup>H]idazoxan binding sites in the frontal cortex of depressed suicide victims</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1016/0006-3223(93)90243-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0006-3223%2893%2990243-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8268335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2cXhvVykt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1993&pages=498-501&author=J.+J.+Meanaauthor=F.+Barturenauthor=I.+Mart%C3%ADnauthor=J.+A.+Garc%C3%ADa-Sevilla&title=Evidence+of+increased+non-adrenoreceptor+%5B3H%5Didazoxan+binding+sites+in+the+frontal+cortex+of+depressed+suicide+victims&doi=10.1016%2F0006-3223%2893%2990243-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence of increased non-adrenoceptor [3H]idazoxan binding sites in the frontal cortex of depressed suicide victims</span></div><div class="casAuthors">Meana, J. Javier; Barturen, Fernando; Martin, Inaki; Garcia-Sevilla, Jesus A.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">498-501</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    </div><div class="casAbstract">This is the first demonstration of an increased d. of binding sites for [3H]idazoxan distinct from α2-adrenoceptors in the frontal cortex of depressed suicide victims.  Moreover, an unchanged binding of the antagonist [3H]idazoxan to the α2-adrenoceptor is also shown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Njo4vl215bVg90H21EOLACvtfcHk0lh9xSEsSPue9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvVykt7c%253D&md5=911efecd8a29c024e6f51da8655551a5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2F0006-3223%2893%2990243-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-3223%252893%252990243-7%26sid%3Dliteratum%253Aachs%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26aulast%3DBarturen%26aufirst%3DF.%26aulast%3DMart%25C3%25ADn%26aufirst%3DI.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DEvidence%2520of%2520increased%2520non-adrenoreceptor%2520%255B3H%255Didazoxan%2520binding%2520sites%2520in%2520the%2520frontal%2520cortex%2520of%2520depressed%2520suicide%2520victims%26jtitle%3DBiol.%2520Psychiatry%26date%3D1993%26volume%3D34%26spage%3D498%26epage%3D501%26doi%3D10.1016%2F0006-3223%2893%2990243-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-
Sevilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribá, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busquets, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaquet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimón, J.</span></span> <span> </span><span class="NLM_article-title">Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.1996.01830090049008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1001%2Farchpsyc.1996.01830090049008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8792757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADyaK28zosVyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1996&pages=803-810&author=J.+Garc%C3%ADa-%0ASevillaauthor=P.+V.+Escrib%C3%A1author=M.+Sastreauthor=C.+Walzerauthor=X.+Busquetsauthor=G.+Jaquetauthor=D.+J.+Reisauthor=J.+Guim%C3%B3n&title=Immunodetection+and+quantitation+of+imidazoline+receptor+proteins+in+platelets+of+patients+with+major+depression+and+in+brains+of+suicide+victims&doi=10.1001%2Farchpsyc.1996.01830090049008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims</span></div><div class="casAuthors">Garcia-Sevilla J A; Escriba P V; Sastre M; Walzer C; Busquets X; Jaquet G; Reis D J; Guimon J</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">803-10</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">BACKGROUND:  Imidazoline receptors are a newly discovered family of receptors, some of which, like alpha 2-adrenoceptors, have a presynaptic inhibitory effect on the release of norepinephrine.  The aim of this study was to identify by immunodetection imidazoline receptor proteins in human platelets and the brain to assess their status in depression and suicide.  METHODS:  Platelets were collected from 26 drug-free depressed patients and 26 controls.  Specimens of frontal cortex (Brodmann area 9) were collected from 13 suicide victims and 11 controls.  Levels of imidazoline receptor proteins were assessed by immunoblotting techniques.  Solubilized imidazoline receptors were separated by gel electrophoresis, transferred to nitrocellulose membranes, labeled with a specific anti-imidazoline receptor antiserum, and quantitated by image analysis.  RESULTS:  Platelet and brain membranes expressed similar 45-kd imidazoline receptor proteins, and their mean +/- SEM immunoreactivities were found to be increased in depressed patients (platelets, 40% +/- 5%) and suicide victims (brain, 51% +/- 14%).  Platelets also expressed a 35-kd imidazoline receptor protein that was also found to be up-regulated in depressed patients (21% +/- 4%).  In contrast, brain membranes did not express this 35-kd protein but revealed a 29/30-kd imidazoline receptor protein that was found to be down-regulated in suicide victims (19% +/- 3%).  In a subset of depressed patients who underwent antidepressant treatment, a change in the immunoreactivity of the up-regulated 45-kd platelet imidazoline receptor protein (-35% +/- 5%), but not of the 35-kd protein, was observed.  CONCLUSION:  The results support a role for the newly discovered imidazoline receptors (mainly the 45-kd receptor expressed in the brain and platelets) in the pathogenesis of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlQEHGUcd1PwaK-_ZudimnfW6udTcc2ebcT6-DEd77mLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28zosVyqtQ%253D%253D&md5=75c7ada01afb6b7f31dd2197b6b52d75</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.1996.01830090049008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.1996.01830090049008%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-%2BSevilla%26aufirst%3DJ.%26aulast%3DEscrib%25C3%25A1%26aufirst%3DP.%2BV.%26aulast%3DSastre%26aufirst%3DM.%26aulast%3DWalzer%26aufirst%3DC.%26aulast%3DBusquets%26aufirst%3DX.%26aulast%3DJaquet%26aufirst%3DG.%26aulast%3DReis%26aufirst%3DD.%2BJ.%26aulast%3DGuim%25C3%25B3n%26aufirst%3DJ.%26atitle%3DImmunodetection%2520and%2520quantitation%2520of%2520imidazoline%2520receptor%2520proteins%2520in%2520platelets%2520of%2520patients%2520with%2520major%2520depression%2520and%2520in%2520brains%2520of%2520suicide%2520victims%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D1996%26volume%3D53%26spage%3D803%26epage%3D810%26doi%3D10.1001%2Farchpsyc.1996.01830090049008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruíz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barturen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">Non-adrenoreceptor [<sup>3</sup>H]idazoxan binding sites (I<sub>2</sub>-imidazoline sites) are increased in postmortem brain from patients with Alzheimer’s disease</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/0304-3940(93)90925-B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0304-3940%2893%2990925-B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=7902542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADyaK2c%252FmslGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1993&pages=109-112&author=J.+Ru%C3%ADzauthor=I.+Mart%C3%ADnauthor=L.+F.+Calladoauthor=J.+J.+Meanaauthor=F.+Barturenauthor=J.+A.+Garc%C3%ADa-Sevilla&title=Non-adrenoreceptor+%5B3H%5Didazoxan+binding+sites+%28I2-imidazoline+sites%29+are+increased+in+postmortem+brain+from+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1016%2F0304-3940%2893%2990925-B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Non-adrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease</span></div><div class="casAuthors">Ruiz J; Martin I; Callado L F; Meana J J; Barturen F; Garcia-Sevilla J A</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience letters</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-12</span>
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    </div><div class="casAbstract">The I2-imidazoline site (a non-adrenergic mitochondrial site for which a glial location has been proposed and that is associated with the B-form of the enzyme monoamine oxidase) was evaluated in postmortem cortical membranes from 9 subjects with Alzheimer's disease (AD) and 9 matched-controls by using [3H]idazoxan (0.6-30 nM) in the presence of 10(-6) M (-)-adrenaline to prevent binding to alpha 2-adrenoceptors.  In AD the density (Bmax) of I2-imidazoline sites was significantly higher (+63%) than in controls whereas no differences were apparent in affinity values (Kd).  The results support the hypothesis that the I2 imidazoline site has a major location on glial (astrocyte) cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvuMd4yNs05TQLBVDQn4bCfW6udTcc2eYFSNzJ6xkgVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252FmslGnsg%253D%253D&md5=6c064f8501729c47d4a02e86e8a174df</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0304-3940%2893%2990925-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3940%252893%252990925-B%26sid%3Dliteratum%253Aachs%26aulast%3DRu%25C3%25ADz%26aufirst%3DJ.%26aulast%3DMart%25C3%25ADn%26aufirst%3DI.%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26aulast%3DBarturen%26aufirst%3DF.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DNon-adrenoreceptor%2520%255B3H%255Didazoxan%2520binding%2520sites%2520%2528I2-imidazoline%2520sites%2529%2520are%2520increased%2520in%2520postmortem%2520brain%2520from%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurosci.%2520Lett.%26date%3D1993%26volume%3D160%26spage%3D109%26epage%3D112%26doi%3D10.1016%2F0304-3940%2893%2990925-B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribá, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouras, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimón, J.</span></span> <span> </span><span class="NLM_article-title">Imidazoline receptor proteins in brains of patients with Alzheimer’s disease</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/S0304-3940(98)00265-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0304-3940%2898%2900265-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9655601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK1cXis1yjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1998&pages=95-98&author=J.+A.+Garc%C3%ADa-Sevillaauthor=P.+V.+Escrib%C3%A1author=C.+Walzerauthor=C.+Bourasauthor=J.+Guim%C3%B3n&title=Imidazoline+receptor+proteins+in+brains+of+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0304-3940%2898%2900265-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline receptor proteins in brains of patients with Alzheimer's disease</span></div><div class="casAuthors">Garcia-Sevilla, Jesus A.; Escriba, Pablo V.; Walzer, Claude; Bouras, Constantin; Guimon, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">2,3</span>),
    <span class="NLM_cas:pages">95-98</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Imidazoline receptors (29/30- and 45-kDa proteins) were quantitated in postmortem brains of patients with Alzheimer's disease (AD) by using immunoblotting techniques and a specific antiserum.  Increased levels of the 29/30-kDa protein (30%), 45-kDa protein (36%) and glial fibrillary acidic protein (88%) were found in the frontal cortex of AD patients.  These findings are in line with the reported higher d. of imidazoline receptors labeled by [3H]idazoxan in AD brains, suggesting that these imidazoline receptor proteins are related to the I2-imidazoline receptor located in mitochondria of glial (astrocyte) cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGophkoEHIqMybVg90H21EOLACvtfcHk0ljX0kC60tqiRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1yjtbg%253D&md5=fe8ceb13ca9328478de26d3aee4d6f8f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0304-3940%2898%2900265-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3940%252898%252900265-1%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26aulast%3DEscrib%25C3%25A1%26aufirst%3DP.%2BV.%26aulast%3DWalzer%26aufirst%3DC.%26aulast%3DBouras%26aufirst%3DC.%26aulast%3DGuim%25C3%25B3n%26aufirst%3DJ.%26atitle%3DImidazoline%2520receptor%2520proteins%2520in%2520brains%2520of%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurosci.%2520Lett.%26date%3D1998%26volume%3D247%26spage%3D95%26epage%3D98%26doi%3D10.1016%2FS0304-3940%2898%2900265-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauri, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caselli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovati, L. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.2147/JPR.S132026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.2147%2FJPR.S132026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=28496359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWksLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=1033-1043&author=E.+Comiauthor=M.+Lanzaauthor=F.+Ferrariauthor=V.+Mauriauthor=G.+Caselliauthor=L.+C.+Rovati&title=Efficacy+of+CR4056%2C+a+first-in-class+imidazoline-2+analgesic+drug%2C+in+comparison+with+naproxen+in+two+rat+models+of+osteoarthritis&doi=10.2147%2FJPR.S132026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis</span></div><div class="casAuthors">Comi, Eleonora; Lanza, Marco; Ferrari, Flora; Mauri, Valeria; Caselli, Gianfranco; Rovati, Lucio Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1033-1043</span>CODEN:
                <span class="NLM_cas:coden">JPROEV</span>;
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Purpose: CR4056, (2-phenyl-6-(1H-imidazol-1yl) quinazoline), an imidazoline-2 (I2) receptor ligand, is a promising analgesic drug that has been reported to be effective in several animal models of pain.  The aim of this study was to evaluate the effects of CR4056 in two well-established rat models of osteoarthritis (OA), mimicking the painful and structural components of human OA.  Methods: Knee OA was induced either by single intra-articular injection of monoiodoacetate (MIA) or by medial meniscal tear (MMT) in the right knee of male rats.  In the MIA model, allodynia and hyperalgesia were measured as paw withdrawal threshold to mech. stimulation.  In the MMT model, pain behavior was analyzed as wt.-bearing asymmetry (i.e. difference in hind paw wt. distribution, HPWD) between the injured and the contralateral limbs.  Results: Acute oral administration of CR4056, 14 days after MIA injection, significantly and dose-dependently reduced allodynia and hyperalgesia 90 min after treatment, whereas acute naproxen administration significantly reduced allodynia but not hyperalgesia.  After 7 days of repeated treatment, both CR4056 and naproxen showed significant anti-allodynic and anti-hyperalgesic effects in the MIA model.  Rats undergoing MMT surgery developed a significant and progressive asymmetry in HPWD compared with sham-operated animals.  Repeated treatment with CR4056 significantly reduced the progression of the pain behavior, whereas naproxen had no effects.  Conclusion: The data presented here show that the I2 ligand CR4056 could be a new effective treatment for OA pain.  The compd. is currently under Phase II clin. evaluation for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpANu0GScmmFrVg90H21EOLACvtfcHk0ljX0kC60tqiRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWksLzN&md5=7fbb8cd6ca7b7bbc647ad4cbd6cacda7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2147%2FJPR.S132026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S132026%26sid%3Dliteratum%253Aachs%26aulast%3DComi%26aufirst%3DE.%26aulast%3DLanza%26aufirst%3DM.%26aulast%3DFerrari%26aufirst%3DF.%26aulast%3DMauri%26aufirst%3DV.%26aulast%3DCaselli%26aufirst%3DG.%26aulast%3DRovati%26aufirst%3DL.%2BC.%26atitle%3DEfficacy%2520of%2520CR4056%252C%2520a%2520first-in-class%2520imidazoline-2%2520analgesic%2520drug%252C%2520in%2520comparison%2520with%2520naproxen%2520in%2520two%2520rat%2520models%2520of%2520osteoarthritis%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2017%26volume%3D10%26spage%3D1033%26epage%3D1043%26doi%3D10.2147%2FJPR.S132026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rovati, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blicharski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonazzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacovelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girolami, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of the firts-in-classs imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and desease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial</span>. <i>Osteoarthritis and Cartilage</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.joca.2019.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.joca.2019.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=31526875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BB3MrptlGgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=22&author=L.+C.+Rovatiauthor=N.+Brambillaauthor=T.+Blicharskiauthor=J.+Connellauthor=C.+Vitaliniauthor=A.+Bonazziauthor=G.+Giacovelliauthor=F.+Girolamiauthor=M.+D%E2%80%99Amato&title=Efficacy+and+safety+of+the+firts-in-classs+imidazoline-2+receptor+ligand+CR4056+in+pain+from+knee+osteoarthritis+and+desease+phenotypes%3A+a+randomized%2C+double-blind%2C+placebo-controlled+phase+2+trial&doi=10.1016%2Fj.joca.2019.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial</span></div><div class="casAuthors">Rovati L C; Brambilla N; Vitalini C; Bonazzi A; Giacovelli G; Girolami F; D'Amato M; Blicharski T; Connell J</div><div class="citationInfo"><span class="NLM_cas:title">Osteoarthritis and cartilage</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  CR4056 is a selective imidazoline-2 (I2) receptor ligand with potent analgesic activity in animal pain models.  This proof-of-concept study tested CR4056 efficacy and safety in patients with knee osteoarthritis (OA) and different phenotypes.  DESIGN:  This is a multicenter, randomized, double-blind, placebo-controlled trial.  Knee OA patients with moderate to severe pain received CR4056 (women 100 mg bid; men 200 mg bid) or placebo (both genders) for 14 days.  The primary outcome was the change in WOMAC pain score (0-100 scale) compared to placebo, analyzed in the intention-to-treat population and pre-defined OA phenotypes.  RESULTS:  213 patients were treated with CR4056 (92 women; 52 men) or placebo (69 overall).  After 14 days, median WOMAC pain improvements were 10 points on placebo and 14, 20 and 16 in women, men, and pooled CR4056 groups (P = 0.184, 0.030 and 0.070 vs placebo, respectively).  Pre-specified subgroup analysis in the metabolic OA phenotype (BMI ≥ 27.5 kg/m(2), N = 156) showed statistically significant differences in all CR4056-treated groups vs placebo of 12-18 points.  Conversely, there were too few patients with a neuropathic or inflammatory phenotype for a meaningful analysis.  CR4056 was well tolerated; the most common adverse event was mild headache.  CONCLUSIONS:  Although the primary endpoint was met in males only, this exploratory phase 2 trial shows that CR4056 might be an effective analgesic against knee OA pain, especially in overweight patients representing the metabolic OA phenotype.  These findings, along with the broad-spectrum analgesic activity of CR4056 in animal models, warrant further clinical investigation in OA and other pain conditions.  CLINICAL TRIAL REGISTRATION NUMBER:  EudraCT 2015-001136-37.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-_ap8hyM_J0loaUqgkFHkfW6udTcc2eatBH99gNlXRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrptlGgtw%253D%253D&md5=2dfafb5acb63d759bb79f95369a9f948</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.joca.2019.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joca.2019.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DRovati%26aufirst%3DL.%2BC.%26aulast%3DBrambilla%26aufirst%3DN.%26aulast%3DBlicharski%26aufirst%3DT.%26aulast%3DConnell%26aufirst%3DJ.%26aulast%3DVitalini%26aufirst%3DC.%26aulast%3DBonazzi%26aufirst%3DA.%26aulast%3DGiacovelli%26aufirst%3DG.%26aulast%3DGirolami%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520the%2520firts-in-classs%2520imidazoline-2%2520receptor%2520ligand%2520CR4056%2520in%2520pain%2520from%2520knee%2520osteoarthritis%2520and%2520desease%2520phenotypes%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25202%2520trial%26jtitle%3DOsteoarthritis%2520and%2520Cartilage%26date%3D2020%26volume%3D28%26spage%3D22%26doi%3D10.1016%2Fj.joca.2019.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyacke, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mick, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passchier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of <sup>11</sup>C-BU99008, a PET ligand for the imidazoline<sub>2</sub> binding site in human brain</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1597</span>– <span class="NLM_lpage">1602</span>, <span class="refDoi"> DOI: 10.2967/jnumed.118.208009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.2967%2Fjnumed.118.208009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=29523627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktVajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=1597-1602&author=R.+J.+Tyackeauthor=J.+F.+M.+Myersauthor=A.+V.+Venkataramanauthor=I.+Mickauthor=S.+Turtonauthor=J.+Passchierauthor=S.+M.+Husbandsauthor=E.+A.+Rabinerauthor=R.+N.+Gunnauthor=P.+S.+Murphyauthor=C.+A.+Parkerauthor=D.+J.+Nutt&title=Evaluation+of+11C-BU99008%2C+a+PET+ligand+for+the+imidazoline2+binding+site+in+human+brain&doi=10.2967%2Fjnumed.118.208009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of 11C-BU99008, a PET ligand for the Imidazoline2 binding site in human brain</span></div><div class="casAuthors">Tyacke, Robin J.; Myers, Jim F. M.; Venkataraman, Ashwin; Mick, Inge; Turton, Samuel; Passchier, Jan; Husbands, Stephen M.; Rabiner, Eugenii A.; Gunn, Roger N.; Murphy, Philip S.; Parker, Christine A.; Nutt, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1597-1602</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The imidazoline2 binding site (I2BS) is thought to be expressed in glia and implicated in the regulation of glial fibrillary acidic protein.  A PET ligand for this target would be important for the investigation of neurodegenerative and neuroinflammatory diseases. 11C-BU99008 has previously been identified as a putative PET radioligand.  Here, we present the first in vivo characterization of this PET radioligand in humans and assess its test-retest reproducibility.  Methods: Fourteen healthy male volunteers underwent dynamic PET imaging with 11C-BU99008 and arterial sampling.  Six subjects were used in a test-retest assessment, and 8 were used in a pharmacol. evaluation, undergoing a second or third heterologous competition scan with the mixed I2BS/α2-adrenoceptor drug idazoxan (n = 8; 20, 40, 60, and 80 mg) and the mixed irreversible monoamine oxidase type A/B inhibitor isocarboxazid (n = 4; 50 mg).  Regional time-activity data were generated from arterial plasma input functions cor. for metabolites using the most appropriate model to derive the outcome measure VT (regional distribution vol.).  All image processing and kinetic analyses were performed in MIAKAT.  Results: Brain uptake of 11C-BU99008 was good, with reversible kinetics and a heterogeneous distribution consistent with known I2BS expression.  Model selection criteria indicated that the 2-tissue-compartment model was preferred.  VT ests. were high in the striatum (105 ± 21 mL·cm-3), medium in the cingulate cortex (62 ± 10 mL·cm-3), and low in the cerebellum (41 ± 7 mL·cm-3).  Test-retest reliability was reasonable.  The uptake was dose-dependently reduced throughout the brain by pretreatment with idazoxan, with an av. block across all regions of about 60% (VT, ∼30 mL·cm-3) at the highest dose (80 mg).  The median ED for idazoxan was 28 mg.  Uptake was not blocked by pretreatment with the monoamine oxidase inhibitor isocarboxazid.  Conclusion: 11C-BU99008 in human PET studies demonstrates good brain delivery, reversible kinetics, heterogeneous distribution, specific binding signal consistent with I2BS distribution, and good test-retest reliability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK69AF7SLNorVg90H21EOLACvtfcHk0lipqaaMlJboCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktVajtrY%253D&md5=49ef228fd095cac95ce9d8edc1d10339</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.208009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.208009%26sid%3Dliteratum%253Aachs%26aulast%3DTyacke%26aufirst%3DR.%2BJ.%26aulast%3DMyers%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DVenkataraman%26aufirst%3DA.%2BV.%26aulast%3DMick%26aufirst%3DI.%26aulast%3DTurton%26aufirst%3DS.%26aulast%3DPasschier%26aufirst%3DJ.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26aulast%3DGunn%26aufirst%3DR.%2BN.%26aulast%3DMurphy%26aufirst%3DP.%2BS.%26aulast%3DParker%26aufirst%3DC.%2BA.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26atitle%3DEvaluation%2520of%252011C-BU99008%252C%2520a%2520PET%2520ligand%2520for%2520the%2520imidazoline2%2520binding%2520site%2520in%2520human%2520brain%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D1597%26epage%3D1602%26doi%3D10.2967%2Fjnumed.118.208009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dervenoulas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyacke, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polychronis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politis, M.</span></span> <span> </span><span class="NLM_article-title">Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s disease: an <i>in vivo</i> <sup>11</sup>C-BU99008 PET study</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">3116</span>, <span class="refDoi"> DOI: 10.1093/brain/awz260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1093%2Fbrain%2Fawz260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=31504212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BB3MrntV2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2019&pages=3116&author=H.+Wilsonauthor=G.+Dervenoulasauthor=G.+Paganoauthor=R.+J.+Tyackeauthor=S.+Polychronisauthor=J.+Myersauthor=R.+N.+Gunnauthor=E.+A.+Rabinerauthor=D.+Nuttauthor=M.+Politis&title=Imidazoline+2+binding+sites+reflecting+astroglia+pathology+in+Parkinson%E2%80%99s+disease%3A+an+in+vivo+11C-BU99008+PET+study&doi=10.1093%2Fbrain%2Fawz260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study</span></div><div class="casAuthors">Wilson Heather; Dervenoulas George; Pagano Gennaro; Polychronis Sotirios; Politis Marios; Tyacke Robin J; Myers Jim; Nutt David; Gunn Roger N; Gunn Roger N; Rabiner Eugenii A; Rabiner Eugenii A</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3116-3128</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Astroglia are multifunctional cells that regulate neuroinflammation and maintain homeostasis within the brain.  Astroglial α-synuclein-positive cytoplasmic accumulations have been shown post-mortem in patients with Parkinson's disease and therefore astroglia may play an important role in the initiation and progression of Parkinson's disease.  Imidazoline 2 binding sites are expressed on activated astroglia in the cortex, hippocampus, basal ganglia and brainstem; therefore, by measuring imidazoline 2 binding site levels we can indirectly evaluate astrogliosis in patients with Parkinson's disease.  Here, we aimed to evaluate the role of astroglia activation in vivo in patients with Parkinson's disease using 11C-BU99008 PET, a novel radioligand with high specificity and selectivity for imidazoline 2 binding sites.  Twenty-two patients with Parkinson's disease and 14 healthy control subjects underwent 3 T MRI and a 120-min 11C-BU99008 PET scan with volume of distribution (VT) estimated using a two-tissue compartmental model with a metabolite corrected arterial plasma input function.  Parkinson's disease patients were stratified into early (n = 8) and moderate/advanced (n = 14) groups according to disease stage.  In early Parkinson's disease, increased 11C-BU99008 VT uptake was observed in frontal (P = 0.022), temporal (P = 0.02), parietal (P = 0.026) and occipital (P = 0.047) cortical regions compared with healthy controls.  The greatest 11C-BU99008 VT increase in patients with early Parkinson's disease was observed in the brainstem (52%; P = 0.018).  In patients with moderate/advanced Parkinson's disease, loss of 11C-BU99008 VT was observed across frontal (P = 0.002), temporal (P < 0.001), parietal (P = 0.039), occipital (P = 0.024), and insula (P < 0.001) cortices; and in the subcortical regions of caudate (P < 0.001), putamen (P < 0.001) and thalamus (P < 0.001); and in the brainstem (P = 0.018) compared with healthy controls.  In patients with Parkinson's disease, loss of 11C-BU99008 VT in cortical regions, striatum, thalamus and brainstem correlated with longer disease duration (P < 0.05) and higher disease burden scores, measured with Movement Disorder Society Unified Parkinson's Disease Rating Scale (P < 0.05).  In the subgroup of patients with moderate/advanced Parkinson's disease, loss of 11C-BU99008 VT in the frontal (r = 0.79; P = 0.001), temporal (r = 0.74; P = 0.002) and parietal (r = 0.89; P < 0.001) cortex correlated with global cognitive impairment.  This study demonstrates in vivo the role of astroglia in the initiation and progression of Parkinson's disease.  Reactive astroglia observed early in Parkinson's disease could reflect a neuroprotective compensatory mechanisms and pro-inflammatory upregulation in response to α-synuclein accumulation.  However, as the disease progresses and significant neurodegeneration occurs, astroglia lose their reactive function and such loss in the cortex has clinical relevance in the development of cognitive impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNZ2xJM2Tbm79KldV63DuefW6udTcc2ea8D9Aoa46oiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrntV2iug%253D%253D&md5=c3c0ba77344dd469deeb0787f8bf41c9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawz260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawz260%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DH.%26aulast%3DDervenoulas%26aufirst%3DG.%26aulast%3DPagano%26aufirst%3DG.%26aulast%3DTyacke%26aufirst%3DR.%2BJ.%26aulast%3DPolychronis%26aufirst%3DS.%26aulast%3DMyers%26aufirst%3DJ.%26aulast%3DGunn%26aufirst%3DR.%2BN.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26aulast%3DNutt%26aufirst%3DD.%26aulast%3DPolitis%26aufirst%3DM.%26atitle%3DImidazoline%25202%2520binding%2520sites%2520reflecting%2520astroglia%2520pathology%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520an%2520in%2520vivo%252011C-BU99008%2520PET%2520study%26jtitle%3DBrain%26date%3D2019%26volume%3D142%26spage%3D3116%26doi%3D10.1093%2Fbrain%2Fawz260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dardonville, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozas, I.</span></span> <span> </span><span class="NLM_article-title">Imidazoline binding sites and their ligands: an overview of the different chemical structures</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1002/med.20007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fmed.20007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=15224384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Witb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=639-661&author=C.+Dardonvilleauthor=I.+Rozas&title=Imidazoline+binding+sites+and+their+ligands%3A+an+overview+of+the+different+chemical+structures&doi=10.1002%2Fmed.20007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoline binding sites and their ligands: an overview of the different chemical structures</span></div><div class="casAuthors">Dardonville, Christophe; Rozas, Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-661</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Since Bousquet et al. discovered the imidazoline binding sites (IBS) two decades ago, when they realized that the antihypertensive drug clonidine interacts not only with the α2-adrenoceptors (α2-AR) but also with a distinct imidazoline preferring binding site, these receptors have been paid a great deal of attention.  At least two subtypes, I1 and I2, have been characterized based on their binding affinity for different radioligands, but their structures still remain unknown.  The pharmacol. profile of these IBSs has been the objective of several and very thorough reviews.  However, a medicinal chem. overview of the different lBS ligands prepd. to date has never been attempted.  In this study, the authors attempt to compile all the different chem. structures reported to date as IBS ligands and classify them in function of their chem. structure and binding affinity for the different IBS subtypes.  Thus, the authors comment on the different endogenous IBS ligands known as well as the drugs described to interact with the I1-IBS which have found application as antihypertensive drugs.  Then, the authors review those compds. described in the literature to interact with the I2-IBS, classifying them by their chem. families (imidazolines, guanidines, 2-aminoimidazolines, 3-carbolines).  Finally, some conclusions are drawn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRNIrzXSLExbVg90H21EOLACvtfcHk0lhbkoGqnLkI2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Witb7N&md5=0fe33c62d6d3e897434ddc37ceacc294</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fmed.20007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20007%26sid%3Dliteratum%253Aachs%26aulast%3DDardonville%26aufirst%3DC.%26aulast%3DRozas%26aufirst%3DI.%26atitle%3DImidazoline%2520binding%2520sites%2520and%2520their%2520ligands%253A%2520an%2520overview%2520of%2520the%2520different%2520chemical%2520structures%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2004%26volume%3D24%26spage%3D639%26epage%3D661%26doi%3D10.1002%2Fmed.20007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abás, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdozain, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Arévalo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escolano, C.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of a structurally new family of high affinity imidazoline I<sub>2</sub> receptors ligands</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00426</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00426" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGqsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=737-742&author=S.+Ab%C3%A1sauthor=A.+M.+Erdozainauthor=B.+Kellerauthor=S.+Rodr%C3%ADguez-Ar%C3%A9valoauthor=L.+F.+Calladoauthor=J.+A.+Garc%C3%ADa-Sevillaauthor=C.+Escolano&title=Neuroprotective+effects+of+a+structurally+new+family+of+high+affinity+imidazoline+I2+receptors+ligands&doi=10.1021%2Facschemneuro.6b00426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective Effects of a Structurally New Family of High Affinity Imidazoline I2 Receptor Ligands</span></div><div class="casAuthors">Abas, Sonia; Erdozain, Amaia M.; Keller, Benjamin; Rodriguez-Arevalo, Sergio; Callado, Luis F.; Garcia-Sevilla, Jesus A.; Escolano, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">737-742</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The imidazoline I2 receptors (I2-IRs) are widely distributed in the brain, and I2-IR ligands may have therapeutic potential as neuroprotective agents.  Since structural data for I2-IR remains unknown, the discovery of selective I2-IR ligands devoid of α2-adrenoceptor (α2-AR) affinity is likely to provide valuable tools in defining the pharmacol. characterization of these receptors.  We report the pharmacol. characterization of a new family of (2-imidazolin-4-yl)phosphonates.  Radioligand binding studies showed that they displayed a higher affinity for I2-IRs than idazoxan, and high I2/α2 selectivity.  In vivo studies in mice showed that acute treatments with 1b and 2c significantly increased p-FADD/FADD ratio (an index of cell survival) in the hippocampus when compared with vehicle-treated controls.  Addnl., acute and repeated treatments with 2c, but not with 1b, markedly reduced hippocampal p35 cleavage into neurotoxic p25.  The present results indicate a neuroprotective potential of (2-imidazolin-4-yl)phosphonates acting at I2-IRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgccGN_OMgMrVg90H21EOLACvtfcHk0lhbkoGqnLkI2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGqsrjJ&md5=6726444171cfbc3c8adab1437fdb34cd</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00426%26sid%3Dliteratum%253Aachs%26aulast%3DAb%25C3%25A1s%26aufirst%3DS.%26aulast%3DErdozain%26aufirst%3DA.%2BM.%26aulast%3DKeller%26aufirst%3DB.%26aulast%3DRodr%25C3%25ADguez-Ar%25C3%25A9valo%26aufirst%3DS.%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26aulast%3DEscolano%26aufirst%3DC.%26atitle%3DNeuroprotective%2520effects%2520of%2520a%2520structurally%2520new%2520family%2520of%2520high%2520affinity%2520imidazoline%2520I2%2520receptors%2520ligands%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D737%26epage%3D742%26doi%3D10.1021%2Facschemneuro.6b00426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abás, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estarellas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escolano, C.</span></span> <span> </span><span class="NLM_article-title">Easy access to (2-imidazolin-4-yl)phosphonates by a microwave assisted multicomponent reaction</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2872</span>– <span class="NLM_lpage">2881</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2015.03.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.tet.2015.03.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVKgu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=2872-2881&author=S.+Ab%C3%A1sauthor=C.+Estarellasauthor=F.+J.+Luqueauthor=C.+Escolano&title=Easy+access+to+%282-imidazolin-4-yl%29phosphonates+by+a+microwave+assisted+multicomponent+reaction&doi=10.1016%2Fj.tet.2015.03.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Easy access to (2-imidazolin-4-yl)phosphonates by a microwave assisted multicomponent reaction</span></div><div class="casAuthors">Abas, Sonia; Estarellas, Carolina; Javier Luque, F.; Escolano, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2872-2881</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An efficient and user-friendly synthetic process involving the combination of multicomponent reaction methodol. and microwave heating generates unprecedented (2-imidazolin-4-yl)phosphonates 1-18.  E.g., reaction of phenethylamine with acetone and di-Et isocyanomethylphosphonate in the presence of 10 mol% AgNO3 in a microwave oven at 40° gave a 91% yield of di-Et [5,5-dimethyl-1-(1-phenethyl)-4,5-dihydro-1H-imidazol-4-yl]phosphonate.  This strategy presents a Ag-catalyzed, operationally simple and environmentally friendly transformation without the need of anhyd. atm. or addnl. solvents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosd6_Cw0V1b7Vg90H21EOLACvtfcHk0lhiUeWScLQqLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVKgu7Y%253D&md5=6437e89b25680b0d9368f6801fa642a2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2015.03.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2015.03.065%26sid%3Dliteratum%253Aachs%26aulast%3DAb%25C3%25A1s%26aufirst%3DS.%26aulast%3DEstarellas%26aufirst%3DC.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DEscolano%26aufirst%3DC.%26atitle%3DEasy%2520access%2520to%2520%25282-imidazolin-4-yl%2529phosphonates%2520by%2520a%2520microwave%2520assisted%2520multicomponent%2520reaction%26jtitle%3DTetrahedron%26date%3D2015%26volume%3D71%26spage%3D2872%26epage%3D2881%26doi%3D10.1016%2Fj.tet.2015.03.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griñán-Ferré, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasilopoulou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abás, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Arévalo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagán, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sureda, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Fuster, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escolano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallàs, M.</span></span> <span> </span><span class="NLM_article-title">Behavioral and cognitive improvement induced by novel imidazoline I<sub>2</sub> receptor ligands in female SAMP8 mice</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1007/s13311-018-00681-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1007%2Fs13311-018-00681-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=30460457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlShtr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=416-431&author=C.+Gri%C3%B1%C3%A1n-Ferr%C3%A9author=F.+Vasilopoulouauthor=S.+Ab%C3%A1sauthor=S.+Rodr%C3%ADguez-Ar%C3%A9valoauthor=A.+Bag%C3%A1nauthor=F.+X.+Suredaauthor=B.+P%C3%A9rezauthor=L.+F.+Calladoauthor=J.+A.+Garc%C3%ADa-Sevillaauthor=M.+J.+Garc%C3%ADa-Fusterauthor=C.+Escolanoauthor=M.+Pall%C3%A0s&title=Behavioral+and+cognitive+improvement+induced+by+novel+imidazoline+I2+receptor+ligands+in+female+SAMP8+mice&doi=10.1007%2Fs13311-018-00681-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral and Cognitive Improvement Induced by Novel Imidazoline I2 Receptor Ligands in Female SAMP8 Mice</span></div><div class="casAuthors">Grinan-Ferre, Christian; Vasilopoulou, Foteini; Abas, Sonia; Rodriguez-Arevalo, Sergio; Bagan, Andrea; Sureda, Francesc X.; Perez, Belen; Callado, Luis F.; Garcia-Sevilla, Jesus A.; Garcia-Fuster, M. Julia; Escolano, Carmen; Pallas, Merce</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">416-431</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">As populations increase their life expectancy, age-related neurodegenerative disorders such as Alzheimer's disease have become more common.  I2-Imidazoline receptors (I2-IR) are widely distributed in the central nervous system, and dysregulation of I2-IR in patients with neurodegenerative diseases has been reported, suggesting their implication in cognitive impairment.  This evidence indicates that high-affinity selective I2-IR ligands potentially contribute to the delay of neurodegeneration.  In vivo studies in the female senescence accelerated mouse-prone 8 mice have shown that treatment with I2-IR ligands, MCR5 and MCR9, produce beneficial effects in behavior and cognition.  Changes in mol. pathways implicated in oxidative stress, inflammation, synaptic plasticity, and apoptotic cell death were also studied.  Furthermore, treatments with these I2-IR ligands diminished the amyloid precursor protein processing pathway and increased Aβ degrading enzymes in the hippocampus of SAMP8 mice.  These results collectively demonstrate the neuroprotective role of these new I2-IR ligands in a mouse model of brain aging through specific pathways and suggest their potential as therapeutic agents in brain disorders and age-related neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpll-tgGobyQbVg90H21EOLACvtfcHk0lhiUeWScLQqLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlShtr%252FK&md5=422a2e7ff722c4dce09dd7ac3a8366f0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs13311-018-00681-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-018-00681-5%26sid%3Dliteratum%253Aachs%26aulast%3DGri%25C3%25B1%25C3%25A1n-Ferr%25C3%25A9%26aufirst%3DC.%26aulast%3DVasilopoulou%26aufirst%3DF.%26aulast%3DAb%25C3%25A1s%26aufirst%3DS.%26aulast%3DRodr%25C3%25ADguez-Ar%25C3%25A9valo%26aufirst%3DS.%26aulast%3DBag%25C3%25A1n%26aufirst%3DA.%26aulast%3DSureda%26aufirst%3DF.%2BX.%26aulast%3DP%25C3%25A9rez%26aufirst%3DB.%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26aulast%3DGarc%25C3%25ADa-Fuster%26aufirst%3DM.%2BJ.%26aulast%3DEscolano%26aufirst%3DC.%26aulast%3DPall%25C3%25A0s%26aufirst%3DM.%26atitle%3DBehavioral%2520and%2520cognitive%2520improvement%2520induced%2520by%2520novel%2520imidazoline%2520I2%2520receptor%2520ligands%2520in%2520female%2520SAMP8%2520mice%26jtitle%3DNeurotherapeutics%26date%3D2019%26volume%3D16%26spage%3D416%26epage%3D431%26doi%3D10.1007%2Fs13311-018-00681-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arróniz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abás, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanera, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escolano, C.</span></span> <span> </span><span class="NLM_article-title">First diastereoselective [3 + 2] cycloaddition reaction of diethyl isocyanomethylphosphonate and maleimides</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1640</span>– <span class="NLM_lpage">1649</span>, <span class="refDoi"> DOI: 10.1039/c3ob26766k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1039%2Fc3ob26766k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=23358611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisVKqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=1640-1649&author=C.+Arr%C3%B3nizauthor=J.+Molinaauthor=S.+Ab%C3%A1sauthor=E.+Molinsauthor=J.+M.+Campaneraauthor=F.+J.+Luqueauthor=C.+Escolano&title=First+diastereoselective+%5B3+%2B+2%5D+cycloaddition+reaction+of+diethyl+isocyanomethylphosphonate+and+maleimides&doi=10.1039%2Fc3ob26766k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">First diastereoselective [3 + 2] cycloaddition reaction of diethyl isocyanomethylphosphonate and maleimides</span></div><div class="casAuthors">Arroniz, Carlos; Molina, Juan; Abas, Sonia; Molins, Elies; Campanera, Josep M.; Luque, F. Javier; Escolano, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1640-1649</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Bicyclic α-iminophosphonates were prepd. via the first diastereoselective silver catalyzed [3 + 2] cycloaddn. reaction of di-Et isocyanomethylphosphonate and diversely N-substituted maleimides.  The redn. of the resulting imine by catalytic hydrogenation led to cyclic α-aminophosphonates, which are α-aminoester surrogates.  The relative stereochem. of the adducts was confirmed by x-ray crystallog. anal. of di-Et (1RS,3aRS,6aRS)-4,6-dioxo-5-phenyl-1,3a,4,5,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate 4.  The diastereoselectivity of the cycloaddn. reaction was rationalized by theor. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1ExSqAVZBT7Vg90H21EOLACvtfcHk0lhiUeWScLQqLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisVKqsbg%253D&md5=9b9c92129362823b987555431ed6aad8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2Fc3ob26766k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3ob26766k%26sid%3Dliteratum%253Aachs%26aulast%3DArr%25C3%25B3niz%26aufirst%3DC.%26aulast%3DMolina%26aufirst%3DJ.%26aulast%3DAb%25C3%25A1s%26aufirst%3DS.%26aulast%3DMolins%26aufirst%3DE.%26aulast%3DCampanera%26aufirst%3DJ.%2BM.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DEscolano%26aufirst%3DC.%26atitle%3DFirst%2520diastereoselective%2520%255B3%2520%252B%25202%255D%2520cycloaddition%2520reaction%2520of%2520diethyl%2520isocyanomethylphosphonate%2520and%2520maleimides%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D1640%26epage%3D1649%26doi%3D10.1039%2Fc3ob26766k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escolano, C.</span>; <span class="NLM_string-name">Pallás, M.</span>; <span class="NLM_string-name">Griñán-Ferré, C.</span>; <span class="NLM_string-name">Abás, S.</span>; <span class="NLM_string-name">Callado, L.-F.</span>; <span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthetic I<sub>2</sub> Imidazoline Receptor Ligands for Prevention or Treatment of Human Brain Disorders</span>. <span class="NLM_patent">WO 2019/121853 A1</span>, June 27, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Escolano&author=M.+Pall%C3%A1s&author=C.+Gri%C3%B1%C3%A1n-Ferr%C3%A9&author=S.+Ab%C3%A1s&author=L.-F.+Callado&author=J.+A.+Garc%C3%ADa-Sevilla&title=Synthetic+I2+Imidazoline+Receptor+Ligands+for+Prevention+or+Treatment+of+Human+Brain+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEscolano%26aufirst%3DC.%26atitle%3DSynthetic%2520I2%2520Imidazoline%2520Receptor%2520Ligands%2520for%2520Prevention%2520or%2520Treatment%2520of%2520Human%2520Brain%2520Disorders%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grijalba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazos, A.</span></span> <span> </span><span class="NLM_article-title">α<sub>2</sub>-Adrenoceptor subtypes in the human brain: a phamacological delineation of [<sup>3</sup>H]RX-821002 binding to membranes and tissue sections</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00381-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0014-2999%2896%2900381-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8880071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK28Xlt1KjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=1996&pages=83-93&author=B.+Grijalbaauthor=L.+F.+Calladoauthor=J.+J.+Meanaauthor=J.+A.+Garc%C3%ADa-Sevillaauthor=A.+Pazos&title=%CE%B12-Adrenoceptor+subtypes+in+the+human+brain%3A+a+phamacological+delineation+of+%5B3H%5DRX-821002+binding+to+membranes+and+tissue+sections&doi=10.1016%2F0014-2999%2896%2900381-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">α2-Adrenoceptor subtypes in the human brain: a pharmacological delineation of [3H]RX-821002 binding to membranes and tissue sections</span></div><div class="casAuthors">Grijalba, Bernardo; Callado, Luis F.; Meana, J. Javier; Garcia-Sevilla, Jesus A.; Pazos, Angel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-93</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In order to study the characterization and localization of [3H]RX-821002 (2-methoxy-idazoxan) binding to α2-adrenoceptor subtypes in several regions of the human brain, we have carried out competition studies using both autoradiog. and membrane binding assays.  The α2A-adrenoceptor subtype was found to be predominant in the different layers of the frontal cortex, cerebellum and hippocampal formation, while in the neostriatum it was the non-α2A- (α2B- and α2C-) adrenoceptor subtype.  In the frontal cortex, in addn. to binding to the α2A-adrenoceptor subtype, [3H]RX-821002 bound also to a small portion of α2B- and α2C-adrenoceptors in layer III, and to an unidentified binding site in the external layers.  In the hippocampus, both α2A- and non-α2A- (α2B- and α2C-) adrenoceptors were labeled in the dentate gyrus and the CA1 field, together with 5-HT1A receptors. 5-HT1A receptors were labeled predominantly in the stratum pyramidale layer.  These results, in addn. to delineate the relative presence of α2-adrenoceptor subtypes, indicate that caution is needed when analyzing RX 821002 binding to human brain tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr01_lWikhGyLVg90H21EOLACvtfcHk0lh835839XyB-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xlt1KjtL4%253D&md5=74ad82e678a1bc11a028e5236926eea2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900381-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900381-0%26sid%3Dliteratum%253Aachs%26aulast%3DGrijalba%26aufirst%3DB.%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26aulast%3DPazos%26aufirst%3DA.%26atitle%3D%25CE%25B12-Adrenoceptor%2520subtypes%2520in%2520the%2520human%2520brain%253A%2520a%2520phamacological%2520delineation%2520of%2520%255B3H%255DRX-821002%2520binding%2520to%2520membranes%2520and%2520tissue%2520sections%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D310%26spage%3D83%26epage%3D93%26doi%3D10.1016%2F0014-2999%2896%2900381-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeztu, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutiérrez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span> <span> </span><span class="NLM_article-title">Differential [<sup>3</sup>H]idazoxan and [<sup>3</sup>H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) binding to imidazoline I<sub>2</sub> receptors in human postmortem frontal cortex</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(01)01097-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0014-2999%2801%2901097-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=11448473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltVGjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2001&pages=109-114&author=L.+F.+Calladoauthor=A.+I.+Maeztuauthor=J.+Ballesterosauthor=M.+Guti%C3%A9rrezauthor=J.+J.+Meana&title=Differential+%5B3H%5Didazoxan+and+%5B3H%5D2-%282-benzofuranyl%29-2-imidazoline+%282-BFI%29+binding+to+imidazoline+I2+receptors+in+human+postmortem+frontal+cortex&doi=10.1016%2FS0014-2999%2801%2901097-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Differential [3H]idazoxan and [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) binding to imidazoline I2 receptors in human postmortem frontal cortex</span></div><div class="casAuthors">Callado, L. F.; Maeztu, A. I.; Ballesteros, J.; Gutierrez, M.; Javier Meana, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">109-114</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">[3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) and [3H]idazoxan are the most used tools to characterize imidazoline I2 receptors.  We evaluated the binding of both radioligands to human postmortem frontal cortex membranes.  Satn. binding analyses revealed that [3H]idazoxan (in the presence of 2 μM efaroxan to avoid radioligand binding to α2-adrenoceptors and imidazoline I1 receptors) and [3H]2-BFI bound with high affinity to an apparent single population of sites.  However, in competition studies whereas [3H]idazoxan (10 nM) binding was displaced monophasically by idazoxan and 2-BFI, both drugs displayed biphasic curves for [3H]2-BFI (1 nM).  The proportion of the low-affinity binding site increased from 17% to 25% when 10 nM [3H]2-BFI was displaced by idazoxan.  Amiloride inhibited [3H]2-BFI (10 nM) binding with low affinity and in a monophasic way.  These data indicate that [3H]2-BFI recognizes in human postmortem brain membranes a second binding site different from the imidazoline I2 receptors labeled by [3H]idazoxan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8wS7zlfj4E7Vg90H21EOLACvtfcHk0lh835839XyB-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltVGjsrg%253D&md5=a1c7b1a2b2a354d79546801271be96fb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901097-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901097-4%26sid%3Dliteratum%253Aachs%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DMaeztu%26aufirst%3DA.%2BI.%26aulast%3DBallesteros%26aufirst%3DJ.%26aulast%3DGuti%25C3%25A9rrez%26aufirst%3DM.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26atitle%3DDifferential%2520%255B3H%255Didazoxan%2520and%2520%255B3H%255D2-%25282-benzofuranyl%2529-2-imidazoline%2520%25282-BFI%2529%2520binding%2520to%2520imidazoline%2520I2%2520receptors%2520in%2520human%2520postmortem%2520frontal%2520cortex%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D423%26spage%3D109%26epage%3D114%26doi%3D10.1016%2FS0014-2999%2801%2901097-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span> BU99008 was
prepared
according to the literature procedure:<span class="NLM_contrib-group"><span class="NLM_string-name">Tyacke, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, E. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation and initial in vitro and in vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1<i>H</i>-imidazol-2-yl)-1-methyl-1<i>H</i>-indole), for the imidazoline<sub>2</sub> binding site</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1002/syn.21541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fsyn.21541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=22290740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFyjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2012&pages=542-551&author=R.+J.+Tyackeauthor=A.+Fisherauthor=E.+S.+J.+Robinsonauthor=P.+Grundtauthor=E.+M.+Turnerauthor=S.+M.+Husbandsauthor=A.+L.+Hudsonauthor=C.+A.+Parkerauthor=D.+J.+Nutt&title=Evaluation+and+initial+in+vitro+and+in+vivo+characterization+of+the+potential+positron+emission+tomography+ligand%2C+BU99008+%282-%284%2C5-dihydro-1H-imidazol-2-yl%29-1-methyl-1H-indole%29%2C+for+the+imidazoline2+binding+site&doi=10.1002%2Fsyn.21541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-Dihydro-1H-imidazol-2-yl)-1- methyl-1H-indole), for the imidazoline2 binding site</span></div><div class="casAuthors">Tyacke, Robin J.; Fisher, Amy; Robinson, Emma S. J.; Grundt, Peter; Turner, Emma M.; Husbands, Stephen M.; Hudson, Alan L.; Parker, Christine A.; Nutt, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">542-551</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The d. of the Imidazoline2 binding site (I2BS) has been shown to change in psychiatric conditions such as depression and addiction, along with neurodegenerative disorders such as Alzheimer's disease and Huntington's chorea.  The presence of I2BS on glial cells and the possibility that they may in some way regulate glial fibrillary acidic protein has led to increased interest into the role of I2BS and I2BS ligands in conditions characterized by marked gliosis.  In addn., it has been suggested that I2BS may be a marker for human glioblastomas.  Therefore, the development of a positron emission tomog. (PET) radioligand for the I2BS would be of major benefit in our understanding of these conditions.  We now report the successful synthesis and initial pharmacol. evaluation of potential PET radioligands for the I2BS as well as the tritiation and characterization of the most favorable of the series, BU99008 (6), both in vitro and ex vivo in rat.  The series as a whole demonstrated excellent affinity and selectivity for the I2BS, with BU99008 (6) selected as the lead candidate to be taken forward for in vivo assessment.  BU99008 (6) showed very good affinity for the I2BS (Ki of 1.4 nM; Kd = 1.3 nM), good selectivity compared with the α2-adrenoceptor (909-fold).  In addn., following peripheral administration, [3H]BU99008 demonstrated a heterogenous uptake into the rat brain consistent with the known distribution of the I2BS in vivo.  This, and the amenability of BU99008 (6) to radiolabeling with a positron-emitting radioisotope, indicates its potential as a PET radioligand for imaging the I2BS in vivo.  Synapse, 2012. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK29aH8onmobVg90H21EOLACvtfcHk0lh835839XyB-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFyjtr0%253D&md5=fa51bf0a89bd4411472a2c3c6223c770</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fsyn.21541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.21541%26sid%3Dliteratum%253Aachs%26aulast%3DTyacke%26aufirst%3DR.%2BJ.%26aulast%3DFisher%26aufirst%3DA.%26aulast%3DRobinson%26aufirst%3DE.%2BS.%2BJ.%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DTurner%26aufirst%3DE.%2BM.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DHudson%26aufirst%3DA.%2BL.%26aulast%3DParker%26aufirst%3DC.%2BA.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26atitle%3DEvaluation%2520and%2520initial%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520the%2520potential%2520positron%2520emission%2520tomography%2520ligand%252C%2520BU99008%2520%25282-%25284%252C5-dihydro-1H-imidazol-2-yl%2529-1-methyl-1H-indole%2529%252C%2520for%2520the%2520imidazoline2%2520binding%2520site%26jtitle%3DSynapse%26date%3D2012%26volume%3D66%26spage%3D542%26epage%3D551%26doi%3D10.1002%2Fsyn.21541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span>CR4056
was prepared according to the literature procedure: <span class="NLM_contrib-group"><span class="NLM_string-name">Giordani, A.</span>; <span class="NLM_string-name">Mandelli, S.</span>; <span class="NLM_string-name">Verpilio, I.</span>; <span class="NLM_string-name">Zanzola, S.</span>; <span class="NLM_string-name">Tarchino, F.</span>; <span class="NLM_string-name">Caselli, G.</span>; <span class="NLM_string-name">Piepoli, T.</span>; <span class="NLM_string-name">Mazzari, S.</span>; <span class="NLM_string-name">Makovec, F.</span>; <span class="NLM_string-name">Rovati, L. C.</span></span> <span> </span><span class="NLM_article-title">6–1H-Imidazo-quinazoline and Quinolines Derivatives, New Potent Analgesics and Anti-inflammatory Agents</span>. <span class="NLM_patent">US 8,193,353 B2</span>, June 5, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+Giordani&author=S.+Mandelli&author=I.+Verpilio&author=S.+Zanzola&author=F.+Tarchino&author=G.+Caselli&author=T.+Piepoli&author=S.+Mazzari&author=F.+Makovec&author=L.+C.+Rovati&title=6%E2%80%931H-Imidazo-quinazoline+and+Quinolines+Derivatives%2C+New+Potent+Analgesics+and+Anti-inflammatory+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGiordani%26aufirst%3DA.%26atitle%3D6%25E2%2580%25931H-Imidazo-quinazoline%2520and%2520Quinolines%2520Derivatives%252C%2520New%2520Potent%2520Analgesics%2520and%2520Anti-inflammatory%2520Agents%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lione, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A. L.</span></span> <span> </span><span class="NLM_article-title">[<sup>3</sup>H]-2-(2-benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I<sub>2</sub> receptors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00131-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0014-2999%2896%2900131-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8813605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK28Xjs1WnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=1996&pages=221-229&author=L.+A.+Lioneauthor=D.+J.+Nuttauthor=A.+L.+Hudson&title=%5B3H%5D-2-%282-benzofuranyl%29-2-imidazoline%3A+a+new+selective+high+affinity+radioligand+for+the+study+of+rabbit+brain+imidazoline+I2+receptors&doi=10.1016%2F0014-2999%2896%2900131-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">[3H]2-(2-Benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors</span></div><div class="casAuthors">Lione, Lisa A.; Nutt, David J.; Hudson, Alan L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">221-229</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">This is the first study characterizing the binding of the new imidazoline I2 receptor selective radioligand [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) to rabbit brain membranes. [3H]2-BFI binding was found to be saturable and of high affinity identifying two binding sites with KD1 = 0.27 nM, Bmax = 111.2 fmol mg-1 protein and KD2 = 8.97 nM, Bmax = 268 fmol mg-1 protein.  Specific binding represented greater than 90% of total binding.  Kinetic studies revealed that the binding was rapid and reversible and also showed [3H]2-BFI interacted with these two sites or two affinity states.  In competition binding studies against [3H]2-BFI, idazoxan, 2-BFI, cirazoline, guanabenz, naphazoline, amiloride and BU224 (2-(4,5-dihydroimidaz-2-yl-quinoline)) displaced [3H]2-BFI with high affinity.  In contrast the α2-adrenoceptor antagonists efaroxan and rauwolscine, the I1 site selective drug moxonidine, the monoamine oxidase-A inhibitor clorgyline and the proposed endogenous imidazoline receptor ligand, agmatine, were weak at displacing [3H]2-BFI binding.  These findings are consistent with [3H]2-BFI recognizing imidazoline receptors of the I2 subtype in rabbit brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1OiDjhS1mSbVg90H21EOLACvtfcHk0lgw5nWLHQts5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjs1WnsrY%253D&md5=6bab1d0772a2dd4271161b22e445ad64</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900131-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900131-8%26sid%3Dliteratum%253Aachs%26aulast%3DLione%26aufirst%3DL.%2BA.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26aulast%3DHudson%26aufirst%3DA.%2BL.%26atitle%3D%255B3H%255D-2-%25282-benzofuranyl%2529-2-imidazoline%253A%2520a%2520new%2520selective%2520high%2520affinity%2520radioligand%2520for%2520the%2520study%2520of%2520rabbit%2520brain%2520imidazoline%2520I2%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D304%26spage%3D221%26epage%3D229%26doi%3D10.1016%2F0014-2999%2896%2900131-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alemany, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">Labelling I<sub>2B</sub>-imidazoline receptors by [<sup>3</sup>H]-2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes</span>. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1007/PL00005026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1007%2FPL00005026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9228188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1Cisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=1997&pages=39-47&author=R.+Alemanyauthor=G.+Olmosauthor=J.+A.+Garc%C3%ADa-Sevilla&title=Labelling+I2B-imidazoline+receptors+by+%5B3H%5D-2-%282-benzofuranyl%29-2-imidazoline+%282-BFI%29+in+rat+brain+and+liver%3A+characterization%2C+regulation+and+relation+to+monoamine+oxidase+enzymes&doi=10.1007%2FPL00005026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Labeling of I2B-imidazoline receptors by [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes</span></div><div class="casAuthors">Alemany, Regina; Olmos, Gabriel; Garcia-Sevilla, Jesus A.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-47</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The novel selective imidazoline radioligand [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) was used to characterize and assess further the nature of I2-imidazoline receptors in rat brain and liver.  In the cerebral cortex, 2-BFI displayed high affinity (Ki= 9.8 nM) for a single class of [3H]2-BFI binding sites.  Other imidazoline/guanidine compds. (e.g. aganodine, cirazoline and idazoxan) displayed biphasic competition curves, indicating the existence of high (KiH= 2.9-78 nM; RH= 61-83%) and low (KiL= 4.7-158 μM) affinity sites.  The pharmacol. profile for [3H]2-BFI binding (aganodine > cirazoline > 2-BFI » clonidine > amiloride » efaroxan) was typical of that for I2-sites.  This profile was almost identical to that obtained against [3H]idazoxan (correlation between pKi values, r = 0.97) which indicated that the sites characterized with [3H]2-BFI in brain corresponded to I2-imidazoline receptors.  The low affinity of amiloride against [3H]2-BFI (Ki= 900 nM) further indicated that these brain I2-sites belong to the I2B-subtype.  [3H]2-BFI binding sites (Bmax= 72 fmol/mg protein) in brain were differentially modulated by treatment (7 days) with cirazoline (up-regulation: 25%) and the MAO inhibitor phenelzine (down-regulation: 31%), indicating that these I2-sites are regulated in vivo, as is the case for those labeled by [3H]idazoxan.  Chronic treatment with 2-phenylethylamine, a phenelzine metabolite and endogenous amine, did not alter the d. of brain of I2-imidazoline receptors labeled by [3H]idazoxan.  Preincubation of liver membranes with the MAO inhibitor clorgyline (10-7 M) abolished the binding of [3H]Ro 41-1049 (N-(2-aminoethyl)-5-(m-fluorophenyl)-4-thiazole carboxamide) to MAO-A, but it die not alter the binding of [3H]Ro 19-6327 (N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide) to MAO-B or that of [3H]2-BFI to I2-sites.  At 10-4 M it also abolished MAO-B sites, but a substantial proportion of I2-sites (40%) remained intact.  Preincubation of liver membranes at 60° also abolished MAO-A/B sites, whereas still 22% of I2-sites remained.  The results indicate that [3H]2-BFI is a good tool for the identification of I2-imidazoline receptors and suggest further that certain I2-sites and MAO are different proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDZh0VOVNH-rVg90H21EOLACvtfcHk0lgw5nWLHQts5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1Cisbk%253D&md5=2a2c118e0fbf26ba1e4db935bf9cba66</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2FPL00005026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00005026%26sid%3Dliteratum%253Aachs%26aulast%3DAlemany%26aufirst%3DR.%26aulast%3DOlmos%26aufirst%3DG.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DLabelling%2520I2B-imidazoline%2520receptors%2520by%2520%255B3H%255D-2-%25282-benzofuranyl%2529-2-imidazoline%2520%25282-BFI%2529%2520in%2520rat%2520brain%2520and%2520liver%253A%2520characterization%252C%2520regulation%2520and%2520relation%2520to%2520monoamine%2520oxidase%2520enzymes%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D1997%26volume%3D356%26spage%3D39%26epage%3D47%26doi%3D10.1007%2FPL00005026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lione, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A. L.</span></span> <span> </span><span class="NLM_article-title">Characterisation and localisation of [<sup>3</sup>H]-2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I<sub>2</sub> receptors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(98)00389-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0014-2999%2898%2900389-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9721049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK1cXltFWkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=1998&pages=123-135&author=L.+A.+Lioneauthor=D.+J.+Nuttauthor=A.+L.+Hudson&title=Characterisation+and+localisation+of+%5B3H%5D-2-%282-benzofuranyl%29-2-imidazoline+binding+in+rat+brain%3A+a+selective+ligand+for+imidazoline+I2+receptors&doi=10.1016%2FS0014-2999%2898%2900389-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization and localization of [3H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors</span></div><div class="casAuthors">Lione, Lisa A.; Nutt, David J.; Hudson, Alan L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">123-135</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">In rat whole brain homogenates, satn. binding anal. revealed that both [3H]2-BFI (2-(2-benzofuranyl)-2-imidazoline) and [3H]idazoxan (in the presence of 5 μM rauwolscine) bound with high affinity to an apparent single population of sites.  However, the Kd for [3H]2-BFI (1.74 nM) was significantly less than that for [3H]idazoxan (10.4 nM).  In competition studies idazoxan, 2-BFI, BU 224 (2-(4,5-dihydroimidaz-2-yl)-quinoline), amiloride and guanabenz displayed high affinity (Ki values=7.32, 1.71, 2.08, 21.80 and 14.90 nM, resp.) for 70-80% of sites, and low μM affinity for the remaining 20-30% of sites labeled by [3H]2-BFI.  In contrast, several α2-adrenoceptor, imidazoline I1 receptor and histamine receptor ligands exhibited only micromolar affinity for the [3H]2-BFI labeled site.  Quant. receptor autoradiog. revealed high binding by [3H]2-BFI to discrete brain nuclei, notably the area postrema, interpeduncular nucleus, arcuate nucleus, mammillary peduncle, ependyma and pineal gland.  These data indicate that [3H]2-BFI recognizes imidazoline I2 receptors in rat brain with higher affinity and selectivity than [3H]idazoxan and thus represents a superior radioligand to [3H]idazoxan for the study of imidazoline I2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2a9GddMzRyrVg90H21EOLACvtfcHk0lipvC8VexIS6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltFWkurs%253D&md5=481f07df94cc3e16a3ec0407c4fd6b00</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2898%2900389-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252898%252900389-6%26sid%3Dliteratum%253Aachs%26aulast%3DLione%26aufirst%3DL.%2BA.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26aulast%3DHudson%26aufirst%3DA.%2BL.%26atitle%3DCharacterisation%2520and%2520localisation%2520of%2520%255B3H%255D-2-%25282-benzofuranyl%2529-2-imidazoline%2520binding%2520in%2520rat%2520brain%253A%2520a%2520selective%2520ligand%2520for%2520imidazoline%2520I2%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D353%26spage%3D123%26epage%3D135%26doi%3D10.1016%2FS0014-2999%2898%2900389-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quaglia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dontenwill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentili, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maranca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piergentili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasili, L.</span></span> <span> </span><span class="NLM_article-title">2-(2-Phenylcyclopropyl)imidazolines: reversed enantioselective interaction at I<sub>1</sub> and I<sub>2</sub> imidazoline receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2737</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm991049m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm991049m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK1MXktlKkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=2737-2740&author=W.+Quagliaauthor=P.+Bousquetauthor=M.+Piginiauthor=A.+Carottiauthor=A.+Carrieriauthor=M.+Dontenwillauthor=F.+Gentiliauthor=M.+Giannellaauthor=F.+Marancaauthor=A.+Piergentiliauthor=L.+Brasili&title=2-%282-Phenylcyclopropyl%29imidazolines%3A+reversed+enantioselective+interaction+at+I1+and+I2+imidazoline+receptors&doi=10.1021%2Fjm991049m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">2-(2-Phenylcyclopropyl)imidazolines: Reversed Enantioselective Interaction at I1 and I2 Imidazoline Receptors</span></div><div class="casAuthors">Quaglia, Wilma; Bousquet, Pascal; Pigini, Maria; Carotti, Angelo; Carrieri, Antonio; Dontenwill, Monique; Gentili, Francesco; Giannella, Mario; Maranca, Francoise; Piergentili, Alessandro; Brasili, Livio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2737-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Depending of the stereochem., replacement of the double bond in Tracizoline structure, which is 10-fold selective for the I2 imidazoline receptor subtype, by a cyclopropyl ring provides ligands selective for either I1 or I2 subtype, with a 6-fold increase of I2 selectivity and a 100-fold increase (reversed) of I1 selectivity.  Thus, the imidazoline I1 and I2 receptor binding sites have stereospecific requirements, the two subtypes showing a reversal of enantioselectivity, which may offer leads to the development of selective imidazoline receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGldzb64JdabVg90H21EOLACvtfcHk0lipvC8VexIS6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktlKkurs%253D&md5=2fca66d374abfb0426d70455cc2a7dc0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm991049m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm991049m%26sid%3Dliteratum%253Aachs%26aulast%3DQuaglia%26aufirst%3DW.%26aulast%3DBousquet%26aufirst%3DP.%26aulast%3DPigini%26aufirst%3DM.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DCarrieri%26aufirst%3DA.%26aulast%3DDontenwill%26aufirst%3DM.%26aulast%3DGentili%26aufirst%3DF.%26aulast%3DGiannella%26aufirst%3DM.%26aulast%3DMaranca%26aufirst%3DF.%26aulast%3DPiergentili%26aufirst%3DA.%26aulast%3DBrasili%26aufirst%3DL.%26atitle%3D2-%25282-Phenylcyclopropyl%2529imidazolines%253A%2520reversed%2520enantioselective%2520interaction%2520at%2520I1%2520and%2520I2%2520imidazoline%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D2737%26epage%3D2740%26doi%3D10.1021%2Fjm991049m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alemany, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribá, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menargues, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">LSL60101, a selective ligand for imidazoline I<sub>2</sub> receptors, on glial fibrillary acidic protein concentration</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(95)00214-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2F0014-2999%2895%2900214-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=7589187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2MXmvVenurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=1995&pages=205-210&author=R.+Alemanyauthor=G.+Olmosauthor=P.+V.+Escrib%C3%A1author=A.+Menarguesauthor=R.+Obachauthor=J.+A.+Garc%C3%ADa-Sevilla&title=LSL60101%2C+a+selective+ligand+for+imidazoline+I2+receptors%2C+on+glial+fibrillary+acidic+protein+concentration&doi=10.1016%2F0014-2999%2895%2900214-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">LSL 60101, a selective ligand for imidazoline I2 receptors, on glial fibrillary acidic protein concentration</span></div><div class="casAuthors">Alemany, Regina; Olmos, Gabriel; Escriba, Pablo V.; Menargues, Angel; Obach, Rossend; Garcia-Sevilla, Jesus A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-10</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The concn. of the astrocytic marker, glial fibrillary acidic protein (GFAP) was quantitated by immunoblotting (Western blotting) in the rat brain after treatment with the novel ligand for imidazoline I2 receptors LSL 60101 [2-(2-benzofuranyl)imidazole] and its 6-methoxy deriv. LSL 60125.  Chronic (7-21 days), but not acute (1 day) or short-term (3 days), treatment with LSL 60101 (10 mg/kg i.p.) markedly increased (44-49%) GFAP immunoreactivity in the rat cerebral cortex.  In contrast, chronic (7 days) treatment with LSL 60125 (10 mg/kg i.p.) did not significantly modify GFAP concns.  In vitro, both drugs displayed moderate high affinity and high selectivity for imidazoline I2 receptors vs. α2-adrenoceptors; however, only chronic treatment with LSL 60101 (10 mg/kg i.p.) but not with LSL 60125 (10 mg/kg i.p.) was assocd. with an up-regulation of imidazoline I2 receptors.  These data indicate that glial imidazoline I2 receptors may have a direct physiol. function related to GFAP expression and that LSL 60101 could be a good tool for the study of the implication of these receptors on astrocyte activation and neuronal regeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9GvqhLzzkvrVg90H21EOLACvtfcHk0lipvC8VexIS6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvVenurs%253D&md5=23df74e2d55e94e471c91612bd98dd11</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2895%2900214-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252895%252900214-6%26sid%3Dliteratum%253Aachs%26aulast%3DAlemany%26aufirst%3DR.%26aulast%3DOlmos%26aufirst%3DG.%26aulast%3DEscrib%25C3%25A1%26aufirst%3DP.%2BV.%26aulast%3DMenargues%26aufirst%3DA.%26aulast%3DObach%26aufirst%3DR.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DLSL60101%252C%2520a%2520selective%2520ligand%2520for%2520imidazoline%2520I2%2520receptors%252C%2520on%2520glial%2520fibrillary%2520acidic%2520protein%2520concentration%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D280%26spage%3D205%26epage%3D210%26doi%3D10.1016%2F0014-2999%2895%2900214-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennuni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caselli, G.</span></span> <span> </span><span class="NLM_article-title">Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.2147/JPR.S18353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.2147%2FJPR.S18353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=21647215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Sgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=111-115&author=F.+Ferrariauthor=S.+Fiorentinoauthor=L.+Mennuniauthor=P.+Garofaloauthor=O.+Letariauthor=S.+Mandelliauthor=A.+Giordaniauthor=M.+Lanzaauthor=G.+Caselli&title=Analgesic+efficacy+of+CR4056%2C+a+novel+imidazoline-2+receptor+ligand%2C+in+rat+models+of+inflammatory+and+neuropathic+pain&doi=10.2147%2FJPR.S18353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain</span></div><div class="casAuthors">Ferrari, Flora; Fiorentino, Simonetta; Mennuni, Laura; Garofalo, Paolo; Letari, Ornella; Mandelli, Stefano; Giordani, Antonio; Lanza, Marco; Caselli, Gianfranco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-125</span>CODEN:
                <span class="NLM_cas:coden">JPROEV</span>;
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Two decades of investigations have failed to unequivocally clarify the functions and the mol. nature of imidazoline-2 receptors (I2R).  However, there is robust pharmacol. evidence for the functional modulation of monoamino oxidase (MAO) and other important enzyme activities by I2 site ligands.  Some compds. of this class proved to be active exptl. tools in preventing both exptl. pain and opioid tolerance and dependence.  Unfortunately, even though these compds. bind with high potency to central I2 sites, they fail to represent a valid clin. opportunity due to their pharmacokinetic, selectivity or side-effects profile.  This paper presents the preclin. profile of a novel I2 ligand (2-phenyl-6-(1H-imidazol-1yl)quinazoline; [CR4056]) that selectively inhibits the activity of human recombinant MAO-A in a concn.-dependent manner.  A sub-chronic four day oral treatment of CR4056 increased norepinephrine (NE) tissue levels both in the rat cerebral cortex (63.1% ± 4.2%; P<0.05) and lumbar spinal cord (51.3% ± 6.7%; P<0.05).  In the complete Freund's adjuvant (CFA) rat model of inflammatory pain, CR4056 was found to be orally active (ED50 = 5.8 mg/kg, by mouth [p.o.]).  In the acute capsaicin model, CR4056 completely blocked mech. hyperalgesia in the injured hind paw (ED50 = 4.1 mg/kg, p.o.; ED100 = 17.9 mg/kg, p.o.).  This effect was dose-dependently antagonized by the non-selective imidazoline I2/α2 antagonist idazoxan.  In rat models of neuropathic pain, oral administration of CR4056 significantly attenuated mech. hyperalgesia and allodynia.  In summary, the present study suggests a novel pharmacol. opportunity for inflammatory and/or neuropathic pain treatment based on selective interaction with central imidazoline-2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ByEw6EQAb7Vg90H21EOLACvtfcHk0ljNFY_SPHvimQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Sgtbo%253D&md5=40c74f3a352a79bae53566311a89bc91</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2147%2FJPR.S18353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S18353%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DF.%26aulast%3DFiorentino%26aufirst%3DS.%26aulast%3DMennuni%26aufirst%3DL.%26aulast%3DGarofalo%26aufirst%3DP.%26aulast%3DLetari%26aufirst%3DO.%26aulast%3DMandelli%26aufirst%3DS.%26aulast%3DGiordani%26aufirst%3DA.%26aulast%3DLanza%26aufirst%3DM.%26aulast%3DCaselli%26aufirst%3DG.%26atitle%3DAnalgesic%2520efficacy%2520of%2520CR4056%252C%2520a%2520novel%2520imidazoline-2%2520receptor%2520ligand%252C%2520in%2520rat%2520models%2520of%2520inflammatory%2520and%2520neuropathic%2520pain%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2011%26volume%3D4%26spage%3D111%26epage%3D115%26doi%3D10.2147%2FJPR.S18353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span> <i>Pentacle</i>, version 1.0.6, <span class="NLM_publisher-name">Molecular
Discovery Ltd.</span>, <span class="NLM_publisher-loc">Perugia, Italy</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Pentacle%2C+version+1.0.6%2C+Molecular%0ADiscovery+Ltd.%2C+Perugia%2C+Italy%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPentacle%26pub%3DMolecular%250ADiscovery%2520Ltd%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawless, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gombar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraczkiewicz, R.</span></span> <span> </span><span class="NLM_article-title">Modeling ADMET</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1425</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-3609-0_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1007%2F978-1-4939-3609-0_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=27311462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsleru7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1425&publication_year=2016&pages=63-83&author=J.+Ghoshauthor=M.+S.+Lawlessauthor=M.+Waldmanauthor=V.+Gombarauthor=R.+Fraczkiewicz&title=Modeling+ADMET&doi=10.1007%2F978-1-4939-3609-0_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling admet</span></div><div class="casAuthors">Ghosh, Jayeeta; Lawless, Michael S.; Waldman, Marvin; Gombar, Vijay; Fraczkiewicz, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1425</span>
        (<span class="NLM_cas:issue">In Silico Methods for Predicting Drug Toxicity</span>),
    <span class="NLM_cas:pages">63-83</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Drug discovery and development is a costly and time-consuming endeavor.  Over the last two decades, computational tools and in silico models to predict ADMET (Adsorption, Distribution, Metab., Excretion, and Toxicity) profiles of mols. have been incorporated into the drug discovery process mainly in an effort to avoid late-stage failures due to poor pharmacokinetics and toxicity.  It is now widely recognized that ADMET issues should be addressed as early as possible in drug discovery.  Here, we describe in detail how ADMET models can be developed and applied using a com. available package, ADMET Predictor 7.2 (ADMET Predictor v7.2. Simulations Plus, Inc., Lancaster, CA, USA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfUDnl_gEbCbVg90H21EOLACvtfcHk0ljNFY_SPHvimQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsleru7fO&md5=0b4ca6adb95de007f55cc4b2c5a8c59a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3609-0_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-3609-0_4%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DJ.%26aulast%3DLawless%26aufirst%3DM.%2BS.%26aulast%3DWaldman%26aufirst%3DM.%26aulast%3DGombar%26aufirst%3DV.%26aulast%3DFraczkiewicz%26aufirst%3DR.%26atitle%3DModeling%2520ADMET%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2016%26volume%3D1425%26spage%3D63%26epage%3D83%26doi%3D10.1007%2F978-1-4939-3609-0_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span>ADMET Predictor, v. 9.5, <span class="NLM_publisher-name">Simulations Plus
Inc.</span>, <span class="NLM_publisher-loc">Lancaster, CA, USA</span>, <span class="NLM_year">2019</span>, <a href="https://www.simulations-plus.com" class="extLink">https://www.simulations-plus.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ADMET+Predictor%2C+v.+9.5%2C+Simulations+Plus%0AInc.%2C+Lancaster%2C+CA%2C+USA%2C+2019%2C+https%3A%2F%2Fwww.simulations-plus.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26pub%3DSimulations%2520Plus%250AInc%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">Swiss ADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small mol</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">42717</span>, <span class="refDoi"> DOI: 10.1038/srep42717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1038%2Fsrep42717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=28256516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42717&author=A.+Dainaauthor=O.+Michielinauthor=V.+Zoete&title=Swiss+ADME%3A+a+free+web+tool+to+evaluate+pharmacokinetics%2C+drug-likeness+and+medicinal+chemistry+friendliness+of+small+mol&doi=10.1038%2Fsrep42717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span></div><div class="casAuthors">Daina Antoine; Michielin Olivier; Zoete Vincent; Michielin Olivier; Michielin Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42717</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.  Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited.  In that context, computer models constitute valid alternatives to experiments.  Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar.  Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch.  Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl_Uk5dOMKs6qcneEtCi92fW6udTcc2eb1JhG3syEeKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D&md5=9715b8cb8a34b17c4c73ff69a5a8cc50</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fsrep42717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42717%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DSwiss%2520ADME%253A%2520a%2520free%2520web%2520tool%2520to%2520evaluate%2520pharmacokinetics%252C%2520drug-likeness%2520and%2520medicinal%2520chemistry%2520friendliness%2520of%2520small%2520mol%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42717%26doi%3D10.1038%2Fsrep42717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span> </span><span class="NLM_article-title">Biopharmaceutics classification system-based biowaivers, International
council for harmonisation of technical requirements for pharmaceutical
for human use</span>. <a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M9/M9EWG_DraftGuideline_Step2_2018_0606.pdf" class="extLink">https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M9/M9EWG_DraftGuideline_Step2_2018_0606.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Biopharmaceutics+classification+system-based+biowaivers%2C+International%0Acouncil+for+harmonisation+of+technical+requirements+for+pharmaceutical%0Afor+human+use.+https%3A%2F%2Fwww.ich.org%2Ffileadmin%2FPublic_Web_Site%2FICH_Products%2FGuidelines%2FMultidisciplinary%2FM9%2FM9EWG_DraftGuideline_Step2_2018_0606.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DBiopharmaceutics%2520classification%2520system-based%2520biowaivers%252C%2520International%250Acouncil%2520for%2520harmonisation%2520of%2520technical%2520requirements%2520for%2520pharmaceutical%250Afor%2520human%2520use" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span>International
council on harmonisation
of technical requirements for registration of pharmaceuticals for
human use. ICH harmonized tripartite guideline. “Stability
testing of new drug substance and products”. Q1A (R2), <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=International%0Acouncil+on+harmonisation%0Aof+technical+requirements+for+registration+of+pharmaceuticals+for%0Ahuman+use.+ICH+harmonized+tripartite+guideline.+%E2%80%9CStability%0Atesting+of+new+drug+substance+and+products%E2%80%9D.+Q1A+%28R2%29%2C+2003."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span>For information
on the Eurofins Lead Profiling Screen, see <a href="http://www.eurofins.com" class="extLink">http://www.eurofins.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+information%0Aon+the+Eurofins+Lead+Profiling+Screen%2C+see+http%3A%2F%2Fwww.eurofins.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cawston, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">1009</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00489.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1111%2Fj.1476-5381.2009.00489.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=19922535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1ektrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2010&pages=1009-1021&author=E.+E.+Cawstonauthor=L.+J.+Miller&title=Therapeutic+potential+for+novel+drugs+targeting+the+type+1+cholecystokinin+receptor&doi=10.1111%2Fj.1476-5381.2009.00489.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor</span></div><div class="casAuthors">Cawston, Erin E.; Miller, Laurence J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1009-1021</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Cholecystokinin (CCK) is a physiol. important gastrointestinal and neuronal peptide hormone, with roles in stimulating gallbladder contraction, pancreatic secretion, gastrointestinal motility and satiety.  CCK exerts its effects via interactions with two structurally related class I guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs), the CCK1 receptor and the CCK2 receptor.  Here, we focus on the CCK1 receptor, with particular relevance to the broad spectrum of signaling initiated by activation with the natural full agonist peptide ligand, CCK.  Distinct ligand-binding pockets have been defined for the natural peptide ligand and for some non-peptidyl small mol. ligands.  While many CCK1 receptor ligands have been developed and have had their pharmacol. well described, their clin. potential has not yet been fully explored.  The case is built for the potential importance of developing more selective partial agonists and allosteric modulators of this receptor that could have important roles in the treatment of common clin. syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtyv1BtMA3crVg90H21EOLACvtfcHk0liRBQKbfSsUcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1ektrg%253D&md5=5226f315676918d3a345674bdb60eb5f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00489.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00489.x%26sid%3Dliteratum%253Aachs%26aulast%3DCawston%26aufirst%3DE.%2BE.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26atitle%3DTherapeutic%2520potential%2520for%2520novel%2520drugs%2520targeting%2520the%2520type%25201%2520cholecystokinin%2520receptor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D159%26spage%3D1009%26epage%3D1021%26doi%3D10.1111%2Fj.1476-5381.2009.00489.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effects of imidazoline receptor ligands on basal and kainic acid-induced neurotoxic signalling in mice</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">886</span>, <span class="refDoi"> DOI: 10.1177/0269881116652579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1177%2F0269881116652579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=27302941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWmur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=875-886&author=B.+Kellerauthor=J.+A.+Garc%C3%ADa-Sevilla&title=Inhibitory+effects+of+imidazoline+receptor+ligands+on+basal+and+kainic+acid-induced+neurotoxic+signalling+in+mice&doi=10.1177%2F0269881116652579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effects of imidazoline receptor ligands on basal and kainic acid-induced neurotoxic signalling in mice</span></div><div class="casAuthors">Keller, Benjamin; Garcia-Sevilla, Jesus A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">875-886</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">This in vivo study assessed the potential of the imidazoline receptor (IR) ligands moxonidine (selective I1-IR), BU224 (selective I2-IR) and LSL61122 (mixed I1/I2-IR) to dampen excitotoxic signalling induced by kainic acid (KA; 45 mg/kg) in the mouse brain (hippocampus and cerebral cortex).  KA triggered a strong behavioral syndrome (seizures; maximal at 60-90 min) and sustained stimulation (at 72 h with otherwise normal mouse behavior) of pro-apoptotic c-Jun-N-terminal kinases (JNK) and calpain with increased cleavage of p35 into neurotoxic p25 (cyclin-dependent kinase 5 [Cdk5] activators) in mouse hippocampus.  Pretreatment (five days) with LSL61122 (10 mg/kg), but not moxonidine (1 mg/kg) or BU224 (20 mg/kg), attenuated the KA-induced behavioral syndrome, and all three IR ligands inhibited JNK and calpain activation, as well as p35/p25 cleavage after KA in the hippocampus (effects also obsd. after acute IR drug treatments).  Efaroxan (I1-IR, 10 mg/kg) and idazoxan (I2-IR, 10 mg/kg), postulated IR antagonists, did not antagonize the effects of moxonidine and LSL61122 on KA targets (these IR ligands showed agonistic properties inhibiting pro-apoptotic JNK).  Brain subcellular prepns. revealed reduced synaptosomal postsynaptic d.-95 protein contents (a mediator of JNK activation) and indicated increased p35/Cdk5 complexes (with pro-survival functions) after treatment with moxonidine, BU224 and LSL61122.  These results showed that I1- and I2-IR ligands (moxonidine and BU224), and esp. the mixed I1/I2-IR ligand LSL61122, are partly neuroprotective against KA-induced excitotoxic signalling.  These findings suggest a therapeutic potential of IR drugs in disorders assocd. with glutamate-mediated neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqp6nvNi5b37Vg90H21EOLACvtfcHk0liRBQKbfSsUcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWmur%252FF&md5=10fc8def3fa26dd5d175dbb8d857eacd</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F0269881116652579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881116652579%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DB.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DInhibitory%2520effects%2520of%2520imidazoline%2520receptor%2520ligands%2520on%2520basal%2520and%2520kainic%2520acid-induced%2520neurotoxic%2520signalling%2520in%2520mice%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2016%26volume%3D30%26spage%3D875%26epage%3D886%26doi%3D10.1177%2F0269881116652579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorn, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. X.</span></span> <span> </span><span class="NLM_article-title">Characterization of the hypothermic effects of imidazoline I<sub>2</sub> receptor agonists in rats</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">1936</span>– <span class="NLM_lpage">1945</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.01894.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1111%2Fj.1476-5381.2012.01894.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=22324428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOrsr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=1936-1945&author=D.+A.+Thornauthor=X.+F.+Anauthor=Y.+Zhangauthor=M.+Piginiauthor=J.+X.+Li&title=Characterization+of+the+hypothermic+effects+of+imidazoline+I2+receptor+agonists+in+rats&doi=10.1111%2Fj.1476-5381.2012.01894.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the hypothermic effects of imidazoline I2 receptor agonists in rats</span></div><div class="casAuthors">Thorn, David A.; An, Xiao-Fei; Zhang, Yanan; Pigini, Maria; Li, Jun-Xu</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1936-1945</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Imidazoline I2 receptors have been implicated in several CNS disorders.  Although several I2 receptor agonists have been described, no simple and sensitive in vivo bioassay is available for studying I2 receptor ligands.  This study examd. I2 receptor agonist-induced hypothermia as a functional in vivo assay of I2 receptor agonism.  Different groups of rats were used to examine the effects of I2 receptor agonists on the rectal temp. and locomotion.  The pharmacol. mechanisms were investigated by combining I2 receptor ligands and different antagonists.  All the selective I2 receptor agonists examd. (2-BFI, diphenyzoline, phenyzoline, CR4056, tracizoline, BU224 and S22687, 3.2-56 mg·kg-1, i.p.) dose-dependently and markedly decreased the rectal temp. (hypothermia) in rats, with varied duration of action.  Pharmacol. mechanism of the obsd. hypothermia was studied by combining the I2 receptor agonists (2-BFI, BU224, tracizoline and diphenyzoline) with imidazoline I2 receptor/ α2 adrenoceptor antagonist idazoxan, selective I1 receptor antagonist efaroxan, α2 adrenoceptor antagonist/5-HT1A receptor agonist yohimbine.  Idazoxan but not yohimbine or efaroxan attenuated the hypothermic effects of 2-BFI, BU224, tracizoline and diphenyzoline, supporting the I2 receptor mechanism.  In contrast, both idazoxan and yohimbine attenuated hypothermia induced by the α2 adrenoceptor agonist clonidine.  Among all the I2 receptor agonists studied, only S22687 markedly increased the locomotor activity in rats.  Imidazoline I2 receptor agonists can produce hypothermic effects, which are primarily mediated by I2 receptors.  These data suggest that I2 receptor agonist-induced hypothermia is a simple and sensitive in vivo assay for studying I2 receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-o3Cxi8jkyLVg90H21EOLACvtfcHk0liRBQKbfSsUcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOrsr7P&md5=95ae5d105c505d90702aee3952f3e4a7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01894.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01894.x%26sid%3Dliteratum%253Aachs%26aulast%3DThorn%26aufirst%3DD.%2BA.%26aulast%3DAn%26aufirst%3DX.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPigini%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BX.%26atitle%3DCharacterization%2520of%2520the%2520hypothermic%2520effects%2520of%2520imidazoline%2520I2%2520receptor%2520agonists%2520in%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D1936%26epage%3D1945%26doi%3D10.1111%2Fj.1476-5381.2012.01894.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craven, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, E. L.</span></span> <span> </span><span class="NLM_article-title">Effects of alpha 2-adrenoceptor antagonists and imidazoline 2-receptor ligands on neuronal damage in global ischaemia in the rat</span>. <i>Clin. Exp. Pharmacol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1111/j.1440-1681.1997.tb01808.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1111%2Fj.1440-1681.1997.tb01808.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9075597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2sXis1Knur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1997&pages=204-207&author=J.+A.+Cravenauthor=E.+L.+Conway&title=Effects+of+alpha+2-adrenoceptor+antagonists+and+imidazoline+2-receptor+ligands+on+neuronal+damage+in+global+ischaemia+in+the+rat&doi=10.1111%2Fj.1440-1681.1997.tb01808.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of α2-adrenoceptor antagonists and imidazoline2-receptor ligands on neuronal damage in global ischemia in the rat</span></div><div class="casAuthors">Craven, John A.; Conway, Elizabeth L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Pharmacology and Physiology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">204-207</span>CODEN:
                <span class="NLM_cas:coden">CEXPB9</span>;
        ISSN:<span class="NLM_cas:issn">0305-1870</span>.
    
            (<span class="NLM_cas:orgname">Blackwell</span>)
        </div><div class="casAbstract">The neuroprotective effects of 3 mg idazoxan/kg, both an α2-adrenoceptor antagonist and imidazoline2-receptor (I2-receptor) ligand, 3 mg methoxyidazoxan/kg, a specific α2-adrenoceptor antagonist, and 0.6 and 3 mg BU224/kg, a selective I2-receptor ligand, were evaluated following 10 min of global ischemia in rats.  Neuronal cell counts in the CA1 region of the hippocampus 8 days postischemia indicated 46-96% cell loss compared with controls and a 320% increase in [3H]-PK11195 binding, used as a marker of gliosis.  No significant neuroprotective effect on these markers of neuronal damage could be detected in the drug-treated groups.  However, in 1 subset of idazoxan-treated rats, neuronal loss and gliosis were minimal.  Mean body temp. during 3 h postischemia was lower in idazoxan-treated rats than in the other treated groups, and there was a correlation between mean body temp. and cell counts and mean body temp. and gliosis in this group.  These results indicate that at the doses used neither BU224 nor methoxyidazoxan is neuroprotective in this ischemia model and they raise the possibility that any neuroprotective effect of idazoxan may be related to hypothermic effects of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_DbikVKDTDbVg90H21EOLACvtfcHk0lgDrkKnhkuDzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1Knur0%253D&md5=e9bb9d97aff36a51e0e874d563ebae84</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1681.1997.tb01808.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1681.1997.tb01808.x%26sid%3Dliteratum%253Aachs%26aulast%3DCraven%26aufirst%3DJ.%2BA.%26aulast%3DConway%26aufirst%3DE.%2BL.%26atitle%3DEffects%2520of%2520alpha%25202-adrenoceptor%2520antagonists%2520and%2520imidazoline%25202-receptor%2520ligands%2520on%2520neuronal%2520damage%2520in%2520global%2520ischaemia%2520in%2520the%2520rat%26jtitle%3DClin.%2520Exp.%2520Pharmacol.%2520Physiol.%26date%3D1997%26volume%3D24%26spage%3D204%26epage%3D207%26doi%3D10.1111%2Fj.1440-1681.1997.tb01808.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marion, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penrod, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obrist, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochanek, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeKosky, S. T.</span></span> <span> </span><span class="NLM_article-title">Treatment of traumatic brain injury with moderate hypothermia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>336</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1056/NEJM199702203360803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1056%2FNEJM199702203360803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9023090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADyaK2s7msVOgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=1997&pages=540-546&author=D.+W.+Marionauthor=L.+E.+Penrodauthor=S.+F.+Kelseyauthor=W.+D.+Obristauthor=P.+M.+Kochanekauthor=A.+M.+Palmerauthor=S.+R.+Wisniewskiauthor=S.+T.+DeKosky&title=Treatment+of+traumatic+brain+injury+with+moderate+hypothermia&doi=10.1056%2FNEJM199702203360803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of traumatic brain injury with moderate hypothermia</span></div><div class="casAuthors">Marion D W; Penrod L E; Kelsey S F; Obrist W D; Kochanek P M; Palmer A M; Wisniewski S R; DeKosky S T</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">540-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Traumatic brain injury initiates several metabolic processes that can exacerbate the injury.  There is evidence that hypothermia may limit some of these deleterious metabolic responses.  METHODS:  In a randomized, controlled trial, we compared the effects of moderate hypothermia and normothermia in 82 patients with severe closed head injuries (a score of 3 to 7 on the Glasgow Coma Scale).  The patients assigned to hypothermia were cooled to 33 degrees C a mean of 10 hours after injury, kept at 32 degrees to 33 degrees C for 24 hours, and then rewarmed.  A specialist in physical medicine and rehabilitation who was unaware of the treatment assignments evaluated the patients 3, 6, and 12 months later with the use of the Glasgow Outcome Scale.  RESULTS:  The demographic characteristics and causes and severity of injury were similar in the hypothermia and normothermia groups.  At 12 months, 62 percent of the patients in the hypothermia group and 38 percent of those in the normothermia group had good outcomes (moderate, mild, or no disabilities).  The adjusted risk ratio for a bad outcome in the hypothermia group was 0.5 (95 percent confidence interval, 0.2 to 1.2).  Hypothermia did not improve the outcomes in the patients with coma scores of 3 or 4 on admission.  Among the patients with scores of 5 to 7, hypothermia was associated with significantly improved outcomes at 3 and 6 months (adjusted risk ratio for a bad outcome, 0.2; 95 percent confidence interval, 0.1 to 0.9 at both intervals), although not at 12 months (risk ratio, 0.3; 95 percent confidence interval, 0.1 to 1.0).  CONCLUSIONS:  Treatment with moderate hypothermia for 24 hours in patients with severe traumatic brain injury and coma scores of 5 to 7 on admission hastened neurologic recovery and may have improved the outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkDoz6qOFQI8ScOqQTSkOffW6udTcc2eaYWLF-5M-S8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7msVOgsQ%253D%253D&md5=4e2ccf1ae3413c12c3e72d2381fbf18f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1056%2FNEJM199702203360803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199702203360803%26sid%3Dliteratum%253Aachs%26aulast%3DMarion%26aufirst%3DD.%2BW.%26aulast%3DPenrod%26aufirst%3DL.%2BE.%26aulast%3DKelsey%26aufirst%3DS.%2BF.%26aulast%3DObrist%26aufirst%3DW.%2BD.%26aulast%3DKochanek%26aufirst%3DP.%2BM.%26aulast%3DPalmer%26aufirst%3DA.%2BM.%26aulast%3DWisniewski%26aufirst%3DS.%2BR.%26aulast%3DDeKosky%26aufirst%3DS.%2BT.%26atitle%3DTreatment%2520of%2520traumatic%2520brain%2520injury%2520with%2520moderate%2520hypothermia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1997%26volume%3D336%26spage%3D540%26epage%3D546%26doi%3D10.1056%2FNEJM199702203360803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maier, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahern, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yenari, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, G. K.</span></span> <span> </span><span class="NLM_article-title">Optimal depth and duration of mild hypothermia in focal model of transient cerebral ischemia: effects on neurologic outcome, infarct size, apopotosis, and inflammation</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2171</span>– <span class="NLM_lpage">2180</span>, <span class="refDoi"> DOI: 10.1161/01.STR.29.10.2171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1161%2F01.STR.29.10.2171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9756600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADyaK1cvivFKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1998&pages=2171-2180&author=C.+M.+Maierauthor=K.+V.+Ahernauthor=M.+L.+Chengauthor=J.+E.+Leeauthor=M.+A.+Yenariauthor=G.+K.+Steinberg&title=Optimal+depth+and+duration+of+mild+hypothermia+in+focal+model+of+transient+cerebral+ischemia%3A+effects+on+neurologic+outcome%2C+infarct+size%2C+apopotosis%2C+and+inflammation&doi=10.1161%2F01.STR.29.10.2171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia: effects on neurologic outcome, infarct size, apoptosis, and inflammation</span></div><div class="casAuthors">Maier C M; Ahern K v; Cheng M L; Lee J E; Yenari M A; Steinberg G K</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2171-80</span>
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Mild hypothermia is possibly the single most effective method of cerebroprotection developed to date.  However, many questions regarding mild hypothermia remain to be addressed before its potential implementation in the treatment of human stroke.  Here we report the results of 2 studies designed to determine the optimal depth and duration of mild hypothermia in focal stroke and its effects on infarct size, neurological outcome, programmed cell death, and inflammation.  METHODS:  Rats underwent a 2-hour occlusion of the left middle cerebral artery.  In the first study (I) animals were kept (intraischemically) at either 37 degreesC (n=8), 33 degreesC (n=8), or 30 degreesC (n=8).  Study II consisted of 4 groups: (1) controls (37 degreesC, n=10), (2) 30 minutes of hypothermia started at ischemic onset (33 degreesC, n=9), (3)1 hour (33 degreesC, n=8), and (4) 2 hours (33 degreesC, n=8).  Brain temperature was measured by a thermocouple probe placed in the contralateral cortex.  After suture removal, all animals were rewarmed and reperfused for 22 hours (I) or 70 hours (II).  RESULTS:  Mild hypothermia to 33 degreesC or 30 degreesC was neuroprotective (17+/-7% and 27+/-6%, respectively) relative to controls (53+/-8%, P<0.02), but 33 degreesC was better tolerated and recovery from anesthesia was faster.  The neurological score of hypothermic animals was significantly better than that of controls (I & II) at both 24 and 72 hours postischemia except for the 30-minute group (II), which showed no improvement.  In Study II, 2 hours of hypothermia reduced injury by 59%, 1 hour reduced injury by 84% whereas 30 minutes did not reduce injury.  Normalized for infarct size, 2 hours of mild hypothermia decreased neutrophil accumulation by 57% whereas both 1 hour and 30 minutes had no effect.  At 72 hours, 1 and 2 hours of mild hypothermia decreased transferase dUTP nick-end labeling (TUNEL) staining by 78% and 99%, respectively, and 30 minutes of hypothermia had no effect.  CONCLUSIONS:  Intraischemic mild hypothermia must be maintained for 1 to 2 hours to obtain optimal neuroprotection against ischemic cell death due to necrosis and apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcokX7KntZvnELvajU9pjPfW6udTcc2eaYWLF-5M-S8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1cvivFKktg%253D%253D&md5=4311bf2c122c068734121571ae2ba626</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1161%2F01.STR.29.10.2171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.STR.29.10.2171%26sid%3Dliteratum%253Aachs%26aulast%3DMaier%26aufirst%3DC.%2BM.%26aulast%3DAhern%26aufirst%3DK.%2BV.%26aulast%3DCheng%26aufirst%3DM.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DYenari%26aufirst%3DM.%2BA.%26aulast%3DSteinberg%26aufirst%3DG.%2BK.%26atitle%3DOptimal%2520depth%2520and%2520duration%2520of%2520mild%2520hypothermia%2520in%2520focal%2520model%2520of%2520transient%2520cerebral%2520ischemia%253A%2520effects%2520on%2520neurologic%2520outcome%252C%2520infarct%2520size%252C%2520apopotosis%252C%2520and%2520inflammation%26jtitle%3DStroke%26date%3D1998%26volume%3D29%26spage%3D2171%26epage%3D2180%26doi%3D10.1161%2F01.STR.29.10.2171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Hernández, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Fuster, M. J.</span></span> <span> </span><span class="NLM_article-title">Improved age-related deficits in cognitive performance and affective-like behavior following acute, but not repeated , 8-OH-DPAT treatments in rats: regulation of hippocampal FADD</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2018.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.neurobiolaging.2018.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=30138765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=115-126&author=E.+Hern%C3%A1ndez-Hern%C3%A1ndezauthor=A.+Mirallesauthor=S.+Estebanauthor=M.+J.+Garc%C3%ADa-Fuster&title=Improved+age-related+deficits+in+cognitive+performance+and+affective-like+behavior+following+acute%2C+but+not+repeated+%2C+8-OH-DPAT+treatments+in+rats%3A+regulation+of+hippocampal+FADD&doi=10.1016%2Fj.neurobiolaging.2018.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Improved age-related deficits in cognitive performance and affective-like behavior following acute, but not repeated, 8-OH-DPAT treatments in rats: regulation of hippocampal FADD</span></div><div class="casAuthors">Hernandez-Hernandez, Elena; Miralles, Antonio; Esteban, Susana; Garcia-Fuster, M. Julia</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-126</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The aims of this study were (1) to behaviorally phenotype rats at different ages for both cognitive performance and affect, (2) to evaluate the possible beneficial effects of 8-OH-DPAT (a 5-HT1A receptor agonist) treatments on improving age-related behavioral deficits, and (3) to uncover putative key brain targets (e.g., Fas-assocd. protein with death domain [FADD] and related partners) that might contribute to the obsd. age-related behavioral changes.  The principal results showed that acute, but not repeated, 8-OH-DPAT treatments improved age-related deficits in cognitive performance and affect while induced hypothermia.  Moreover, multifunctional FADD protein decreased with age specifically in the hippocampus (as compared to the prefrontal cortex) and was further decreased following acute 8-OH-DPAT.  The major conclusions indicate a parallelism between the beneficial effects obsd. following acute 8-OH-DPAT on improving the neg. consequences of aging on cognition and affect, together with the acute induction of hypothermia and hippocampal FADD regulation.  Because these effects were not obsd. following repeated treatment (i.e., obsd. tolerance to acute hypothermia), the results suggest 5-HT1A receptors desensitization and/or the activation of compensatory adaptive mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquC2U2RVr0fbVg90H21EOLACvtfcHk0li30sorpOdhQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgsL%252FN&md5=cad916a633c8cfb6a20581fef14cbefd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2018.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2018.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DHern%25C3%25A1ndez-Hern%25C3%25A1ndez%26aufirst%3DE.%26aulast%3DMiralles%26aufirst%3DA.%26aulast%3DEsteban%26aufirst%3DS.%26aulast%3DGarc%25C3%25ADa-Fuster%26aufirst%3DM.%2BJ.%26atitle%3DImproved%2520age-related%2520deficits%2520in%2520cognitive%2520performance%2520and%2520affective-like%2520behavior%2520following%2520acute%252C%2520but%2520not%2520repeated%2520%252C%25208-OH-DPAT%2520treatments%2520in%2520rats%253A%2520regulation%2520of%2520hippocampal%2520FADD%26jtitle%3DNeurobiol.%2520Aging%26date%3D2018%26volume%3D71%26spage%3D115%26epage%3D126%26doi%3D10.1016%2Fj.neurobiolaging.2018.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Hernández, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Fuster, M. J.</span></span> <span> </span><span class="NLM_article-title">Repeated treatment with the α2-adrenoceptor agonist UK-14304 improves cognitive performance in middle-age rats: role of hippocampal Fas-associated death domain</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1177/0269881117742667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1177%2F0269881117742667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=29207901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivVanurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=248-255&author=E.+Hern%C3%A1ndez-Hern%C3%A1ndezauthor=A.+Mirallesauthor=S.+Estebanauthor=M.+J.+Garcia-Fuster&title=Repeated+treatment+with+the+%CE%B12-adrenoceptor+agonist+UK-14304+improves+cognitive+performance+in+middle-age+rats%3A+role+of+hippocampal+Fas-associated+death+domain&doi=10.1177%2F0269881117742667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated treatment with the a2-adrenoceptor agonist UK-14304 improves cognitive performance in middle-age rats: Role of hippocampal Fas-associated death domain</span></div><div class="casAuthors">Hernandez-Hernandez, Elena; Miralles, Antonio; Esteban, Susana; Garcia-Fuster, M. Julia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">248-255</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">The cell fate regulator Fas-assocd. death domain (FADD) balances cell death with non-apoptotic actions via its phosphorylated form.  A recent study assocd. loss of cortical FADD with cognitive decline and increased risk of clin. dementia.  Since the activation of cortical α2A-adrenoceptors improved memory deficits in various animal models of working memory loss, the present study evaluated whether UK-14304, an α2-adrenoceptor agonist known to acutely regulate brain FADD forms, would improve cognitive function in middle-aged rats.  Sprague-Dawley rats were treated with UK-14304 (0.3 or 1 mg/kg) or saline (1 mL/kg) for seven days.  Cognitive performance was evaluated in the eight-arm radial maze.  FADD protein content was measured in the prefrontal cortex and hippocampus by Western blot anal.  The results showed that UK-14304 (1 mg/kg) improved cognitive performance (less time: -310±45 s, p=0.025 and fewer errors: -2.75±1.06, p=0.043 to complete the maze) and increased FADD selectively in the hippocampus (+35±11%, p=0.029).  Interestingly, hippocampal FADD content neg. correlated with the time (r=-0.651, p<0.01) needed to complete the maze.  Thus, better cognitive scores were assocd. with higher FADD hippocampal content.  These results support a role for α2-adrenoceptors in ameliorating cognition and suggest FADD protein content as a possible correlate for cognitive performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquOawyd4UagLVg90H21EOLACvtfcHk0li30sorpOdhQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivVanurs%253D&md5=42f6ba8731dd93e02bbb47fde4f9e77a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1177%2F0269881117742667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881117742667%26sid%3Dliteratum%253Aachs%26aulast%3DHern%25C3%25A1ndez-Hern%25C3%25A1ndez%26aufirst%3DE.%26aulast%3DMiralles%26aufirst%3DA.%26aulast%3DEsteban%26aufirst%3DS.%26aulast%3DGarcia-Fuster%26aufirst%3DM.%2BJ.%26atitle%3DRepeated%2520treatment%2520with%2520the%2520%25CE%25B12-adrenoceptor%2520agonist%2520UK-14304%2520improves%2520cognitive%2520performance%2520in%2520middle-age%2520rats%253A%2520role%2520of%2520hippocampal%2520Fas-associated%2520death%2520domain%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2018%26volume%3D32%26spage%3D248%26epage%3D255%26doi%3D10.1177%2F0269881117742667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bilkei-Gorzo, A.</span></span> <span> </span><span class="NLM_article-title">Genetic mouse models of brain ageing and Alzheimer’s disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2013.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.pharmthera.2013.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=24362083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2014&pages=244-257&author=A.+Bilkei-Gorzo&title=Genetic+mouse+models+of+brain+ageing+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.pharmthera.2013.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic mouse models of brain ageing and Alzheimer's disease</span></div><div class="casAuthors">Bilkei-Gorzo, Andras</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">244-257</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Progression of brain ageing is influenced by a complex interaction of genetic and environmental factors.  Anal. of genetically modified animals with uniform genetic backgrounds in a standardized, controlled environment enables the dissection of crit. determinants of brain ageing on a mol. level.  Human and animal studies suggest that increased load of damaged macromols., efficacy of DNA maintenance, mitochondrial activity, and cellular stress defences are crit. determinants of brain ageing.  Surprisingly, mouse lines with genetic impairment of anti-oxidative capacity generally did not show enhanced cognitive ageing but rather an increased sensitivity to oxidative challenge.  Mouse lines with impaired mitochondrial activity had critically short life spans or severe and rapidly progressing neurodegeneration.  Strains with impaired clearance in damaged macromols. or defects in the regulation of cellular stress defences showed alterations in the onset and progression of cognitive decline.  Importantly, reduced insulin/insulin-like growth factor signalling generally increased life span but impaired cognitive functions revealing a complex interaction between ageing of the brain and of the body.  Brain ageing is accompanied by an increased risk of developing Alzheimer's disease.  Transgenic mouse models expressing high levels of mutant human amyloid precursor protein showed a no. of symptoms and pathophysiol. processes typical for early phase of Alzheimer's disease.  Generally, therapeutic strategies effective against Alzheimer's disease in humans were also active in the Tg2576, APP23, APP/PS1 and 5xFAD lines, but a large no. of false pos. findings were also reported.  The 3xtg AD model likely has the highest face and construct validity but further studies are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR3CR6awT_MLVg90H21EOLACvtfcHk0li30sorpOdhQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1ehug%253D%253D&md5=50cbc54477a66f45648d574960c034ec</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2013.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2013.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DBilkei-Gorzo%26aufirst%3DA.%26atitle%3DGenetic%2520mouse%2520models%2520of%2520brain%2520ageing%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2014%26volume%3D142%26spage%3D244%26epage%3D257%26doi%3D10.1016%2Fj.pharmthera.2013.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antunes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biala, G.</span></span> <span> </span><span class="NLM_article-title">The novel object recognition memory: neurobiology, test procedure, and its modifications</span>. <i>Cogn. Process.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1007/s10339-011-0430-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1007%2Fs10339-011-0430-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=22160349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BC38zoslWlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=93-110&author=M.+Antunesauthor=G.+Biala&title=The+novel+object+recognition+memory%3A+neurobiology%2C+test+procedure%2C+and+its+modifications&doi=10.1007%2Fs10339-011-0430-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The novel object recognition memory: neurobiology, test procedure, and its modifications</span></div><div class="casAuthors">Antunes M; Biala G</div><div class="citationInfo"><span class="NLM_cas:title">Cognitive processing</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Animal models of memory have been considered as the subject of many scientific publications at least since the beginning of the twentieth century.  In humans, memory is often accessed through spoken or written language, while in animals, cognitive functions must be accessed through different kind of behaviors in many specific, experimental models of memory and learning.  Among them, the novel object recognition test can be evaluated by the differences in the exploration time of novel and familiar objects.  Its application is not limited to a field of research and enables that various issues can be studied, such as the memory and learning, the preference for novelty, the influence of different brain regions in the process of recognition, and even the study of different drugs and their effects.  This paper describes the novel object recognition paradigms in animals, as a valuable measure of cognition.  The purpose of this work was to review the neurobiology and methodological modifications of the test commonly used in behavioral pharmacology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQocv30hVI3YVf1XRtfYM0dfW6udTcc2ebY58Cg1sPZ8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zoslWlsQ%253D%253D&md5=4f73ed1bafb04056c5aef19b1b86c802</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs10339-011-0430-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10339-011-0430-z%26sid%3Dliteratum%253Aachs%26aulast%3DAntunes%26aufirst%3DM.%26aulast%3DBiala%26aufirst%3DG.%26atitle%3DThe%2520novel%2520object%2520recognition%2520memory%253A%2520neurobiology%252C%2520test%2520procedure%252C%2520and%2520its%2520modifications%26jtitle%3DCogn.%2520Process.%26date%3D2012%26volume%3D13%26spage%3D93%26epage%3D110%26doi%3D10.1007%2Fs10339-011-0430-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heneka, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">Inflammasome signalling in brain function and neurodegenerative disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1038/s41583-018-0055-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1038%2Fs41583-018-0055-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=30206330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSnt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=610-621&author=M.+T.+Henekaauthor=R.+M.+McManusauthor=E.+Latz&title=Inflammasome+signalling+in+brain+function+and+neurodegenerative+disease&doi=10.1038%2Fs41583-018-0055-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammasome signalling in brain function and neurodegenerative disease</span></div><div class="casAuthors">Heneka, Michael T.; McManus, Roisin M.; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The mammalian CNS is an intricate and fragile structure, which on one hand is open to change in order to store information, but on the other hand is vulnerable to damage from injury, pathogen invasion or neurodegeneration.  During senescence and neurodegeneration, activation of the innate immune system can occur.  Inflammasomes are signalling complexes that regulate cells of the immune system, which in the brain mainly includes microglial cells.  In microglia, the NLRP3 (NOD-, LRR- and pyrin domain-contg. 3) inflammasome becomes activated when these cells sense proteins such as misfolded or aggregated amyloid-β, α-synuclein and prion protein or superoxide dismutase, ATP and members of the complement pathway.  Several other inflammasomes have been described in microglia and the other cells of the brain, including astrocytes and neurons, where their activation and subsequent caspase 1 cleavage contribute to disease development and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNcYCoTzamKLVg90H21EOLACvtfcHk0lhZZvRkMP192g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSnt7jO&md5=140aef541b7b1eaae9ca1b71b848c2ce</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fs41583-018-0055-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41583-018-0055-7%26sid%3Dliteratum%253Aachs%26aulast%3DHeneka%26aufirst%3DM.%2BT.%26aulast%3DMcManus%26aufirst%3DR.%2BM.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DInflammasome%2520signalling%2520in%2520brain%2520function%2520and%2520neurodegenerative%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2018%26volume%3D19%26spage%3D610%26epage%3D621%26doi%3D10.1038%2Fs41583-018-0055-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.-M.</span>; <span class="NLM_string-name">Zhou, H.</span>; <span class="NLM_string-name">Hong, J. S.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress, neuroinflammation, and neurodegeneration</span>. In  <i>Neuroinflammation and neurodegeneration</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, P. K.</span>, <span class="NLM_string-name">Toborek, M.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2014</span>; pp  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">104</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1007%2F978-1-4939-1071-7_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=81-104&author=H.-M.+Gao&author=H.+Zhou&author=J.+S.+Hongauthor=P.+K.+Peterson&author=M.+Toborek&title=Neuroinflammation+and+neurodegeneration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-1071-7_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-1071-7_5%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DH.-M.%26atitle%3DOxidative%2520stress%252C%2520neuroinflammation%252C%2520and%2520neurodegeneration%26btitle%3DNeuroinflammation%2520and%2520neurodegeneration%26aulast%3DPeterson%26aufirst%3DP.%2BK.%26pub%3DSpringer%26date%3D2014%26spage%3D81%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekert, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, R. J.</span></span> <span> </span><span class="NLM_article-title">TNF alpha inhibitors in Alzheimer’s disease: a systematic review</span>. <i>Int. J. Geriatr. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">688</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1002/gps.4871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fgps.4871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=29516540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A280%3ADC%252BC1MrovVOjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=688-694&author=J.+O.+Ekertauthor=R.+L.+Gouldauthor=G.+Reynoldsauthor=R.+J.+Howard&title=TNF+alpha+inhibitors+in+Alzheimer%E2%80%99s+disease%3A+a+systematic+review&doi=10.1002%2Fgps.4871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">TNF alpha inhibitors in Alzheimer's disease: A systematic review</span></div><div class="casAuthors">Ekert Justyna O; Gould Rebecca L; Howard Robert J; Reynolds Gemma</div><div class="citationInfo"><span class="NLM_cas:title">International journal of geriatric psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">688-694</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The objective of this study was to evaluate the effect of tumour necrosis factor-alpha inhibitors (TNF-αI) on Alzheimer's disease-associated pathology.  DESIGN:  A literature search of PubMed, Embase, PsychINFO, Web of Science, Scopus, and the Cochrane Library databases for human and animal studies that evaluated the use of TNF-αI was performed on 26 October 2016.  RESULTS:  The main outcomes assessed were cognition and behaviour, reduction in brain tissue mass, presence of plaques and tangles, and synaptic function.  Risk of bias was assessed regarding blinding, statistical model, outcome reporting, and other biases.  Sixteen studies were included, 13 of which were animal studies and 3 of which were human.  All animal studies found that treatment with TNF-αI leads to an improvement in cognition and behaviour.  None of the studies measured change in brain tissue mass.  The majority of studies documented a beneficial effect in other areas, including the presence of plaques and tangles and synaptic function.  The amount of data from human studies was limited.  Two out of 3 studies concluded that TNF-αI are beneficial in Alzheimer's disease patients, with one being an observational study and the latter being a small pilot study, with a high risk of bias.  CONCLUSION:  It was concluded that a large-scale randomized controlled trial assessing the effectiveness of TNF-αI on humans is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwUdIMvEaLnTslzEEsg76ufW6udTcc2ebY58Cg1sPZ8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrovVOjug%253D%253D&md5=87fe8070b58d57832042842ad7d04ef4</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fgps.4871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgps.4871%26sid%3Dliteratum%253Aachs%26aulast%3DEkert%26aufirst%3DJ.%2BO.%26aulast%3DGould%26aufirst%3DR.%2BL.%26aulast%3DReynolds%26aufirst%3DG.%26aulast%3DHoward%26aufirst%3DR.%2BJ.%26atitle%3DTNF%2520alpha%2520inhibitors%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520systematic%2520review%26jtitle%3DInt.%2520J.%2520Geriatr.%2520Psychiatry%26date%3D2018%26volume%3D33%26spage%3D688%26epage%3D694%26doi%3D10.1002%2Fgps.4871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iadecola, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, M. E.</span></span> <span> </span><span class="NLM_article-title">Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">9157</span>– <span class="NLM_lpage">9164</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.17-23-09157.1997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1523%2FJNEUROSCI.17-23-09157.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9364062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK2sXnsFWksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=9157-9164&author=C.+Iadecolaauthor=F.+Zhangauthor=R.+Caseyauthor=M.+Nagayamaauthor=M.+E.+Ross&title=Delayed+reduction+of+ischemic+brain+injury+and+neurological+deficits+in+mice+lacking+the+inducible+nitric+oxide+synthase+gene&doi=10.1523%2FJNEUROSCI.17-23-09157.1997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene</span></div><div class="casAuthors">Iadecola, Costantino; Zhang, Fangyi; Casey, Robyn; Nagayama, Masao; Ross, M. Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9157-9164</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Inducible nitric oxide synthase (iNOS), an enzyme that produces toxic amts. of nitric oxide, is expressed in a no. of brain pathologies, including cerebral ischemia.  The authors used mice with a null mutation of the iNOS gene to study the role of iNOS in ischemic brain damage.  Focal cerebral ischemia was produced by occlusion of the middle cerebral artery (MCA).  In wild-type mice, iNOS mRNA expression in the post-ischemic brain began between 24 and 48 h, peaked at 96 h and subsided 7 d after MCA occlusion.  INOS mRNA induction was assocd. with expression of iNOS protein and enzymic activity.  In contrast, mice lacking the iNOS gene did not express iNOS message or protein after MCA occlusion.  The infarct and the motor deficits produced by MCA occlusion were smaller in iNOS knockouts than in wild-type mice.  Such redn. in ischemic damage and neurol. deficits was obsd. 96 h after ischemia but not at 24 h, when iNOS is not yet expressed in wild-type mice.  The decreased susceptibility to cerebral ischemia in iNOS knockouts could not be attributed to differences in the degree of ischemia or vascular reactivity between wild-type and knockout mice.  These findings indicate that iNOS expression is one of the factors contributing to the expansion of the brain damage that occurs in the post-ischemic period.  INOS inhibition may provide a novel therapeutic strategy targeted specifically at the secondary progression of ischemic brain injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAQjGLMFFg3LVg90H21EOLACvtfcHk0ljqHhsQEHpueQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsFWksLs%253D&md5=2224c658f3fa78e7722efc27c0219944</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.17-23-09157.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.17-23-09157.1997%26sid%3Dliteratum%253Aachs%26aulast%3DIadecola%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DCasey%26aufirst%3DR.%26aulast%3DNagayama%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DM.%2BE.%26atitle%3DDelayed%2520reduction%2520of%2520ischemic%2520brain%2520injury%2520and%2520neurological%2520deficits%2520in%2520mice%2520lacking%2520the%2520inducible%2520nitric%2520oxide%2520synthase%2520gene%26jtitle%3DJ.%2520Neurosci.%26date%3D1997%26volume%3D17%26spage%3D9157%26epage%3D9164%26doi%3D10.1523%2FJNEUROSCI.17-23-09157.1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schipper, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavitian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cressatti, M.</span></span> <span> </span><span class="NLM_article-title">The sinister face of heme oxygenase-1 in brain aging and disease</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2018.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.pneurobio.2018.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=30009872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWhsrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=40-70&author=H.+M.+Schipperauthor=W.+Songauthor=A.+Tavitianauthor=M.+Cressatti&title=The+sinister+face+of+heme+oxygenase-1+in+brain+aging+and+disease&doi=10.1016%2Fj.pneurobio.2018.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The sinister face of heme oxygenase-1 in brain aging and disease</span></div><div class="casAuthors">Schipper, Hyman M.; Song, Wei; Tavitian, Ayda; Cressatti, Marisa</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-70</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Under stressful conditions, cellular heme catabolism to carbon monoxide, iron and biliverdin is mediated by the 32 kDa enzyme, heme oxygenase-1 (HO-1).  A wide range of pro-oxidant and inflammatory stimuli act on diverse consensus sequences within the Hmox1 promoter to rapidly induce the gene.  There is ample evidence attesting to the beneficial effects of HO-1 upregulation in brain.  By converting pro-oxidant heme to the antioxidants, biliverdin and bilirubin, HO-1/biliverdin reductase may help restore a more favorable tissue redox microenvironment.  Contrariwise, in some cell types and under certain circumstances, heme-derived carbon monoxide and iron may amplify intracellular oxidative stress and exacerbate the disease process.  This inimical side of neural HO-1 has often been ignored in biomedical literature promulgating interventions aimed at boosting central HO-1 expression for the management of diverse CNS conditions and is the focus of the current review.  A comprehensive model of astroglial stress is presented wherein sustained Hmox1 induction promotes oxidative mitochondrial membrane damage, iron sequestration and mitophagy (macroautophagy).  The HO-1 mediated gliopathy renders nearby neuronal constituents vulnerable to oxidative injury and recapitulates 'core' neuropathol. features of many aging-related neurodegenerative and some neurodevelopmental brain disorders.  A balanced literature should acknowledge that, in a host of chronic human CNS afflictions, the glial HO-1 response may serve as a robust transducer of noxious stimuli, an important driver of relevant neuropathol. and a potentially disease-modifying therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRgFe9imcJ3rVg90H21EOLACvtfcHk0ljqHhsQEHpueQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWhsrnL&md5=68c2e441383714dd479bc3acb64d618f</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2018.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2018.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DSchipper%26aufirst%3DH.%2BM.%26aulast%3DSong%26aufirst%3DW.%26aulast%3DTavitian%26aufirst%3DA.%26aulast%3DCressatti%26aufirst%3DM.%26atitle%3DThe%2520sinister%2520face%2520of%2520heme%2520oxygenase-1%2520in%2520brain%2520aging%2520and%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2019%26volume%3D172%26spage%3D40%26epage%3D70%26doi%3D10.1016%2Fj.pneurobio.2018.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griñán-Ferré, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarroca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puigoriol-Illamola, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguado, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfeliu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallàs, M.</span></span> <span> </span><span class="NLM_article-title">Epigenetic mechanisms underlying cognitive impairment and Alzheimer disease hallmarks in 5xFAD mice</span>. <i>Aging</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">664</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.18632/aging.100906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.18632%2Faging.100906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=27013617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVymtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=664-684&author=C.+Gri%C3%B1%C3%A1n-Ferr%C3%A9author=S.+Sarrocaauthor=A.+Ivanovaauthor=D.+Puigoriol-Illamolaauthor=F.+Aguadoauthor=A.+Caminsauthor=C.+Sanfeliuauthor=M.+Pall%C3%A0s&title=Epigenetic+mechanisms+underlying+cognitive+impairment+and+Alzheimer+disease+hallmarks+in+5xFAD+mice&doi=10.18632%2Faging.100906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic mechanisms underlying cognitive impairment and Alzheimer disease hallmarks in 5XFAD mice</span></div><div class="casAuthors">Grinan-Ferre, Christian; Sarroca, Sara; Ivanova, Aleksandra; Puigoriol-Illamola, Dolors; Aguado, Fernando; Camins, Antoni; Sanfeliu, Coral; Pallas, Merce</div><div class="citationInfo"><span class="NLM_cas:title">Aging</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">664-684</span>CODEN:
                <span class="NLM_cas:coden">AGINCN</span>;
        ISSN:<span class="NLM_cas:issn">1945-4589</span>.
    
            (<span class="NLM_cas:orgname">Impact Journals LLC</span>)
        </div><div class="casAbstract">5XFAD is an early-onset mouse transgenic model of Alzheimer disease (AD).  Up to now there are no studies that focus on the epigenetic changes produced as a result of Aβ-42 accumulation and the possible involvement in the different expression of related AD-genes.  Under several behavioral and cognition test, we found impairment in memory and psychoemotional changes in female 5XFAD mice in ref. to wild type that worsens with age.  Cognitive changes correlated with alterations on protein level anal. and gene expression of markers related with tau aberrant phosphorylation, amyloidogenic pathway (APP, BACE1), Oxidative Stress (iNOS, Aldh2) and inflammation (astrogliosis, TNF-α and IL-6); no changes were found in non-amyloidogenic pathway indicators such as ADAM10.  Epigenetics changes as higher CpG methylation and transcriptional changes in DNA methyltransferases (DNMTs) family were found.  Dnmt1 increases in younger 5XFAD and Dnmt3a and b high levels in the oldest transgenic mice.  Similar pattern was found with histone methyltransferases such as Jarid1a and G9a.  Histone deacetylase 2 (Hdac2) or Sirt6., both related with cognition and memory, presented a similar pattern.  Taken together, these hallmarks presented by the 5XFAD model prompted its use in assessing different potential therapeutic interventions based on epigenetic targets after earlier amyloid deposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy0gsGdoC1kbVg90H21EOLACvtfcHk0ljqHhsQEHpueQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVymtLg%253D&md5=a805b5c900563cec2dcb6d218192ed04</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.18632%2Faging.100906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Faging.100906%26sid%3Dliteratum%253Aachs%26aulast%3DGri%25C3%25B1%25C3%25A1n-Ferr%25C3%25A9%26aufirst%3DC.%26aulast%3DSarroca%26aufirst%3DS.%26aulast%3DIvanova%26aufirst%3DA.%26aulast%3DPuigoriol-Illamola%26aufirst%3DD.%26aulast%3DAguado%26aufirst%3DF.%26aulast%3DCamins%26aufirst%3DA.%26aulast%3DSanfeliu%26aufirst%3DC.%26aulast%3DPall%25C3%25A0s%26aufirst%3DM.%26atitle%3DEpigenetic%2520mechanisms%2520underlying%2520cognitive%2520impairment%2520and%2520Alzheimer%2520disease%2520hallmarks%2520in%25205xFAD%2520mice%26jtitle%3DAging%26date%3D2016%26volume%3D8%26spage%3D664%26epage%3D684%26doi%3D10.18632%2Faging.100906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becke, A. D.</span></span> <span> </span><span class="NLM_article-title">Density-functional thermochemistry. III. The role of exact exchange</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">5648</span>, <span class="refDoi"> DOI: 10.1063/1.464913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1063%2F1.464913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK3sXisVWgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1993&pages=5648&author=A.+D.+Becke&title=Density-functional+thermochemistry.+III.+The+role+of+exact+exchange&doi=10.1063%2F1.464913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Density-functional thermochemistry. III. The role of exact exchange</span></div><div class="casAuthors">Becke, Axel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5648-52</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Despite the remarkable thermochem. accuracy of Kohn-Sham d.-functional theories with gradient corrections for exchange-correlation, the author believes that further improvements are unlikely unless exact-exchange information is considered.  Arguments to support this view are presented, and a semiempirical exchange-correlation functional (contg. local-spin-d., gradient, and exact-exchange terms) is tested for 56 atomization energies, 42 ionization potentials, 8 proton affinities, and 10 total at. energies of first- and second-row systems.  This functional performs better than previous functionals with gradient corrections only, and fits expt. atomization energies with an impressively small av. abs. deviation of 2.4 kcal/mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3BqpycUTBwLVg90H21EOLACvtfcHk0likA_kbi0VURA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVWgtrw%253D&md5=291bbfc119095338bb1624f0c21c7ca8</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1063%2F1.464913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.464913%26sid%3Dliteratum%253Aachs%26aulast%3DBecke%26aufirst%3DA.%2BD.%26atitle%3DDensity-functional%2520thermochemistry.%2520III.%2520The%2520role%2520of%2520exact%2520exchange%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1993%26volume%3D98%26spage%3D5648%26doi%3D10.1063%2F1.464913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, R. G.</span></span> <span> </span><span class="NLM_article-title">Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density</span>. <i>Phys. Rev. B: Condens. Matter Mater. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">785</span>, <span class="refDoi"> DOI: 10.1103/PhysRevB.37.785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1103%2FPhysRevB.37.785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=9944570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL1cXktFWrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1988&pages=785&author=C.+Leeauthor=W.+Yangauthor=R.+G.+Parr&title=Development+of+the+Colle-Salvetti+correlation-energy+formula+into+a+functional+of+the+electron+density&doi=10.1103%2FPhysRevB.37.785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density</span></div><div class="casAuthors">Lee, Chengteh; Yang, Weitao; Parr, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Physical Review B:  Condensed Matter and Materials Physics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">785-9</span>CODEN:
                <span class="NLM_cas:coden">PRBMDO</span>;
        ISSN:<span class="NLM_cas:issn">0163-1829</span>.
    </div><div class="casAbstract">A correlation-energy formula due to R. Colle and D. Salvetti (1975), in which the correlation energy d. is expressed in terms of the electron d. and a Laplacian of the 2nd-order Hartree-Fock d. matrix, is restated as a formula involving the d. and local kinetic-energy d.  On insertion of gradient expansions for the local kinetic-energy d., d.-functional formulas for the correlation energy and correlation potential are then obtained.  Through numerical calcns. on a no. of atoms, pos. ions, and mols., of both open- and closed-shell type, it is demonstrated that these formulas, like the original Colle-Salvetti formulas, give correlation energies within a few percent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8yJ1cBkpi67Vg90H21EOLACvtfcHk0likA_kbi0VURA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktFWrtbw%253D&md5=ee7b59267a2ff72e15171a481819ccf8</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1103%2FPhysRevB.37.785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1103%252FPhysRevB.37.785%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DParr%26aufirst%3DR.%2BG.%26atitle%3DDevelopment%2520of%2520the%2520Colle-Salvetti%2520correlation-energy%2520formula%2520into%2520a%2520functional%2520of%2520the%2520electron%2520density%26jtitle%3DPhys.%2520Rev.%2520B%253A%2520Condens.%2520Matter%2520Mater.%2520Phys.%26date%3D1988%26volume%3D37%26spage%3D785%26doi%3D10.1103%2FPhysRevB.37.785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitznagel, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleyer, P. v. R.</span></span> <span> </span><span class="NLM_article-title">Efficient diffuse function-augmented basis sets for anion calculations. III. The 3-21+G basis set for first-row elements, Li–F</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1002/jcc.540040303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fjcc.540040303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL3sXlt1ymsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1983&pages=294-301&author=T.+Clarkauthor=J.+Chandrasekharauthor=G.+W.+Spitznagelauthor=P.+v.+R.+Schleyer&title=Efficient+diffuse+function-augmented+basis+sets+for+anion+calculations.+III.+The+3-21%2BG+basis+set+for+first-row+elements%2C+Li%E2%80%93F&doi=10.1002%2Fjcc.540040303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient diffuse function-augmented basis sets for anion calculations.  III.  The 3-21 + G basis set for first-row elements, lithium to fluorine</span></div><div class="casAuthors">Clark, Timothy; Chandrasekhar, Jayaraman; Spitznagel, Guenther W.; Schleyer, Paul v. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">294-301</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    </div><div class="casAbstract">The relatively small diffuse function-augmented basis set, 3-21+G, describes anion geometries and proton affinities adequately.  The diffuse sp orbital exponents are recommended for general use to augment larger basis sets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAg8Jhz7uoELVg90H21EOLACvtfcHk0likA_kbi0VURA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlt1ymsb8%253D&md5=2c6dc9df839e5a23820c29db41ce68dc</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fjcc.540040303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.540040303%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DT.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DSpitznagel%26aufirst%3DG.%2BW.%26aulast%3DSchleyer%26aufirst%3DP.%2Bv.%2BR.%26atitle%3DEfficient%2520diffuse%2520function-augmented%2520basis%2520sets%2520for%2520anion%2520calculations.%2520III.%2520The%25203-21%252BG%2520basis%2520set%2520for%2520first-row%2520elements%252C%2520Li%25E2%2580%2593F%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1983%26volume%3D4%26spage%3D294%26epage%3D301%26doi%3D10.1002%2Fjcc.540040303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wadt, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, P. J.</span></span> <span> </span><span class="NLM_article-title">Ab initio effective core potentials for molecular calculations. Potentials for K to Au including the outermost core orbitals</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">284</span>, <span class="refDoi"> DOI: 10.1063/1.448800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1063%2F1.448800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL2MXht1SjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1985&pages=284&author=W.+R.+Wadtauthor=P.+J.+Hay&title=Ab+initio+effective+core+potentials+for+molecular+calculations.+Potentials+for+K+to+Au+including+the+outermost+core+orbitals&doi=10.1063%2F1.448800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Ab initio effective core potentials for molecular calculations.  Potentials for main group elements sodium to bismuth</span></div><div class="casAuthors">Wadt, Willard R.; Hay, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">284-98</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">A consistent set of ab initio effective core potentials (ECP) was generated for the main group elements from Na to Bi by using the procedure originally developed by Kahn (1976).  For Rb to Bi the ECP's are generated from the relativistic Hartree-Fock at. wave functions of Cowan which incorporate the Darwin and mass-velocity terms.  Energy-optimized valence basis sets of (3s3p) primitive Gaussians are presented for use with the ECP's.  Comparisons between all-electron and valence-electron ECP calcns. are presented for NaF, NaCl, Cl2, Cl2-, Br2, Br2-, and Xe2+.  The results show that the av. errors introduced by the ECP's are generally only a few percent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt2lGOejwqOLVg90H21EOLACvtfcHk0liLPH7ipR-I-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXht1SjtLk%253D&md5=16288166d7c3a65ba452c4673b7c7d2a</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1063%2F1.448800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.448800%26sid%3Dliteratum%253Aachs%26aulast%3DWadt%26aufirst%3DW.%2BR.%26aulast%3DHay%26aufirst%3DP.%2BJ.%26atitle%3DAb%2520initio%2520effective%2520core%2520potentials%2520for%2520molecular%2520calculations.%2520Potentials%2520for%2520K%2520to%2520Au%2520including%2520the%2520outermost%2520core%2520orbitals%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1985%26volume%3D82%26spage%3D284%26doi%3D10.1063%2F1.448800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, H. B.</span></span> <span> </span><span class="NLM_article-title">An improved algorithm for reaction path following</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">2154</span>, <span class="refDoi"> DOI: 10.1063/1.456010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1063%2F1.456010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL1MXhsVahtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1989&pages=2154&author=C.+Gonzalezauthor=H.+B.+Schlegel&title=An+improved+algorithm+for+reaction+path+following&doi=10.1063%2F1.456010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">An improved algorithm for reaction path following</span></div><div class="casAuthors">Gonzalez, Carlos; Schlegel, H. Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2154-61</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">A new algorithm is presented for obtaining points on a steepest descent path from the transition state of the reactants and products.  In mass-weighted coordinates, this path corresponds to the intrinsic reaction coordinate.  Points on the reaction path are found by constrained optimizations involving all internal degrees of freedom of the mol.  The points are optimized so that the segment of the reaction path between any two adjacent points is given by an arc of a circle, and so that the gradient at each point is tangent to the path.  Only the transition vector and the energy gradients are needed to construct the path.  The resulting path is continuous, differentiable and piecewise quadratic.  In the limit of small step size, the present algorithm is shown to take a step with the correct tangent vector and curvature vector; hence, it is a second order algorithm.  The method was tested on the following reactions: HCN → CNH, SiH2 + H2 → SiH4, CH4 + H → CH3 + H2, F- + CH3F → FCH3 + F-, and C2H5F → C2H4 + HF.  Reaction paths calcd. with a step size of 0.4 a.u. are almost identical to those computed with a step size of 0.1 a.u. or smaller.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpndb7Cg_0ZNbVg90H21EOLACvtfcHk0liLPH7ipR-I-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhsVahtbk%253D&md5=17e5199cc364324ce3c55c6701342b58</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1063%2F1.456010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.456010%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez%26aufirst%3DC.%26aulast%3DSchlegel%26aufirst%3DH.%2BB.%26atitle%3DAn%2520improved%2520algorithm%2520for%2520reaction%2520path%2520following%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1989%26volume%3D90%26spage%3D2154%26doi%3D10.1063%2F1.456010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, D. G.</span></span> <span> </span><span class="NLM_article-title">MN-15: A new local exchanged-correlation functional for Kohn-Sham density functional theory broad accuracy for atoms, molecules, and solids</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1280</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.5b01082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b01082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12qsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1280-1293&author=H.+S.+Yuauthor=X.+Heauthor=D.+G.+Truhlar&title=MN-15%3A+A+new+local+exchanged-correlation+functional+for+Kohn-Sham+density+functional+theory+broad+accuracy+for+atoms%2C+molecules%2C+and+solids&doi=10.1021%2Facs.jctc.5b01082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">MN15-L: A New Local Exchange-Correlation Functional for Kohn-Sham Density Functional Theory with Broad Accuracy for Atoms, Molecules, and Solids</span></div><div class="casAuthors">Yu, Haoyu S.; He, Xiao; Truhlar, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1280-1293</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kohn-Sham d. functional theory is widely used for applications of electronic structure theory in chem., materials science, and condensed-matter physics, but the accuracy depends on the quality of the exchange-correlation functional.  Here, we present a new local exchange-correlation functional called MN15-L that predicts accurate results for a broad range of mol. and solid-state properties including main-group bond energies, transition metal bond energies, reaction barrier heights, noncovalent interactions, at. excitation energies, ionization potentials, electron affinities, total at. energies, hydrocarbon thermochem., and lattice consts. of solids.  The MN15-L functional has the same math. form as a previous meta-nonseparable gradient approxn. exchange-correlation functional, MN12-L, but it is improved because we optimized it against a larger database, designated 2015A, and included smoothness restraints; the optimization has a much better representation of transition metals.  The mean unsigned error on 422 chem. energies is 2.32 kcal/mol, which is the best among all tested functionals, with or without nonlocal exchange.  The MN15-L functional also provides good results for test sets that are outside the training set.  A key issue is that the functional is local (no nonlocal exchange or nonlocal correlation), which makes it relatively economical for treating large and complex systems and solids.  Another key advantage is that medium-range correlation energy is built in so that one does not need to add damped dispersion by mol. mechanics in order to predict accurate noncovalent binding energies.  We believe that the MN15-L functional should be useful for a wide variety of applications in chem., physics, materials science, and mol. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbBt4RRpG2aLVg90H21EOLACvtfcHk0liLPH7ipR-I-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12qsQ%253D%253D&md5=009604f205a3b5524da28a9dd4beb8d4</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b01082%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BS.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DTruhlar%26aufirst%3DD.%2BG.%26atitle%3DMN-15%253A%2520A%2520new%2520local%2520exchanged-correlation%2520functional%2520for%2520Kohn-Sham%2520density%2520functional%2520theory%2520broad%2520accuracy%2520for%2520atoms%252C%2520molecules%252C%2520and%2520solids%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D1280%26epage%3D1293%26doi%3D10.1021%2Facs.jctc.5b01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marenich, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, D. G.</span></span> <span> </span><span class="NLM_article-title">Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">6378</span>– <span class="NLM_lpage">6396</span>, <span class="refDoi"> DOI: 10.1021/jp810292n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp810292n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksV2is74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=6378-6396&author=A.+V.+Marenichauthor=C.+J.+Cramerauthor=D.+G.+Truhlar&title=Universal+solvation+model+based+on+solute+electron+density+and+on+a+continuum+model+of+the+solvent+defined+by+the+bulk+dielectric+constant+and+atomic+surface+tensions&doi=10.1021%2Fjp810292n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Universal Solvation Model Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic Surface Tensions</span></div><div class="casAuthors">Marenich, Aleksandr V.; Cramer, Christopher J.; Truhlar, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6378-6396</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-6106</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a new continuum solvation model based on the quantum mech. charge d. of a solute mol. interacting with a continuum description of the solvent.  The model is called SMD, where the "D" stands for "d." to denote that the full solute electron d. is used without defining partial at. charges.  "Continuum" denotes that the solvent is not represented explicitly but rather as a dielec. medium with surface tension at the solute-solvent boundary.  SMD is a universal solvation model, where "universal" denotes its applicability to any charged or uncharged solute in any solvent or liq. medium for which a few key descriptors are known (in particular, dielec. const., refractive index, bulk surface tension, and acidity and basicity parameters).  The model separates the observable solvation free energy into two main components.  The first component is the bulk electrostatic contribution arising from a self-consistent reaction field treatment that involves the soln. of the nonhomogeneous Poisson equation for electrostatics in terms of the integral-equation-formalism polarizable continuum model (IEF-PCM).  The cavities for the bulk electrostatic calcn. are defined by superpositions of nuclear-centered spheres.  The second component is called the cavity-dispersion-solvent-structure term and is the contribution arising from short-range interactions between the solute and solvent mols. in the first solvation shell.  This contribution is a sum of terms that are proportional (with geometry-dependent proportionality consts. called at. surface tensions) to the solvent-accessible surface areas of the individual atoms of the solute.  The SMD model has been parametrized with a training set of 2821 solvation data including 112 aq. ionic solvation free energies, 220 solvation free energies for 166 ions in acetonitrile, methanol, and DMSO, 2346 solvation free energies for 318 neutral solutes in 91 solvents (90 nonaq. org. solvents and water), and 143 transfer free energies for 93 neutral solutes between water and 15 org. solvents.  The elements present in the solutes are H, C, N, O, F, Si, P, S, Cl, and Br.  The SMD model employs a single set of parameters (intrinsic at. Coulomb radii and at. surface tension coeffs.) optimized over six electronic structure methods: M05-2X/MIDI!6D, M05-2X/6-31G*, M05-2X/6-31+G**, M05-2X/cc-pVTZ, B3LYP/6-31G*, and HF/6-31G*.  Although the SMD model has been parametrized using the IEF-PCM protocol for bulk electrostatics, it may also be employed with other algorithms for solving the nonhomogeneous Poisson equation for continuum solvation calcns. in which the solute is represented by its electron d. in real space.  This includes, for example, the conductor-like screening algorithm.  With the 6-31G* basis set, the SMD model achieves mean unsigned errors of 0.6-1.0 kcal/mol in the solvation free energies of tested neutrals and mean unsigned errors of 4 kcal/mol on av. for ions with either Gaussian03 or GAMESS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrvm7K8c8dLVg90H21EOLACvtfcHk0lhT8tyOJtVd1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksV2is74%253D&md5=54931a64c70d28445ee53876a8b1a4b9</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjp810292n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp810292n%26sid%3Dliteratum%253Aachs%26aulast%3DMarenich%26aufirst%3DA.%2BV.%26aulast%3DCramer%26aufirst%3DC.%2BJ.%26aulast%3DTruhlar%26aufirst%3DD.%2BG.%26atitle%3DUniversal%2520solvation%2520model%2520based%2520on%2520solute%2520electron%2520density%2520and%2520on%2520a%2520continuum%2520model%2520of%2520the%2520solvent%2520defined%2520by%2520the%2520bulk%2520dielectric%2520constant%2520and%2520atomic%2520surface%2520tensions%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2009%26volume%3D113%26spage%3D6378%26epage%3D6396%26doi%3D10.1021%2Fjp810292n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span></span>; <span class="NLM_etal"></span> <i>Gaussian 16</i>, revision B.01, <span class="NLM_publisher-name">Gaussian, Inc.</span>: <span class="NLM_publisher-loc">Wallingford, CT</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+J.+Frisch&title=Gaussian+16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26jtitle%3DGaussian%252016%26pub%3DGaussian%252C%2520Inc%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callado, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabilondo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meana, J. J.</span></span> <span> </span><span class="NLM_article-title">[<sup>3</sup>H] RX821002 (2-methoxyidazoxan) binds to α<sub>2</sub>-adrenoceptor subtypes and a non-adrenoceptor imidazoline binding site in rat kidney</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(96)00692-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2FS0014-2999%2896%2900692-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=8982708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaK28Xnt1Krtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=1996&pages=359-368&author=L.+F.+Calladoauthor=A.+M.+Gabilondoauthor=J.+J.+Meana&title=%5B3H%5D+RX821002+%282-methoxyidazoxan%29+binds+to+%CE%B12-adrenoceptor+subtypes+and+a+non-adrenoceptor+imidazoline+binding+site+in+rat+kidney&doi=10.1016%2FS0014-2999%2896%2900692-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">[3H]RX 821002 (2-methoxyidazoxan) binds to α2-adrenoceptor subtypes and a non-adrenoceptor imidazoline binding site in rat kidney</span></div><div class="casAuthors">Callado, Luis F.; Gabilondo, Ane M.; Meana, J. Javier</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">359-368</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The binding of [3H]RX 821002 was evaluated in rat kidney membranes.  [3H]RX 821002 (0.13-16 nM) recognized a single, saturable binding site with high affinity.  Different binding site densities were calcd. depending on non-specific binding as defined by (-)-adrenaline or RX 821002 (10 μM).  Competition assays using (-)-adrenaline and the subtype-selective drugs ARC 239 (2-[2-[4-(o-methoxyphenyl)-piperazin-1-yl]-ethyl]-4,4-dimethyl-1,3(2H,4H)-isoquinolindione), BRL 44408 (2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole), oxymetazoline or prazosin for [3H]RX 821002 binding sites revealed the presence of α2B-adrenoceptors (33-51%), α2D-adrenoceptors (15-28%) and an adrenaline-insensitive population (34-40%), sensitive to imidazolines.  After the addn. of (-)-adrenaline (3 μM) to mask α2-adrenoceptors, [3H]RX 821002 specifically identified a saturable binding site with high affinity (Kd = 4.9 nM).  The pharmacol. profile of this non-adrenoceptor, [3H]RX 821002 binding site (potencies: efaroxan>clonidine>guanabenz>BRL 44408>ARC 239>BU 224 (2-(4,5-dihydroimidaz-2-yl)quinoline)>moxonidine>(-)-noradrenaline>cimetidine) is different to that of imidazoline I1 or imidazoline I2 binding sites.  Alternative incubation in the presence of ARC 239 (50 nM) to mask α2B-adrenoceptors or BRL 44408 (100 nM) to mask α2D-adrenoceptors confirmed the existence of both α2-adrenoceptor subtypes and a non-adrenoceptor imidazoline binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_fNrKA8UDdbVg90H21EOLACvtfcHk0lhT8tyOJtVd1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt1Krtrw%253D&md5=a9c19d6fc068713870455004efe28674</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2896%2900692-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252896%252900692-9%26sid%3Dliteratum%253Aachs%26aulast%3DCallado%26aufirst%3DL.%2BF.%26aulast%3DGabilondo%26aufirst%3DA.%2BM.%26aulast%3DMeana%26aufirst%3DJ.%2BJ.%26atitle%3D%255B3H%255D%2520RX821002%2520%25282-methoxyidazoxan%2529%2520binds%2520to%2520%25CE%25B12-adrenoceptor%2520subtypes%2520and%2520a%2520non-adrenoceptor%2520imidazoline%2520binding%2520site%2520in%2520rat%2520kidney%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D316%26spage%3D359%26epage%3D368%26doi%3D10.1016%2FS0014-2999%2896%2900692-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span>MarvinSketch 5.5.1.0. <span class="NLM_publisher-name">ChemAxon</span>, <span class="NLM_publisher-loc">Budapest, Hungary</span>, <span class="NLM_year">2011</span>; software available
at <a href="https://www.chemaxon.com" class="extLink">https://www.chemaxon.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MarvinSketch+5.5.1.0.+ChemAxon%2C+Budapest%2C+Hungary%2C+2011%3B+software+available%0Aat+https%3A%2F%2Fwww.chemaxon.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26pub%3DChemAxon%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. J. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of parameters for semiempirical methods I. Method</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/jcc.540100208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fjcc.540100208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL1MXkt1ylu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1989&pages=209-220&author=J.+J.+P.+Stewart&title=Optimization+of+parameters+for+semiempirical+methods+I.+Method&doi=10.1002%2Fjcc.540100208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of parameters for semiempirical methods.  I.  Method</span></div><div class="casAuthors">Stewart, James J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-20</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    </div><div class="casAbstract">A new method for obtaining optimized parameters for semiempirical methods is developed and applied to the MNDO method.  The method uses derivs. of calcd. values for properties with respect to adjustable parameters to obtain the optimized values of parameters.  The large increase in speed is a result of using a simple series expression for calcd. values of properties rather than employing full semiempirical calcns.  With this optimization procedure, the rate-detg. step for parameterizing elements changes from the mechanics of parameterization to the assembling of exptl. ref. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwG85ot7_Rq7Vg90H21EOLACvtfcHk0lhT8tyOJtVd1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkt1ylu70%253D&md5=cbf1b7604277340a97e061539b65af71</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1002%2Fjcc.540100208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.540100208%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DJ.%2BJ.%2BP.%26atitle%3DOptimization%2520of%2520parameters%2520for%2520semiempirical%2520methods%2520I.%2520Method%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1989%26volume%3D10%26spage%3D209%26epage%3D220%26doi%3D10.1002%2Fjcc.540100208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. J. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of parameters for semiempirical methods II.Method</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1002/jcc.540100209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1002%2Fjcc.540100209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADyaL1MXkt1ylu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1989&pages=221-264&author=J.+J.+P.+Stewart&title=Optimization+of+parameters+for+semiempirical+methods+II.Method&doi=10.1002%2Fjcc.540100209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of parameters for semiempirical methods.  II.  Applications</span></div><div class="casAuthors">Stewart, James J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-64</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    </div><div class="casAbstract">MNDO/AM1-type parameters for 12 elements were optimized using a newly developed method for optimizing parameters for semiempirical methods.  With the new method, MNDO-PM3, the av. difference between the predicted heats of formation and exptl. values for 657 compds. is 7.8 kcal/mol, and for 106 hypervalent compds., 13.6 kcal/mol.  For MNDO the equiv. differences are 13.9 and 75.8 kcal/mol, while those for AM1, in which MNDO parameters are used for Al, P, and S, are 12.7 and 83.1 kcal/mol, resp.  Av. errors for ionization potentials, bond angles, and dipole moments are intermediate between those for MINDO and AM1, while errors on bond lengths are slightly reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofaR7BHv7vB7Vg90H21EOLACvtfcHk0lhUpuYCkhbYig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkt1ylu7o%253D&md5=b94fa02ec95f5b1b2d62c2014ac4c288</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fjcc.540100209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.540100209%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DJ.%2BJ.%2BP.%26atitle%3DOptimization%2520of%2520parameters%2520for%2520semiempirical%2520methods%2520II.Method%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1989%26volume%3D10%26spage%3D221%26epage%3D264%26doi%3D10.1002%2Fjcc.540100209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hehre, W. J.</span>; <span class="NLM_string-name">Radom, L.</span>; <span class="NLM_string-name">Schleyer, PvR.</span>; <span class="NLM_string-name">Pople, J. A.</span></span> <i>Ab initio molecular orbital theory</i>; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1986</span>; Vol  <span class="NLM_volume">1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&author=W.+J.+Hehre&author=L.+Radom&author=PvR.+Schleyer&author=J.+A.+Pople&title=Ab+initio+molecular+orbital+theory"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHehre%26aufirst%3DW.%2BJ.%26btitle%3DAb%2520initio%2520molecular%2520orbital%2520theory%26pub%3DWiley%26date%3D1986%26volume%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span>; <span class="NLM_string-name">Trucks, G. W.</span>; <span class="NLM_string-name">Schlegel, H. B.</span>; <span class="NLM_string-name">Scuseria, G. E.</span>; <span class="NLM_string-name">Robb, M. A.</span>; <span class="NLM_string-name">Cheeseman, J. R.</span>; <span class="NLM_string-name">Scalmani, G.</span>; <span class="NLM_string-name">Barone, V.</span>; <span class="NLM_string-name">Mennucci, B.</span>; <span class="NLM_string-name">Petersson, G. A.</span>; <span class="NLM_string-name">Nakatsuji, H.</span>; <span class="NLM_string-name">Caricato, M.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Hratchian, H. P.</span>; <span class="NLM_string-name">Izmaylov, A. F.</span>; <span class="NLM_string-name">Bloino, J.</span>; <span class="NLM_string-name">Zheng, G.</span>; <span class="NLM_string-name">Sonnenberg, J. L.</span>; <span class="NLM_string-name">Hada, M.</span>; <span class="NLM_string-name">Ehara, M.</span>; <span class="NLM_string-name">Toyota, K.</span>; <span class="NLM_string-name">Fukuda, R.</span>; <span class="NLM_string-name">Hasegawa, J.</span>; <span class="NLM_string-name">Ishida, M.</span>; <span class="NLM_string-name">Nakajima, T.</span>; <span class="NLM_string-name">Honda, Y.</span>; <span class="NLM_string-name">Kitao, O.</span>; <span class="NLM_string-name">Nakai, H.</span>; <span class="NLM_string-name">Vreven, T.</span>; <span class="NLM_string-name">Montgomery, J. A.,  Jr.</span>; <span class="NLM_string-name">Peralta, J. E.</span>; <span class="NLM_string-name">Ogliaro, F.</span>; <span class="NLM_string-name">Bearpark, M.</span>; <span class="NLM_string-name">Heyd, J. J.</span>; <span class="NLM_string-name">Brothers, E.</span>; <span class="NLM_string-name">Kudin, K. N.</span>; <span class="NLM_string-name">Staroverov, V. N.</span>; <span class="NLM_string-name">Kobayashi, R.</span>; <span class="NLM_string-name">Normand, J.</span>; <span class="NLM_string-name">Raghavachari, K.</span>; <span class="NLM_string-name">Rendell, A.</span>; <span class="NLM_string-name">Burant, J. C.</span>; <span class="NLM_string-name">Iyengar, S. S.</span>; <span class="NLM_string-name">Tomasi, J.</span>; <span class="NLM_string-name">Cossi, M.</span>; <span class="NLM_string-name">Rega, N.</span>; <span class="NLM_string-name">Millam, J. M.</span>; <span class="NLM_string-name">Klene, M.</span>; <span class="NLM_string-name">Knox, J. E.</span>; <span class="NLM_string-name">Cross, J. B.</span>; <span class="NLM_string-name">Bakken, V.</span>; <span class="NLM_string-name">Adamo, C.</span>; <span class="NLM_string-name">Jaramillo, J.</span>; <span class="NLM_string-name">Gomperts, R.</span>; <span class="NLM_string-name">Stratmann, R. E.</span>; <span class="NLM_string-name">Yazyev, O.</span>; <span class="NLM_string-name">Austin, A. J.</span>; <span class="NLM_string-name">Cammi, R.</span>; <span class="NLM_string-name">Pomelli, C.</span>; <span class="NLM_string-name">Ochterski, J. W.</span>; <span class="NLM_string-name">Martin, R. L.</span>; <span class="NLM_string-name">Morokuma, K.</span>; <span class="NLM_string-name">Zakrzewski, V. G.</span>; <span class="NLM_string-name">Voth, G. A.</span>; <span class="NLM_string-name">Salvador, P.</span>; <span class="NLM_string-name">Dannenberg, J. J.</span>; <span class="NLM_string-name">Dapprich, S.</span>; <span class="NLM_string-name">Daniels, A. D.</span>; <span class="NLM_string-name">Farkas, O.</span>; <span class="NLM_string-name">Foresman, J. B.</span>; <span class="NLM_string-name">Ortiz, J. V.</span>; <span class="NLM_string-name">Cioslowski, J.</span>; <span class="NLM_string-name">Fox, D. J.</span></span> <i>Gaussian 09</i>, revision D.01, <span class="NLM_publisher-name">Gaussian Inc.</span>: <span class="NLM_publisher-loc">Wallingford, CT</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+J.+Frisch&author=G.+W.+Trucks&author=H.+B.+Schlegel&author=G.+E.+Scuseria&author=M.+A.+Robb&author=J.+R.+Cheeseman&author=G.+Scalmani&author=V.+Barone&author=B.+Mennucci&author=G.+A.+Petersson&author=H.+Nakatsuji&author=M.+Caricato&author=X.+Li&author=H.+P.+Hratchian&author=A.+F.+Izmaylov&author=J.+Bloino&author=G.+Zheng&author=J.+L.+Sonnenberg&author=M.+Hada&author=M.+Ehara&author=K.+Toyota&author=R.+Fukuda&author=J.+Hasegawa&author=M.+Ishida&author=T.+Nakajima&author=Y.+Honda&author=O.+Kitao&author=H.+Nakai&author=T.+Vreven&author=J.+A.+Montgomery&author=J.+E.+Peralta&author=F.+Ogliaro&author=M.+Bearpark&author=J.+J.+Heyd&author=E.+Brothers&author=K.+N.+Kudin&author=V.+N.+Staroverov&author=R.+Kobayashi&author=J.+Normand&author=K.+Raghavachari&author=A.+Rendell&author=J.+C.+Burant&author=S.+S.+Iyengar&author=J.+Tomasi&author=M.+Cossi&author=N.+Rega&author=J.+M.+Millam&author=M.+Klene&author=J.+E.+Knox&author=J.+B.+Cross&author=V.+Bakken&author=C.+Adamo&author=J.+Jaramillo&author=R.+Gomperts&author=R.+E.+Stratmann&author=O.+Yazyev&author=A.+J.+Austin&author=R.+Cammi&author=C.+Pomelli&author=J.+W.+Ochterski&author=R.+L.+Martin&author=K.+Morokuma&author=V.+G.+Zakrzewski&author=G.+A.+Voth&author=P.+Salvador&author=J.+J.+Dannenberg&author=S.+Dapprich&author=A.+D.+Daniels&author=O.+Farkas&author=J.+B.+Foresman&author=J.+V.+Ortiz&author=J.+Cioslowski&author=D.+J.+Fox&title=Gaussian+09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26jtitle%3DGaussian%252009%26pub%3DGaussian%2520Inc%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">CambridgeSoft Corporation</span>.  <i>ChemBio3D
Ultra</i>, version 13.0; <span class="NLM_publisher-name">CambridgeSoft</span>, <span class="NLM_publisher-loc">Cambridge, MA, USA</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=CambridgeSoft+Corporation&title=ChemBio3D%0AUltra"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DChemBio3D%250AUltra%26pub%3DCambridgeSoft%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durán, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamora, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, M.</span></span> <span> </span><span class="NLM_article-title">Suitability of GRIND-Based principal properties for the description of molecular similarity and ligand-based virtual screening</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2138</span>, <span class="refDoi"> DOI: 10.1021/ci900228x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900228x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2jsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2129-2138&author=%C3%81.+Dur%C3%A1nauthor=I.+Zamoraauthor=M.+Pastor&title=Suitability+of+GRIND-Based+principal+properties+for+the+description+of+molecular+similarity+and+ligand-based+virtual+screening&doi=10.1021%2Fci900228x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Suitability of GRIND-Based Principal Properties for the Description of Molecular Similarity and Ligand-Based Virtual Screening</span></div><div class="casAuthors">Duran, Angel; Zamora, Ismael; Pastor, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2129-2138</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The information provided by the alignment-independent GRid Independent Descriptors (GRIND) can be condensed by the application of principal component anal., obtaining a small no. of principal properties (GRIND-PP), which is more suitable for describing mol. similarity.  The objective of the present study is to optimize diverse parameters involved in the obtaining of the GRIND-PP and validate their suitability for applications, requiring a biol. relevant description of the mol. similarity.  With this aim, GRIND-PP computed with a collection of diverse settings were used to carry out ligand-based virtual screening (LBVS) on std. conditions.  The quality of the results obtained was remarkable and comparable with other LBVS methods, and their detailed statistical anal. allowed to identify the method settings more determinant for the quality of the results and their optimum.  Remarkably, some of these optimum settings differ significantly from those used in previously published applications, revealing their unexplored potential.  Their applicability in large compd. database was also explored by comparing the equivalence of the results obtained using either computed or projected principal properties.  In general, the results of the study confirm the suitability of the GRIND-PP for practical applications and provide useful hints about how they should be computed for obtaining optimum results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphtRXLhSV-07Vg90H21EOLACvtfcHk0lgPOdReby2ZRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2jsbfL&md5=72cd0eb456ccecf5ae7a9270abc1f158</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fci900228x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900228x%26sid%3Dliteratum%253Aachs%26aulast%3DDur%25C3%25A1n%26aufirst%3D%25C3%2581.%26aulast%3DZamora%26aufirst%3DI.%26aulast%3DPastor%26aufirst%3DM.%26atitle%3DSuitability%2520of%2520GRIND-Based%2520principal%2520properties%2520for%2520the%2520description%2520of%2520molecular%2520similarity%2520and%2520ligand-based%2520virtual%2520screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D2129%26epage%3D2138%26doi%3D10.1021%2Fci900228x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durán, Á.</span>; <span class="NLM_string-name">Pastor, M.</span></span> <i>Pentacle, An advanced tool for computing and handling grid-independent descriptors</i>. User Manual Version 1.06; <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=%C3%81.+Dur%C3%A1n&author=M.+Pastor&title=Pentacle%2C+An+advanced+tool+for+computing+and+handling+grid-independent+descriptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DDur%25C3%25A1n%26aufirst%3D%25C3%2581.%26jtitle%3DPentacle%252C%2520An%2520advanced%2520tool%2520for%2520computing%2520and%2520handling%2520grid-independent%2520descriptors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, K.</span></span> <span> </span><span class="NLM_article-title">Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection</span>. <i>Chemom. Intell. Lab. Syst.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.chemolab.2011.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1016%2Fj.chemolab.2011.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVamsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2011&pages=146-161&author=P.+K.+Ojhaauthor=K.+Roy&title=Comparative+QSARs+for+antimalarial+endochins%3A+Importance+of+descriptor-thinning+and+noise+reduction+prior+to+feature+selection&doi=10.1016%2Fj.chemolab.2011.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection</span></div><div class="casAuthors">Ojha, Probir Kumar; Roy, Kunal</div><div class="citationInfo"><span class="NLM_cas:title">Chemometrics and Intelligent Laboratory Systems</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-161</span>CODEN:
                <span class="NLM_cas:coden">CILSEN</span>;
        ISSN:<span class="NLM_cas:issn">0169-7439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The emergence of multidrug resistance of the currently available antimalarial drugs has led to the need of the discovery and development of new antimalarial compds.  In the present study, we have selected a series of 53 endochin analogs with antimalarial activity against the clin. relevant multidrug resistant malarial strain TM-90-C2B to develop robust QSAR models using different chemometric tools such as stepwise regression, factor anal. followed by multiple linear regression (FA-MLR), factor anal. followed by partial least squares (FA-PLS) anal., genetic function approxn. (GFA) and genetic partial least squares (G/PLS) techniques.  We have tried to emphasize on importance of descriptor-thinning prior to feature selection step.  For this purpose, we have partitioned the total pool of descriptors into three categories followed by running stepwise regression sep. for all three categories of descriptors for selection of variables.  Then we have applied genetic methods of model development on the selected pool of descriptors.  We have validated the models using different validation parameters to check the statistical quality and reliability of the models.  It has been found that models developed from variable selection by stepwise regression followed by GFA and G/PLS are the best two models.  This study reflects the importance of descriptor-thinning and noise redn. prior to feature selection for the development of QSAR models.  According to the best two models, we interpreted that substitutions with rotatable bond contg. groups (e.g., long alkyl chains), limited vol. of the mols., absence of ≡ C-R group, presence of electroneg. (like -Br) fragments, absence of cycles or rings in the mols. are important for the antimalarial activity.  The developed models are believed to comply with the OECD guidelines for QSAR models.  The results also confirmed that the QSAR models developed from the reduced pool of descriptors were better than those obtained from the entire pool of descriptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-k6pitRvJF7Vg90H21EOLACvtfcHk0lgPOdReby2ZRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVamsb7E&md5=348f7175dfd99da4e2eb3a0914223d93</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.chemolab.2011.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemolab.2011.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DOjha%26aufirst%3DP.%2BK.%26aulast%3DRoy%26aufirst%3DK.%26atitle%3DComparative%2520QSARs%2520for%2520antimalarial%2520endochins%253A%2520Importance%2520of%2520descriptor-thinning%2520and%2520noise%2520reduction%2520prior%2520to%2520feature%2520selection%26jtitle%3DChemom.%2520Intell.%2520Lab.%2520Syst.%26date%3D2011%26volume%3D109%26spage%3D146%26epage%3D161%26doi%3D10.1016%2Fj.chemolab.2011.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kilkenny, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuthill, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, D. G.</span></span> <span> </span><span class="NLM_article-title">Improving biocesce research reporting: the ARRIVE guidelines for reporting animal research</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e1000412</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.1000412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1371%2Fjournal.pbio.1000412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=20613859" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=e1000412&author=C.+Kilkennyauthor=W.+J.+Browneauthor=I.+C.+Cuthillauthor=M.+Emersonauthor=D.+G.+Altman&title=Improving+biocesce+research+reporting%3A+the+ARRIVE+guidelines+for+reporting+animal+research&doi=10.1371%2Fjournal.pbio.1000412"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1000412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1000412%26sid%3Dliteratum%253Aachs%26aulast%3DKilkenny%26aufirst%3DC.%26aulast%3DBrowne%26aufirst%3DW.%2BJ.%26aulast%3DCuthill%26aufirst%3DI.%2BC.%26aulast%3DEmerson%26aufirst%3DM.%26aulast%3DAltman%26aufirst%3DD.%2BG.%26atitle%3DImproving%2520biocesce%2520research%2520reporting%253A%2520the%2520ARRIVE%2520guidelines%2520for%2520reporting%2520animal%2520research%26jtitle%3DPLoS%2520Biol.%26date%3D2010%26volume%3D8%26spage%3De1000412%26doi%3D10.1371%2Fjournal.pbio.1000412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oakley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillozet-Bongaarts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disterhoft, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s desease mutations: potential factors in amyloid plaque formation</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">10129</span>– <span class="NLM_lpage">10140</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1202-06.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=10.1523%2FJNEUROSCI.1202-06.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=17021169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVymurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=10129-10140&author=H.+Oakleyauthor=S.+L.+Coleauthor=S.+Loganauthor=E.+Mausauthor=P.+Shaoauthor=J.+Craftauthor=A.+Guillozet-Bongaartsauthor=M.+Ohnoauthor=J.+Disterhoftauthor=L.+Van+Eldikauthor=R.+Berryauthor=R.+Vassar&title=Intraneuronal+beta-amyloid+aggregates%2C+neurodegeneration%2C+and+neuron+loss+in+transgenic+mice+with+five+familial+Alzheimer%E2%80%99s+desease+mutations%3A+potential+factors+in+amyloid+plaque+formation&doi=10.1523%2FJNEUROSCI.1202-06.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation</span></div><div class="casAuthors">Oakley, Holly; Cole, Sarah L.; Logan, Sreemathi; Maus, Erika; Shao, Pei; Craft, Jeffery; Guillozet-Bongaarts, Angela; Ohno, Masuo; Disterhoft, John; Van Eldik, Linda; Berry, Robert; Vassar, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">10129-10140</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Mutations in the genes for amyloid precursor protein (APP) and presenilins (PS1, PS2) increase prodn. of β-amyloid 42 (Aβ42) and cause familial Alzheimer's disease (FAD).  Transgenic mice that express FAD mutant APP and PS1 overproduce Aβ42 and exhibit amyloid plaque pathol. similar to that found in AD, but most transgenic models develop plaques slowly.  To accelerate plaque development and investigate the effects of very high cerebral Aβ42 levels, we generated APP/PS1 double transgenic mice that coexpress five FAD mutations (5XFAD mice) and additively increase Aβ42 prodn.  5XFAD mice generate Aβ42 almost exclusively and rapidly accumulate massive cerebral Aβ42 levels.  Amyloid deposition (and gliosis) begins at 2 mo and reaches a very large burden, esp. in subiculum and deep cortical layers.  Intraneuronal Aβ42 accumulates in 5XFAD brain starting at 1.5 mo of age (before plaques form), is aggregated (as detd. by thioflavin S staining), and occurs within neuron soma and neurites.  Some amyloid deposits originate within morphol. abnormal neuron soma that contain intraneuronal Aβ.  Synaptic markers synaptophysin, syntaxin, and postsynaptic d.-95 decrease with age in 5XFAD brain, and large pyramidal neurons in cortical layer 5 and subiculum are lost.  In addn., levels of the activation subunit of cyclin-dependent kinase 5, p25, are elevated significantly at 9 mo in 5XFAD brain, although an upward trend is obsd. by 3 mo of age, before significant neurodegeneration or neuron loss.  Finally, 5XFAD mice have impaired memory in the Y-maze.  Thus, 5XFAD mice rapidly recapitulate major features of AD amyloid pathol. and may be useful models of intraneuronal Aβ42-induced neurodegeneration and amyloid plaque formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIhU1MNDa0RrVg90H21EOLACvtfcHk0lihLYU5DpnQYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVymurbK&md5=a47a3bedd25b37812f9172ebca81fb1d</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1202-06.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1202-06.2006%26sid%3Dliteratum%253Aachs%26aulast%3DOakley%26aufirst%3DH.%26aulast%3DCole%26aufirst%3DS.%2BL.%26aulast%3DLogan%26aufirst%3DS.%26aulast%3DMaus%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DP.%26aulast%3DCraft%26aufirst%3DJ.%26aulast%3DGuillozet-Bongaarts%26aufirst%3DA.%26aulast%3DOhno%26aufirst%3DM.%26aulast%3DDisterhoft%26aufirst%3DJ.%26aulast%3DVan%2BEldik%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DR.%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DIntraneuronal%2520beta-amyloid%2520aggregates%252C%2520neurodegeneration%252C%2520and%2520neuron%2520loss%2520in%2520transgenic%2520mice%2520with%2520five%2520familial%2520Alzheimer%25E2%2580%2599s%2520desease%2520mutations%253A%2520potential%2520factors%2520in%2520amyloid%2520plaque%2520formation%26jtitle%3DJ.%2520Neurosci.%26date%3D2006%26volume%3D26%26spage%3D10129%26epage%3D10140%26doi%3D10.1523%2FJNEUROSCI.1202-06.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i82"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02080">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_53868"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b02080?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02080</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental procedures for synthesis of <b>10a</b>–<b>10c</b> and <b>11</b>, theoretical calculations, 3D-QSAR study, in vitro BBB assay, DMPK assays, receptor characterization panel, in vivo data, tables of <sup>1</sup>H and <sup>13</sup>C spectra, and X-ray crystallography data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_001.pdf">jm9b02080_si_001.pdf (14.37 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02080/suppl_file/jm9b02080_si_003.csv">jm9b02080_si_003.csv (3.77 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02080&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-7%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02080%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02080" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67997b243add1923","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
